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ABSTRACT 
A number of studies have indicated that adverse events from anticoagulants are 
significant contributors to health care system expenditure. Adverse events 
comprise three groups: under-use, over-use and misuse. In Australia, it was 
estimated in 1992 that adverse events from warfarin cost $100 million in direct 
hospital costs alone. 
Part one of this thesis gives an overview of atrial fibrillation (AF) and the 
use of antithrombotics. This part provides comprehensive background on the 
significance of AF and its contribution to stroke and details the extensive 
evidence of antithrombotic drug efficacy in the prevention of stroke in AF. 
Despite overwhelming evidence that antithrombotics are effective in 
reducing the risk of stroke in AF, they remain under-utilised. Studies conducted 
internationally and nationally have shown that, in general, less than half of 
eligible patients receive anticoagulants. Described in part two of this thesis is two 
studies aimed at improving the use of antithrombotics for stroke prevention in AF. 
A nationwide survey of a random sample of general practitioners (GPs), 
cardiologists and other specialists was undertaken assessing barriers to the use of 
anticoagulants for stroke prevention in AF. This survey identified a number of 
key barriers to the use of anticoagulants and identified a number of key 
interventions to improve the prescribing of anticoagulants. Targeting the 
identified barriers to the use of anticoagulants, an educational intervention 
directed at GPs was initiated, aimed at improving the prescribing of 
antithrombotics in AF. The educational intervention utilised mailed guidelines 
and the process of academic detailing. The effect of the intervention was analysed 
using a controlled before and after study design. The educational intervention 
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significantly improved the use of anticoagulants, but recognised that there is still 
significant room for more improvement. 
Findings of the nationwide survey of doctors identified portable 
International Normalised Ratio (INR) monitors as a key intervention to improve 
the prescribing of anticoagulants in AF, and improve the management of existing 
patients on anticoagulants. Part three of this thesis evaluated the use of portable 
INR monitors in three practice settings: an outpatient hospital anticoagulant 
clinic, rural general practices and rural community pharmacies. The portable INR 
monitors performed well in these three settings. They were found to give accurate 
and reproducible results when compared to pathology testing and the use of the 
monitors was well received by GPs, community pharmacists and patients. 
Findings from these three studies show that the use of portable INR monitors has 
the potential to significantly reduce health care expenditure associated with 
anticoagulant therapy, and provides a number of alternative models for 
anticoagulant management in the community setting. 
The final part of the thesis was an intervention aimed at reducing the 
incidence of bleeding complications amongst patients commenced on warfarin in 
hospital and discharged to GP care. Patients were randomised to a control or 
intervention group, where the control group received standard care from their GP 
and the intervention group received education after discharge and alternate day 
INR monitoring using a portable INR monitor for four visits after discharge. The 
intervention significantly reduced the incidence of bleeding complications 
assessed 90 days after initial discharge, and provided a reproducible model of care 
for patients commenced on warfarin in hospital and discharged to the community. 
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The body of work conducted in this thesis provides a number of system 
solutions aimed at reducing the incidence of anticoagulant-related misadventure 
and under-use. It is clear that while this thesis provides preliminary evidence that 
adverse events associated with warfarin can be reduced, more work targeting the 
use of portable INR monitors in the initiation of warfarin therapy and transfer to 
the community setting, and education for stroke prevention in AF should 
continue. 
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PART ONE: OVERVIEW OF ATRIAL FIBRILLATION 
AND ANTITHROMBOTIC THERAPY 
CHAPTER ONE: ATRIAL FIBRILLATION 
1.1 Definition 
Atrial Fibrillation (AF) is a supraventricular tachyarrhythmia characterised by 
uncoordinated atrial activation with subsequent deterioration of atrial mechanical 
function. AF is characterised by the replacement of consistent P waves that vary 
in size, shape and timing with "irregularly irregular" ventricular contractions 
Figure 1. 1, 2 Normally, heart rate is correlated with the body's physiological 
needs by the sinoatrial node, which maintains a rate of about 60 beats per minute 
at rest. During AF, atrial cells can fire at rates of 400-600 times per minute. 3 If 
each atrial impulse were conducted to the ventricles, the extremely rapid 
ventricular rate would lead to ineffective cardiac contraction and death. 3 The 
ventricular rate during AF is in the region of 150 times per minute in the absence 
of drug therapy. 3 AF may occur in isolation or in association with other 
arrythmias, most commonly atrial flutter or atrial tachycardia. 1 Atrial flutter may 
degenerate into AF. AF may also initiate atrial flutter or the ECG pattern may 
alternate between atrial flutter and AF. 1 
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Figure 1 	Standard 12-lead electrocardiograph displaying AF. 
Reproduced from ACC/AHA/ESC guidelines for the management  of patients with AF. 1 
1.2 Classification 
AF can have very diverse clinical presentations. It can occur in the absence or 
presence of detectable heart disease or related symptoms. 1 An episode of AF may 
be self-limited or require medical intervention for termination. The pattern of AF 
may be defined in terms of the number of episodes, duration, frequency, mode of 
onset, possible triggers and response to therapy. However, these features may be 
impossible to identify when AF is first encountered in an individual patient. 
A number of types or classifications of AF have been used  to describe the 
pattern of AF, however there is no universal consensus on the nomenclature or 
classification of AF. Some proposed types have included acute, chronic, 
paroxysmal (PAF), intermittent, constant, persistent and permanent. A simple and 
clinically relevant classification has been proposed by the American College of 
Cardiology/American Heart Association/ European Society of Cardiology 
(ACC/AHA/ESC) practice guidelines for the management of AF (Figure 2). 1 At 
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presentation with a first detected episode of AF, it needs to be assessed whether it 
is symptomatic or self-limited, whilst recognising there may be uncertainty about 
the duration of the episode and about previous undetected episodes. Recent 
guidelines have proposed that classification be redefined according to treatment. 
The "three P's" of the new classification system are "paroxysmal," "persistent," 
and "permanent" (Figure 2). I 
When a patient has had 2 or more episodes, AF is considered recurrent. If 
the arrhythmia terminates spontaneously, recurrent AF is considered paroxysmal, 
if the arrhythmia is sustained it is designated persistent. In the case of persistent 
AF, it may require reversion by pharmacological or electrical mechanisms. 1 The 
terms chronic AF and Permanent AF are sometimes used interchangeably and are 
when AF is present on a permanet basis. 
4, 5 About a quarter of diagnosed cases of AF are paroxysmal. Patients with 
PAF tend to be younger and have less comorbid illness than those with persistent 
AF. Limited data suggest that roughly 20% of patients with PAF will progress to 
sustained AF over a 4-year period. 6  The category PAF covers a wide spectrum of 
rhythm abnormalities, varying by frequency and length of AF episodes. For 
example, in a recent large trial, 12% of patients with PAF had more than 1 
episode daily, while another 25% reported only 1 episode every 6 months. 7 
AF can be acute (episodes last less than 30 seconds) and occur in relation 
to a reversible cause. Common causes of acute AF are: acute myocardial 
infarction, (AMI) cardiac surgery, pericarditis, myocarditis, hyperthyroidism, 
pulmonary embolism (PE), and infections. In these circumstances, AF is not the 
primary problem and treatment of the underlying disorder with management of 
the AF usually results in termination of the arrhythmia without recurrence. 1 
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"Lone AF" generally applies to young individuals (under 60 years of age) without 
clinical or echocardiographic evidence of cardiac disease. I In general, the 
frequency of lone AF is less than 10%. 8 These individuals have a favourable 
prognosis with respect to thromboembolism and mortality. However, as time goes 
by, cardiac abnormalities can develop such as enlargement of the left atrium 
(LA). The term "non-valvular AF' (NVAF) is given to cases in which the rhythm 
disturbance occurs in the absence of rheumatic mitral valve disease or a prosthetic 
valve. I 
First detected 
AF 
Paroxysmal AF 	 Persistent AF (not 
(self terminating) self terminating) 
• 
Permanent AF 
Figure 2 	Classification system for different types of AF. 
Reproduced from ACC/AHA/ESC guidelines for the management of patients with AF. 
1.3 Epidemiology and risk factors 
AF is the most common rhythm abnormality, and much of our knowledge comes 
9 from the Framingham Heart study. The prevalence of AF is estimated to be 
0.4%4% of the general population and increases with age. 1 ' 5 The prevalence of 
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AF is less than 1% in those under 60 years of age and reaches 10% in those over 
12 10- 80 years (Figure 3). 8, 	AF is prevalent in patients with congestive cardiac 
failure (CCF) and valvular disease and the incidence increases with the severity of 
these conditions. 1 AF commonly complicates cardiac surgery and AM!. 
Multivariate analysis has identified increasing age, CCF, smoking, diabetes, 
hypertension, male gender, left ventricular (LV) hypertrophy, AMI and valvular 
heart disease as risk factors for the development of AF. 9 AF is an independent 
risk factor for death, with a relative risk factor for death of 1.5 for men and 1.9 for 
women after adjustment for known risk factors. 13 As the baby boom generation 
reaches its 70s and 80s, the prevalence of AF will increase markedly. AF is often 
asymptomatic, therefore, it may occur even more frequently than estimates 
suggest. 14 
11 
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Figure 3 	Prevalence of AF in 2 American epidemiological studies. The 
Framingham Heart Study and the Cardiovascular Health Study (CHS). 
Reproduced from Furberg et al. 8 
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1.4 Mechanisms of AF 
The traditional view of AF mechanisms is, that the arrhythmia results from 
multiple re-entrant wavelets that move randomly throughout the atria, colliding, 
being extinguished, and arising again. 2 ' 15 Re-entry is promoted by decreased 
atrial refractory periods, slowed conduction and an increased mass of cardiac 
tissue. Recently it has been shown that atrial tachyarrhythmias, including AF, 
alter atrial electrical properties promoting multiple-circuit re-entrant AF. 2 A 
second distinct mechanism causing AF has recently been recognised, a rapidly 
firing focus (or foci), usually located in or near the pulmonary vein. 3 15 16  
Catheter ablation of AF is a useful approach for patients with symptomatic AF 
recurrences, it reduces the frequency of recurrent AF in the majority of patients, 
however, the risk of recurrent AF is 30% to 50% over the first year. I 
Sustained AF causes important reductions in cellular contractility, 
resulting in tachycardia-induced atrial cardiomyopathy that may be responsible 
for delayed thromboembolic events as contractility recovers after cardioversion. 2 
Shortening of the atrial refractory period is a fundamental change that helps to 
perpetuate the arrhythmia, by allowing more wavelets in the atrial mass. 
Paroxysmal and persistent AF are associated with shortening of the atrial 
refractory period, but this change can become more permanent in long-term AF. 
This gives rise to the adage that "AF begets AF" the notion that AF tends to 
perpetuate itself. 
Individuals with recurrent AF can develop increasing problems over time 
and many progress to permanent AF. 15 The ability to cardiovert to sustained 
sinus rhythm is greatly reduced in patients who have been in persistent AF for 
longer than 12 months. 15 Atrial hypertrophy and dilatation may be either a cause 
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of or a consequence of persistent AF, because progressive atrial enlargement has 
been demonstrated in patients with AF. 17 Renin-angiotensin activation appears to 
play an important role in CCF-related atrial remodeling, which can be attenuated 
by treatment with an angiotensin converting enzyme (ACE) inhibitor. 2 AF may 
result from increased vagal tone that leads to episodes during sleep, after meals, 
from alcohol and or caffeine. 1 
1.5 Acute AF 
Common causes of acute AF are: AMI, cardiac surgery, pericarditis, myocarditis, 
hyperthyroidism, PE, and infections. Although AF may occur after noncardiac 
surgery, the incidence of atrial arrhythmias after open-heart surgery is between 20 
and 50%. 18 ' 19 Postoperative AF usually occurs within five days of cardiac 
surgery, with a peak incidence on day 2. A number of studies have shown an 
increased risk of stroke in coronary artery bypass graft (CABG) patients after the 
procedure, so anticoagulation is appropriate when AF persists for more than 48 
hours. 20,21 
1.6 Haemodynamic consequences 
AF is associated with the loss of the atrial contribution to ventricular filling 15 and 
can result in a decrease in ventricular stroke volume of up to 20 percent. 15 Three 
factors can contribute to deterioration in haemodynamic function: loss of 
synchronous atrial activity, irregularity of ventricular response, and an 
inappropriately rapid heart rate. 1 A marked decrease in cardiac output may occur 
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with the loss of atrial contraction, especially in patients with impaired ventricular 
filling, hypertension, mitral stenosis and cardiomyopathy. I A persistently 
elevated ventricular rate during AF can produce tachycardia-induced 
cardiomyopathy. 
1.7 Clinical manifestations 
AF may be symptomatic or asymptomatic, 2 even in the same patient. I In fact, 
asymptomatic episodes occur more frequently than symptomatic ones. 14 The 
arrhythmia may present for the first time with an embolic complication or 
exacerbation of CCF, but most patients with AF complain of palpitations, chest 
pain, dyspnoea, fatigue, lightheadedness, or syncope, I however, Fatigue and 
other non-specific symptoms are the most common. 22 The cognitive function of 
elderly patients with persistent AF is lower compared to age-matched controls in 
sinus rhythm. 23 AF may be associated with a fast ventricular response, leading to 
tachycardia-induced cardiomyopathy, especially in patients who are unaware of 
the arrhythmia. 1 Symptoms vary with the ventricular rate, underlying functional 
status, duration of AF, and individual patient perceptions. I Data suggests that the 
quality of life for patients during AF is significantly impaired as compared to the 
quality of life after sinus rhythm is restored. 15 
1.8 Examination and investigations 
The initial evaluation of a patient with suspected or proven AF includes 
elucidating the pattern of the arrhythmia as paroxysmal or persistent, determining 
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its cause and defining associated cardiac factors. The evaluation of a patient 
with AF can be implemented in an outpatient encounter, but delays can occur 
when the rhythm have not been specifically or successfully documented. The 
diagnosis of AF requires electrocardiograph (ECG) documentation, which may be 
facilitated by review of emergency department records, Holter monitoring, or 
transtelephonic or telemetric recordings. If episodes are frequent, a 24-hour 
Holter monitor can be used. If episodes are infrequent, then an event recorder may 
be used I (not currently used in Australia). 
Transoesophageal echocardiography (TOE) places high-frequency 
ultrasound transducers in close proximity to the heart to provide high-quality 
images of cardiac structure and function. 24 ' 25 It is the most sensitive and specific 
technique to detect sources and potential mechanisms for cardiac embolism. 
1.9 Thromboembolism 
The rapid and irregular atrial activity causes a loss of atrial contraction, in which 
the atria only quiver, leading to stasis of blood in the atria. 3 This promotes clot 
formation and the occurrence of thromboemboli. 3 The left atrial appendage 
(LAA) is an elongated cul-de-sac lined with endothelium, a remnant of the 
embryonic atrium and a unique substrate for stroke. 26 The contractility of the 
appendage is reduced in AF, but the degree varies widely and is an important 
determinant of stasis and thrombus formation. Stasis is fundamental to the 
formation of LAA thrombi in AF. Formation of a thrombus in the LAA begins 
with Virchow's conditions of: stasis, endothelial dysfunction, and a 
hypercoagulable state. I The LAA is the origin of at least 90% of all left atrial 
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clots 27 and the resulting systemic emboli cause approximately 25% of all 
strokes. 27 
TOE provides a sensitive and specific method to detect thrombotic 
material (Figure 4). 1 Conventional management is based on the presumption that 
thrombus formation requires continuation of AF for approximately 48 hours, but 
thrombi have been identified by TOE within shorter intervals. 28 ' 29 Endothelial 
dysfunction has been difficult to demonstrate as a distinct mechanism 
contributing to thrombus formation, although systemic and atrial tissue levels of 
von Willebrand factor (a marker of endothelial dysfunction) are elevated in some 
patients. 1 AF has been associated with elevated levels of biochemical markers of 
coagulation and platelet activation (fibrinogen and fibrin D-dimer levels) that may 
reflect a systemic hypercoagulable state. 30 The levels of some of these markers 
fall to normal during anticoagulation therapy 31  and some markers increase 
immediately after conversion to sinus rhythm and then normalise. 32 
Thromboemboli tend to propagate, particularly to the brain (approximately 25% 
of blood from the heart supplies the brain) but also to other organs (including the 
kidneys, mesenteric circulation and the heart itself), potentially leading to 
infarction. 3 
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Figure 4 	Transesophageal echocardiographic image of a thrombus in the left 
atrial appendage in a patient with AF. 
Reproduced from ACC/AHA/ESC guidelines for the management  of patients with AF.' 
Recently, high plasma homocysteine has shown to be an independent risk 
33 factor for LA thrombus formation in patients with stroke caused  by AF. High 
homocysteine fulfills 2 criteria of Virchow's triad by  its endothelial toxic effect 
and prothrombotic properties. 33 In conditions associated with abnormal blood 
flow such as stasis, high levels of homocysteine enhance thrombus formation. 
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1.10 Stroke 
Stroke is defined by the World Health Organisation (WHO) as the clinical 
syndrome of rapid onset of focal (or global, as in subarachnoid haemorrhage) 
cerebral deficit, lasting more than 24 hours or leading to death, with no apparent 
cause other than a vascular one. 34 
The most feared complication of AF is stroke. AF is associated with a 
five-fold increase in the risk of stroke compared to age-matched controls. Most 
patients with atrial fibrillation never experience a stroke. 35 The stroke rate varies 
more than 20-fold, from 0.5% for young patients with lone AF 36 to 12% per year 
for patients with AF who have had a previous stroke. 37-39 Embolism even in 
patients with chronic, sustained AF can be intermittent, separated by days or 
years, suggesting that the formation of LAA thrombi occurs intermittently. 26 
Embolism of LAA thrombi accounts for most strokes in AF patients, particularly 
the larger, more disabling strokes. 26 About two-thirds of strokes in AF patients 
are due to atrial thrombi. This varies according to the distribution of additional 
risk factors and antithrombotic therapy. 26  
The diagnosis of stroke (versus no stroke) is made, reasonably accurately 
on clinical grounds alone, by specialists, but in general medical and emergency-
department settings up to 15% of patients with suspected stroke turn out to have 
another diagnosis. 40 Infarction cannot be reliably distinguished from 
haemorrhage without brain imaging. Whichever imaging method is used, the 
radiologist needs to know the time and date of stroke onset to interpret the images 
properly. Computed tomography (CT) is the most reliable method of 
demonstrating acute haemorrhage within the first week after stroke onset. Small 
haemorrhages progressively lose their characteristic white (hyperdense) 
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appearance and can easily be mistaken for infarcts, therefore, if patients delay 
seeking medical attention, perhaps because the stroke symptoms were mild, or if 
their doctors delay scanning, imaging might not be done until 2 weeks or longer 
after the stroke; an infarct could then be misdiagnosed on CT, and inappropriate 
management could follow. 41 ' 42 
CT may or may not show a definite infarct, but a normal scan does not 
necessarily mean that the patient have not had a stroke. CT is quick and can be 
done in almost all patients, however ill. Its value in excluding haemorrhages and 
tumours more than outweighs any deficiency in positively identifying infarcts. 
About 50% of infarcts never become visible on CT; the proportion is higher in 
patients with milder strokes (lacunar and small cortical or brainstem infarcts) and 
lower in patients with severe strokes (medium to large cortical or cerebellar 
infarcts). The proportion visible also depends on the timing of scanning. Within 
the first few hours, few infarcts can be seen, 43 but they become visible over the 
first 1-7 days as dark hypodense wedge-shaped areas (or round if lacunar), with 
mass effect. 
1.11 Risk factors for stroke 
The rate of stroke in patients with AF is related to the presence of concomitant 
cardiovascular disease. 36,44,45  There i 1 n e s a strong association between hypertension 
and stroke, probably mediated primarily by embolism originating in the LAA, 46 
due to reduced LAA flow velocity. 
noncardioembolic strokes in AF. 46 ' 49 Whether sustained control of hypertension 
lowers the risk for cardioembolic stroke remains unclear. In addition to 
47, 48 Hypertension also increases the risk of 
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hypertension, prior thromboembolism, CCF and diabetes have emerged as 
independent risk factors for stroke. 36 ' 37 ' 45 A list of predictive risk factors for 
stroke is displayed in Table 1. Table 2 displays relative risks of some risk factors 
for stroke in patients with AF compared to control patients without AF. 
Consistent independent predictors 
Advancing age 
Hypertension 
Prior stroke or transient ischaemic attack (TIA) 
Left ventricular dysfunction (clinical CCF or systolic dysfunction on 
echocardiography 
Possible independent predictors 
Diabetes mellitus 
Systolic blood pressure > 160 mm Hg 
Women over age 75 
Post menopausal hormone replacement therapy 
Regular alcohol use (>14 drinks/2weeks) (decreased risk) 
Coronary artery disease 
Postoperative status 
Mitral regurgitation (decreased risk) 
On TOE: appendage thrombi, spontaneous dense echocontrast, reduced 
appendage flow velocity 
Not independently predictive 
Left atrial diameter 
Intermittency (i.e., paroxysmal)  
Table 1 	Predictors of ischaemic stroke in AF 
Adapted from Hart and Halperin. 26 
Risk factors (control groups) 	 Relative risk 
Previous stroke 	 2.5 
History of hypertension 	 1.6 
CCF 	 1.4 
Advanced age (continuous, per decade) 	 1.4 
Diabetes mellitus 	 1.7 
Coronary artery disease 	 1.5 
Table 2 	Risk factors for ischaemic stroke and systemic embolism in AF. 
Adapted from Laupacis et al. 36 
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Nearly half of all strokes occur in patients over 75 years of age and AF is 
the most frequent cause of disabling stroke in elderly women. 10 The effect of 
advancing age in increasing stroke risk is multifactorial. In patients with AF, 
aging is associated with LA enlargement and reduced LAA flow velocity all of 
which predispose to LA thrombus formation. 17 47 Age is also a risk factor for 
atherosclerosis and is associated with stroke independently of AF. 50  In the Stroke 
Prevention in Atrial Fibrillation (SPAF) studies, age was a more potent risk factor 
when combined with other risk factors such as hypertension or female gender, 37 
placing women over the age of 75 years with AF at particular risk for 
cardioembolic strokes. 51 LV dysfunction, as indicated by a history of CCF or 
transthoracic echocardiographic measurements, predicts ischaemic stroke in AF 
44, 45 patients who receive no antithrombotic therapy. 	52 In the SPAF study, the 
annual rate of stroke was similar for patients with recurrent or permanent AF. 53 
1.12 Risk stratification criteria 
Estimating the risk of stroke for individual AF patients is a crucial factor in the 
decision to use antithrombotic therapy for individual patients with AF, 35 and 
accurate prediction of stroke risk has become an important clinical issue. A 
number of clinical schema have been proposed in the literature to categorise an 
individual risk of stroke, in view of making the choice of antithrombotic therapy 
easier. Displayed in Table 3 are five clinical schemes to stratify the risk of 
ischaemic stroke in AF patients based on analysis of prospectively monitored 
cohorts of participants and expert opinions. 54 ' 55 Each of the schema is predictive 
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of stroke, but the small differences between them can be sometimes very 
important for individual patient management. 
_ 
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Risk 
Study High 	 I Intermediate Low 
Atrial 	Fibrillation 
Investigators 56 
• High to intermediate risk: Age > 65 years. History of hypertension or diabetes • Age < 65 years. 
• No high risk features 
American 	College 	of 
Chest 	Physicians 
Consensus 57 
• Age > 75 years 
• History of hypertension, left 
ventricular dysfunction or > 1 
moderate risk factor 
• Age 65-75 years 
• Diabetes or coronary artery disease 
• Age < 65 years 
• No risk factors 
Stroke 	Prevention 	in 
Atrial Fibrillation study 58 
• Women aged > 75 years 
• Systolic blood pressure > 160 
mm Hg or left ventricular 
dysfunction 
• History of hypertension 
• No high risk features 
• No high risk features 
• No history of hypertension 
Lip (United Kingdom) 59 • Patients aged > 75 years and 
with diabetes or hypertension 
• Patients with clinical 
evidence of CCF, thyroid 
disease, and impaired left 
ventricular function on 
echocardiography 
• Patients aged < 65 years with clinical 
risk factors: diabetes, hypertension, 
peripheral arterial disease, ischaemic 
heart disease 
• Patients aged > 65 not in high risk group 
• Patients aged < 65 years 
with no risk factors 
Hankey (Australia) 60 • Age > 65 years and 
hypertension or diabetes 
• Previous TIA or stroke 
• Recent myocardial infarction 
• CCF or impaired left 
ventricular dysfunction on 
echocardiography 
• Thyroid disease or left atrial 
thrombus 
• Age <65 years and hypertension or 
diabetes 
• Age > 65 years and not in high risk 
group 
• Age < 65 years and no 
hypertension, diabetes, TIA, 
stroke or other clinical risk 
factors 
Table 3 	Published risk stratification schema prevention of stroke in AF. 
Usual maintenance dose (oral) 
for elderly 
62.5-12511g once daily (doses may be 
higher in some individuals) 
180-360mg once daily 
160-240mg daily 
Major side effects 
Digitalis toxicity, heart block, 
bradycardia 
Hypotension, heart block, heart 
failure 
Hypotension, heart block, heart 
failure, digoxin interactions, 
constipation 
Drug 
Digoxin 
Diltiazem 
Verapamil 
1.13 Treatment of AF 
1.13.1 Rate control 
The major issues in management of patients with AF are related to the arrhythmia 
itself and to the prevention of thromboembolism. In patients with persistent AF, 
there are 2 ways to manage the arrhythmia: to restore and maintain sinus rhythm 
or to allow AF to continue and ensure that the ventricular rate is controlled 
(Table 4). 1 The criteria for rate control vary with patient age. The rate is 
generally considered controlled when the ventricular rate ranges between 60 and 
80 beats per minute at rest and between 90 and 115 beats per minute during 
moderate exercise. 1 
P-Blockers 
Atenolol 
Metoprolol 
Carvedilol 
25-50mg once daily 
25-50mg once daily 
Titrated to heart failure response (may 
be particularly useful for patients with 
AF and CCF) 
Hypotension, heart block, 
bradycardia, asthma, heart failure, 
fatigue 
Amiodarone 	200-400mg three times daily for 1 week, 
then 200-400mg twice daily for I week, 
then maintenance dose of 200-400mg 
daily 
Pulmonary toxicity, skin 
discolouration, hypo- and 
hyperthyroidism, corneal deposits, 
optic neuropathy, warfarin 
interactions and proarrhythmia 
Table 4 	Oral agents commonly used for rate and rhythm control in AF 
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1.13.2 Rhythm control 
Reasons for restoration and maintenance of sinus rhythm in patients with AF 
include . relief of symptoms, prevention of embolism, and avoidance of 
cardiomyopathy. The decision to convert AF (as opposed to controlling the rate 
and allowing AF to continue) is commonly intended to alleviate all these 
problems. Conversion to and maintenance of sinus rhythm offers the theoretical 
advantages of reducing the risk of thromboembolism, but has been questioned 
recently. 61 
1.13.3 Rationale for cardioversion 
Cardioversion is often performed electively to restore sinus rhythm in patients 
with persistent AF. The need for cardioversion may be immediate when the 
arrhythmia is the main factor responsible for acute CCF, hypotension and angina. 
Cardioversion carries a risk of thromboembolism unless anticoagulation 
prophylaxis is given before the procedure, and this risk appears greatest when the 
arrhythmia has been present for more than 48 hours. 1 
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1.13.4 Pharmacological cardioversion 
Whether AF is paroxysmal or persistent, AF is a chronic disorder and recurrence 
is likely at some point in most patients. 62 , 63 Pharmacological cardioversion 
appears to be most effective when initiated within 7 days after the onset of AF 
(Table 4). I The reversion to sinus rhythm is much less effective in patients with 
persistent AF. 
1.13.5 Direct current cardioversion 
Direct current cardioversion involves delivery of an electrical shock synchronised 
with the intrinsic activity of the heart. Successful cardioversion of AF depends on 
the nature of the underlying heart disease and the intensity of the shock delivered 
to the atrial myocardium. The initial energy delivered may be as low as 50 joules 
(J) for conversion of atrial flutter, but higher energies are needed for AF 
conversion, starting with at least 200 J. The energy output is increased 
successively in increments of 100 J until a maximum of 400 J is reached. The 
success of cardioversion is related to: the size and composition of the electrode 
paddles, the contact medium between the electrodes and skin, the distance 
between the paddles, body size, phase of the respiratory cycle, number of shocks 
delivered and interval between shocks. 1 Rates of successful cardioversion vary 
from 70% to 90%, with diminishing success rates if the arrhythmia has been 
present for longer than one year. 64 Multivariate analysis has revealed short 
duration of AF and younger age as independent predictors of success. In contrast, 
LA enlargement, underlying heart disease and cardiomegaly predicted failure. 64 
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The rate of relapse after cardioversion is high unless concomitant antiarrhythmic 
drug treatment is given. 
1.13.6 Cardioversion to sinus rhythm and risk of thromboembolism 
A higher risk of stroke had been identified in patients undergoing cardioversion of 
AF, and this could be reduced with pre-treatment with anticoagulation for 3 to 4 
weeks before and after cardioversion. 65 Nowadays, it is common practice to 
administer oral anticoagulants to patients with AF of more than 48 hours duration 
when they are prepared for cardioversion. Cardioversion of AF to sinus rhythm 
results in transient mechanical dysfunction of the LA and LAA 66 known as "atrial 
stunning," which can occur after spontaneous, pharmacological 67 ' 68 or electrical 
conversion of AF. 68 Recovery of mechanical function may be delayed for several 
weeks, depending on the duration of AF before cardioversion. 69 ' 70 This could 
explain why some patients with no demonstrable LA thrombus on TOE before 
cardioversion subsequently experience thromboembolic events. 71 Presumably, a 
thrombus forms during the period of atrial stunning and is expelled after the 
return of mechanical function, which may explain the cluster of thromboembolic 
events that occur in the first 10 days after cardioversion. 72 
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Vitamin K quinol Vitamin K epoxide 
Warfarin 
Carboxylase 
N-terminal glutamyl residue 
of vitamin K dependent proteins 
y-carboxy-glutamyl residue 
Biological function 
 
CHAPTER TWO: ANTITHROMBOTICS 
2.1 Warfarin 
2.1.1 Mechanism of action 
Warfarin is the most widely used anticoagulant in the western world. It exerts its 
anticoagulant effect by interfering with the interconversion of vitamin K quinol 
and its 2,3 epoxide (vitamin K epoxide) (Figure 5). Vitamin K (phylloquinine) is 
a co-factor needed for the carboxylation of glutamate residues to 7- 
carboxyglutamates of vitamin K-dependent proteins. 73 These proteins, which 
include the coagulation factors II, VII, IX & X, require ycarboxylation by 
vitamin K for biological activity. By inhibiting the vitamin K conversion cycle, 
warfarin causes hepatic production of partially decarboxylated proteins with 
reduced coagulant activity, which in turn exerts an anticoagulant effect 
(Figure 6). 73 Vitamin K antagonists also inhibit the carboxylation of the 
regulatory anticoagulants protein C and protein S. 
Figure 5 	Mechanism of action of vitamin K antagonists. 
Reproduced from Blann et al. 74 
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Intrinsic pathway 	Extrinsic pathway 
Factors IX XI. XH Factor \./1 
Prothrombinase complex 
Factors V. X, calcium phospholipids 
Factor XiII 
Factor II 
Prothrombin 
Factor Ila 
Thrombin 
Factor XIIla 
Fibrinogen 	I 	  Soluble fibrin 
     
     
     
     
Insoluble fibrin 
Figure 6 	Description of the coagulation cascade. 
Reproduced from Blann et al. 74 
Anticoagulants have no direct effect on an established thrombus, nor do 
they reverse ischaemic tissue damage. However, once a thrombus has occurred, 
the aim of anticoagulant treatment is to prevent further extension of the existing 
clot, and to prevent secondary thromboembolic complications, which may result 
in serious and possibly fatal sequelae. 
2.1.2 Pharmacokinetics and pharmacodynamics 
Warfarin is a racemic mixture of 2 active isomers, the R and S forms, in roughly 
equal proportions. It is rapidly absorbed from the Gastro-Intestinal (GI) tract and 
73 has high bioavailability. Racemic warfarin has a half-life of 36 to 42 hours, is 
highly bound to albumin, and the two isomers are metabolised in the liver via 
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different pathways. 73 The S-enantiomer is approximately 5-times more potent as 
a vitamin K antagonist compared to the R-isomer. 
The relationship between the dose of warfarin and the response is 
influenced by genetic and environmental factors, including common mutations in 
the cytochrome P-450 enzyme responsible for oxidative metabolism of the 
warfarin S-isomer. 73 The cytochrome P450 (CYP450) isozymes involved in the 
metabolism of warfarin include 2C9, 2C19, 2C8, 2C18, 1A2 and 3A4. 75 The 
principal form of human liver P450 which modulates the anticoagulant activity of 
warfarin is 2C9. 75 Only the unbound drug in the plasma is metabolised, thus the 
high protein binding characteristics of warfarin dramatically affect the total body 
clearance. 
2.1.3 Monitoring anticoagulation intensity 
The Prothrombin Time (PT) is the most common test used to monitor 
anticoagulant therapy. The PT responds to reduction in 3 of the 4 vitamin K 
dependent procoagulant-clotting factors (II, VII and X), which are reduced by 
warfarin at a rate proportionate to their respective half-lives. Thromboplastins 
vary in responsiveness to the anticoagulant effects of warfarin according to their 
source, phospholipid content, and preparation. 73 An unresponsive thromboplastin 
produces less prolongation of the PT for a given reduction in vitamin K dependent 
factors than a responsive one. The responsiveness of a thromboplastin can be 
measured by assessing its International Sensitivity Index (ISI). PT monitoring of 
warfarin is very imprecise when expressed as a PT ratio (patients value: normal 
control value) because of the variation in thromboplastin responsiveness. These 
differences in responsiveness were responsible for excessive and erratic 
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anticoagulation in North America in the late 1980's and early 1990's, where less 
responsive thromboplastins were in widespread use. 
The recognition of the shortcomings in PT monitoring stimulated the 
development of the INR standard, and the adoption of this standard improved the 
monitoring, and hence the safety of anticoagulant therapy. 73 
The INR can be calculated as follows: 
INR= (patient PT/mean normal PT) Isl 
Or 	log INR= ISI (log observed PT ratio), 
Where ISI is the international sensitivity index of the thromboplastin used to 
measure the PT. 
Thromboplastins with recombinant tissue factor have been introduced 
with ISI values close to 1.0. The INR could be made more precise by using 
reagents with low ISI values, higher ISI values result in higher coefficients of 
variation. 73 
2.1.4 Patient specific requirements 
The optimal use of warfarin has been hampered by its greater than ten-fold inter-
patient variability in the doses required to attain therapeutic responses. 75 
Exaggerated responses to warfarin can occur in the elderly and reflects its reduced 
clearance with age and also impaired clotting factor synthesis. 73 Hepatic 
dysfunction can potentiate the response to warfarin through impaired synthesis of 
coagulation factors and elimination of warfarin. 73 Hypermetabolic states 
produced by fever or hyperthyroidism can increase the response to warfarin, 
probably due to increased catabolism of vitamin K dependent coagulation 
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factors. 73 Pharmacogenetic polymorphisms of CYP450 have been associated with 
impaired elimination of warfarin. 75 
2.1.5 Drug interactions 
The anticoagulant response to warfarin is influenced by pharmacokinetic factors; 
interacting drugs may influence the pharmacokinetics of warfarin by reducing GI 
absorption or disrupting metabolic clearance. Stereoselective interactions may 
affect metabolism of either the R- or S-isomer of warfarin, inhibition of 5-
warfarin metabolism is more important. 
Drugs such as aspirin, clopidogrel, dipyridamole, and non-steroidal anti-
inflammatory drugs (NSAIDs) increase the risk of warfarin associated bleeding 
by inhibiting platelet function. 73 Aspirin and NSAIDs can also produce gastric 
erosions that increase the risk of upper GI bleeding. The INR should be measured 
more regularly when any drug or herbal medicine is added or withdrawn from the 
regimen of a patient treated with warfarin. 73 Table 5 displays a list of important 
drug interactions with warfarin. 76 ' 77 
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Herbal medicines 
Aniseed Alfalfa 
Co-enzyme Q10 
Horse chestnut 
Chamomile 
Fenugreek  
Quassia Red clover 
Celery 
Dong quai 
Prickly ash 
Ginseng 	 
Herbal medicines 
St John's wort 
Medications  
Barbiturates 
Cholestyramine 
Carbamazepine 
Griseofulvin 
Phenytoin 
Quinine 
Rifampicin 
Propylthiouracil 
Raloxifene 
vitamin K (menadione, 
	phytomenadione) 
Azathioprine 
Carbimazole  
Mercaptopurine 
Quinidine 
Rifabutin 
Aspirin 
NSAIDs 
Clopidogrel Dipyridamole 
Increased bleeding risk because of effect on platelets 
Medications 
Herbal medicines 
Gingko biloba 
Willow bark  
Increased bleeding risk by effects on gastric mucosa 
Medications 
Feverfew 
Liquorice 
Garlic 
Increased effect from warfarin (elevated INR) 
Medications 
Amiodarone Anabolic steroids Carbimazole 
Celecoxib Cimetidine Ciprofloxacin 
Co-trimoxazole Dextropropoxyphene Disulfiram 
Erthromycin and other 
macrolides 
Fluconazole Flutamide 
Getnfibrozil Ketoconazole Itraconazole 
Metronidazole Miconazole Nilutamide 
Norfloxacin Omeprazole Phenytoin 
Paracetamol Propylthiouracil Quinine/Quinidine 
1 t 
Rofecoxib 	1 
1 
SSRIs (especially fluvoxamine 
or fluoxetine) 
Tamoxifen 
1 
Tetracyclines Thyroxine Tramadol 
Zafirlukast 
Decreased effect from warfarin (decreased INR) 
Aspirin 	 NSAIDs/C0X-2 	 SSRIs  
Table 5 	Clinically important drug-drug interactions with warfarin 
Adapted from Hirsh et al. 78 and Myers. 79 
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2.1.6 Food interactions 
Patients receiving warfarin therapy are sensitive to fluctuating levels of dietary 
vitamin K. Health care professionals should encourage adherence to the principle 
of consumption of a consistent intake of foods containing vitamin K, because 
dose requirements will be dependant on an individual's vitamin K intake. 
Increased intake of dietary vitamin K sufficient to reduce the anticoagulant 
response to warfarin occurs in patients consuming green vegetables or vitamin K 
containing supplements. 73 Reduced dietary vitamin K intake potentiates the effect 
of warfarin; most significantly in sick patients and malnourished patients. The 
current daily requirement for vitamin K is lgg/kg body weight. Vitamin K can 
overcome the disruption of the vitamin cycle associated with warfarin by 
generating the active hydroquinone cofactor through a warfarin insensitive 
pyridine nucleotide dependent pathway and also by displacing warfarin 
(competitive binding) from the binding sites. It has been demonstrated that as 
little as 0.5mg of vitamin K is effective in reversing anticoagulant warfarin 
therapy. 80  
The literature suggests that most adults consume intakes of vitamin K in 
the range of 60-200g 81 g/day, but vitamin K intakes of 600gg/day or more have 
been reported in some individuals. 81 Of all the fat-soluble vitamins, vitamin K 
has the highest individual daily variation in both dietary intake and corresponding 
plasma concentrations, 81 which increases the risk of complications through poor 
anticoagulant control. Although dark green vegetables are the highest contributors 
of vitamin K, they are not consistently consumed on a daily basis by a substantial 
proportion of the population. 
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The vitamin K concentrations of plant leaves are strongly correlated to 
their chlorophyll content, a general rule of thumb is that the greener the plant, the 
higher the vitamin K content. 81 Freezing, boiling, steaming, or microwaving 
vegetables does not significantly change the vitamin K content. 81 Fresh herbs are 
also rich sources of vitamin K, but their dietary contribution is not significant 
when consumed in small quantities. 
The other primary dietary sources of vitamin K are four plant oils: 
soybean, canola, cottonseed, and olive. Salad dressings, margarines, mayonnaise, 
cakes and pastries may be rich in vitamin K if prepared with any of these four 
oils. 81 In contrast, peanut, corn, safflower, and sesame oils have a very low 
vitamin K content. 81 
The vitamin K content of most other foods is very low. Root vegetables, 
such as potatoes, onions and squash, are poor sources of vitamin K. As a general 
rule, animal products are also poor dietary sources of vitamin K, including dairy 
products and liver. However, the addition of vitamin K-rich oils to meats and eggs 
will increase the dietary intakes of vitamin K. 81 Table 6 displays common foods 
that have a vitamin K content of lOgg or more per serve. 81 
Many clinical reports attribute a dietary vitamin K-warfarin interaction to 
diets designed for weight loss, which are often self prescribed after warfarin 
therapy has been initiated and stabilised. Warfarin antagonism, or 
underanticoagulation, has been reported when patients started on weight-loss diets 
that promoted green leafy vegetables. 81 
The recommended daily allowance of 11.tg/kg of vitamin K is based on 
coagulation factor function. Substantially higher recommended daily doses are 
being suggested as a result of findings that the requirement for vitamin K is 
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greater for the extra-hepatic vitamin K-dependent proteins, including those found 
in bone. 82 Thus, the approach of restricting vitamin K intake to improve stability 
of anticoagulant control is not appropriate to maintain optimal function of vitamin 
K-dependent proteins, and could lead to deficiencies of other nutrients such as 
carotenoids found in the same foods. 83 
Food Serving Size Mean vitamin K 
content per serve 
(Pig) 
Collards, fresh/frozen, boiled 1/2 Cup 	 374.0 
Spinach, fresh/frozen, boiled 1/2 Cup 324.0 
Brussel sprouts, fresh/frozen, boiled 1/2 Cup 	 225.0 
Coleslaw with dressing 1 Cup 119.0 
Broccoli, fresh/frozen, boiled V2 Cup 	 88.0 
Cabbage, fresh, boiled V2 Cup 73.0 
Asparagus, fresh/frozen, boiled 1/2 Cup 	 72.0 
Okra, fresh/frozen, boiled V2 Cup 32.0 
Iceberg lettuce, raw 1/6 Medium head 	28.0 
Tuna canned in oil, drained 100 grams 25.0 
1 
Green peas, fresh/frozen, boiled 1/2 Cup 	 19.0 
Celery, raw 1 Medium stalk 	17.0 
Mixed vegetables, frozen, boiled 1/2 Cup 	 15.0 
Sauerkraut, canned 1/2 Cup 15.0 
French salad dressing, regular 2 Tablespoons 	15.0 
Apple pie, fresh/frozen, commercial  1 Slice 14.0 
Carrot, fresh, boiled 1 Medium 12.0 
Cauliflower, fresh, boiled 1/2 Cup 	 12.0 
Grapes, red/green, seedless, raw V2 Cup 12.0 
Plums, raw 2 Medium 	 11.0 
Green beans, fresh/frozen, boiled 1/2 Cup 10.0 
Table 6 	Vitamin K content of commonly consumed foods having >10gg 
vitamin K per serve 
Adapted from Booth and Centurelli. 81 
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2.1.7 Indications for anticoagulation 
2.1.7.1 Treatment of venous thromboembolism 
Treatment regimens for Deep Vein Thrombosis (DVT) and PE are similar 
because the two conditions are commonly considered manifestations of the same 
disease process. The optimum duration of oral anticoagulant therapy is influenced 
by the competing risks of bleeding and recurrent venous thromboembolism 
(VTE). The risk of recurrent thromboembolism when anticoagulant therapy is 
discontinued depends on whether the thrombosis is unprovoked (idiopathic) or is 
secondary to a reversible cause; a longer course of therapy is warranted when 
thrombosis is idiopathic or associated with a continuing risk factor. 84-87 Table 7 
displays risk factors and conditions that may predispose to VTE. The reported risk 
of recurrence in patients with idiopathic proximal vein thrombosis has been 
reported to be between 10% and 27% when anticoagulants are discontinued after 
3 months. 84, 85, 87 Extending therapy beyond 6 months seems to reduce the risk of 
recurrence to 7% during the year after treatment is discontinued. 88 
Patients should generally be treated with anticoagulants for a minimum of 
3 months. Moderate-intensity anticoagulation (INR 2.0 to 3.0) has been shown to 
be as effective as a more intense regimen (INR 3.0 to 4.5) and is also associated 
with less bleeding. 89 Treatment should be longer in patients with proximal vein 
thrombosis than in those with distal thrombosis and in patients with recurrent 
thrombosis versus those with an isolated episode. Laboratory evidence of 
thrombophilia also may warrant a longer duration of anticoagulant therapy. 
Indefinite anticoagulant therapy should be considered in patients with >1 episode 
of idiopathic proximal vein thrombosis, thrombosis complicating malignancy, or 
idiopathic venous thrombosis and homozygous factor V Leiden genotype, the 
56 
antiphospholipid antibody syndrome, or deficiencies of antithrombin III, protein 
C, or protein S. 90-92 
• History of venous thromboembolism 
• Surgery, particularly lower limb orthopaedic operations, and major pelvic or abdominal 
operations 
• Trauma: For example, hip fractures and acute spinal injury 
• Prolonged immobility 
• Prolonged confinement to bed or lower limb paralysis 
• Cancer, especially metastatic adenocarcinomas 
• Major medical illnesses such as AMI, ischaemic stroke, CCF, acute respiratory failure 
• Oestrogen use in pharmacological doses: For example, oral contraception pills, hormone 
replacement therapy 
• Obesity 
• Inherited hypercoaguable states: Activated protein C resistance (factor V Leiden 
mutation), protein C deficiency, protein S deficiency, antithrombin deficiency, 
prothrombin gene mutation 
• Aquired hypercoagulable states: Lupus anticoagulant and antiphospholipid antibodies, 
hyperhomocysteinaemia, dysfibrinogenaemia, myeloproliferative disorders such as 
polycythaemia rubra vera 
• Age >40 years 
Table 7 	Risk factors and conditions predisposing to VTE 
Adapted from Turpie et al. 93 
It was recently found by Agnelli et al. 85 studying patients with idiopathic 
DVT, that the clinical benefit associated with extending the duration of 
anticoagulant therapy to one year, reduced the recurrence of DVT to 0.7% in the 
anticoagulant group compared with 8.3% in the discontinuation group. This, 
however, was not maintained after the therapy was discontinued in the 
anticoagulant group. When follow-up was continued to at least two years the rate 
of recurrent VTE was 15.7% and 15.8%, respectively. 
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2.1.7.2 Prevention of ischaemic coronary events 
Effectiveness of oral anticoagulants in the long-term management of patients with 
a history of AMI is supported by the results of a meta-analysis of data pooled 
from 7 randomised trials published between 1964 and 1980, which showed that 
oral anticoagulants reduced the combined end points of mortality and nonfatal 
reinfarction by Ski 20% during treatment periods of between 1 and 6 years. 94 From 
the results of clinical trials, the following conclusions can be drawn about long-
term treatment of patients with acute myocardial ischaemia: 73 
1. High-intensity oral anticoagulation (INR RI 3.0 to 4.0) is more effective than aspirin but is 
associated with more bleeding; 
2. The combination of aspirin and moderate-intensity warfarin (INR 2.0 to 3) is more 
effective than aspirin but is associated with a greater risk of bleeding; 
3. The combination of aspirin and moderate-intensity warfarin (INR 2.0 to 3.0) is as 
effective as high-intensity warfarin and is associated with a similar risk of bleeding; 
4. The contemporary trials have not addressed the effectiveness of moderate-intensity 
warfarin (111•1R 2.0 to 3.0), and in the absence of direct evidence, it cannot be assumed that 
moderate-intensity warfarin is any more effective than aspirin in preventing death or 
reinfarction; and 
5. There is no evidence that the combination of aspirin and low-intensity warfarin (INR < 
2.0) is more effective than aspirin alone, despite the fact that the combination produces 
more bleeding. 
Therefore, the choice for long-term management involves aspirin alone, 
aspirin plus moderate-intensity warfarin (INR 2.0 to 3.0), or high-intensity 
warfarin (INR 3.0 to 4.0). The latter 2 regimens are more effective than aspirin 
but are associated with more bleeding and are much less convenient to 
administer. 73 
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Old generation 
	
New generation 
       
Starr-Edwards Medtronic Hall 
and 
Bjork-Shiley 
St Jude Medical 
 
Sorin Bicarbon 
      
Single tilting disc I 	Second generation 	Third generation . bileaf let 	 bileaflet 
Caged ball 
Homograft Porcine 
Animal Human 
Stented or stentless 	Stented or stentless 
2.1.7.3 Prosthetic heart valves 
The type, number, location of the prosthetic valve and risk factors for systemic 
embolism need to be considered when deciding on the use of anticoagulation 
therapy (Figure 7 displays types of valves). Risk factors that increase the 
incidence of systemic embolism should be considered when deciding the need to 
start antithrombotic therapy. These include age, smoking, hypertension, diabetes, 
hyperlipidaemia, presence of AF, CCF or low cardiac output, size of the LA, 
previous thromboembolism and abnormalities of the coagulation system. 95 
Mechanical 
Biological 
Figure 7 	Types of heart valve prostheses. 
Reproduced from Goldsmith et al. 95 
Mechanical valves are more thrombogenic than bioprosthetic valves 
(Table 8 for thrombogenicity) and patients with mechanical valves require 
lifelong anticoagulant treatment. Patients with porcine or pericardial 
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bioprostheses may be started on lifelong antiplatelet treatment with low dose 
aspirin as soon as possible after surgery. The risk of embolism is greater with a 
valve in the mitral position (mechanical or biological) compared with a valve in 
the aortic position. With either type of prosthesis or valve location, the risk of 
emboli is probably higher in the first few days and months after valve insertion, 
before the valve is fully endothelialised. Because of an increased risk of 
thromboemboli in the first 3 months after implantation of a biological prosthetic 
valve, anticoagulation with warfarin is usually recommended. 95 
Type of valve 	 Model 	 Thrombogenicity 
Mechanical 
Caged ball 	 Starr-Edwards 	 ++++ 
Single tilting Bjork-Shiley, Medtronic Hall 	 +++ 
disc 
Bileaflet 	 St Jude Medical, Sorin Bicarbon, Carbomedics 	 ++ 
Bioprosthetic 
Heterografts 	Carpentier-Edwards, Tissue Med (Aspire), Hancock II 	+ to ++ 
Homografts 
Table 8 	Types of prosthetic valves and thrombogenicity 
Reproduced from Goldsmith et al. 95 
2.1.8 Warfarin dosing protocols 
The dosing of warfarin can be separated into initial and maintenance phases. An 
anticoagulant effect is seen within 2 to 7 days after initiating warfarin, according 
to the dose administered. When a rapid effect is required, heparin [unfractionated 
or low-molecular weight heparin, (LMWH)] should be given concomitantly with 
warfarin until the INR > 2.0 for at least two days. Starting doses of approximately 
5mg daily usually results in an INR > 2.0 after 4 or 5 days. It has been suggested 
that starting doses of less than 5mg should be used in the elderly 96 and in those at 
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increased risk of bleeding. Roberts et al. have proposed a new age-adjusted 
protocol (described in Table 9) and this is endorsed by the Australian Medicines 
Handbook (AMH). 97 The INR is usually checked daily or second daily until the 
therapeutic range has been reached and sustained for two consecutive days, then 2 
or 3 times weekly for 1 to 2 weeks then less often, according to the stability of the 
results. Once the INR has become stable, the interval of monitoring can be 
extended to as long as four weeks. It has been suggested that estimated 
maintenance doses or lower doses than are traditionally used for initiation are 
followed 73 ' 98 however, this results in a longer time to therapeutic INR and has 
significant impacts on hospital length of stay and associated healthcare costs. 
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2.8-3.1 3 
Dose (mg) according to age (years) 
<50 	51-65 	66-80 	I >80 
Day 	INR 
<1.5 	10-15 	9-14 
1.6 8 
1.7-1.8 	7 
1.9 
2.0-2.6 
2.7-3.0 	4 
3.1-3.5 	' 3.5 
3.6-4.0 	3 
4.1-4.5 	
Omit next dose, then 
1 1-2 
<1.7 
>1.6 
2.4-2.7 
3.2-3.5 	1.5 
3.6-4.0 	0.5 
>4 	1,0 
<1.4 
1.8-2.3 	5 
0.5 
10 
10 
0.5-1.5 
4.5 
2.5 
3 
4.5 	4 
0.5 	1 0.5 
3.5 
0.5 	I 0.5 
9 7.5 
2.5 	2 
9 	7.5 
9 7.5 
3.5 3 
1.5 	Ii 
0.5-1.5 	0.5-1 
7.5-11 
>4.5 	I Nil. Hold dose 
4.5 
2.5 
6 
6  
0.5  
6  
3  
2  
1  
1  
0.5  
0  
6-9 
5 
4 
3.5 
3 
2.5 
2 
1.5 
Table 9 	Age adjusted warfarin initiation protocol. 
Adapted from Roberts et al. 99 
If dose adjustments are required, frequent monitoring is needed. Recently, 
two other nomograms have also been proposed in the literature. These comprise 
loading doses of 5mg 100 (Table 10) and recently Kovacs and associates 101 (Table 
11) have proposed a 10mg loading nomogram. The latter nomogram uses 10mg 
loading doses on days 1 and 2 of initiation and the doses are adjusted according to 
response on day 3. The generalisability of these protocols has been questioned, 102 
therefore, these initiation schedules are generally only appropriate for patients in 
whom a rapid rise in 1NR is needed such as outpatient treatment of VTE. 
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Day INR Warfarin dose (mg) 
1 5 
5 
3 <1.5 10 
1.5-1.9 5 
2.0-3.0 2.5 
>3.0 0 
4 <1.5 10 
1.5-1.9 7.5 
2.0-3.0 5 
>3.0 0 
5 <2.0 10 
2.0-3.0 5 
>3.0 0 
6 <1.5 12.5 
1.5-1.9 10 
2.0-3.0 7.5 
>3.0 0 
Table 10 	5-mg warfarin initiation nomogram 
too Adapted from Crowther et al. 
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Day 3 INR Warfarin dose on 
days 3 & 4 (mg) 
Day 5 INR Warfarin dose on 
days 5, 6 & 7 (mg) 
<2.0 15, 15, 15 
<1.3 15, 15 2.0-3.0 7.5, 5, 7.5 
1.3-1.4 10, 10 3.1-3.5 0, 5,5 
>3.5 0, 0, 2.5 
<2.0 7.5, 7.5, 7.5 
1.5-1.6 10, 5 2.0-3.0 5, 5, 5 
1.7-1.9 5, 5 3.1-3.5 2.5, 2.5, 2.5 
>3.5 0, 2.5, 2.5 
<2.0 5, 5, 5 
2.0-2.2 2.5, 2.5 2.0-3.0 2.5, 5, 2.5 
2.3-3.0 0, 2.5 3.1-3.5 0, 2.5, 0 
>3.5 0, 0, 2.5 
<2.0 2.5, 2.5, 2.5 
>3.0 0, 0 2.0-3.0 2.5, 0, 2.5 
3.1-4.0 0, 2.5, 0 
>4.0 0, 0, 2.5 
Table 11 	10-mg warfarin initiation nomogram. tot Adapted from Kovacs et al. 
2.1.9 Contraindications to anticoagulation 
In the absence of clear evidence or consensus statements about what disorders 
should be included as contraindications to anticoagulants, most research groups 
have adapted the exclusion criteria used in the SPAF trial. 58 These criteria 
included: GI or genitourinary bleeding in the previous 6 months, determined from 
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the medical records; a history of three or more falls in the previous year assessed 
at interview, or recurrent or injurious falls in the medical record of the previous 
year; an inability to comply with anticoagulants, judged by the family physician; 
excessive alcohol intake, reported on the questionnaire to be more than 28 
standard units during the previous week in men and 21 units in women; blood 
pressure of more than 180/100 mm Hg (uncontrolled hypertension); and daily use 
of NSAIDs. 
In a population based survey of a large cohort of patients who were 
aged > 65 years in northern England, standard contraindications to long-term oral 
anticoagulants were present in 43% of patients and irreversible contraindications 
were present in 26% of patients. 103 Uncontrolled hypertension and use of 
NSAIDs were taken as reversible, if hypertension was adequately treated or 
NSAlDs replaced with alternative therapy, which would allow the patient to take 
anticoagulants. 
The Australian prescription products guide 104 lists contraindications to warfarin 
as: 
• History of falls or tendency to fall, 
• Dementia or unsupervised psychosis, 
• Chronic alcoholism or tendency to abuse alcohol, 
• Chronic liver disease, 
• Uncontrolled hypertension, 
• Blood dyscrasias (platelet count <100*10 91L) or documentation of any coagulation 
defects (congenital or induced), 
• Bleeding tendencies that increased the risk of bleeding such as peptic ulcer, diverticular 
disease, genitourinary tract disease, sub-acute bacterial endocarditis, pericardial effusion 
or cerebral haemorrhage, 
• Compliance, 
• History of problems with warfarin in the past (e.g. poor control of INR, allergy) and 
• A comorbid condition with a poor prognosis such as malignancy. 
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2.1.10 Warfarin-related bleeding complications 
2.1.10.1 	Bleeding risk of warfarin therapy 
The main complication of oral anticoagulant therapy is bleeding. These 
complications are generally classified as major if they are intracranial or 
retroperitoneal, if it leads directly to death or if it results in hospitalisation or 
transfusion. 105 Most bleeding problems are clinically minor, although patients are 
unlikely to view such bleeds in these terms. The problems include nosebleeds 
(epistaxis), bruising, and excessive bleeding after minor injury such as shaving. 
Patients should be made aware of these common problems and be reassured that 
these events are expected in patients receiving warfarin treatment. 106 
Overall, the rates of warfarin-related bleeding in the studies shown in 
Table 12 have been low and the rates vary according to reason for treatment. In 
108 two meta-analyses 107, 	of 12 trials of warfarin for stroke prevention, warfarin 
increased the odds of major bleeding; but the absolute risk increase was only 
0.3%/yr. 108 Although intracranial bleeding was more frequent in patients treated 
with warfarin in these trials (0.3%/yr vs 0.1%/yr in patients not treated with 
warfarin or aspirin), the absolute difference was small and overwhelmed by the 
substantial reduction in the frequency of stroke. 
One study 58  (SPAF II) raised concern that the risk for warfarin-related 
bleeding, especially intracranial haemorrhage (ICH), may be increased 
substantially in patients > 75 years old. The rate of major bleeding while 
receiving warfarin was 2.3%/yr, compared with 1.1%/yr for patients receiving 
aspirin, 325mg per day. However, the rate of major warfarin-related bleeding was 
4.2%/yr in patients > 75 years old, compared with 1.7%/yr in younger patients; 
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the rates for intracranial bleeding were 1.8%/yr and 0.6%/yr, respectively. The 
reason why these rates are substantially higher than those observed in the other 
clinical trials of warfarin in patients with AF is likely to be related to the intensity 
of anticoagulant therapy: virtually all ICH in SPAF H, as in the other clinical 
trials, were associated with an INR > 3.0. 58 In contrast, in the SPAF III trial 
(targeted INR 2.0 to 3.0), the mean age was 71 years and the rate of ICH was 
0.5%/yr. 38  
Source Treatment Patients. No. 
Bleedingf 
Targeted 
INII Major Fatal 
Petersen et aro Warfarin 335 1 1(0.3) 2.8-4.2 
Asn (75 mg) 336 1 0 
Placebo 336 I o 
SPAF•• Warfarin 201 1.7/yr 1 2.03.5 
ASA (325 mg) 192 0.9/yr 1 
Placebo 195 1.2/yr I 
B oston65 Warfarin 212 8(3.8) 1(0.5) 13-2.7 
No treatment 208 8(3.8) 1(0.5) 
Connolly et al73 Warfarin 187 5(2.7) 2(1.1) 2.0-3.0 
Placebo 191 1(0.5) 0 
SPAF IP fA'arfarin S 75 yr 358 1.7/yr I 2.0-4.5 
ASA s 75 yr 357 MYT I 
Warfarin > 75 yr 197 4.2/yr§ 1 
ASA > 75 yr 188 1.6/yr / 
European" Warfarin 225 13(5.8) 3(1.3) 2.5-4.0 
Placebo 230 3(1.3) 1(0.4) 
ASA (300 nig) 404 6(1.5) 2(0.5) 
EzekovAtz et art Warfarin 260 6(2.3) 0 1.4-2.8 
Placebo 265 4(1.5) 1(0.4) 
SPAF 11174 Warfarin plus ASA (325 mg) 521 13 (2.4/yr) 3 (0.6/yr) 1.2-1.5 
Warfarin 523 12 (2. Ur) 2 (0.4/yr) 2.0-3.0 
Morocutti Cl are Warfarin 454 6(1.3) 1(0.2) 2.0-3.5 
Indobufen 462 1(0.2) o _ 
Guilov et ar Warfarin 170 1.1/yr 0.3/yr 2.0-3.0 
Warfarin (1.25 mg) 167 0.8/yr o - 
Warfarin plus aspirin (1.25 mg and 300 trig) 171 0.3/yr o - 
Aspirin (300 mg) 169 1.4/yr 0.3/yr - 
Pengo et al's Warfarin 153 2.6/yr 1 2.0-3.0 
Warfarin (1.25 mg) 150 1.0/yr t - 
Ilellemons et ar, Phenprocoumon/acenocoumarol 131 0.5/yr I 2.5-3.5 
Phenprocoumon/acenocoumarol 122 "Yr 1 1.1-1.6 
Aspirin (150 mg) 141 1.4/yr I - 
•Boston  = The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators; European = The European Atrial Fibrillation Trial Study 
Group. 
f Data presented as No. (%), %/yr. or No. (%/yr). 
t Not reported in publications. 
§p <0.04. 
Table 12 	Bleeding risk from anticoagulant trials in patients with AF. 
Reproduced from Levine et al. 1°5 
In recent meta-analyses of bleeding during oral anticoagulant therapy by 
Linkins, Choi and Douketis, the risk of bleeding in the first three months of 
therapy (2.06%) was nearly the same as that in the remaining time to one year 
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(2.74%). Table 13 displays major bleeding rates in a number of different studies 
• analysed by Linkins, Choi and Douketis. 
Table 1. Major Weeding Events in Patients Receiving Oral Anticoagulant Therapy* 
Study. Year 	 Study 	Patients 
(9eference) TYP4 Readying Oral 
Antbcoaguturts 
Duration of 
follovnup 
Major 
abrading 
Episodes 
Casa 
fatality 
Rate 
MAU&1t141 
Medina 
Episodes 
Um to 
Folloor•up 
a IT n (S) le n n (S) 
	
" 	--- franderri et at. 1992 (53) 	RCI 	i70 . 
_____ 
8-(5) - - 13- 
0 
1 
9 	 i 
0 
tcpaciuk et at. 1992 (49) RCT 146 3 0 0 0 0 	I 
gran(fleS et at. 1992 (37) RCT 	320 
Mull et at., 1992(37) 	 OCT 432— 
6 5 (4) 
- 	17(4) 	 
0 0 
18 o 2 	 1 
0  
. 
0 Phi et at, 1994 (56) 
Levine at at. 1995 (48) ocr 	301 _ 3 1 (3) 100 
0 
25 
1 
21 (5) 	--1 0 	, 
Sandman M at, 1995 (a) 	RCT 454 6 5 (1) 2 
2 linanarker et al.. 1996 (59) Cohort 	434 3 4(0.9) 
400 3 5 (1) 40 1 , 4 (1) _ 
Das, 1996 (39) 	 RCT 	55 , 	, 3 0 0 , 0 , 3 (5) 	i 
8ounamearnt et at. 1997 (36) 	— 	RCT 47 3 0 0 0 0 
Columbus Investigatca. 1997 (34) 	RCT 	1021 3 29 (3) 
11 (5) 
18(3) 
7 
18 
17 
NA 0 	i 
Scbtarran et at. 1997 (7) 	 RCT 227 
Sinsoneeau et al., 1997 (54) PCI 	612 
6 a 48 
3 
1 
Morava et M. 1998 (60) CA)110,d 244 . 3 or6 . 	.. 2(0.83 	, 0 0 Wells et aL, 1998 (61) 	 194 , 	, 3 4 (2) 0 
29 
0 . 0 	al 
Charbonnier et al., 1998 (38) 	PCI 651 3 17 (3) 1 1(0.2) 
_ 	,._...., 	-.....,, 	 111 -3 (3), _. 
7(3) 29 
o 
---0= (awe( et al,. 1998 1471 	 kr-- 	-223 -' 
Lopaclub et at. 1999 (50) RCT 	95 3 ...  
24 
6 
-100.0 4., 19.?..?„(49„----.RC.T.-„--._  
U')  
3 (4) 
0 
0 
0  
0 
 	0 	, 
-0 
0 	,:_1 
b 	-1 
Maw et at., 1999 (83 	 la 	79 
Kvonberg et at, MO (42) RCT 538 2ö (4) 15 
_Bottalon 03_al.._2000 (35) 	_ . _ 	RCT 	201 
-20-031-41) 	 -kr --- 	 200  
6 - 4 (2) - — 
0 1 (3) 
Rembrandt Investigators. 2X0 (55) 	. 	RCT 	119 3 3 (3) 0 NA 0 
Agnelli at at, 2001 (9) 	 RCT 	134 12 4 (3) 0 	 _4 _ 
0 
..„ 
0 
",..] 
38 
Mali ot al, 2001 (51) i ó 1 15 (2) 
finede et al. 2031 (52) PCI 	631 .— - 3 0,6 
3 
15 (2)
7-(0.6) 
276 
- 
0 
1  _-_ ., 
0 
24 
28reddlnet at, 2001 (56) 	PCI 1137 
Total 	 10 757 
• NA = nor available; Rer = randocnittd, controlkd trial. 
Table 13 	Bleeding events in patients receiving oral anticoagulant therapy. 
Reproduced from Linkins, Choi and Douketis. 109 
2.1.10.2 	Relationship to the INR 
The safety and efficacy of warfarin depends on maintaining the INR within the 
therapeutic range as displayed in Figure 8. Analysis of primary prevention trials 
for stroke prevention in AF, found that a large number of thromboembolic and 
bleeding events occurred when the INR was outside of the therapeutic range. 110 
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1.0 	2.0 	3.0 	4.0 	5.0 	6.0 	7.0 	8.0 
International Normalized Ratio 
Figure 8 	Adjusted odds ratios for ischaemic stroke and intracranial bleeding 
in relation to intensity of anticoagulation in randomised trials of antithrombotic 
therapy for patients with AF. 
Reproduced from Hylek et al. 
Analysis of other cohort studies have shown a sharp increase in the risk of 
bleeding when the INR is higher than the upper limit of the therapeutic 
112-114 range 	and the risk of thromboembolism is increased when the INR falls 
below 2.0. 38 ' 111 A recent study showed an excess mortality from all causes with 
increased INR as shown in Figure 9. 115 
In randomised clinical trials for DVT and mechanical heart valves, the 
frequency of major bleeding in patients randomly assigned to less intense 
warfarin therapy (INR approximately 2.0 to 3.0) has been less than half the 
frequency in patients randomly assigned to more intense warfarin therapy 
(targeted INR > 3.0). 105 The intensity of anticoagulant effect is probably the most 
important risk factor for ICH, independent of the indication for therapy, with the 
risk increasing dramatically with an INR > 4.0. 110  
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Figure 9 	Risk of death associated with different levels of anticoagulation. 
Reproduced from Oden et al. 115 
The incidence of major bleeding from five randomised trials for AF was 
1.3% for warfarin (INR 2.0 to 3.0), compared to 1.0% with placebo. 36 Increased 
variation in the INR is associated with an increased frequency of haemorrhage 
independent of the mean INR. 116, 117 This effect is probably attributable to 
increased frequency and degree of marked elevations in the INR. 
The cumulative risk of bleeding is directly related to the length of 
anticoagulant therapy. A number of studies have reported that the risk of bleeding 
associated with warfarin is highest early in the course of therapy. 105, 116, 118-120 in  
one of these studies, for example, the frequency of major bleeding decreased from 
3.0% during the first month of outpatient warfarin therapy to  0.8% per month 
during the rest of the first year of therapy and to 0.3% per month thereafter. 121  
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2.1.10.3 	Risk factors and predictors of bleeding 
Contributing factors to the risk of bleeding are the underlying clinical 
, disorders 89' 122-125 and concomitant use of aspirin, NSAIDs or other drugs that 
impair platelet function, produce gastric erosions or impair synthesis of vitamin K 
dependent clotting factors. A validated bleeding index showed that the risk of 
major bleeding is also related to age > 65 years, a history of stroke or GI bleeding, 
and comorbid conditions such as renal insufficiency or anaemia. 89, 122  
Importantly, these risk factors were considered additive; patients with 2 or 3 risk 
factors had a much higher incidence of warfarin associated bleeding than those 
with none or one. The cumulative incidence of major bleeding at 48 months was 
53% in high-risk patients (three or four risk factors), 12% in middle-risk patients 
(one or two risk factors), and 3% in low-risk patients (no risk factors). 
Kuijer et al. 126 recently developed another prediction model based on age, 
gender, and the presence of malignancy. In patients classified at high, middle, and 
low risk, the frequency of major bleeding was 7%, 4%, and 1%, respectively after 
3 months of therapy. 127  The elderly are more prone to bleeding even after 
110 controlling for anticoagulation intensity. 	Bleeding that occurs at an INR of 
< 3.0 is frequently associated with trauma or an underlying lesion in the GI or 
urinary tract. 89 
In at least eight separate clinical studies, possession of the CYP2C9*2 or 
CYP2C9*3 variant alleles, which result in decreased enzyme activity, has been 
associated with a significant decrease in a mean warfarin dose requirement. 128  
Aithal et al. 129 in a case-control study showed a significant relationship with 
variant alleles of the CYP2C9 enzyme and low warfarin dose requirement 
compared to patients higher dose requirements. Furthermore patients in the low- 
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dose requirement group were more likely to have difficulties at the time of 
induction of warfarin therapy and to have an increased risk of major bleeding 
complications. A recent review of the relationship between CYP2C9 and warfarin 
dose stated, "relationships between CYP2C9 genotype, enzyme activity, 
metabolism of probe substrates, dosage requirements and bleeding complications 
should be interpreted with caution, and further studies are required". 75 
2.1.10.4 	Managing elevated INR or warfarin associated bleeding 
A number of approaches can be undertaken to lower an elevated 1NR. The first 
step is to stop or withhold warfarin; the next step can be to acIminister vitamin K 
and the third and most effective way is to infuse fresh frozen plasma (FFP) or 
prothrombin concentrate, which is highly expensive. After warfarin is withheld, 
the INR falls over several days (an INR between 2.0 and 3.0 falls to the normal 
range 4 to 5 days after warfarin is stopped). 130 The INR declines substantially 
within 24 hours after treatment with vitamin K. 131 
Even when the INR is elevated, the absolute daily risk of bleeding is low. This 
leads many physicians to manage patients with INR levels as high as 5 to 10 by 
withholding warfarin, unless the patient is at very high risk of bleeding or 
bleeding has already developed. Oral vitamin K is the treatment of choice unless 
very rapid reversal of anticoagulation is critical, when vitamin K can be 
administered by slow intravenous (IV) infusion (5 to 10 mg over 30 minutes). The 
anticoagulant reversal effect is mediated by vitamin K through another quinone 
reductase, 73 which is operative at high tissue concentrations of vitamin K, and is 
not inhibited by warfarin. In 2001, the American College of Chest Physicians 132 
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published the following recommendations for managing patients on coumarin 
anticoagulants who need their 1NRs lowered because of either actual or potential 
bleeding. 
• When the INR is above the therapeutic range but < 5, and the patient has not developed 
clinically significant bleeding, and rapid reversal is not required for surgical intervention, 
the dose of warfarin can be reduced or the next dose omitted and resumed (at a lower 
dose) when the 1NR approaches the desired range. 
• If the 1NR is between 5 and 9 and the patient is not bleeding and has no risk factors that 
predispose to bleeding, the next 1 or 2 doses of warfarin can be omitted and warfarin 
reinstated at a lower dose when the INR falls into the therapeutic range. Alternatively, the 
next dose of warfarin may be omitted and vitamin K (1 to 2.5 mg) given orally. This 
approach should be used if the patient is at increased risk of bleeding. 
• When more rapid reversal is required to allow urgent surgery or dental extraction, vitamin 
K can be given orally in a dose of 2 to 5 mg, anticipating reduction of the INR within 24 
hours. An additional dose of 1 or 2 mg vitamin K can be given if the INR remains high 
after 24 hours. 
• If the 1NR is > 9 but clinically significant bleeding has not occurred, vitamin K, 3 to 5 
mg, should be given orally, anticipating that the INR will fall within 24 to 48 hours. The 
INR should be monitored closely and vitamin K repeated as necessary. 
• When rapid reversal of anticoagulation is required because of serious bleeding or major 
warfarin overdose (e.g., INR > 20), vitamin K should be given by slow IV infusion in a 
dose of 10 mg, supplemented with transfusion of fresh plasma or prothrombin complex 
concentrate, according to the urgency of the situation. It may be necessary to give 
additional doses of vitamin K every 12 hours. 
• In cases of life-threatening bleeding or serious warfarin overdose, prothrombin complex 
concentrate replacement therapy is indicated, supplemented with 10 mg of vitamin K by 
slow IV infusion; this can be repeated, according to the INR. If warfarin is to be resumed 
after administration of high doses of vitamin K, then heparin can be given until the effects 
of vitamin K have been reversed and the patient again becomes responsive to warfarin. 
73 
2.1.10.5 	Pen operative management of anticoagulation 
The management of patients treated with warfarin when there are events that 
require the interruption of anticoagulation can be troublesome. Most patients can 
undergo dental procedures, arthrocentesis, cataract surgery, and diagnostic 
endoscopy without alteration of their regimen. 133  For other invasive and surgical 
procedures, oral anticoagulation needs to be withheld, and the decision whether to 
pursue an aggressive strategy of perioperative administration of IV heparin or 
subcutaneous LMWH should be individualised as suggested in Table 14. 
Indication for 	 Examples 	 Recommendation 
anticoagulation 
Indication with low annual 	AF without history of 	Withhold oral anticoagulation 
risk of thromboembolic stroke 	thromboembolic stroke 
(<4%) without anticoagulation 
Indication with moderate 
annual risk of thromboembolic 
stroke (4%-7%) without 
anticoagulation 
Mechanical aortic valve Withhold oral anticoagulation. 
Optional administration of 
either treatment dose of IV 
heparin or SC LMWH whilst 
INR is sub-therapeutic 
Indication with high annual 	Mechanical mitral valve; AF 	Withhold oral anticoagulation 
risk of thromboembolic stroke 	with history of 	and administer either treatment 
(>7%) without anticoagulation 	thromboembolic stroke 	dose of IV heparin or 
treatment dose of SC LMWH 
whilst INR is sub-therapeutic 
Table 14 	Guidelines for the perioperative management of anticoagulation 
Adapted from Dunn et al. 133 
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2.2 Antiplatelets 
2.2.1 Aspirin 
Aspirin (or acetylsalicylic acid) irreversibly inhibits cyclooxygenase-1 (COX-1) 
(Figure 10) in platelets and megakaryocytes and thereby blocks the formation of 
thromboxane A2 (TXA2), which is a potent vasoconstrictor and platelet 
aggregant. 134  Because platelets are unable to regenerate COX, the immediate 
antithombotic effect of aspirin remains for the lifespan of the platelet (8-10 days). 
After stopping aspirin therapy, normal haemostasis may be regained when about 
20% of platelets have normal COX activity; therefore daily aspirin intake is 
recommended. 
Aspirin is readily absorbed from the GI tract, with peak concentrations 
achieved in 30-40 minutes. When given as a single oral dose, at least 160mg of 
soluble aspirin is required to maximally inhibit platelet function within 30 
minutes. 135 Soluble and enteric-coated aspirin have a cumulative effect, so that 
platelet TXA2 formation is maximally inhibited after 4-5 days. 135 The evidence 
from randomised controlled trials supports daily doses of aspirin in the range 75— 
150 mg for the long-term prevention of serious vascular events in high-risk 
patients. 136 Higher doses of 500-1500 mg aspirin daily are no more effective than 
lower doses. 136 
Aspirin use is associated with dose-related symptoms of upper-GI toxicity 
(nausea, heartburn, epigastric pain). High doses of aspirin (500-1500 mg daily), 
compared with medium (75-325 mg daily) or low (30 mg) doses, significantly 
increase the risk of upper-GI symptoms 135 Enteric-coated aspirin may cause less 
gastric irritation than soluble aspirin. 135 
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Figure 10 	Pivotal roles of platelets in thrombosis and the sites of action of 
currently approved antiplatelet drugs. 
Adhesion of platelets to proteins (collagen, von Willebrand factor), particularly under conditions 
of high shear stress, and the action of platelet agonists (adrenaline, thrombin, ADP, thromboxane 
A2) leads to the mobilisation of calcium ion (Ca++), which functions as a mediator of platelet 
activation. Aspirin inhibits thromboxane A2 synthesis by irreversibly acetylating cyclooxygenase-
1; the thienopyridines (clopidogrel, ticlopidine) irreversibly block the ADP receptor; and 
glycoprotein IIb/IIIa inhibitors block the final common pathway of platelet activation leading to 
fibrinogen cross-linking of platelets and platelet aggregation. Phosphodiesterase inhibitors 
(dipyridamole, cilostazol) elevate intracellular cyclic AMP levels and thereby inhibit platelet 
function. Abbreviations: ADP=adenosine diphosphate; ASA=aspirin; cAMP=cyclic adenosine 
monophosphate; GP=glycoprotein; PGG2=prostaglandin G2; PAR=Protease activated receptor; 
PGH2=pro staglandin H2; PGI2=prostacycl in; PI=phosphodiesterase inhibitor; 
TXA2=thromboxane A2; vWF=von Willebrand factor. 
Reproduced from Hankey and Eikelboom. 135 
Aspirin is associated with about a 60%-70% relative increase in risk of 
non-fatal extracranial haemorrhage (mostly from the GI tract), which corresponds 
to an absolute excess risk of about one to two per 1000 patients treated per year. 
136, 137 Aspirin is associated with an increased risk of ICH of about one per 1000 
patients treated for 3 years. 138 
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2.2.2 ADP-receptor antagonists 
The thienopyridine derivatives (clopidogrel and ticlopidine) are metabolised in 
the liver to active compounds, which covalently bind to the adenosine phosphate 
(ADP) receptor on platelets and dramatically reduce platelet activation 
(Figure 10). Repeated daily oral doses of 75 mg clopidogrel are required to 
achieve a steady-state maximal platelet inhibition, which is comparable with that 
produced by 250mg ticlopidine orally, twice daily. 60 Compared with aspirin, the 
thienopyridines are associated with a lower risk of GI haemorrhage and upper-GI 
symptoms and an increased risk of diarrhoea and skin rash. Clopidogrel has 
replaced ticlopidine because the latter is associated with an excess of neutropaenia 
compared with aspirin particularly in the early months of therapy, whereas 
clopidogrel is not. 139  Furthermore, ticlopidine is associated with significant 
excess of thrombocytopaenia and of thrombotic thrombocytopaenic purpura. 135 If 
ticlopidine is to be used, haematological monitoring should be undertaken at 
commencement and every 2 weeks in the first 4 months of therapy. 135 
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2.3 Antithrombotics for stroke prevention 
2.3.1 Clinical trials of antithrombotic therapies 
Before 1990, antithrombotic therapy for prevention of ischaemic stroke in AF was 
mainly limited to those patients with rheumatic (valvular) heart disease and or 
prosthetic heart valves. 10 Anticoagulation was also only accepted therapy for 
patients who had s‘ustained an ischaemic stroke, and was only advocated for other 
groups of patients such as those with CCF and concomitant AF. Five large 
randomised trials published between 1989 and 1992 evaluated oral 
anticoagulation, and 2 tested aspirin for primary prevention of thromboembolism 
143 in NVAF. 140- A sixth trial focused on secondary prevention among patients 
who had survived nondisabling stroke or TIA. 39 
Table 15 displays all antithrombotic treatment trials for stroke prevention 
in AF. 38, 39, 58, 140-150 All of the listed trials excluded patients considered at high 
risk of bleeding. Recommendations from the AHA/ACC/ESC are that: 
"Antithrombotic therapy (oral anticoagulation or aspirin) should 
be offered to all patients with AF to prevent thromboembolism". I 
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Trials Reference 
Year 
Published 
No. of 
Patients Intaventions 
Large Published Trials 
Copenhagen Atrial Fibrillation, Aspirin, Anticoaguhtion I 468 1989 1,007 OA, ASA, placebo 
(A FASAK 1) 
Copenhagen Atrial Fibrillation, Aspirin, Anticoagulation II 
(AFASAIC II) 
487 1998 677 OA, ASA, 0/V+ASA, 
OA' 
Stroke Prevention in Atrial Fibrillation I (SPAF I) 32 1991 1,330 OA, ASA, placebo 
Stroke Prevention in Atrial Fibrillation II (SPAF III 4:*: 1994 1,100 OA, ASA 
Stroke Prevention in Atrial Fibrillation III (SPAF III) 438 1996 1,044 0A, 0A•+ASA 
Boston Arcs Anticoagulation Trial for Atrial Fibrillation 456 1990 420 OA, control 
(BAATAF) 
Canadian Atrial Fibrillation Anticoagulation (CAFA) 489 1991 378 OA, placebo 
Stroke Prevention in Nombetunatic Atrial Fibrillation 469 1992 571 OA, placebo 
(SP1NAF) 
European Atrial Fibrillation Trial (EMT) 439 1993 1,007 OA, ASA, placebo 
Studio Italian° Fibrillazione Atriale (SIM) 490 1997 916 OA, indobufin 
Minidosc Warfarin in Nontheumatic Atrial Fibrillation 491 1998 303 OA, OA' 
Prevention of Arterial Thromboembolism in Atrial 461 1999 729 OA, OA', ASA 
Fibrillation (PATAF) 
Small or pilot trials 
Flambe% et al. 492 1993 75 LMW heparin, control 
Low-dose Aspirin. Stroke, Atrial Fibrillation (LASAF) 493 1996 285 ASA, placebo 
Subgroups with AF in other trials 
European Stroke Prevention Study II (ESPS II) 494 1997 429 ASA, dipyridamole, placebo 
Ongoing or unpublished AF trials 
French Aspirin Couniarin Collaborative Study OA, 0A+ASA 
Swedish Atrial Fibrillation Trial ... 
Stroke Prevention using an Oral Thrombin Inhibitor in 0A, thrombin inhibitor 
Atrial Fibrillation (SPORTIF) 
AV indirates atrial fibrilLation; 0A. oral anticoagulation: OA'. low-dose oral anticoagulation: AS/i. aspirin: 1..%1W. low-molecular-weight. 
Adapted with permission from Hart et al. (460) Ann intern Med 1999;I3l:492-501. (The American College of Physicians-American Society of Internal 'Medicine is not 
responsibk for the accuracy of the transkuion.) 
Table 15 	Randomised trials of antithrombotic therapy in patients with AF. 
Adapted from ACC/AHA/ESC guidelines for the management of patients with AF 
2.3.2 Warfarin 
Five trials with relatively similar study designs have addressed anticoagulant 
therapy for primary prevention of ischaemic stroke in patients with NVAF. The 
SPAF study, the Boston Area Anticoagulation Trial for Atrial Fibrillation 
(BAATAF), 141  and the Stroke Prevention In Nonvalvular Atrial Fibrillation 
(SPINAF) 143 trial were carried out in the United States; the Atrial Fibrillation, 
Aspirin, Anticoagulation study (AFASAK) 142 was carried out in Denmark; and 
the Canadian Atrial Fibrillation Anticoagulation (CAFA) study 145 was stopped 
before completion because of convincing results in 3 of the other trials. 36 
Meta-analyses 151  according to intention to treat principle showed that 
adjusted dose oral anticoagulation is highly efficacious for prevention of stroke, 
with a risk reduction of 62% (95% CI 48% to 72%) vs placebo as displayed in 
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for both disabling and non-disabling strokes. Excluding patients not  
Figure 11. The reduction was similar for both primary and secondary prevention  
undergoing oral anticoagulation at the time of stroke, the efficacy exceeded 80%,  
36% (95% CI 14% to 52%) as shown in Figure 12.  
shown that the stroke risk reduction offered by warfarin compared to aspirin is  
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Figure 12 	Antithrombotic therapy for stroke prevention in AF: Warfarin 
compared with aspirin. 
Reproduced from Lip et al. 154 
Oral anticoagulation may be most beneficial for AF patients at high 
thromboembolic risk, offering only modest reduction over aspirin in both the 
relative and absolute rates of stroke for AF patients at low risk. Recent 
recommendations from the AI-IA/ACC/ESC suggest the following: 
"Anticoagulation adjusted to achieve an INR of 2.0 to 3.0 in 
patients at high risk of stroke unless contraindicated, and the 
selection of antithrombotic therapy should be irrespective of the 
type of AF". I 
2.3.3 Optimal intensity of anticoagulation 
The target intensity of anticoagulation involves a balance between prevention of 
ischaemic stroke and avoidance of haemorrhagic complications. Targeting the 
lowest intensity of anticoagulation to minimise the risk of bleeding is particularly 
important for elderly AF patients. Maximum protection against stroke in AF is 
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11 Ill, 	3 , probably achieved with an INR range of 2.0 to 3.0, 38 	whereas an INR 
range of 1.6 to 2.5 appears to be associated with incomplete efficacy, estimated at 
approximately 80% of that achieved with higher-intensity anticoagulation. 111 
Two randomised trials with a target INR of 1.4 to 2.8 (estimated mean 
INR achieved 2.0 to 2.1) found the largest relative risk reduction (RRR) for 
ischaemic stroke. For primary prevention in most AF patients under 75 years of 
age and for secondary prevention, an INR of 2.5 (target range 2.0 to 3.0) is 
recommended. 1 A target LNR of 2.0 (target range 1.6 to 2.5) is reasonable for 
primary prevention in those patients aged over 75 years. 1 In clinical trials, INRs 
achieved were more often below than above the target range. 
2.3.4 Secondary prevention 
The reduction in relative risk with warfarin applies equally to primary and 
secondary prevention but, as history of stroke confers an increased annual stroke 
risk (12% versus 4.5%), the absolute risk reduction (ARR) is greater for 
secondary prevention. The number of patients with AF needing treatment with 
warfarin to prevent one stroke is therefore about three times greater in primary 
prevention than in secondary prevention. 60 
It is now known that the early risks of subsequent strokes are high, in fact 
10% of patients with TIA presenting to an emergency department in the USA had 
a stroke within 90 days (even with standard treatment). 155 Clearly, patients must 
be investigated and treatment started as quickly as possible for greatest effect. 
Patients with TIA or very mild ischaemic strokes can start oral anticoagulants 
within a day or so, but in patients with larger infarcts anticoagulation should 
probably be delayed a week or two. 
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2.3.5 Aspirin 
The threshold risk of stroke that warrants anticoagulation undergoes intense 
discussion; those patients whose stroke risk is less than about 2% per year when 
taking aspirin do not benefit substantially from alternative treatment with oral 
anticoagulation. 1,57,154 
Figure 13 	Antithrombotic therapy for stroke prevention in AF: Aspirin 
compared with placebo. 
Reproduced from Lip et al. 154 
Aspirin offers only modest protection against stroke for patients with AF 
compared with warfarin and against placebo as shown in Figure 12 & Figure 13, 
respectively. Meta-analyses of 5 randomised trials showed a stroke reduction of 
19% (95% CI 2% to 34%). 151 The effect of aspirin on stroke in these trials was 
151 less consistent than oral anticoagulation. 56, 	Aspirin reduced stroke occurrence 
by 33% in primary prevention studies (average stroke rate with placebo was 5% 
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per year) versus 11% for secondary prevention trials (average stroke rate with 
placebo was 14% per year). 151 
Aspirin may be more beneficial for reduction of noncardioembolic strokes 
compared with cardioembolic strokes in AF. 46 Cardioembolic strokes are, on 
average, more disabling than noncardioembolic strokes. 49 Therefore, because of a 
greater risk of cardioembolic strokes in AF, less protection is afforded by 
aspirin. 49 Recent guidelines from the ACC/AHA/ESC suggest the following 
"Aspirin as an alternative in low-risk patients or in those with 
certain contra-indications to oral anticoagulation" I 
2.3.6 Combination therapy 
The SPAF III study compared anticoagulation with a target 1NR of 2.0 to 3.0 vs 
anticoagulation targeted at an INR of 1.2 to 1.5 plus aspirin at 325 mg per day. 38 
This trial enrolled patients at high risk for ischaemic stroke. The results were 
dramatic and led to stopping the study early. Those in the low-intensity 
anticoagulation plus aspirin group experienced a yearly rate of thromboembolism 
of 7.9% vs 1.9% in the INR 2.0 to 3.0 group, for a RRR of 74%—essentially the 
same as full anticoagulation vs nothing. An INR of 1.2 to 1.5 provided no 
protective effect. The SPAF III study also added evidence that aspirin has little 
efficacy in AF patients at high risk for stroke. 
The combination of low-dose oral anticoagulation (INR less than 1.5) with 
aspirin adds little protection against stroke compared with aspirin alone in patients 
with AR 38 Combining aspirin with an oral anticoagulant at higher 
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anticoagulation intensities may increase the risk of ICH, particularly in elderly 
patients. 156 Recent guidelines from the ACC/AHA/ESC conclude the following 
"A low dose of aspirin or clopidogrel may be given concurrently 
with anticoagulation, in patients who have coronary artery 
disease. These strategies have not been fully evaluated and may 
have an increased risk of bleeding". I 
2.3.7 Other antiplatelet agents 
A single trial compared adjusted-dose warfarin and indobufen, an antiplatelet 
agent, in patients with AF who had had recent TIA or ischaemic stroke. Fewer 
strokes occurred among persons who received warfarin than among those who 
received indobufen (18 compared with 23, respectively). 146  
The addition of dipyridamole to aspirin for patients at high-risk of 
vascular events (such as those with previous AMI) has not been shown to produce 
significant additional reductions in serious vascular events. 136 However, one 
large trial in patients with TIA and ischaemic stroke showed substantial 
reductions in recurrent stroke, but not in AMI or vascular death. 135 Reasons for 
part or all of the favourable effect on stroke in that study include the possibility 
that the newer (and more bioavailable) formulation of dipyridamole was more 
effective than the older preparation used in earlier trials, that dipyridamole 
reduced stroke by lowering blood pressure rather than an antiplatelet effect, that 
the comparative dose of aspirin (25 mg twice daily) was insufficient (i.e., a 
placebo), and random error (chance). The combination of dipyridamole and 
aspirin is being tested further in the European and Australian Stroke Prevention In 
Reversible Ischaemia Trial (ESPRIT). 
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The combination of clopidogrel and aspirin results in additive benefits 
against vascular events, with only a modest increase in bleeding, and as stated by 
Connolly "a trial of combined antiplatelet therapy in AF is warranted". 157 This 
has lead to the ACTIVE study of 6500 patients which aims to compare 
clopidogrel plus aspirin against warfarin for stroke prevention in AF 
2.3.8 Thrombin inhibitors 
Ximelagatran is a prodrug of melagatran, an active site-directed thrombin 
inhibitor. Ximelagatran is well absorbed from the GI tract and undergoes rapid 
biotransformation to melagatran via 2 intermediate metabolites, H338/57 and 
H415/04. 158 ' 159 Ximelagatran has a plasma half-life of 3 to 4 hours and is 
administered twice daily. The drug produces a predictable anticoagulant response 
after oral administration, and no coagulation monitoring seems to be necessary. 
However, melagatran, the active agent, is eliminated via the kidneys, and dose 
0 adjustments may be needed in the elderly 16 and in patients with renal 
insufficiency. One of the side effects of ximelagatran is elevation of liver 
transaminases, which occurs in approximately 6% of patients. 160 Typically, 
changes in liver enzymes were asymptomatic and reversible, even if the 
medication was continued. 
The Stroke Prevention Using Oral Thrombin Inhibitor in Atrial 
Fibrillation (SPORTIF) program has been investigating the safety and efficacy of 
ximelagatran for the prevention of stroke in patients with AF. Promising data 
from phase II (SPORTEF II) studies that compared ximelagatran with warfarin in 
patients with NVAF 161 prompted 2 phase III trials. In a randomised, open-label, 
parallel-group study of approximately 3400 patients (SPORTIF III), fixed-dose 
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twice-daily ximelagatran was at least as effective at warfarin targeted to an INR of 
2.0 to 3.0 in preventing stroke and systemic thromboembolism. Although the 
combined incidence of major and minor bleeding was significantly lower in those 
receiving ximelagatran than in those receiving warfarin, there was no statistically 
significant difference between the 2 groups with respect to major bleeding or ICH. 
SPORTM V enrolled a total of 3922 patients who had NVAF as well as at 
least one more risk factor; age 75 years or older, prior stroke or systemic 
embolism, CCF, hypertension or a combination of advanced age and diabetes or 
coronary artery disease. There were 37 and 51 strokes or systemic embolic events 
in the warfarin and ximelagatran groups, respectively. This equated to rates of 
systemic embolic events of 1.2% and 1.6% per year, respectively. 
2.3.9 Other agents 
Elevated homocysteine has been shown to be a risk factor for thrombus 
33 formation, 	and sub-optimal levels of folic acid are associated with high 
homocysteine levels. It has been shown that homocysteine levels can be reduced 
by about 25% using a dose of folic acid between 0.5mg and 5mg/day, even in 
patients who are not vitamin deficient. 
should be added to aspirin therapy for patients who have contraindications to 
anticoagulants 
Other agents are being tested for stroke prevention in AF. Idrapinaux is a 
novel factor-Xa-specific pentasaccharide that is given once a week by 
subcutaneous injection. Idrapinaux is being compared with warfarin in the 
AMADEUS study of 5700 patients. 
162 It remains to be seen whether folic acid 
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2.3.10 Rate control versus rhythm control 
Apart from the use of antithrombotic drug therapy to reduce the risk of stroke, 163 
there are two main options in managing recurrent or persistent AF: 164 
• Rhythm control, in which treatment is directed toward restoring and 
maintaining sinus rhythm; and 
• Rate control, in which AF is allowed to continue or recur unimpeded, and 
medications are given to control ventricular rate. 
It had widely been accepted and the natural assumption was that rate 
control (control of the ventricular rate) was inferior to rhythm control (reversion 
to sinus rhythm). Theoretically, the advantages of maintaining sinus rhythm 
should include fewer thromboembolic complications, reduced need for 
anticoagulation and less cardiac failure. 
However, antiarrhythmic medications have only modest efficacy for 
preventing AF recurrences, both symptomatic and asymptomatic, so rate-
controlling and anticoagulant drugs must also be used in many patients being 
treated primarily for rhythm control. Also, antiarrhythmic medications can have 
serious adverse reactions, including life-threatening proarrhythmia and in the case 
of the commonly used drug, amiodarone, pulmonary fibrosis, thyroid dysfunction 
and hepatic toxicity. 165 
Recently published results from one large 61 and two smaller randomised 
166, 167 	 168 trials, 	in addition to a previously published study, 	have shed light on the 
two treatment strategies. The primary finding in all of the trials was that rate 
control was not inferior to rhythm control, and that there was some trend towards 
superiority of rate control. 
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The Atrial Fibrillation Follow-up Investigation of Rhythm Management 
(AFFIRM) trial found that 5-year mortality was 21.3% for rate control versus 
23.8% for rhythm control (p = 0.08). 61 Seventy-one percent of patients had 
hypertension and 38% had coronary artery disease. The patient populations that 
were studied were minimally symptomatic and had a mean age of 69 ± 9 years, 
and the findings indicate the benefits of rhythm-control do not, in general, 
outweigh the risks. 164 Amiodarone was used in 38% of patients being treated for 
rhythm control initially and in 63% at some time in the trial. Sotalol was used in 
31% initially, and by 41% at some time during the trial. 
In the RAte Control versus Electrical cardioversion for persistent AF 
(RACE) study, 167  the primary composite endpoint of cardiovascular mortality, 
heart failure, thromboembolic complications, bleeding, pacemaker implantation 
and severe adverse drug reactions occurred in 17.2% assigned to rate control 
versus 22.6% in the rhythm control arm, which also failed narrowly to reach 
statistical significance. 
The proportion of patients who remained on anticoagulants was 70% in 
the AFFIRM study and above 86% in the RACE study; doctors were allowed to 
cease warfarin if sinus rhythm had been present for longer than one month. 
However, despite this high rate of anticoagulant treatment, rhythm control failed 
to reduce the rates of stroke or bleeding complications compared to rate control. 
Of the 80 ischaemic strokes incurred in the AFFIRM trial's rhythm-control arm, 
55% occurred after discontinuation of warfarin. A further 21% occurred during 
warfarin treatment while patients' 1NR readings were sub-therapeutic (< 2.0). 
Interestingly, only 31% had AF at the time of their stroke. This finding may be 
related to episodes of undetected asymptomatic AF, which may keep patients at 
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continued risk of stroke. A recent study has shown that asymptomatic AF escaped 
documentation by ECG recordings in 59% of patients and freedom from AF for 
longer than three months does not preclude subsequent long-lasting AF 
recurrences. 169 
In the AFFIRM study, patients in the rhythm control group were 
significantly more likely to be hospitalised and have adverse medication effects 
than those in the rate control group, which has important cost implications to the 
health care system. 61 The Pharmacological Intervention in Atrial Fibrillation 
(PIAF) study showed that relief of symptoms and quality of life measures were 
similar between rate control and rhythm control groups, but that hospital 
admissions were more prevalent in the latter. 168 
In sub-group analyses of the AFFIRM trial, rate control had lower risk of 
death for patients older than 64 years, those without pre-existing CCF, and those 
with coronary artery disease. A trend in favour of rate control in patients with 
hypertension in the AFFIRM trial is supported by superiority (primary endpoint 
17.3 % v 30.8% for rhythm control) in the corresponding subgroup analysis of the 
RACE study. 
Women had a statistically significant excess of primary end points in the 
RACE study. Women are prone to more serious side effects associated with 
antiarrhythmic drugs, since they are at greater risk for excessive drug induced 
prolongation of the QT interval and torsade de pointes. 170 Female gender, 
independent of concomitant risk factors may also be a risk factor for stroke 
among older patients with AF. 37 
None of the presumed benefits of rhythm control were confirmed in the 
trials. This implies that rate control should be considered a primary approach to 
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treatment and that rhythm control, if used, should be abandoned early if it is not 
fully satisfactory. These findings also suggest that it may be unsafe to stop 
anticoagulation for AF patients treated with a rhythm-control strategy, unless 
there are no other risk factors for stroke. The populations studied in these trials 
were representative of the majority of elderly patients with AF. Patients who are 
elderly (65 years or older) have the highest incidence of AF and this population is 
increasing in number. 
The American College of Physicians has recently endorsed these 
recommendations for patients with newly detected AF. 171 
"Rate control with chronic anticoagulation is the recommended strategy 
for the majority of patients with AF. Rhythm control has not been shown 
to be superior to rate control (with chronic anticoagulation) in reducing 
morbidity and mortality, and may be inferior in some patient subgroups 
to rate control." 
Therefore, rate control is safe and should not be considered inferior to 
rhythm control for minimally symptomatic patients in whom AF is considered 
likely to recur after cardioversion. 
2.3.11 Patient preferences and perceptions 
The framing of risks, both numerically and linguistically, and the value 
individuals place on the various gains and losses perceived, have an effect on the 
choices that they make. This has considerable ethical implications for information 
providers if manipulation of individuals and populations is to be avoided. 172 
Good quality information and graphics are needed to explain risks associated with 
medical conditions and options—for patients in consultation with their doctors, 
but increasingly also for members of the public attempting to take responsibility 
for their own health. 172 
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All patients taking warfarin need to understand its risks and the 
requirements for regular monitoring and accurate dosing. They need to be 
engaged in the initial decision and in the ongoing process of taking 
anticoagulants. Many patients view serious strokes as worse than death and would 
tolerate GI haemorrhages to avoid a stroke. 173 Even after an initial decision is 
made to take warfarin, there are barriers to smooth anticoagulation. Some patients 
tire of repeated blood tests, attention to new medications and dietary changes, or 
minor bleeding and bruising. More substantial bleeding may occur leading to 
medical visits, diagnostic evaluations, or hospitalisations. These barriers take their 
toll, with a small proportion of patients ceasing anticoagulant therapy each year. 
Patients presented with visual aids depicting the risks and benefits of 
warfarin therapy elected to take warfarin at a lower level of stroke risk than their 
physicians preferred to prescribe it. 174 This finding is very important because if 
patients are more actively involved in the decision making process for stroke 
prevention it may result in a higher proportion of patients treated with 
anticoagulants. However, patients need to be educated regarding the implications 
of AF as a medical condition. In a cohort of patients treated with warfarin for 
stroke prophylaxis in AF, the majority (61%) of patients' felt that AF was 'not 
serious', whereas 33% felt it was 'severe' and 6% felt it was a 'very severe' 
condition. 175 
Although there appears to be incomplete application of trial evidence in 
real-world practice, the extent of the gap is uncertain since the decision to initiate 
anticoagulation depends heavily on individual patient preferences and some 
patients may well decline proven efficacious therapies. 175 ' 176 In fact, AF is one 
condition in which active patient involvement in treatment decisions may 
92 
substantially impact management, and there is mounting evidence that shared 
decision making (i.e., patients and clinicians collaborating in devising 
management plans) for chronic conditions such as AF improves health 
outcomes. 177 
Despite the desire of many patients to play a more active role in the 
management of their health, not to mention the evidence that knowledgeable and 
actively involved patients fare better, patients frequently report difficulties in 
obtaining information about their condition and its treatment from their health 
professionals. 178 For example, in an observational study of more than 1000 
patient-physician encounters, patients were told the benefits and risks of 
prescribed therapies less than one-sixth of the time, and only 2% of the 
encounters included a check that the patient had understood whatever information 
was offered. 179 Further, there may be concerns about the quality of some 
information that clinicians do offer. 180 Decision aids have been shown to improve 
patient knowledge and comfort with their therapies for a variety of conditions, 
including AF, as well as stimulate their participation in decision making without 
increasing anxiety. 181 
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PART TWO: IMPROVING ANTITHROMBOTIC USE 
IN AF 
CHAPTER THREE: INTRODUCTION 
UNDER-UTILISATION OF ANTITHROMBOTICS FOR AF 
3.1 Burden and cost of stroke in Australia 
Stroke is one of the leading causes of death and disability throughout the world. It 
is the third commonest cause of death in developed countries, exceeded only by 
coronary artery disease and cancer. 182 About 50% of all ischaemic strokes and 
TIAs are probably due to atherothrombotic disease of the extracranial or less 
commonly large intracranial arteries, about 20% arise from emboli from the heart, 
and about 25% are called lacunar infarcts, probably due to occlusion of one of the 
small, deep, perforating cerebral arteries; and the remainder are due to much rarer 
causes (e.g., vasculitis, arterial dissection, Figure 14) 
Stroke caused 3% of the world's disability burden in 1990, and by 2020, 
stroke mortality will have doubled, mainly as a result of an increase in the 
proportion of older people and the future effects of current smoking patterns in 
less developed countries. However, stroke attracts far less research funding than 
heart disease or cancer. 183 About 30% of patients die within a year of a stroke, 
and of stroke survivors, nearly half are left dependent. 
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Figure 14 	Classification of stroke by mechanism, with estimates of the 
frequency of various categories of abnormalities. 
Reproduced from Lip et al. 182 
In Australia the incidence of first in a lifetime ischaemic stroke was 
estimated to be 22 246 184 in 1997 and the total costs was estimated at over $A150 
million dollars for these events. 185 The total number of strokes first-ever and 
recurrent in Australia is estimated at about 40,000 per annum.  184, 186 The 
incidence and costs of strokes indicates that the impact of stroke on the healthcare 
system is enormous. Any program that aims to reduce the incidence of stroke 
from any cause has the potential to save the healthcare system a huge amount of 
money in the short and long-term. 185 
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3.2 Applying clinical trial results in practice 
There have been concerns that the dramatic results from the stroke prevention 
trials published in the early 1990s might not translate directly to typical clinical 
practice. Patients enrolled in the trials were highly selected (e.g., <10% of those 
screened in the SPAF study were enrolled), 140 few very elderly patients 
participated, and the high quality of anticoagulation management in the trials 
might not be duplicated in clinical settings. 103 
A number of clinical practice observational studies have indeed found that 
the risk reduction for stroke in AF afforded by anticoagulants is similar to that 
189 reported in clinical trials. 187- 	In a large cohort of patients in clinical practice 
with AF without contraindications to anticoagulation (11,526 patients) warfarin 
reduced the risk of ischaemic stroke and peripheral embolism by 51% compared 
with no warfarin therapy. 189  Anticoagulation was associated with nearly a 
doubling in the relative rate of ICH, but the additional absolute risk of ICH on 
anticoagulation was low. 189 As concluded by Go et al. 189 "results of randomised 
trials of anticoagulation translate well into clinical care for patients with AF'. 
3.3 Under-utilisation of antithrombotics in AF 
An early review of studies that assessed under-utilisation of antithrombotics in 
AF, documented that of those patients with AF whom have no contraindications 
to warfarin, only 15% to 44% are prescribed warfarin. 174 More recent data is 
displayed in Table 16 confirming the under-use of antithrombotics in AF 
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Reported Rates of Warfarin Use in Patients Without Contraindications* 
Retain= 
No. of 
Patlentsf 
Patient 
Population Setting 
Warfarin 
Prescribed, No. (%) 
of Patients 
Albers et al," 1997 171 (60) AF and stroke, mean age of 75 y 6 University hospitals in United States 22 (19.8) 
Antani et a1, 13 1996 98 AF, mean age of 76 y 2 Hospitals and 5 general practices in United 36 (36.7)t 
States 
Bath et a1, 14 1993 95 (20) AF, aged 32-100 y Hospital in England 22 (29.3) 
Beyth et a1, 1 '1996 189 NVAF United States hospital (n = 104) and office-
based visits (n = 85) 
124g§ 
Brass et al," 1997 488 (184) AF, aged ..?..65 y: 54% were aged Medicare patients in United States 117 (38.4) 
65-74y 
Gottlieb and 238 (40) AF, mean age of 69 y HMO patients in hospitals in United States 156 (78.8) 
Salem-Schatz," 1994 
Gurwitz et al,'I 1997 413 AF, 66% aged L-85 y Long-term care facility in United States 130 (31.5) 
Hendry et al,'' 1994 131 (52) NVAF, aged 53-95 y Geriatric and medical units in Scotland 12 (15.2) 
Lip et al," 1997 111 AF, aged 50-105y 2 General practices in England 27 (22.3) 
lip et a1,2 ' 1994 170 (49) AF, aged 38-95 y General hospital in Scotland 40 (36.0) 
Munschauer et al," 1997 651 (42) Chronic AF 2 Community and 2 tertiary referral hospitals 
in United States 
232 (38.1) 
O'Connell and Gray," 1996 91 (22) AF, mean age of 71 y General practice in England 14 (24.1) 
Stafford and Singer,24 1996 3.1 x106 Visits AF, mean age of 70y Office-based physician visits in United States (32.0)§ 
Sudlow et al," 1998 207 AF, aged 	65y 26 General practices in England 44 (23)11 
COIN Investigators," 1998 3575 AF, aged l9-104y 12 Canadian hospitals 852 (23.8) 
Whittle et al," 1997 172 AF, mean age of 80 y Medicare beneficiaries at 5 hospitals in 76 (44.1) 
United States 
*COIN indicates Clinical Quality Improvement Network; AF, atrial fibrillation; NVAF, nonvaNular AF; and HMO, health maintenance organization. 
tNumber in parentheses indicates number of patients with contraindications to warfarin. 
$1ndicates those in whom therapy with warfarin Ms deemed appropriate by a physician panel. 
§Enct number of patients not available. 
IlOata are given as presented in Sudlow et al. 6 
Table 16 	Studies showing under-utilisation of antithrombotics in AF 
Reproduced from ACC/AHA/ESC guidelines for the management of patients with AF. 
The largest clinical practice database of AF and subsequent antithrombotic 
use is a cohort of ambulatory patients with AF from the Kaiser Permanente 
Medical Care Program in northern California (the An-Ticoagulation and Risk 
Factors in Atrial Fibrillation [ATRIA] study cohort). Go and colleagues 19° found 
that 55% of patients without contraindications received warfarin. In a smaller 
study, Gottlieb and Salem-Schatz 191 found that nearly 79% of eligible patients in 
the Harvard Community Health Plan were prescribed long-term warfarin therapy, 
although this institution was a participant in the large clinical trials, which may 
explain the high usage of warfarin in this cohort. 
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A recently published study by Fang et al., 192 examining trends in 
antithrombotic use from 1991-1992 to 1999-2000, found oral anticoagulant use 
increased from 28% to 41%, (P = .01 for trend), with the greatest increase in 
patients aged 80 years and older from 14% to 48%, (P<.001 for trend). Despite 
this, only 46.5% of patients at high risk for stroke were taking anticoagulants in 
1999-2000. As stated by Fang et al. 192 "Although oral anticoagulant use 
increased, it remains concerning that many patients at high stroke risk are not 
anticoagulated. As new evidence becomes available on the optimal management 
of AF, continued monitoring of trends in clinical practice is crucial to help 
identify areas for quality assessment and practice improvement". 
3.4 Local data indicating under-utilisation of antithrombotics for 
AF 
A retrospective review of the medical records for consecutive patients who had 
AF documented on ECG at the major teaching hospital in Tasmania between 1 
January 1997 and 30 June 1999 was performed. Most patients were older than 75 
years and had at least one condition associated with an increased risk of stroke, 
risk stratification resulted in most patients (79%) with previously diagnosed 
chronic or PAF being grouped into the high-risk category. Analysis of the use of 
antithrombotic drugs in these patients indicated that a large proportion was not 
taking appropriate therapy. Only 34% of the patients in the high-risk group were 
taking warfarin (or warfarin plus aspirin) on admission, with 24% taking no 
antithrombotic at all, as displayed in Table 17. 193 
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Groups 
On admission to hospital care 
Antithrombotics (% of patients) 
Warfarin Aspirin Both None 
High risk (n = 359) 25.1 42.3 8.9 23.7 
Medium risk (n = 84) 31.0 41.7 7.1 20.2 
Low risk (n = 13) 7.7 15.4 0 76.9 
Total (n = 456) 25.7 40.6 8.3 24.6 
On discharge from hospital care 
Antithrombotics (% of patients) 
Groups Warfarin Aspirin Both None 
High risk (n = 347) 32.3 39.8 9.8 18.2 
Medium risk (n = 77) 31.2 49.4 6.5 13.0 
Low risk (n = 14) 7.1 14.3 7.1 71.4 
Total (n = 438) 31.3 40.6 9.1 19.0 
Table 17 	Antithrombotic drug use according to risk of stroke. 
Adapted from Jackson et al. 193 
Patients treated with warfarin were significantly younger, on average, than 
the non-recipients. For patients in the high-risk category for stroke, the median 
ages were 75 years and 80 years for recipients and non-recipients, respectively 
(P < 0.0001). This age difference was evident across both genders. All patients 
aged less than 54 years and at high risk for stroke with no contraindications were 
receiving warfarin. This steadily declined to 60% of the patients aged 65-74 
years, and only 20% of the eligible patients aged greater than 85 years. The use of 
aspirin was unrelated to patient age and there were no significant gender 
differences in the use of either aspirin or warfarin. 
Thirty-five per cent of all patients (39% of patients in the high-risk 
category and 24% of the medium-risk category) possessed at least one 
documented reason for not using warfarin. Of the high-risk patients without any 
contraindications, 43% and 55% were receiving warfarin (or warfarin plus 
aspirin) on hospital admission and discharge, respectively. Of the high-risk 
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patients who were not taking warfarin, 53% had no apparent contraindication to 
warfarin. For those high-risk patients who had a possible contraindication to 
warfarin and were not receiving the drug, only 47% had been prescribed aspirin. 
3.5 Predictors for under-utilisation of antithrombotics for AF 
The reasons for the underuse of antithrombotics for stroke prevention are still 
emerging, but they include physician concern that the benefits of prescribing 
antithrombotic therapy in clinical trials may not translate into everyday 
practice. 194-196  This concern may arise because the randomised trials excluded 
most of the potential participants, with some trials excluding >90% of screened 
140, 143, 145 The patients. n most common reasons for trial exclusion were advanced 
age and relative contraindications to anticoagulation. 
A study by Gage et al. 197 showed that in univariate analyses, patient age 
and gender were significantly related to antithrombotic therapy prescription, as 
was location of the facility at which treatment occurred. Patients aged? 76 years 
were less likely to receive antithrombotic therapy than were younger patients 
•(P <0.001), females were less likely than males to receive antithrombotic therapy 
(P = 0.02), and patients treated in rural facilities were prescribed antithrombotic 
therapy less frequently than patients in metropolitan facilities (P = 0.02). 
In a study by Johnston et al., 198 warfarin users were more likely to be 
younger and to have conditions predisposing them to ischaemic stroke 
(hypertension, CCF, and diabetes mellitus). Warfarin users were less likely to 
have had a prior GI or Id, conditions predisposing them to falls, alcohol or other 
drug abuse or dependence, and perceived risk factors for poor compliance. No 
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significant differences were noted in warfarin use by race or sex. Differences in 
the prevalence of past TIA or stroke, prior AMI, prior other haemorrhage, liver 
disease, and renal insufficiency were not significant. In general, patients with 
more risk factors for stroke were more likely to receive warfarin therapy, while 
those with more risk factors for haemorrhage were less likely to be treated. 198 
3.6 Barriers to prescribing antithrombotics for AF 
Enormous evidence-based treatment gaps still exist between knowledge and 
prescribing practice. For example, even though unequivocal evidence from long-
term effectiveness studies shows that control of hypertension reduces morbidity 
and mortality, only a minority of older adults with hypertension has adequately 
controlled blood pressures. 199 
These evidence-based gaps are due to patient, physician, and healthcare 
system factors. Patient factors include poor adherence to complex drug regimens; 
low tolerance of side effects; and the inability to prioritise long-term health 
outcomes (including survival) over more immediate issues, such as avoidance of 
nuisance side effects or competing financial demands. Physician factors include 
incomplete acceptance of recommended standards of care, competing clinical 
demands, and barriers to effective communication with patients about the health 
benefits of adherence. 200 System factors include lack of access to health care, 
high medication costs, poor longitudinal tracking data on medication use, and 
complicated formularies. 
Several physician surveys have examined the barriers to prescribing 
anticoagulant therapy. 194-196, 201-205 Review of these studies has also revealed the 
101 
same three main categories of barriers to warfarin prescribing: patient-, physician, 
and healthcare system-related factors. 174 
Patient-related factors such as age, perceived embolic risk and perceived 
risk of haemorrhage are consistently identified as influencing the decision to 
prescribe warfarin. 174 Increasing age has consistently been identified as a barrier 
to anticoagulation. 174  Physicians will also target a lower intensity of INR than 
recommended in randomised controlled trials for elderly patients. 174 
Few studies have directly questioned physicians regarding their perceived 
barriers to anticoagulation. The primary factor determining the use of 
anticoagulants appears to be the weighting of the benefit versus risk in the 
individual patient. Physicians with good or excellent experiences with warfarin 
were more likely to prescribe it, but still did not prescribe warfarin for half of 
their patients. 194  Clinical uncertainty, for example, about the risks and benefits of 
anticoagulation have not been clearly defined within surveys and the importance 
of clinical uncertainty remains to be clarified. Clinical uncertainty has ranged 
from being uncommon, to common enough for physicians to request practice 
guidelines outlining eligibility for anticoagulant therapy. 
The expectation of managing anticoagulation at the level reported in clinical 
trials requires that health care system services are appropriately planned and 
resourced. Physicians' fear of haemorrhage likely arises because the risk of 
haemorrhage doubles in patients prescribed anticoagulants outside of 
experimental trials. 118 206 The emphasis on avoiding haemorrhagic strokes and 
other iatrogenic events may cause physicians and patients to choose therapy that 
minimises side effects rather than therapy that maximises benefit. 
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To identify the relative importance of barriers to the prescribing of 
warfarin, Bungard et al. 174 have suggested a rating scale of barrier importance 
directly eliciting physician responses. Bungard et al. 180 found that physicians 
underestimated the RRR with warfarin therapy (mean estimate of 53%) compared 
with that shown in the RCTs (68%) and overestimated the risk of major 
haemorrhage (10% absolute annual risk versus 1% respectively). In contrast, the 
mean RRR of aspirin was estimated to be higher (27%) than that documented in 
RCTs (21%). 56 Interestingly, family physicians estimated aspirin to be 
significantly more efficacious and the risk of major haemorrhage with warfarin to 
be significantly higher than the specialists had estimated. Because warfarin 
therapy is typically monitored by family physicians, these misperceptions may 
affect a large absolute number of patients. 
The estimation of a higher risk of haemorrhage with warfarin by GPs 
(compared with specialists) has been reported previously. 195 ' 196 This may be due 
to several factors. First, GPs monitor warfarin therapy on a long-term basis and, 
therefore, they are more likely to witness adverse outcomes in clinical practice. As 
such, there may be a natural tendency to remember these consequences selectively 
when the therapeutic benefits are not immediately evident (the avoidance of a 
thromboembolic event). Second, the higher rates of haemorrhage reported by GPs 
may reflect the reality of anticoagulant control outside RCTs. Specialists 
commonly recommend or initiate warfarin therapy based on clinical guidelines 
and RCTs, or both, but the long-term follow-up is left to the GPs. Patients outside 
RCTs typically have more concomitant diseases and take more drugs, making it 
more difficult to provide them with appropriate anticoagulation therapy. What is 
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needed is further clinician education and strategies to quantify explicitly 
individual patients' risks and the potential benefits of antithrombotics. 180 
3.7 Underuse of preventive medicine 
Studies to improve prescribing for older adults are especially important with 
respect to drug safety, but under-use of potentially effective medications is also a 
problem. Some drugs are nearly always inappropriate for older adults because 
safer alternatives are available. 207 Studies have framed the need for better 
prescribing practices in all settings caring for the elderly. 208  Early studies 
reported that one in five elderly patients receive an inappropriate drug or 
dosage. 208 Recent reports suggest that clinicians continue to prescribe potentially 
210 harmful drugs. 209, 	While the prescribing of inappropriate drugs or dosages is a 
major problem for older adults, some drugs are underused in these patients-for 
instance, statins for primary prevention of cardiovascular events, 211 and ACE-
inhibitors and B-adrenergic antagonists for cardiovascular disease. 212 
For every patient harmed by lapses in patient safety, more will experience 
or die from deficient health care and flawed delivery systems, which are problems 
that a perfect safety record will not take away. People are less likely to die of an 
overdose of warfarin (a lapse in safety) than of not receiving warfarin at all. The 
attention that policymakers give to safety should be coupled with a 
proportionately larger effort to deal with defects in health care that affect more 
lives. 213 
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3.8 Aims and objectives: Doctors' beliefs on antithrombotic 
therapy in AF 
This thesis includes two studies examining and modifying the determinants of 
antithrombotic drug use in AF. The intention of the first study was to learn more 
about the reasons for the under-utilisation of antithrombotic drugs in clinical 
practice, by performing a comprehensive survey of Australian doctors 
investigating the barriers to the prescription of antithrombotic therapy in patients 
with AF and the relative importance of these barriers. The identification and 
weighting of these barriers would facilitate the development of programs and 
educational packages designed to improve the efficacy and safety of 
antithrombotic drug use in patients with AF. 
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CHAPTER FOUR: METHODS 
DOCTORS' BELIEFS ON ANTITHROMBOTIC THERAPY IN AF 
4.1 Recipients of the survey 
The survey was performed Australia-wide. Approximately 10% of all registered 
GPs and physicians (i.e. specialists in internal medicine, including cardiologists, 
general physicians, neurologists and geriatricians, but excluding specialists such 
as gastroenterologists, infectious diseases physicians etc.). A total sample of 
2,500 doctors, were randomly selected from the Medical Directory of Australia, 
2000 (Australasian Medical Publishing Company Ltd.), which lists details of 
qualifications and specialty of all registered doctors in Australia. The ratio of 
selected GPs to physicians was 4:1, to match the Australian ratio. 214 The 
generation of the random sample was performed by AMPCo Direct, Australasian 
Medical Publishing Company Ltd. 
4.2 Conduct of the survey 
Those doctors selected were sent a personalised letter containing a letter of 
explanation about the study (Appendix 1) and the 4-page survey form (Appendix 
2). Replies were returned via an enclosed postage paid envelope. A follow-up 
reminder letter was sent to all the doctors 3 weeks after the initial letter was sent 
(Appendix 3). A brief preliminary section of the survey form dealt with the 
demographics of the doctor sample (e.g. years since graduation, gender, 
qualifications, location of practice - state and whether city/rural, working hours). 
Also included were questions to ascertain the type and patient demographics of 
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the practice (e.g. how often the doctor makes therapeutic decisions about patients 
with AF). 
There were 6 case vignettes, hypothetical patients with chronic NVAF, for 
which the doctors had to indicate what they perceived their risk of ischaemic 
stroke would be and what treatment they felt would be appropriate. Also, they had 
to indicate the target lNR they would aim for if using warfarin. The correct 
classification of risk and the recommended therapy were according to the 
guidelines of Lip, 59 but were also consistent with others. 35, 107, 215, 216 
The major section of the survey form was to seek the doctors' opinions on 
the appropriate use and barriers to the use of antithrombotic drugs in patients with 
NVAF. This section predominantly utilised responses on 100 mm visual analogue 
scales — with extremes marked "no, not at all" and "yes, most definitely". Issues 
included previous bad experiences with the use of warfarin; perceptions of age of 
the patient as a barrier to the use of warfarin; GI bleeding, haemorrhage, falls, 
dementia, alcoholism, liver disease, severe anaemia and poorly controlled 
hypertension as potential contraindications to the use of warfarin; and views on 
whether monitoring of anticoagulation is too difficult/inconvenient to arrange. 
4.3 Statistical analysis 
The data of the completed survey were stored and then statistically analysed 
(Statview® 5.01 for PC/Macintosh computer; SAS Institute Inc., Cary, NC, USA). 
The median response and its variability were examined for each visual analogue 
item in the questionnaire, with measurements with a ruler to the nearest integer 
(in millimetres) for responses to questions with a visual analogue scale. 
Relationships between some variables (e.g. GP/physician/cardiologist or city/rural 
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practice versus perceptions of barriers to the use of anticoagulation) were 
investigated using the appropriate nonparametric statistical procedures (e.g. 
Spearman rank correlation or Kruskal-Wallis test). For the relationships between 
the types of doctor versus the responses to the case scenarios, a X2 test was used. 
A p-value below 0.05 was considered statistically significant. 
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CHAPTER FIVE: RESULTS 
DOCTORS' BELIEFS ON ANTITHROMBOTIC THERAPY IN AF 
5.1 Demographics of respondents 
Of the 2500 doctors surveyed, 818 (33 %) responded. Seventy-nine were retired 
or not in practice at the time of the survey and 28 stated that they did not deal 
with the types of patients in the survey. The 711 relevant responses yielded a 30% 
response rate. The demographics of respondents are displayed in Table 18. 
The respondents were practicing in NSW (33.2%), VIC (24.9%), QLD 
(17.7%), SA (9.2%), WA (8.8%), TAS (4.1%), ACT (1.8%), NT (0.4%) with no 
significant difference in state of practice between the different specialties 
(p = 0.56). Most doctors were located in a city (39%) or in a suburban practice 
(38%). Most of the cardiologists and other specialists were located in the city, 
77% and 57% respectively, whereas most of the GPs, 43%, were located in a 
suburban practice (p <0.0001). In general, the patients seen by physicians were a 
mix of young and older people (61%). Most of the cardiologists and other 
specialists had older patients, 73% and 60% respectively, whereas most of the 
GPs, 70%, were seeing a mix of young and older people (p <0.0001). 
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Characteristic All doctors GPs Cardiologists Other 
specialist? 
P value 
Number' 711 525 51 132 
Percentage (74) (7) (19) 
Gender: males 508 354 48 106 
Percentage (72) (67) (94) (80) <0.000 1` 
Years registered 
(median and range) 21 21 20 20 0.8d 
(1 - 59) (2 - 59) (5 - 50) (1 - 52) 
Location of practice 
(Percentage) 
City 39 31 77 57 
Suburban 38 43 22 26 < 0.0001' 
Rural 21 24 2 16 
Consulting 
hours/week 40 40 40 32.5 <005d 
(median and range) (0- 130) (3- 130) (4 - 60) (0 - 80) 
Patient 
demographics 
(Percentage) 
Young 10 13 0 3 
Old 29 16 73 60 < 0.0001' 
Mix of young and 
old 
61 70 27 37 
New AF cases/year 
(median and range) 5 4 50 22.5 < cwoo 1 d 
(0 - 325) 	(0- 100) 	(10 - 300) 	(0 - 325) 
a Other specialists include physicians, neurologists and geriatricians 
b Some respondents did not indicate their specialty 
c x2 test 
d Mann-Whitney test (responses from cardiologist and other specialist combined and compared to GPs) 
Table 18 	Characteristics of the responding doctors 
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5.2 Risk stratification and treatment of case studies 
The following case scenarios of patients with AF were used: 
(a) 65-year-old male with a history of thromboembolic stroke secondary to AF. 
(b) 75-year-old male with a history of thromboembolic stroke secondary to AF. 
(c) 76-year-old female with diabetes, hypertension and a previous AMI 10 years 
ago. 
(d) 45-year-old male with hypertension, diabetes, ischaemic heart disease and a 
past history of TIAs. 
(e) 60-year-old female with no contributory risk factors. 
(f) 50 year old male with hypertension and ischaemic heart disease and a 
resolved past history of gastrointestinal bleeding. 
The responses to the case scenarios are summarised in Table 19, Table 20 & 
Table 21. In case scenarios A and B, there was no significant difference between 
the groups of doctors in risk stratification for the patient, treatment regimen and 
the chosen INR. It was noteworthy that 14% of the cardiologists indicated a target 
INR above 3.0 for each case. 
There was a significant difference for risk stratification of the patients in 
scenarios C and D, with the GPs doing better than the cardiologists and other 
specialists. Only 50% and 71% of all doctors nominated cases C and D as high-
risk patients respectively. GPs were more accurate than cardiologists and other 
specialists at indicating the risk category of stroke for the two cases. An even 
lower proportion of all doctors recommended that anticoagulants were the 
treatment of choice (47% and 60% respectively). However, in each case, the 
cardiologists were more likely to use the recommended therapy, warfarin. 
Nearly 80% of all doctors indicated patient E was at low risk of stroke with no 
difference between the specialties. but a higher proportion of cardiologists 
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selected warfarin as the appropriate agent for this low-risk individual. Over 40% 
of all the respondents indicated that they would give no antithrombotic therapy. 
The GPs also performed slightly better in categorising patient F according to 
risk of stroke, with the cardiologists again more likely to initiate anticoagulation. 
Over one-third of cardiologists and other specialists indicated that this patient was 
at low risk of stroke. Thirty-six percent of GPs, 20% of other specialists and 16% 
of cardiologists indicated they would use antithrombotic agents other than aspirin 
or warfarin, such as clopidogrel, dipyridamole or a combination of these. Twenty 
percent of all the doctors stated that they would use clopidogrel in this case. 
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Case Correct All doctors GPs Cardiologists Other specialists P value 
scenario answer (%) (%) (%) (%) 
(x2) 
High;medium;low High;medium;low High;medium;low High;medium;low 
A High 84 	15 	1 85 	14 	1 84 16 0 80 	20 	0 0.2 
B High 91 	8 	1 90 	9 	1 90 8 2 93 	6 	1 0.8 
C High 50 	45 	5 54 	42 	4 42 50 8 37 	53 	10 <0.001 
D High 71 	28 	2 75 	24 	1 51 49 0 62 	34 	4 <0.001 
E Low 2 	20 	78 3 	20 	77 0 29 71 2 	14 	85 0.2 
F Medium 13 	59 	28 13 	61 	25 4 57 39 13 	51 	35 <0.05 
Table 19 	Perceived risk of ischaemic stroke for the six different AF patients 
5.3 	Antithrombotic therapy for case studies 
Case 
scenario 
Correct 
answer 
All doctors 
(%) 
Wara ; war/aspb; asp 
GPs 
(%) 
War; war/asp; asp 
Cardiologists 
(%) 
War; war/asp; asp 
Other specialists 
%) 
War; war/asp; asp 
P value 
(x2 ) 
A Warfarin 91 7 2 90 7 3 90 10 0 95 4 1 0.5 
B Warfarin 85 6 6 84 6 7 94 6 0 90 4 6 0.6 
C Warfarin 40 7 48 39 6 50 62 14 24 39 6 52 <0.05 
D Warfarin 51 13 26 52 11 27 56 30 8 47 14 28 <0.01 
E Aspirin 20 0 39 20 1 40 36 0 40 11 0 38 <0.05 
Fc Warfarin or 
aspirin 
22 1 24 19 1 20 40 4 34 28 1 35 <0.0001 
a warfarin 
b aspirin and warfarin 
20% of all doctors chose clopidogrel 
Table 20 	Treatment selections for the six different AF patients 
Case 
scenario 
Correct 
answer 
All doctors 
(%) 
GPs 
(%) 
Cardiologists 
(%) 
Other specialists 
(%) 
P value 
(x2 ) 
<2; 2-3; >3 <2; 2-3; >3 <2; 2-3; >3 < 2 ; 2 — 3 ; >3 
A Between 2-3 2 91 7 2 91 7 0 86 14 2 92 7 0.3 
B Between 2-3 6 87 7 6 87 7 0 86 14 6 89 5 0.2 
C Between 2-3 6 89 5 6 89 5 3 89 8 5 91 3 0.9 
D Between 2-3 2 89 9 2 89 9 2 86 12 1 91 8 0.9 
E Between 2-3 8 88 5 8 89 3 6 89 6 7 79 14 0.4 
Between 2-3 6 91 3 7 91 2 10 90 0 3 88 9 0.3 
Table 21 	Nominated target INR if using warfarin for the six different AF patients 
5.4 Doctors' views and knowledge on antithrombotic therapy in AF 
The cardiologists were clearly the most accurate when stating the risk of stroke 
for PAF as compared to chronic AF (Table 22). Less than one-third of all doctors 
said that the risk of stroke from PAF was the same as for chronic AF. There was a 
significant difference between the groups of doctors in estimating the stroke risk 
reduction with warfarin and aspirin. Slightly over one-third of all doctors 
indicated the risk reduction with warfarin was 66%. 
There was a tendency for cardiologists to overestimate the risk reduction 
with both drugs, while the other specialists and GPs often underestimated the 
proven benefit of warfarin. Seventy percent of all doctors indicated that the RRR 
with the use of aspirin was 20%, with other specialists and GPs being most 
accurate. 
The other specialists and GPs also often overestimated the reported risk of 
major bleeds with warfarin. Forty percent of GPs indicated the risk of major 
bleeding whilst on warfarin treatment was 5% per year. The cardiologists were 
clearly the most accurate at estimating major bleeding risk; 88% stated the risk 
was 1%. 
Doctors most likely to state the correct answers for each of (i) the relative 
risk of stroke from paroxysmal versus chronic AF, (ii) the reduction in risk of 
stroke with aspirin therapy and (iii) the annual risk of major bleeding in AF 
patients treated with warfarin were those with the highest numbers of new AF 
cases per year (Kruskal-Wallis H = 21.3, 16.7 and 29.6, respectively, all p < 
0.001). Performance on these questions was not related to the location of the 
doctor's practice (city/suburban/rural). 
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Doctors registered longer were less likely to state the correct answers for 
each of (i) the relative risk of stroke from paroxysmal versus chronic AF and (ii) 
the reduction in risk of stroke with aspirin therapy (Kruskal-Wallis H = 11.3 and 
12.9, respectively, both p < 0.01). Increasing duration of registration as a medical 
practitioner was also generally related to a poorer performance on classifying 
patients according to the risk of stroke - this reached statistical significance with 
cases A, B and E (Kruskal-Wallis H = 6.5, 10.0 and 6.3, respectively, all p < 
0.05). 
The number of new AF cases seen per year by the doctor, location of 
practice (city/suburban/rural), and the number of hours spent in practice per week 
were not significantly related to performance on classifying patients according to 
the risk of stroke. Years registered as a medical practitioner and numbers of new 
AF cases seen per year were not significantly correlated (Spearman rho = 0.04, 
p = 0.3). 
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All GPs Cardiologists Other P value 
Doctors (%) (%) Specialists 
(x2) 
(%) (%) 
34 37 30 25 
<0.0001 
37 39 10 40 
29 24 60 35 
7 7 2 5 
40 41 24 43 
<0.01 
38 37 40 40 
15 14 34 12 
70 68 58 84 
25 26 41 13 
<0.001 
5 6 0 2 
0 0 0 0 
58 52 88 67 
36 40 12 30 <0.0001 
6 7 0 3 
1 1 0 0 
1% 
5% 
10% 
20% 
Do you believe that the 
risk of stroke from 
paroxysmal AF is: 
less than for chronic AF 
greater than for chronic 
AF 
same as for chronic AF 
Warfarin reduces the risk 
of stroke in chronic AF by 
approximately: 
20% 
50% 
66% 
85% 
Aspirin reduces the risk of 
stroke in chronic AF by 
approximately: 
20% 
50% 
66% 
85% 
The annual risk of major 
bleeding' in patients with 
chronic AF treated with 
warfarin is approximately: 
Table 22 	Knowledge of risks of AF and antithrombotic therapy 
ae.g. Intracranial or intracerebral haemorrhage, or requiring blood transfusion. 
Correct response in bold 
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5.5 Barriers to the prescribing of warfarin 
The outcome of the section of the survey form, to seek the doctors' opinions on 
the appropriate use and barriers to the use of antithrombotic drugs in patients with 
AF are summarised in Table 23 and Table 24. 
A number of factors were perceived by the respondents as being potent 
barriers to the use of warfarin in patients with AF. Variables with a median 
response of at least 75 mm on the 100 mm visual analogue scales, in decreasing 
order of importance, were: active GI bleeding, previous ICH, alcoholism, a 
history of daily falls, liver disease, severe anaemia, and the concurrent use of 
NSAIDs. The cardiologists were generally more concerned than GPs about 
supervised dementia, alcoholism, and a history of falls or poorly controlled 
hypertension as potential barriers to the use of anticoagulation, but less concerned 
about a history of resolved GI bleeding or the concurrent use of NSAIDs. While a 
patient living distant from routine medical care was rated a major barrier to the 
use of anticoagulation, it was surprising that this was ranked a significantly 
greater barrier by city and suburban doctors than their rural counterparts (Kruskal-
Wallis H = 12.1, p <0.01). 
The cardiologists and other specialists were generally more likely to agree 
that there are clear guidelines that can be referred to if unsure of whether to 
anticoagulate patients with AF, anticoagulation is under-utilised in patients with 
AF, and most patients with chronic AF would accept treatment with warfarin, and 
less likely to agree that the risk of haemorrhage with warfarin outweighs the 
potential benefit for stroke prevention in patients with AF. GPs were more 
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convinced that the availability of portable INR monitors would assist with the 
management of patients with AF. 
There were several statistically significant, albeit weak, correlations when 
comparing the number of new AF cases seen per year and years registered as a 
medical practitioner against potential factors that could act as barriers to the use 
of anticoagulation. Doctors with the highest numbers of new AF cases per year 
generally had less concern about bad experiences with prescribing warfarin in the 
past, advancing age of the patient, prior resolved GI bleeding, and the concurrent 
use of NSAlDs as potential barriers to the use of anticoagulation, but increased 
concern about a history of falls or poorly controlled hypertension. Increasing 
period of registration as a medical practitioner was associated with a slight 
decline in concern about most of the possible barriers to the use of 
anticoagulation, particularly active GI bleeding, a history of falls, and liver 
disease. 
As expected, a number of the variables and attitudes were significantly 
inter-related. For instance, doctors who stated the correct answers for the relative 
risk of stroke from paroxysmal versus chronic AF, the reduction in risk of stroke 
with aspirin and warfarin therapy, and the annual risk of major bleeding in AF 
patients treated with warfarin, were most likely to agree that there are clear 
guidelines for anticoagulation in AF, anticoagulation is under-utilised in patients 
with AF, the results given in the large clinical trials can be translated into 
Australian clinical practice, and most patients with chronic AF would accept 
treatment with warfarin. Also, these doctors were less likely to agree with the 
statements that the risk of haemorrhage with warfarin outweighs the potential 
benefit in stroke prevention in patients with AF, anticoagulation treatment has a 
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negative impact on quality of life in patients with AF, most patients with AF find 
the need for close monitoring while receiving treatment with warfarin too 
inconvenient, or anticoagulation for AF should be initiated in the hospital setting. 
These respondents tended to be the doctors seeing more new cases of AF each 
year and, to a lesser extent, doctors who had been registered for longer. 
Correlation between (i) number of new cases of AF seen per annum and (ii) years 
registered as a doctor with perceived barriers to anticoagulant use in AF is 
displayed in Table 25. 
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Barrier All doctors 
Median (range) 
GPs 
Median (range) 
Cardiologists 
Median (range) 
Other specialists 
Median (range) 
P value 
(Kruskal- 
Wallis) 
Bad experience prescribing warfarin 25 (0 - 100) 25 (0 - 100) 25 (0 - 85) 25 (0 - 95) 0.8 
Advancing age of patient 60 (0 - 100) 60 (0 - 100) 60 (0 - 90) 60 (0 - 100) 0.9 
Active GI bleeding 95 (0 - 100) 95 (0- 100) 95 (0- 100) 95 (5 - 100) 0.4 
Prior resolved GI bleeding 65 (5 - 100) 65 (5 - 100) 55 (10 - 95) 55 (5 - 95) <0.0001 
Previous ICH 90 (0 - 100) 90 (0 - 100) 85 (20- 100) 85 (15 - 100) 0.1 
Poor control INR 65 (0 - 100) 65 (0- 100) 65 (0- 100) 75 (5 - 100) <0.0001 
History of daily falls 75 (0- 100) 75 (0- 100) 85 (10- 100) 90 (25 - 100) <0.0001 
History of twice-yearly falls 50 (0 - 100) 45 (0- 100) 55 (5 - 95) 55 (5 - 95) <0.0001 
Dementia in an institutionalised setting 60 (0- 100) 55 (0- 100) 82.5 (0- 100) 65 (0- 100) <0.0001 
Alcoholism 80 (0- 100) 75 (0 - 100) 85 (0- 95) 85 (5 - 100) <0.001 
Liver disease 75 (0- 100) 75 (0- 100) 75 (10 - 95) 75 (0- 100) <0.05 
Severe anaemia 75 (0 - 100) 72.5 (0- 100) 75 (5 - 100) 75 (0- 100) 0.3 
Poorly controlled hypertension 55 (0- 100) 50 (0 - 100) 65 (25 - 95) 70 (0- 100) <0.0001 
Concomitant use of NSAIDs 75 (0- 100) 75 (0- 100) 55 (5 -95) 75 (0- 100) <0.001 
Patient living distant from medical care 65 (0- 100) 65 (0 - 100) 65 (10-95) 65 (5 - 100) 0.6 
Table 23 	Perceived barriers to anticoagulant use in AF, and differences between groups of doctors. 
The numbers represent median responses (and ranges) on a 100 mm visual analogue scale, where 0 corresponds to "no, not all" and 100 to "yes, most definitely." 
Statement All doctors 
Median (range) 
GPs 
Median (range) 
Cardiologists 
Median (range) 
Other specialists 
Median (range) 
P value 
(Kruskal- 
Wallis) 
Clear guidelines available 50 (0 - 100) 45 (0 - 100) 62.5 (5 - 95) 67.5 (0 - 100) <0.0001 
Clinical trials results can be translated into 
clinical practice 
75 (5 - 100) 75 (5 - 100) 75 (5 - 100) 75 (15 - 100) 0.08 
Patients accept treatment with warfarin 70 (5 - 100) 70 (5 - 100) 72.5 (35 - 100) 75 (15 - 100) <0.01 
Anticoagulation should be initiated in hospital 30 (0 - 100) 30 (0- 100) 25 (0- 95) 30 (0 - 100) 0.3 
Anticoagulation is under-utilised 70 (0 - 100) 70 (0- 100) 75 (5 - 100) 80 (10 - 100) <0.0001 
Risk of haemorrhage outweighs potential 
benefit of warfarin 
25 (0- 100) 25 (0- 100) 15 (0- 95) 20 (0 - 100) <0.0001 
Anticoagulation treatment has a negative 
impact on quality of life 
35 (0- 100) 35 (0 - 100) 35 (0 - 90) 30 (0- 95) 0.1 
Patients find the need for close monitoring too 
inconvenient with warfarin treatment 
40 (0 - 100) 40 (0- 100) 40 (0 - 85) 35 (0- 85) 0.2 
INR monitors would assist management 70 (0 - 100) 75 (0- 100) 50 (0- 95) 62.5 (0- 100) <0.0001 
Table 24 	Opinions on anticoagulation in patients with AF, and differences between groups of doctors. 
The numbers represent median responses (and ranges) on a 100 mm visual analogue scale, where 0 corresponds to "no, not all" and 100 to "yes, most definitely". 
Statement Correlation with 
AF cases 
(Spearman rho) 
P value Correlation with 
years registered 
(Spearman rho) 
P value 
Bad experience prescribing warfarin -0.16 <0.0001 -0.04 0.3 
Advancing age of patient -0.09 <0.05 -0.08 0.05 
Active gastrointestinal bleeding -0.02 0.7 -0.18 <0.0001 
Prior resolved gastrointestinal 
bleeding 
-0.23 <0.0001 0.04 0.3 
Previous ICH -0.06 0.1 -0.02 0.5 
Poor control INR 0.05 0.2 -0.08 <0.05 
History of daily falls 0.15 <0.0001 -0.18 <0.0001 
History of twice-yearly falls 0.11 <0.01 -0.09 <0.05 
Dementia in an institutionalised setting 0.08 0.05 -0.01 0.8 
Alcoholism 0.01 0.8 -0.09 <0.05 
Liver disease 0.01 0.8 -0.11 <0.01 
Severe anaemia -0.01 0.9 -0.06 0.1 
Poorly controlled hypertension 0.14 <0.001 -0.08 <0.05 
Concomitant use of NSAIDs -0.11 <0.01 0.01 0.8 
Patient living distant from medical 
care 
-0.06 0.1 0.03 0.5 
Clear guidelines available 0.16 <0.0001 0.09 <0.05 
Clinical trials results can be translated 
into clinical practice 
0.08 <0.05 0.12 <0.01 
Patients accept treatment with warfarin 0.15 <0.0001 0.10 <0.05 
Anticoagulation should be initiated in 
hospital 
-0.11 <0.01 -0.01 0.8 
Anticoagulation is under-utilised 0.20 <0.0001 -0.09 <0.05 
Risk of haemorrhage outweighs 
potential benefit of warfarin 
-0.16 <0.0001 0.10 <0.05 
Anticoagulation treatment has a 
negative impact on quality of life 
-0.13 <0.001 -0.04 0.3 
Patients find the need for close 
monitoring too inconvenient with 
warfarin treatment 
-0.16 <0.0001 -0.07 0.07 
INR monitors would assist 
management 
-0.11 <0.01 -0.01 0.9 
Table 25 	Correlation between (i) number of new cases of AF seen per annum 
and 
(ii) years registered as a doctor with opinions on anticoagulation in patients with 
AF 
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CHAPTER SIX: DISCUSSION 
DOCTORS' BELIEFS ON ANTITHROMBOTIC THERAPY IN AF 
The intention of this comprehensive survey was to learn more about the reasons 
for the discrepancy between the clinical trial evidence and prescribing patterns in 
Australian clinical practice. The response rate of 30% was similar to that achieved 
in other surveys of doctors' treatment practices 217 and was considered acceptable 
for this form of research, especially given the relatively long questionnaire. 218 
Overall, the doctors performed well in classifying the case scenarios 
according to the risk of stroke associated with AF. Perhaps surprisingly, the GPs 
performed better than the cardiologists and other specialists in estimating the risk 
of stroke. On the other hand, when it came to the selection of the appropriate drug 
therapy in these cases, the cardiologists were more likely to nominate the 
recommended treatment. Possibly because of seeing more patients with AF and 
being more familiar with the use of warfarin, the cardiologists had a more 
accurate perception of the potential benefit of warfarin, or even tended to 
overestimate the benefit, and were less hesitant to recommend its prescription. 
However, almost half the cardiologists overestimated the reported benefit of 
aspirin and to a lesser extent, warfarin, in AF. Over one-third of the cardiologists 
went as far as to give warfarin to a low-risk patient (case E). 
Overall, it appears that the cardiologists are more enthusiastic in using 
antithrombotic therapy. Sometimes, however, this may not always be justified and 
may pose some risks to the patients. Even though they seemed to have a better 
understanding of the risk of stroke in patients with AF, GPs were more cautious, 
tending to overstate the likelihood of bleeding with warfarin and the importance 
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of some possible contraindications, and to underestimate the benefits of 
anticoagulation. 
The responses to case scenario C were most disturbing, with only half the 
doctors correctly nominating the patient (a 76 year old female with diabetes, 
hypertension and a previous AM!) as being at high risk of stroke. This 
classification and the recommended therapy should have been indisputable 
according to an array of Australian and international published guidelines. 59 '  219- 
222 In contrast to the other high-risk cases, this patient did not have a history of 
previous stroke or TIAs, confirming the importance of these as key determinants 
224 223 190, 	, of the use of anticoagulation in AF. 187, 	 There is apparently under- 
recognition of other risk factors for stroke in patients with AF, and a greater 
acceptance of the prescribing of warfarin for the secondary prevention of stroke 
rather than as a primary prevention approach. 
4 With the exception of one survey 20 all evaluations have used case 
vignettes, which can have several methodological limitations. 194-196, 201-203, 205  
Vignettes attempt, but often are not successful in, mimicking a clinical scenario 
for the physician. Their use rests on the assumption that responses in hypothetical 
situations reflect actual clinical practice patterns. Some studies report that 
physician response to vignettes may not be representative of their clinical practice 
patterns. 174 
The identification of prescribing barriers is identified indirectly through 
case vignettes. Assumptions must be made regarding factors triggering the 
physician's decision. These may be factors in the vignette, however, there may be 
factors outside of the case that may influence the decision. This information 
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cannot be captured in this format. Case vignette format does not allow for the 
assessment of the relative importance of each of the barriers in prescribing. 
Responses to case scenario F (a 50 year old male with hypertension and 
ischaemic heart disease, and a resolved past history of GI bleeding) were also 
interesting. Almost one-third of all the respondents, and more of the GPs, 
indicated that they would use antithrombotic agents other than aspirin or warfarin. 
It would appear that doctors perceive the newer antiplatelet agents, especially 
clopidogrel, to carry a lower risk of GI bleeding than conventional agents. We are 
unaware of any published studies of the benefit of clopidogrel in patients with 
AF, and the case's details fall outside the approved prescribing indications for the 
drug in Australia (secondary prevention of ischaemic stroke, TIAs, AMI or 
unstable angina in patients unable to tolerate aspirin or in whom low-dose aspirin 
therapy was unsuccessful). Only 4% of the patients in the Clopidogrel versus 
Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) study had NVAF, 225 SO 
its results are not relevant. 59 A Cochrane review concluded that the small absolute 
benefit of a reduction in GI haemorrhage (0.4% ARR) for clopidogrel compared 
to aspirin is partially offset by an increased incidence of rash, leading to 
withdrawal (0.5% absolute risk increase). 139 There is also recent concern about 
the association between clopidogrel use and thrombotic thrombocytopaenic 
purpura. 226  Our results would suggest that clopidogrel has been effectively 
marketed to doctors by the pharmaceutical industry. 
The major barriers to the use of warfarin in patients with AF were active 
GI bleeding, previous ICH, alcoholism, a history of daily falls, liver disease, 
severe anaemia, and the concurrent use of NSAIDs. These factors would usually 
constitute clear contraindications to anticoagulation. 220 Some of these factors are 
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uncommon and it may be that other, more common factors that were ranked 
slightly lower as barriers to the use of warfarin (e.g. patient living distant from 
medical care, poor control of INR in the past, or advancing age of the patient) are 
more important in practice. Some doctors, particularly cardiologists, rated 
dementia (in an institutionalised setting) as a major barrier to the use of warfarin. 
While unsupervised dementia is considered a relative contraindication to 
warfarin, this does not apply to supervised dementia, which has been previously 
reported as a determinant of non-treatment with warfarin in AF. 227 '  228 
Despite the evidence that the elderly patient with AF benefits most from 
anticoagulation, many doctors still view advancing age of patient as a barrier to 
the use of warfarin in patients with AF. 144, 187, 196, 201, 224, 227 There are obviously 
concerns in practice regarding the possibility of poor anticoagulant control and an 
increased risk of bleeding complications with warfarin therapy in the elderly, an 
issue that remains in dispute. 144, 216, 229, 230 
The responding doctors generally agreed that the results given in large 
clinical trials can be translated into Australian clinical practice, anticoagulation is 
under-utilised in patients with AF, most patients with chronic AF would accept 
treatment with warfarin, and the availability of portable INR monitors would 
assist with the management of their patients with AF, while disagreeing that the 
risk of haemorrhage with warfarin outweighs the potential benefit in stroke 
prevention in patients with AF. However, the doctors, especially the GPs were not 
convinced of the availability of clear guidelines that can be referred to if unsure of 
whether to anticoagulate patients with AF. The lack of clear guidelines was also 
frequently mentioned in the comments section of the questionnaire. 
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Several overseas surveys of doctors have been performed to examine the 
205 201, barriers to prescribing anticoagulant therapy. 195, 196, 	These studies were 
performed before the publication of the most recent clinical trials. In contrast to 
our results, one study indicated that cardiologists believed the risk for ischaemic 
stroke relative to haemorrhage to be lower than did GPs, and therefore 
cardiologists were less likely to prescribe warfarin. 195 Monette et al. 205 in a study 
of doctors providing primary care to elderly patients, reported similar key barriers 
to the use of warfarin in AF as this study: excessive risk of falls, GI bleeding, and 
previous ICH. 
In conclusion, our results indicate scope for improvement in doctors' 
knowledge about the appropriate use of antithrombotic drug therapy in NVAF and 
awareness of the results of recent clinical trials. The proven benefit of warfarin 
was underestimated by almost half the doctors, whereas almost one-third 
overestimated the benefit of aspirin. 
This thesis intended to use the results to design and evaluate an 
intervention program targeting the identified barriers to the prescribing of 
warfarin for stroke prevention among suitable candidates. It is evident from the 
results of this study that some of these potentially important strategies could 
include the compilation and dissemination of clear guidelines that can be referred 
to if unsure of whether to anticoagulate patients, focused education on (i) some of 
the other risk factors, apart from previous stroke or TIAs, in patients with NVAF 
and (ii) an evidence-based approach to the use of new antiplatelet agents, and 
trials of portable INR monitors by doctors and selected patients. 
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CHAPTER SEVEN: INTRODUCTION 
INFLUENCING PRESCRIBING BEHAVIOUR 
7.1 Overview 
As discussed previously in this thesis, there is increasing recognition of the failure 
to translate research findings into practice. This has led to greater awareness of 
the importance of using active dissemination and implementation strategies. Table 
26 displays interventions and definitions of these interventions designed to 
promote the uptake of research findings. An overview of 41 systematic reviews 
suggests that the most promising approaches are to use a variety of interventions, 
including audit and feedback, reminders, and educational outreach. 231 
7.2 Strategies to improve physician prescribing 
Single interventions likely to be effective include educational outreach, opinion 
leaders, patient-mediated interventions, and reminders. Grimshaw et al. concluded 
in a systematic review that multifaceted interventions and studies that undertook a 
"gap analysis" to inform the development of the intervention were more likely to 
be successful. 231 They also concluded in a review of passive dissemination of 
consensus recommendations that there was little evidence that passive 
dissemination alone resulted in provider behaviour change. 231  It concluded that 
guidelines can change clinical practice and that guidelines were more likely to be 
effective if they took into account local circumstances, were disseminated by 
active educational interventions, and were implemented by patient-specific 
reminders. There was inconclusive evidence about whether guidelines developed 
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by the end users (e.g., local guidelines) were more likely to be effective than 
guidelines developed without involvement of the end users (e.g., national 
guidelines). 231 They concluded that there were no "magic bullets" for provider 
behaviour change: a range of interventions could lead to provider behaviour 
change, but no single intervention was always effective for changing behaviour. 
Multifaceted interventions combining more than 1 intervention tended to 
be more effective but might be more expensive. 231 Mailed educational materials 
alone were generally ineffective, educational outreach approaches and ongoing 
feedback was generally effective, and there was insufficient evidence to 
determine the effectiveness of reminder systems and group education. 231 
Freemantle and colleagues reviewed 11 studies evaluating the effects of the 
dissemination of educational materials. 232 None of the studies found statistically 
significant improvements in practice. 
Thomson and associates 233 reviewed the effectiveness of educational 
outreach visits (academic detailing). Most observed statistical improvements in 
care (especially when social marketing techniques were used), although the 
effects were small to moderate. Educational outreach was observed to be more 
effective than audit and feedback in 1 study, although the cost effectiveness of 
educational outreach was unclear. 
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APPENDIX A. TABLE 1. INTERVENTIONS To PROMOTE PROFESSIONAL BEHAVIORAL CHANGE THAT COULD BE USED 
TO IMPLEMENT RESEARCH FINDINGS 
Educational materials—Distribution of published or printed recommendations for clinical care, including clinical 
practice guidelines, audio-visual materials, and electronic publications. The materials may have been delivered 
personally or through personal or mass mailings. 
Conferences—Participation of health care providers in conferences, lectures, workshops, or traineeships. 
Local Consensus Process—Inclusion of participating providers in discussion to ensure that they agree that the 
chosen clinical problem is important and the approach to managing the problem (ie, the clinical practice 
guideline or definition of adequate care) is appropriate. The consensus process might also address the design 
of an intervention to improve performance. 
Educational outreach visits—Use of a trained person who meets with providers in their practice settings to provide 
information with the intent of changing the provider's performance. The information given may include 
feedback on the provider's performance. 
Local opinion leaders—Use of providers nominated by their colleagues as "educationally influential." The 
investigators must explicitly state that "the opinion leaders were identified by their colleagues." 
Patient-mediated interventions—Any intervention aimed at changing the performance of health care providers 
where specific information was sought from or given to patients: for instance, direct mailings to patients; 
patient counselling delivered by someone other than the targeted providers; clinical information collected from 
patients by others and given to the provider; educational materials given to patients or placed in waiting 
rooms. 
Audit and feedback—Any summary of clinical performance over a specified period of time. Summarized 
information may include the average number of diagnostic tests ordered, the average cost per test or per 
patient, the average number of prescriptions written, the proportion of times a desired clinical action was 
taken, etc. The summary may also include recommendations for clinical care. The information may be given in 
a written or verbal format. 
Reminders (manual or computerized)—Any intervention that prompts the health care provider to perform a 
patient- or encounter-specific clinical action. 
Marketing—Use of personal interviewing, group discussion ("focus groups"), or a survey of targeted providers to 
identify barriers to change and the subsequent design of an intervention that addresses these barriers. 
Multifaceted interventions—Any intervention that includes two or more of the above. 
Table 26 	Interventions to promote professional behavioural change that 
could be used to implement research findings 
Reproduced from Freemantle et al. 232 
Thomson and coworkers reviewed the effectiveness of local opinion 
leaders. 234 They identified 6 studies; 5 of the 6 trials observed improvements in at 
least 1 process of care variable, although these results were only statistically and 
clinically significant in 1 trial. One of 3 trials observed an improvement in patient 
outcome that was of practical importance. Opinion leaders were observed to be 
more effective than group audit and feedback in 1 study. They concluded that 
using local opinion leaders resulted in mixed effects and that further research was 
required before the widespread use of this intervention could be justified. 
Thomson and associates undertook a review of audit and feedback. 235 
They identified 13 studies that compared audit and feedback with a no-
intervention control group; 8 reported statistically significant changes in favour of 
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the experimental group in at least 1 major outcome measure, but the effects were 
small to moderate. The review concluded that "audit and feedback can be 
effective in improving performance, in particular for prescribing and test 
ordering, although the effects are small to moderate" and that the "widespread use 
of audit and feedback" was not supported by the review. 
Hunt and colleagues reviewed the effectiveness of computer-based 
decision support systems. 236 Significant improvements were observed in 9 of 15 
drug-dosing studies, 1 of 5 studies on diagnosis, 14 of 19 studies on prevention, 
19 of 26 studies on general management of a problem, and 4 of 7 studies on 
patient outcome. They concluded that computer-based decision support systems 
might enhance clinical performance for most aspects of care, but not diagnosis. 
Another review found that different information interventions improved care, 
including provider prompts, patient prompts, computer-assisted patient education, 
and computer-assisted treatment planners. 237 
These systematic reviews identified a variety of dissemination and 
implementation strategies that are effective under certain conditions, but current 
knowledge is imperfect. Passive dissemination (e.g., mailing educational 
materials to targeted clinicians) is generally ineffective and is unlikely to result in 
behaviour change when used alone; however, this approach may be useful for 
raising awareness of the desired behaviour change. Active approaches are more 
likely to be effective but are also likely to be more costly. Interventions of 
variable effectiveness include audit and feedback, and use of local opinion 
leaders. Generally effective strategies include educational outreach (for 
prescribing behaviour) and reminders. Multifaceted interventions based on an 
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assessment of potential barriers to change are more likely to be effective than 
single interventions. 
Publication of new evidence in peer-reviewed journals is associated with 
modest changes in clinical practice, and these changes may occur soon after the 
evidence becomes available. 238 Furthermore, adoption of new evidence appears 
to be accelerated by active promotion. To help narrow the gap between available 
evidence and best practice, researchers, educators, and policymakers need to 
move beyond publishing articles and creating practice guidelines. Rather, more 
active promotional strategies will be needed to accelerate the adoption of new 
evidence into routine clinical practice. 
7.3 Aims and objectives: Improving antithrombotic prescribing in 
AF 
The second part of the study modifying antithrombotic drug use in AF described 
in this thesis was an educational intervention using the process of academic 
detailing, 239 targeting identified barriers to the use of anticoagulation for stroke 
prevention in AF, including the compilation and dissemination of clear 
guidelines. The overall aim was to promote the rational prescribing of 
antithrombotics for stroke prevention in AF. 
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CHAPTER EIGHT: METHODS 
IMPROVING ANTITHROMBOTIC PRESCRIBING IN AF 
8.1 Guideline development 
Guidelines for stroke prevention in AF (Figure 16) were developed from the 
international 1 ' 57 ' 154 and national literature. 60 The guidelines were incorporated 
into a flow chart and endorsed by the Royal Hobart Hospital (RHH) 
anticoagulation group. The anticoagulation group consisted of a haematologist, 
geriatrician, general physicians, cardiologist and clinical pharmacists. Each 
member of the guideline group would be considered an opinion leader in each of 
their respective fields. A flow chart design was decided upon to streamline the 
risk stratification and treatment decisions. The guidelines were incorporated in the 
2002 edition of the RHH anticoagulation guidelines (Appendix 4). The Southern 
Tasmanian Division of General Practice also endorsed the guidelines. 
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CLI NICAL AP PROACH TO REDUC ING THE RISK OF STROKE I N 
CH RONIC OR PA ROXYSMAL NON- VALVULAR ATRI AL FIBRILLATI ON *  
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The intervention study was conducted in Southern Tasmania (population 
Passive dissemination of the guidelines  
230,000), using the remainder, the North of the State (population 245,000) as the  
control area. The two regions are similar in terms of size, number of GPs, degree  
of urbanisation and organisation of quality improvement initiatives. The 
guidelines, with an explanatory cover letter (Appendix 5), were sent to each GP 
(n=272) practicing within Southern Tasmania, in early February 2002. The 
covering letter highlighted local data showing that antithrombotic therapy was 
being under-utilised. 193 
8.3 Process of academic detailing 
SLJ contacted each practice to arrange a convenient time to discuss the rationale 
for prescribing antithrombotic therapy for stroke prevention in AF (May-
September 2002). Additional reference material was provided whenever 
requested. The length and content of each visit varied, depending upon factors 
such as whether the guidelines had been read, the individual GP's interest, the 
demographics of the GP's practice and time constraints. 
The GPs were supplied with a number of further educational materials. 
These included a computer mouse pad embossed with the AF guidelines (Figure 
17) and the RHH anticoagulation guidelines, which contained a number of items 
promoting the safe and judicious use of anticoagulants. They were shown a 
Medical Director (Health Communications Network Ltd. Bundaberg, QLD, 
Australia) risk stratification computer program (computer-based patient 
education, an example for a patient 75 years or older with risk factors is given in 
Appendix 6), which was useful in visually representing to patients their individual 
risk of stroke. 
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CLINICAL APPROACH TO REDUCING THE RISK OF STROKE 
IN CHRONIC OR PAROXYSMAL NON-VALVULAR ATRIAL FIBRILLATION 
1101.0001w Atrial fibrillation 	  
<65 years 65 - 75 years >75 years 
\ Airy No RI \ Any RF No RI \Any RF high RF 
aspinn 	warfarin 	aspirin 	warfarin 	consider 	warfarin 
consider warfarin 	 warfarin 
rf any mod RF iesp. if female) 
High and moderate risk factors (RE) for stroke in patients with AF: 
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Figure 17 
	
Computer mousepad embossed with stroke prevention in AF 
guidelines 
8.4 Assessment of effectiveness 
8.4.1 General practitioner evaluation 
Participating GPs were anonymously surveyed (using a visual analogue scale) to 
assess the usefulness of the mailed information and academic detailing visit. The 
extremes of the scale were marked (0 not useful or strongly disagree) and (10 
useful or strongly agree). The completed evaluation forms were returned via 
reply-paid envelopes. 
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8.4.2 Pharmaceutical Benefits Scheme data 
For comparative purposes, Pharmaceutical Benefits Scheme (PBS) and 
Repatriation Pharmaceutical Benefits Scheme (RPBS) data were obtained from 
the Drug Utilisation Sub-committee of the Department of Health & Ageing. 
Specifically, PBS and RPBS dispensing data for all preparations of warfarin and 
single preparations of aspirin were obtained for each of the two major regions of 
Tasmania: South (postcodes 7000-7199) and North (7200-7499), for the periods, 
1 st February 2001 to 31 st January 2002 (pre-intervention) and 1 st Feb 2002 to 31 st 
January 2003 (post-intervention). The unit quantities of warfarin dispensed were 
converted into defined daily doses (DDDs) per 1000 of population; the unit 
quantities of aspirin were given as number of prescriptions dispensed per 1000 of 
population. 
Changes in the relative prescribing of warfarin and aspirin between and 
within the control and intervention regions were studied. Statistical comparisons 
were made between the different areas of the State (i.e. South/intervention region 
versus north/control region), both before and after intervention, and within each 
study area (before versus after the intervention) using a normal approximation to 
the binomial distribution. 
8.4.3 Admissions to Royal Hobart Hospital 
Similar to a previously published study conducted by SLJ, 193 data were collected 
on patients admitted to the RHH, a 450-bed acute care teaching hospital and the 
only major public hospital in the southern region (intervention) of Tasmania. 
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Abstractors who were unaware of the project objectives obtained data 
retrospectively. 
Admission data were analysed for those patients who had a diagnosis of 
AF or other related conditions as a primary or secondary diagnosis on admission 
to hospital. Information collected included risk factors for stroke, 
contraindications to anticoagulation and medications on admission and discharge 
Patients were categorised according to their risk of stroke using Australian 
endorsed guidelines. 60 The baseline sample consisted of consecutive patients 
admitted during the period 1 st February 2001 to 31 st January 2002. Post-
intervention data was for a smaller random sample of patients admitted during the 
period 1 st February 2002 to 31 st January 2003, after the educational intervention 
had commenced. Patients with acute AF, severe valvular disease, who lived out of 
the region of southern Tasmania or whose medical notes were incomplete were 
excluded. 
The proportions of eligible patients receiving antithrombotics (warfarin 
and aspirin) in the periods pre- and post-intervention were analysed using X2 tests. 
A p value less than 0.05 were considered statistically significant. The statistical 
analyses were performed using Statview® 5.01 (Abacus Concepts Inc., Berkeley, 
CA, USA). 
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CHAPTER NINE: RESULTS 
IMPROVING ANTITHROMBOTIC PRESCRIBING IN AF 
9.1 Educational intervention uptake 
During the educational intervention, 272 guidelines were originally mailed and 
subsequently 162 GPs (60% of those in Southern Tasmania) were visited and the 
guidelines discussed. One hundred and ten GPs were not seen as they did not 
want the academic detailer to visit (n = 62), were overseas, on maternity leave, 
de-registered or otherwise unavailable (n = 8) or were 'too busy' to be seen (n = 
40). In some of these cases, computer mouse pads, RI-111 anticoagulation 
guidelines and SU' s contact details were left at the general practice (n = 49). The 
median duration of the educational visits was 15 minutes (range 5-60 minutes), 
with 40% of GPs seen individually. 
9.2 General practitioner survey evaluation 
There was an evaluation questionnaire response rate of 76% and the responses are 
summarised in Figure 18. Unsolicited comments made from visited doctors are 
displayed in Table 27 
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Academic detailing is a good way of receiving up-to-date unbiased information. 
  
• 1 
Strongly 
agree 
Strongly 
disagree 
 
The academic detailing session has reinforced my knowledge about antithrombotic (warfarin 
or aspirin) therapy for stroke prevention in atrial fibrillation 
  
I 
Strongly 
agree 
Strongly 
disagree 
 
Prior to the visit by SLJ, I routinely considered antithrombotic therapy for stroke prevention 
in atrial fibrillation 
Strongly 
	
Strongly 
disagree agree 
Following the visit, I am now more likely to consider antithrombotic therapy for stroke 
prevention in atrial fibrillation 
Strongly 
	
Strongly 
disagree agree 
The RHH anticoagulation guidelines will be useful for general practice 
	 e 
Strongly 	 Strongly 
disagree agree 
Figure 18 	Median responses to evaluation questionnaire: Improving 
antithrombotic drug use in AF 
(Ranges are plotted on 10 th and 90 th percentiles) 
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• Helpful, thank you. 
• Worthwhile session, thanks. 
• Easy way to receive up to date info. 
• These sessions are very useful and helpful. Perhaps provision of a pharmacist's number 
over any questions may also be worthwhile. Please keep them up. 
• The session was excellent and there will hopefully be more of them. They are a time 
efficient way of learning, revising and updating. Also not drug company biased. 
• Very useful meeting. 
• I enjoyed Shane's visit. 
• I was already using the yellow card from the hospital sent by Dr Vial. 
• Extremely useful and informative. 
• All patients of mine with AF see a cardiologist. A more useful exercise is the purple 
book, great. 
• The major problem with any detailing is time. It needs to be incorporated into our CME 
prgramme via liaison with the GP Division. 
• Was very good exercise. 
• Cardiologists seem to be able to distinguish between chronic and acute AF. 
• Academic detailing on targeted topics is very effective and enjoyable. Shane is very 
practical and knows his stuff very good. 
• Very helpful, thank you 
• If antithrombotic Rx is initiated in hospital and after hours or weekends, please ensure 
sufficient supply of medications, as some items are not instantly available at local 
pharmacy. Almost as important is a letter to say dosage given or requirement I have had 
several unfortunate incidents. 
• Very approachable, non-threatening mode of learning as there are no vested interests. 
This was a good way of getting info and clarifying the mirrors and smoke of drug reps. 
• Thank you Shane. 
• Would be useful when the patient is discharged and not began on warfarin, the reason for 
that decision is clearly delineated, so that the GP knows that it has been seriously 
considered. 
• I found this session very helpful and supportive and would appreciate strongly further 
sessions via the university or division of general practice for provision of unbiased 
information to balance drug company representative's approach. 
• Need other information regarding warfarin cessation if needed pre-op and type of 
operation and dental work. 
• Thank you, questions answered knowledgeably, useful revision. 
• Thank you. 
• Good. 
• Very useful exercise. 
• I must admit that I'm not keen on warfarin initiation. Probably not so necessary in an 
urban setting. 
• Very useful session, much more efficient use of time compared with drug reps. Please do 
more topics. 
• Excellent concise presentation, more please. 
Table 27 
	
Comments made from visited GPs 
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9.3 Antithrombotic therapy from patients admitted to the Royal 
Hobart Hospital 
The characteristics of patients admitted to the RHH with AF are displayed in 
Table 28. There were no significant differences between the two groups (before 
and after) with regards to key demographic and clinical variables. Table 29 
displays antithrombotic therapies for patient groups at baseline and after the 
intervention. There was a significant increase in the use of warfarin across all 
patients, those at high risk and patients with chronic AF. There was no significant 
increase in the use of aspirin. 
The use of warfarin on discharge from the hospital reflected the 
differences between the two groups on admission. Thirty-nine percent of all 
patients at baseline were discharged on warfarin, compared with 51% post-
intervention (x2 = 5.1, p < 0.05). Forty percent of high-risk patients at baseline 
were discharged on warfarin compared with 56% post-intervention (x 2 = 7.7, p < 
0.01). Of the high-risk patients without contraindications to warfarin, 49% and 
64% received warfarin at discharge at baseline and post-intervention, respectively 
(x2 = 4.8, p <0.05). 
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Baseline 
(n=245) 
Post-Intervention 
(n=157) 
Females (%) 50 52 
Median age (years) 75 75 
Chronic AF (%) 51 45 
Previous stroke (%) 14 12 
Previous TIA (%) 10 8 
Previous stroke/TIA (%) 20 18 
Hypertension (%) 64 67 
Diabetes (%) 22 25 
Ischaemic heart disease (%) 42 43 
Previous AMI (%) 23 20 
Congestive cardiac failure (%) 29 28 
Previous echocardiography (%) 69 76 
Contraindications to warfarin (%) 32 33 
Rhythm control drug therapy (%) 26 27 
Rate control drug therapy (%) 54 57 
Stroke risk 60 	High (%) 78 80 
Medium (%) 15 16 
Low (%) 7 4 
Table 28 	Hospital patient characteristics before and after the education 
program 
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Baseline 
(n=245) (%) 
Post-Intervention 
(n=157) (%) 
P 
value 
Warfarin 81/245 (33) 67/157 (43) 0.05 
Aspirin (if not on warfarin) 103/164 (63) 54/90 (60) 0.66 
Patients at high risk of stroke 
Warfarin 64/192 (33) 58/125 (46) 0.02 
Aspirin (if not on warfarin) 85/128 (66) 47/67 (70) 0.60 
High risk (no C/I* to warfarin) 
Warfarin 50/127 (39) 46/87 (53) 0.05 
Aspirin (if not on warfarin) 56/77 (73) 31/41 (76) 0.74 
Patients at intermediate risk 
Warfarin 11/37 (30) 9/25 (36) 0.60 
Aspirin (if not on warfarin) 15/26 (58) 7/16 (44) 0.38 
Chronic AF 
Warfarin 49/124 (40) 42/71 (59) 0.008 
Chronic AF at high Risk 
Warfarin 38/101 (37) 35/59 (59) 0.008 
Warfarin (no C/I to warfarin) 27/66 (41) 27/41 (66) 0.01 
Paroxysmal AF 
Warfarin 32/121 (26) 25/86 (29) 0.68 
Paroxysmal AF at high Risk 
Warfarin 26/91 (29) 23/66 (35) 0.40 
Warfarin (no C/I to warfarin) 23/61 (38) 19/46 (41) 0.71 
* C/I = contraindication 
Table 29 	Antithrombotic therapies on admission to the RHH at baseline and 
post-educational intervention 
9.4 Antithrombotic prescribing from Pharmaceutical Benefits 
Scheme data 
Dispensing data for antithrombotics in the intervention and control regions of 
Tasmania are displayed in Table 30. There was a significant increase in the use of 
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warfarin within the control region, but the increase within the intervention region 
was greater (Z = 6.48, p < 0.0001). There was also an increase in the use of 
aspirin in the intervention region compared with the control region; however the 
two regions had significantly different usage rates of aspirin prior to the 
intervention. 
Warfarin use (DDDs per 1000 of 	Aspirin use (Prescriptions per 1000 of 
population) 	 population) 
Region 2001 2002 Statistics 2001 2002 Statistics 
Intervention 
(South) 
1124 1191 Z = 14.1, 
p < 0.0001 
79.0 81.1 Z = 2.69, 
p = 0.01 
Control 
(North) 
1127 1149 Z = 4.83, 
p < 0.0001 
88.1 88.4 Z = 0.28, 
p= 0 . 79  
Statistics Z = 0.95, Z = 8.76, #Z = 6.48, Z= 11.49, Z = 9.03, 
p = 0.34 p < 0.0001 p < 0.0001 p < 0.0001 p < 0.0001 
The increase in the use of warfarin within the intervention region was significantly greater than 
within the control region 
Table 30 	Dispensing of warfarin and aspirin under the PBS and RPBS in 
Tasmania for the periods pre- and post-intervention 
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CHAPTER TEN: DISCUSSION 
IMPROVING ANTITHROMBOTIC PRESCRIBING IN AF 
In this project, educational material and the technique of academic detailing were 
employed to target the prescribing of antithrombotic therapy for stroke prevention 
in AF. Success of the educational program was indicated by a significantly greater 
increase in the prescribing of warfarin in the intervention region and also a 
significant increase in the use of aspirin compared with the control region. There 
was also a significant rise in the use of warfarin in a series of patients admitted to 
hospital with AF, before and after the intervention. 
It was apparent that a statistically significant improvement in the 
prescribing of warfarin occurred in the control region of the state over the course 
of the study, and this result was not unexpected. The issue of antithrombotics for 
stroke prevention in AF has received considerable attention and coverage in 
professional journals over the past few years. It was pleasing that our program 
was able to achieve significant changes in prescriber behaviour despite this 
background noise of educational activity. Also, contamination of the two groups 
of prescribers via professional contact is likely to some extent in any population, 
particularly a relatively confined one like Tasmania. An improvement in 
prescribing in the same control region has occurred in a number of previous 
academic detailing programs conducted in Tasmania. 240-242  The two regions are 
similar in regards to demographics and treatment practices, and recently, it was 
shown that the therapeutic management of patients with CCF was very similar 
between the North and South. 243 
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It is evident that there was a clear increase in the use of warfarin following 
the intervention. From the hospital admission data there was a 10% absolute 
increase for all patients in the use of warfarin, with higher absolute increases of 
up to 25% recorded in sub-groups of patients with chronic AF. The likely 
increases in treatments from educational interventions are generally small, and the 
effect sizes in this study are consistent with Cochrane reviews. 233 
It was interesting to note the low rates of antithrombotic prescribing for 
patients with paroxysmal AF - 29% and 35% of high-risk patients in the baseline 
and post-intervention groups, respectively, were receiving warfarin on admission. 
This may reflect under-recognition of the link between paroxysmal AF and 
stroke. A key educational point that was reinforced to GPs was that patients with 
paroxysmal and chronic AF have a similar risk of stroke. The findings from the 
AFFIRM 61 study were released after the education program had finished, so the 
recommendations from this study were not covered during the visits. The findings 
from AI-1-1RM and other rate control versus rhythm control trials need to be 
developed into educational packages and implemented at a general practice level. 
This program employed important strategies in relation to guideline 
dissemination and implementation 244  - the use of guidelines that were well 
supported by the evidence, with local adaptation through opinion leaders, 245 a 
"diagnostic analysis" of the target group was implemented prior to the 
intervention, 246 and a multi-faceted approach with written material, feedback 
from a local audit of antithrombotic therapy, and an outreach visit was employed. 
The use of a simplistic flow chart design to assist in risk stratification was 
a key change strategy for GPs in applying the evidence of antithrombotics for 
stroke prevention. Another study utilised an algorithm or flow chart to influence 
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prescribing with success. 247 This study was conducted in a hospital setting, and 
increased prescribing of appropriate antithrombotics from 48% before the 
intervention to 78%, following the intervention. 
While academic detailing has been shown to be an effective tool for 
modifying health professional behaviour, especially prescribing, 33 further 
research is needed on the specific characteristics that result in practice change. 233 
This is the first project to our knowledge that has demonstrated that academic 
detailing can increase the use of antithrombotics for stroke prevention in patients 
with AF. However, there clearly is room for further improvement. 
The total lifetime cost of ischaemic strokes in Australia was estimated to 
be Aus$936.8 million (US$709.7 million). 185 It is estimated that AF constitutes 
15% 154 of the 40,000 strokes that occur in Australia each year. 184, 186 By 
increasing the proportion of eligible (approximately 70% of all high risk patients 
would have no contraindications to anticoagulants) high-risk AF patients treated 
with anticoagulants, from 39% to 53% as shown in this study, we conservatively 
estimate that this project has the potential to reduce the number of AF-related 
strokes by 10% per annum, decreasing the total number of strokes per annum by 
about 1.5% or 600 strokes if applied across Australia. The reduction in health-
care costs associated with stroke would correspond to approximately Aust$14 
million per annum. To signify the benefit of this type of intervention, Australia's 
peak quality use of medicines organisation, the National Prescribing Service 
(NPS) is conducting detailing visits on antithrombotics in 2004 with a focus on 
antithrombotics for stroke prevention in AF. 248 
This study did not include a formal economic analysis, although as 
mentioned under-use of antithrombotics can have a huge impact on the healthcare 
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system. It is likely that the cost of these types of educational interventions 
targeting GPs would be small in comparison. There is some evidence that 
academic detailing can be cost-effective in influencing prescribing behaviour. 249 
There are some limitations to this study. The long-term effects of the 
intervention are unknown, and key educational messages should be regularly 
reinforced. In order to assess the effectiveness of the intervention, prescribing 
data were utilised, which assessed the same time periods of one year (to minimise 
secular trends biasing data), prior and post-intervention. Our results do not 
indicate whether patients were receiving warfarin for AF or any other indication, 
however the use of a control group minimises the risk of bias occurring with this 
data analysis. 
The GPs in the intervention and control groups were not selected 
randomly, and a controlled before and after study was employed utilising a 
historical control. It is not known if there were confounders in the geographical 
areas that may be responsible for the difference in the prescribing of warfarin 
using the PBS and RPBS data. However, these two areas have been used in 
previous studies with success u 240-242 and, as noted by Eccles 250, it is not 
appropriate just to consider evaluations only by randomised controlled trial given 
the complex nature of educational interventions. 
The use of before and after data analysis for the hospital cohort of patients 
may have some limitations in the interpretation of data. It could be suggested that 
the increase in warfarin use is a secular trend, however, there was little change in 
the use of antithrombotics for stroke prevention in the same population from 1999 
to 2001. In fact, 34% of high-risk patients from the 1999 study 193 were receiving 
warfarin compared to 33% in 2001. Also, the analysis occurred at the patient 
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level, while the intervention was applied to GPs. Thus, the analysis did not 
account for the nesting of patients within physicians, which may lead to artificial 
inflation of statistical significance. 
This educational program significantly improved the prescribing of 
warfarin for stroke prevention in AF, and if implemented across the spectrum of 
general practice could significantly reduce the incidence of stroke in patients with 
AF and its contribution to health-care expenditure. 
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PART THREE: PORTABLE INR MONITORS 
CHAPTER ELEVEN: INTRODUCTION 
11.1 Conventional laboratory or pathology testing 
Traditionally, primary care physicians or pathology services manage outpatient 
anticoagulation. The patient goes to a laboratory (usually a pathology specimen 
collection centre or general practice in Australia) to have their 1NR measured, and 
the result is reported to the physician, who determines the need for dosage 
adjustments. The need for physician-patient communication can be inconvenient 
for both parties. The inability to make timely contact with the patient and the 
potential for misinterpretation of information conveyed by the physician could 
result in dosage errors. 251 
The method of laboratory 1NR testing in Australia is by a 5mL venous 
sample of blood. The blood is drawn to fill a tube containing buffered sodium 
citrate and centrifuged. The INR is then determined using an analyser with 
thromboplastin reagent of varying ISI. 
11.2 Point-of-care testing 
There are several types of commercial devices available and manufacturers often 
do not disclose the way they work. Currently available devices use venous or 
capillary (fingerprick) blood. Blood flow from the fingerprick, contamination of 
blood with tissues, haematocrit and platelets are important pre-analytical variables 
that might affect INR results. In this respect, point-of-care (POC) testing devices 
are more prone to errors than conventional systems because the fingerprick 
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method is more difficult to standardise than venepuncture. On the other hand, it 
should be realised that preanalytical variability may be also high for conventional 
plasma lNR measurement if one considers the effect of different blood collection 
systems 252, 253 and the time/condition of specimen storage before testing. 254 
These variables do not affect POC testing. Table 31 shows the different types of 
POC testing devices available. 
Instrument 
Cbt Detectial 
Methodobg 
Type of 
Sample 
HMG US 
PPProva 
Protime Monitor 10GO Cbt initiation: Thromteplastin Capillary ViB No 
Coumatrar 
Ciba Coming 512 Coagulation Mcnitor 
Clot detedion: Cernation of bbod fiCIN through 
capillary channel 
Vencus WB 
CcagJCheic Plus' 
CoagiCtiek Pro' 
CcexClutic ProlDM' 
CoagiChek Clot in 	Thrombophstin Capillary WB Yast 
Catratheic S Clot detection: Cessation of movement of iren Venan WB Plasma (CoaaJChl 
Thromboktic Assassmecrt System partidas cnly) 
Rapidpoint Coag 
ProTIME Monitor Clot initiation: Thromb3plastin Dapillary WB Yes 
Heinrich= Jr 
GEM PC4 
Cbt detedion: Carnation of bbod flow through 
capillary channel 
Venous 5413 
Avosure Fto+§ Clot initiation: Thromboplastin Capillary WB Yes 
Avosure Pro§ 
Avosure PTh 
Clot detedion: Thrombin generations detected 
by fluorescent thrombin probe 
Vencus WB Plasma 
Harmony Clot initiation: Thromtoplastin Capillary WB Yes 
Clot detedbn: Cessation of bbod flan through 
capillary channel 
Vencus VIB 
INEttbll Cbt initiation: Thmmtoplastin Capillary WB Yes 
Clot detectbn: Change in impedance in sample Vencus 54B 
YiB Niceties atiob blood. 
'All instruments h this cdsgay are based on the original Biatrack model (Protime Monitor 1000) and lioansad under diffen 
names. The late version available is The CoaguChek Pro and Pro/DM (as models evoked, they acquted ached capabilitiasX ear 
mcdels are no bnger 
tCoaguChek not actively marketed for home use at the time of this wiling. Ihrombolytic Ass3ssment System not availabb for hi 
USB. 
Hemochren Jr and GEM PCL are simplified versicns of the oTIME Monitor. 
VCOSUID hstruments removed from market Olen manufacturer (Ancet, tic) ceased operations (2C01). Tedthology has sinoo Ix 
pJrchased by Beclanan Carter. 
IINRange system manufaclued by Hemcsense, lit, currently in dembpment. 
Table 31 	Capillary whole blood point-of-care INR instruments. 
Reproduced from Hirsh et al. 73 
11.3 CoaguChek S INR monitor 
The CoaguChek S concept comprises determination of INR using either capillary 
or whole venous blood. 253 A number of studies have evaluated the CoaguChek 
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system that was first introduced in 1993, continuing via the improved CoaguChek 
PT Test mini test strip in 1998, up to the introduction of the CoaguChek S in early 
2000. 253 ' 255-273 
The CoaguChek INR monitor (Figure 19) is a portable, laser coagulometer 
that measures the INR using whole blood obtained by fingerprick. 274 The test 
itself comprises insertion of a test strip into the monitor and the application of a 
drop of blood onto the test strip. The surface of the test strip is coated with a 
mixture of iron oxide particles and rabbit brain thromboplastin. The strip is 
inserted into the monitor and prewarmed to 37 °C. A drop of blood (401.tL) is then 
applied to the application field of the test strip where it is drawn by capillary 
action into the reaction field, where it comes into contact with thromboplastin, 
triggering the coagulation cascade. Inside the monitor are located two magnets, 
which cause perpendicular alignment of rod-shaped iron oxide particles found on 
the test strip. This gives rise to a regular pulsating pattern, which is registered by a 
photoelectric cell. As the fibrin matrix forms, the movement of iron oxide 
particles is progressively impeded, before becoming completely impeded. This 
results in a decrease in reflection that is interpreted by the monitor as the onset of 
coagulation. 
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Figure 19 	The CoaguChek S Reflectance Photometer 
The monitor measures the time interval between first contact of the blood 
sample with thromboplastin and the onset of coagulation and calculates this value 
as an INR with the aid of a calibration curve. This calibration curve data is stored 
in a lot-specific code-chip. Cartridges provided by the manufacturer contain 
several different lots; these lots are standardised by the manufacturer so that the 
ISI of the cartridges remains constant at 1.70. 256 An INR result is provided within 
one minute of application of the blood sample to the CoaguChek S monitor. 256 
With the introduction of the CoaguChek S system in early 2000, 
evaluation studies confirmed that there were no monitor specific influences on 
test results, no difference in scatter observed between INR values obtained via 
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CoaguChek and CoaguChek S, and the newer model monitor was rated highly by 
most study participants. Furthermore, a recent study has confirmed that the 
CoaguChek S is a suitable alternative to the CoaguChek with comparable 
accuracy and precision to that of the older system, with a lower amount of 
technical errors. 257 
11.4 Accuracy and reproducibility 
The accuracy of the INR measured with POC testing devices depends essentially 
on the calibration. Presently, the responsibility of calibration rests entirely with 
manufacturers because access to the software to change encoded parameters is not 
possible for the majority of commercial devices. Easier calibration procedures for 
POC testing devices are currently under investigation by the European Concerted 
Action on Anticoagulation (ECAA) working group. 263-265, 267-270, 272, 275-277  
To check the performance of POC testing, comparing the INRs measured 
using the devices with those measured using conventional methods is a common 
method. By definition, the true INR of a given plasma sample should be the one 
measured with the primary international reference preparation (IRP) for 
thromboplastin, called 67/40, coupled with the manual (tilt-tube) technique to 
detect clot formation (defined as the standard method). However, the IRP 67/40 
was discontinued many years ago and replaced by other IRPs, which were 
calibrated against their predecessors. Therefore, the true INR is not known. For 
practical purposes, it can be assumed that the INR measured with one of the 
established ERPs for thromboplastin coupled with the manual (tilt-tube) technique 
is a good approximation of the true value. The INR measured with other 
conventional systems may also be considered as a good approximation of the true 
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value only if they have been calibrated against an 1RP. The reproducibility 
assessed for one commercial POC testing device was acceptable (median CV = 
4.18%), but poorer than that of the conventional laboratory INR measurement 
(median CV < 1.5%). 278 
The College of American Pathologists suggests if one method of 
monitoring anticoagulation is to be replaced or supplemented by another method, 
the new method should be calibrated against the old method. 279 Therefore, a 
correlation study of both methods is a crucial step prior to implementing the POC 
method. 
11.5 Statistical & clinical agreement 
The agreement between paired 1NR measurements (i.e. those obtained with the 
POC testing device and those obtained with the standard method) can be assessed 
by statistically or clinically relevant criteria. Statistically relevant criteria are 
concerned with the correlation analysis of paired 1NR measurements and/or 
comparison of mean values. Although they are widely used it should be realised 
that these statistical evaluations, if used alone, are not very informative. For 
instance, two methods might be highly correlated (high correlation coefficient) 
even though their results are systematically biased. It is more useful to plot the 
differences of paired measurements against the average value. 280 This enables an 
assessment of systematic differences over the whole range of measured INRs. 
Clinically relevant criteria usually rely on the assumption that the INR 
values measured for the same patient by two systems are in agreement, if using 
either INR does not result in changes of dose prescription. Requirements for 
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agreement of paired 1NR measurements have been developed 256' 281 and may  
form the basis for POC testing assessment. Being more closely related to decision 
making on dose prescription, the agreement based on clinically relevant criteria 
should be considered more meaningful than that based on statistically relevant 
criteria. 
11.6 Clinical endpoints 
The reliability of POC testing devices has also been assessed in prospective 
studies using appropriate end-points i.e. the time in the therapeutic interval and 
289 the occurrence of haemorrhagic or thrombotic complications. 282- These studies 
have provided evidence on the reliability of POC testing devices but also on the 
efficacy of patients self-testing or self-management. A number of studies have 
been performed on relatively small series of selected patients over the last few 
years. Generally, all studies found the management with POC testing devices 
better or at least as effective as the management run by specialists or GPs in 
combination with conventional laboratory control. Similar conclusions were also 
reached in those studies in which the comparison of effectiveness has been made 
versus specialised anticoagulant clinics. 284-286  
11.7 Aims and objectives: Royal Hobart Hospital anticoagulation 
clinic 
The objective of the third study in this thesis was to assess the accuracy, 
reproducibility and clinical agreement of the CoaguChek S portable INR monitor 
in the Australasian outpatient setting, prior to its evaluation in general medical 
practice. 
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CHAPTER TWELVE: METHODS 
ROYAL HOBART HOSPITAL ANTICOAGULATION CLINIC 
12.1 Clinic participants 
The study was undertaken at the anticoagulation outpatient clinic at the RHH, a 
450-bed acute care teaching hospital and the only major public hospital in the 
southern region of Tasmania, Australia (serving a population of approximately 
230,000). This small clinic is conducted weekly and mainly manages patients 
whose anticoagulant control has been difficult in the community setting. Over a 
16-month period, patients who attended the clinic gave informed consent to 
undergo fingerprick testing with the CoaguChek S INR monitor, in addition to 
having a normal laboratory INR test. Patients with lupus anticoagulant were 
excluded, as some of these patients are known to produce errant INR values with 
phospholipid-based tests. 290 
12.2 Pathology methods for determination of INR 
Trained nurses drew the venous blood samples by standard techniques into 
0.129M (3.8%) sodium citrate tubes. Centrifuged samples were then analysed by 
the ICA6000 (Sysmex, Japan, distributed by Dade Behring in Australia) within 4 
hours of the venepuncture. The thromboplastin reagent used by the laboratory 
changed from Innovin (Dade Behring) to Recombiplastin (IL) when the Innovin 
was discontinued in March 2002. The ISI of the Innovin thromboplastin was 1.13, 
and the Recombiplastin 1.10. 
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12.3 Point-of-care methods for determination of INR 
Two operators performed all tests, with basic training in the use of the 
CoaguChek S monitor. The result from the CoaguChek S was recorded for later 
comparison with the patient's corresponding laboratory 1NR value. 
12.4 Comparison of techniques 
Clinical agreement was measured by discrepant INR values and by INR values 
resulting in a different clinical decision. Discrepant values were defined as INR 
results from the CoaguChek S that were different from the laboratory in the 
categorisation of the individual patient's INR value. The INR categories were 
nominated as 1.0-1.9, 2.0-3.0, 3.1-3.9 and? 4.0. 
The number of 1NR values that would have resulted in a different 
therapeutic decision was based upon clinician decision to leave the warfarin dose 
the same, or to increase or decrease the dose based upon clinical judgment. This 
was achieved by giving the attending haematology registrar a list of patients with 
the two INR readings. The clinician was blinded as to which 1NR was the 
CoaguChek S or laboratory value. The clinician indicated whether to maintain the 
same anticoagulant dose, or to increase or decrease it based on each of the values 
and the patient's history. The usual therapeutic ranges were 2.0-3.0 for AF and 
other thromboembolic disorders, and 2.5-3.5 for patients with mechanical heart 
valves. 132 
Published criteria for clinical agreement (expanded and narrow) 256 were 
also assessed. Expanded agreement was achieved if comparison between tests 
fulfilled any of the following: both the CoaguChek S and the laboratory 1NR were 
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within, above or below the patient's targeted range, or the difference between the 
CoaguChek S and the laboratory INR when one of the pair was within the 
targeted range was no more than 0.5 units. Narrow agreement was achieved if 
comparison between tests fulfilled any of the following: both the CoaguChek S 
and the laboratory INR were within the patient's targeted range; both the 
CoaguChek S and the laboratory INR were above the targeted range and the 
values were within 0.8 units; both the CoaguChek S and the laboratory INR were 
below the therapeutic range and the values were within 0.4 units; or the difference 
between the CoaguChek S and the laboratory INR when one of the pair was 
within the targeted range was no more than 0.5 units. 
12.5 Statistical methods 
Accuracy of the CoaguChek S was determined by comparing the INRs from the 
monitor and the laboratory values on a linear regression analysis. A Bland-
Altman plot 280 was utilised to assess the magnitude of disagreement between the 
monitor and the laboratory INRs. A paired t-test (p <0.05 considered significant) 
was used to compare the INR values with the CoaguChek S and laboratory 
methods. Reproducibility was defined by the coefficient of variation with three 
repeated tests done in a random sub-set of clinic patients (n = 21). 
12.6 Interpatient variability 
A total of 27 patients had more than five repeated tests over the course of the 
evaluation. The results were analysed by a number of different measures, these 
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included correlation coefficient, mean difference, mean percentage difference, 
category agreement (categories were 1.0-1.9, 2.0-3.0, 3.1-3.9 and >4.0), expanded 
and narrow agreement, 256 proportion within 10% of laboratory INR and 
proportion within 0.5 INR units of the laboratory INR. Patients were categorised 
in the anticoagulation clinic as low agreement if the following variables were 
satisfied: mean percentage difference was greater than 20% and the mean 
difference was greater than 0.5 INR units. 
Post-hoc analyses of factor levels (F) were assessed in a convenience 
sample of patients who had low agreement (n=4) and high agreement (n=12). 
Two patients had died when factor analyses were undertaken and one patient had 
ceased attending the clinic. Coagulation factors II (FII), VII (FVII) and X (FX) 
activity expressed in (U/mL) was determined using RecombiPlasTin (Ortho-
Clinical Diagnostic Systems, Bucks, UK) using specific factor deficient plasma. 
Coagulation factor IX (FIX) activity expressed in (U/mL) was determined by an 
aPTT-based assay (Dade-Behring, Marburg, Germany) using specific factor 
deficient plasma. Lupus anticoagulant was determined using a dilute Russell viper 
venom time (DRVVT)-based assay (Gradipore, Australia) 
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CHAPTER THIRTEEN: RESULTS 
ROYAL HOBART HOSPITAL ANTICOAGULATION CLINIC 
13.1 Accuracy & reproducibility 
A total of 248-paired samples were obtained from 43 different patients. The mean 
1NR values for the laboratory and CoaguChek S, as well as the status of the 
anticoagulant control, are listed in Table 32. The CoaguChek S INR values were 
significantly correlated with the laboratory INR values (r = 0.90, p < 0.0001; 
Figure 20). The mean difference in INR (laboratory minus CoaguChek S) was 
0.19 (95% confidence interval (CI): 0.14 - 0.25; paired t = 6.7, df = 247, p < 
0.0001). The mean coefficient of variation for 21 individual patients with the 
CoaguChek S INR was 4%, with a range of 0% to 9.1%. 
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Parameter CoaguChek S Laboratory 
INR (mean ± SD) 
Mean difference ± SD 
Percentage within 0.5 1NR units 
Percentage within 10% of laboratory 
HR 
INR value, n (%) 
2.44 ± 0.82 
44.0 
248 (100) 
- 0.19 ± 0.46 
82.5 
2.64 ± 1.03 
248 (100) 
< 1.9 69 (27.8) 52 (21.0) 
Mean INR ± SD 1.67 ± 0.26 1.69 ± 0.26 
Mean difference ± SD - 0.02 ± 0.23 
Percentage within 0.5 INR 
units 
92.2 
Percentage within 10% 53.9 
2.0-3.5 155 (62.5) 162 (65.3) 
Mean INR ± SD 2.51 ± 0.38 2.56 ± 0.43 
Mean difference ± SD - 0.16 ± 0.37 
Percentage within 0.5 1NR 
units 
81.1 
Percentage within 10% 42.6 
> 3.6 24 (9.7) 34 (13.7) 
Mean INR ± SD 4.25 ± 0.90 4.44 ± 1.48 
Mean difference ± SD - 0.67 ± 0.70 
Percentage within 0.5 INR 
units 
50.0 
Percentage within 10% 35.3 
Table 32 	Comparison of anticoagulation clinic CoaguChek S and laboratory 
INR results 
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Figure 20 	Relationship between CoaguChek S and laboratory INR values: 
Anticoagulation clinic 
The Bland-Altman style plot is shown in Figure 21. The CoaguChek S 
showed only slight variation compared with laboratory testing for INR values < 
3.5, with increased scatter around zero as the INR increased to > 3.5. The 
CoaguChek S was more likely to underestimate the INR, relative to the 
laboratory, particularly at values > 3.5. 
166 
C
o
a
g
u
C
he
k 
S 
IN
R
 -
  L
a
bo
ra
to
ry
  I
N
R
 
-1 
-2 
3 
0 
1 
• • 
• 
• 
• 
• 
• 
	
0 
	
2 	 4 	 6 
Mean of CoaguChek S and Laboratory INRs 
Figure 21 	Bland-Altman plot for CoaguChek S and laboratory INR values: 
Anticoagulation clinic 
The categorisation of laboratory and CoaguChek S INRs is shown in Table 33. 
There was a significant relationship between the two methods (x2 = 261, df = 9, p 
<0.0001). Discrepant categorisation of the INR value between the laboratory and 
CoaguChek S occurred in 31% of the samples. That is, 69% (170/248) of 
CoaguChek S values were placed in the same nominal category as the laboratory 
INR. Twenty-four percent were falsely lowered with the CoaguChek S 
(corresponded to a higher laboratory reading) and 8% were falsely elevated 
(corresponded to a lower laboratory result). 
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INR Range 
CoaguChek S INR 
1.0-1.9 
(n = 68) 
2.0-3.0 
(n = 135) 
3.1-3.9 
(n = 34) 
?4.0 
(n = 11) 
1.0-1.9 
82 18 0 0 
(n = 51) 
Laboratory 2.0-3.0 
20 73 6 1 INR (n = 131) 
3.1-3.9 
0 53 45 2 
(n = 51) 
?4.0 
0 13 27 60 
(n = 15) 
Values given as percentage of laboratory readings 
Table 33 	Comparison of anticoagulation clinic INR categories for 
CoaguChek S and laboratory results 
13.2 Clinical decision making 
An analysis of the warfarin dosage decisions of the blinded hematology registrar is 
shown in Table 34. The relationship between decisions based on the CoaguChek S 
and those based on laboratory INRs was statistically significant (x 2 = 154, df = 4, 
p <0.0001). It can be seen from this table that 73% of all CoaguChek S readings 
would have prompted the same clinical decision as the corresponding laboratory 
value - 42% for a decision to decrease anticoagulant dosage based on the 
laboratory result, 80% for a decision to increase dosage of anticoagulant and 80% 
for a decision to leave the dose of anticoagulant the same. The mean laboratory 
INR for dose decreases that were not in agreement was 3.6. Expanded and narrow 
agreement 256 between the two INR values occurred 90% and 88% of the time, 
respectively. 
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Warfarin 
dosage 
decision 
CoaguChek S 
Decrease 
(n = 24) 
Same 
(n = 157) 
Increase 
(n = 67) 
Laboratory 
Decrease 
(n = 45) 
42 58 0 
Same 
(n = 152) 
3 80 17 
Increase 
(n = 51) 
0 20 80 
Values given as percentage of laboratory readings 
Table 34 	Analysis of clinician decisions based on CoaguChek S compared 
with laboratory INR result in the anticoagulation clinic 
13.3 Interpatient variability 
A total of 27 patients provided more than 5 tests over the trial period amounting 
to 213 paired INR measurements with a correlation coefficient (r) of 0.9. The 
individual results are summarised in Table 35. The mean coagulation factor levels 
for high agreement and low agreement patients are displayed in Table 36. 
Previous laboratory results did not reveal abnormal haematocrit levels for the 
patients with poor agreement. 
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Patient Number 
of tests 
R Mean 
difference 
Mean % 
difference 
Category 
agreement 
(%) 
Expanded 
agreement 
(%) 
Narrow 
agreement 
(%) 
Within 0.5 
INR units 
(%) 
Within 
10% 
(%) 
1 8 0.30 -0.23 10.7 100 100 100 100 38 
2 5 0.99 -0.14 5 100 100 100 100 60 
3 5 0.91 -0.14 6.6 80 100 100 100 60 
4 9 0.62 -0.14 7 78 100 100 100 56 
5 8 0.94 -0.63 29.7 25 50 38 50 0 
6 9 0.85 -0.44 20.7 56 89 89 78 22 
7 12 0.85 -0.11 3.7 92 100 100 92 83 
8 7 0.78 0.29 10.5 57 100 100 72 57 
9 9 0.98 -0.57 13.7 67 89 78 78 22 
10 10 0.99 -0.59 29.4 80 80 60 50 10 
11 11 0.91 -0.15 9.1 91 100 100 100 63 
12 5 0.99 -0.26 6.9 60 100 100 80 60 
13 10 0.83 -0.15 0.4 70 100 100 100 50 
14 11 0.27 -0.02 7.3 80 90 90 91 73 
15 8 0.91 -0.33 11.1 63 88 75 75 50 
16 11 0.96 -0.67 30.5 55 64 64 27 0 
17 7 0.97 -0.10 3.7 86 100 100 100 85 
18 12 0.82 -0.39 15.4 42 92 92 83 25 
19 6 0.95 -0.12 5.1 50 100 100 100 50 
20 6 0.28 0.27 7.5 83 83 83 83 50 
21 9 0.99 -0.19 7.7 89 89 89 89 67 
22 5 0.79 0.14 6.5 100 100 100 100 60 
23 6 0.86 -0.53 27.8 17 83 67 33 0 
24 6 0.99 -0.20 4.9 100 100 100 83 67 
25 5 0.82 -0.42 15.4 40 80 80 80 20 
26 5 0.78 -0.40 1.9 60 80 80 80 60 
27 8 0.93 0.15 6.5 63 100 100 88 63 
Patients with low agreement are highlighted 
Table 35 	Agreement between CoaguChek S and Laboratory INR for individual patients in the 
anticoagulation clinic 
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II 	VII 	IX 	X 
High agreement (n=12) 0.439 0.290 0.488 0.190 
Low agreement (n=4) 0.458 0.378 0.542 0.245 
P value 	 0.86 	0.32 	0.50 	0.40 
Table 36 	Mean factor levels for poor and high agreement 
patients in the anticoagulation clinic 
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CHAPTER FOURTEEN: DISCUSSION 
ROYAL HOBART HOSPITAL ANTICOAGULATION CLINIC 
When comparing the accuracy of the CoaguChek S to the laboratory method for 
INR measurement, one problem is the lack of a gold standard for comparison. The 
true gold standard for the INR value is a test using the manual tilt-tube technique 
with the use of a WHO IRP thromboplastin. 257 It is important to note that the 
laboratory analysis is therefore not infallible, and that aberrant results may have 
been a combination of over or underestimation by the CoaguChek S and vice-
versa by the laboratory analysis. For instance, previous studies have found that 
the variation between portable coagulometers and the laboratory was not larger 
than the variation encountered between different laboratories measuring a single 
sample. 278  However, as the comparison to the true gold standard was not 
available, the laboratory must be treated as the gold standard for the purposes of 
this evaluation. 
In a study designed to test the accuracy of CoaguChek S INR readings 
compared to laboratory-tested INR values, we found the CoaguChek S to be 90% 
accurate against expanded agreement criteria and 88% accurate against narrow 
agreement criteria. 256 This compares favourably with data from other previously 
published studies where the older model of CoaguChek monitor was found to be 
90% accurate against expanded agreement criteria 281 and 86% accurate against 
narrow agreement criteria. 256 A recent study showed 98% and 97% agreement 
against expanded and narrow criteria, respectively, with the CoaguChek. 272 
Using the clinician-defined agreement criteria for warfarin dosing, the 
CoaguChek S was found to be accurate 73% of the time for all decisions. It is 
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important to note that a decision to increase the anticoagulant dose based on the 
CoaguChek S value never resulted in a clinical decision to decrease the 
anticoagulant dose based on the laboratory value. Similarly, the clinician would 
not have decreased the anticoagulant dose based on the CoaguChek S when they 
actually increased the dose based on the laboratory value. 
The CoaguChek S performed well for dose increases and when no change 
was made to therapy, however it performed less adequately when dose decreases 
were compared. It would appear that the CoaguChek S generally gives an 
adequate indication of high INRs if they are above 3.5. If dose decreases are made 
on the cusp of the therapeutic range the monitor performs less consistently in 
clinical terms. The definition of agreement used in this analysis was based on the 
clinician decision to maintain, lower, or increase the dose of anticoagulant, based 
on each of the paired samples, and took into account factors such as prior INR 
values, patient factors and trends in INR. This method of comparison is more 
relevant to actual practice than the arbitrary expanded and narrow agreement 
criteria used in prior evaluations. 
In a recent study analysing the CoaguChek S, 257 agreement was found 
75.5% of the time. The agreement criteria in this case were stricter than any 
previously used in the literature. The criteria for discrepancy was defined as 1 
INR outside of the therapeutic range and the other value within the range, or both 
INR values outside of the therapeutic range and differing by > 0.5 INR units. 
The CoaguChek S produced reproducible INR results, with a mean 
coefficient of variation below 5%. This study found that the CoaguChek S had a 
similar correlation (r = 0.90) with laboratory INRs as those seen in prior studies of 
the CoaguChek and the CoaguChek S (r = 0.91-0.97). 291 Regression analysis is 
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only a measure of correlation, not accuracy; a far superior measure is the Bland-
Altman analysis. 280 Both of these analyses indicated a general underestimation of 
the INR, which may need to be factored in to the interpretation of INR results 
given by the CoaguChek S monitor. Eighty-three percent of all dual 
measurements were within 0.5 INR units in this study, which compares 
favourably to the figure of 79% reported by Douketis et al. 256 
As with prior evaluations, the CoaguChek S was most accurate when 
within the bounds of therapeutic 1NRs. This finding has also been observed with 
292 278, other portable INR monitors. 274, 	The proportion of dual INR measurements 
within 0.5 INR units for laboratory INR ranges of <2.0, 2.0-3.0, 3.1-4.0 and >4.0 
was found by Douketis et al. to be 98%, 87%, 57% and 21%, respectively. These 
data closely match our data for similar ranges of <1.9, 2.0-3.5 and 3.5, giving 
values of 92%, 81% and 50%, respectively, within 0.5 INR units. 256 They 
concluded from the results of their study that the CoaguChek monitor "achieved a 
clinically acceptable level of accuracy when compared to the traditional 
laboratory method and provides a suitable alternative method of monitoring the 
273 1NR in patients receiving warfarin". 	It has also been noted "as with any 
method of measuring the 1NR, if a high value is found that is not consistent with 
what was expected, a repeat test with an alternative method may be 
considered". 257 
This and most other studies have shown that the CoaguChek and CoaguChek S 
devices produce 1NR values that are highly correlated with laboratory INR values 
(r = 0.91 - 0.97) and agree with the laboratory 1NR in therapeutic decisions or 
294 293 291 278 259, 	, 	, 	, dosage alterations in 81-92% of cases. 256, 	 A recent study by 
Reiss et al. 295 has been the only study that has found that the CoaguChek system 
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showed relatively poor agreement with the laboratory method. The findings of 
this study were that mean differences in paired INR values were small, but 95% 
CIs were wide (-1.08 to 1.36), and the correlation coefficient (r) was found to be 
0.72. 
The anticoagulation clinic utilised in this study is used by GPs for patients 
with poor control of their 1NR. Four of the patients with multiple testing had low 
agreement compared to conventional laboratory INR. There may be an underlying 
or idiopathic reason that causes these patients to be unstable with their INRs and 
subsequently give lower correlated readings with the CoaguChek S monitor. 
278 Variation between laboratories has been observed in previous studies, 	296 and 
theories such as the insensitivity of thromboplastins used have been proposed as 
reasons for this. 278,297 
Recently, Atterman 298 has proposed that the validity of predicted INR is 
affected by two components; a systematic error in the slope estimate and the 
interaction between patients and PT systems. Previous studies have noted that 
individual sample differences exist when stored samples have been tested. 299 
There are a number of pre-analytical variables that can affect the accuracy of the 
POC coagulation monitors, these include squeezing of the finger and the 
temperature of the patients' fingers. 
Factor VII dysfunction has been reported to adversely affect the accuracy 
of rabbit brain thromboplastin tests 3® while not adversely affecting bovine or 
human thromboplastins. Although there was no significant difference between the 
factor levels for patients with high and low agreement, the patient numbers were 
small and statistical power is low. This is the first evaluation that has reported 
individual patient accuracy with the use of the CoaguChek S monitor; further 
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studies are needed to identify patients with low agreement and reasons behind this 
phenomenon. 
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CHAPTER FIFTEEN: METHODS 
RURAL GENERAL PRACTICE INR MONITORING 
15.1 Rural general practice INR monitoring 
This project aimed to evaluate the usefulness and accuracy of portable LNR 
monitors in Australian rural medical practice. 
15.2 General practices and training methods 
The CoaguChek S monitor was evaluated in 15 rural medical practices: in 
Tasmania (8), South Australia (4) and Northern Queensland (3). The rural 
practices were identified by liaison with University Departments of Rural Health 
(UDRH) in each state. Once identified, SLJ and another researcher traveled to 
each site to educate the GPs and/or practice nurses on the accurate and effective 
use of the monitor. They were given a laminated A4 sheet (Appendix 7) outlining 
the use of the monitor and a list of common problems and their management. 
They were instructed to obtain written informed consent to undertake testing on 
patients (Appendix 8). All sites received the same training with the CoaguChek S 
and all had access to further assistance from investigators if required. A monitor 
was left at each practice for approximately 2 to 3 months. 
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15.3 Methods for laboratory and point-of-care determination of INR 
The laboratory procedure for INR determination varied between the general 
practice sites, and as such was not uniform for the entire analysis. Patients taking 
warfarin at these practices were asked to provide a fingerprick sample of blood 
for the CoaguChek S at the same time, as they were to have a venous sample 
taken for normal laboratory measurement of INR. The results were tabulated on 
an individual patient form (Appendix 9) and compared once the pathology result 
was obtained. The GPs or practice nurses also completed a series of questions for 
each patient. 
15.4 Evaluations 
A questionnaire was supplied to each practice and completed at the end of the 
trial period by the primary user of the CoaguChek S monitor. Responses were 
assessed quantitatively via a visual analogue scale with the aim of evaluating the 
user's overall experience with the monitor. The extremes of the 10-cm scales 
were marked with (0) "No, not at all" and (10) "Yes, most definitely". 
15.5 Statistical methods 
The INR values from CoaguChek S and the laboratory were compared using 
regression analysis. A Bland-Altman plot 280 was utilised to assess the magnitude 
of disagreement between the CoaguChek S and the laboratory. The accuracy of 
the CoaguChek S at INR values < 1.9, between 2.0-3.5 and > 3.6 was also 
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evaluated. Examined in these categories was the mean difference of the INR 
value, the magnitude of the INR difference, the proportion of INR measurements 
within 10% 268 and the proportion of dual measurements that were within 0.5 INR 
units. Published criteria for clinical agreement; (expanded and narrow) 256 were 
also assessed, as in the anticoagulation clinic. 
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CHAPTER SIXTEEN: RESULTS 
RURAL GENERAL PRACTICE INR MONITORING 
16.1 Descriptive analysis 
In total, 401-paired samples were measured from 169 anticoagulated patients 
from the 15 rural general practices that completed the evaluation. Table 37 shows 
the number of patients and INR readings from each site, as well as the correlation 
coefficient between laboratory and CoaguChek S 1NR values for each site. 
Practice & location INR values n 
(% of total) 
Patients n 
(% of total) 
r 
1 Nthn Qld 19(4.7) 7(4.1) 0.92 
2 Nthn Qld 54 (13.5) 30 (17.8) 0.84 
3 Nthn Qld 50 (12.5) 13 (7.7) 0.91 
4 Tas 61 (15.2) 19 (11.2) 0.91 
5 Tas 15(3.7) 10(5.9) 0.98 
6 Tas 43 (10.7) 16 (9.5) 0.93 
7 Tas 18(4.5) 9(5.3) 0.86 
8 Tas 13(3.2) 6(3.6) 0.96 
9 Tas 3(0.7) 2(1.2) 0.99 
10 Tas 35(8.7) 12(7.1) 0.92 
11 Tas 34 (8.5) 12 (7.1) 0.93 
12 Sth Aust 11(2.7) 3(1.8) 1.00 
13 Sth Aust 21(5.2) 21 (12.4) 0.85 
14 Sth Aust 16 (4.0) 6 (3.6) 0.92 
15 Sth Aust 8 (2.0) 3 (1.8) 0.94 
Table 37 	Individual general practice results 
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16.2 Accuracy and clinical agreement 
Figure 22 and Figure 23 show conventional regression analysis of CoaguChek S 
versus laboratory results and a Bland-Altman plot, respectively. The CoaguChek 
S INR values were significantly correlated with the laboratory 1NR values (r = 
0.89, p < 0.0001). The CoaguChek S showed slight variation compared with 
laboratory testing for INR values <3.5, with increased scatter around zero as the 
INR increased to >3.5. This finding suggests that the system was more likely to 
underestimate the INR value, relative to the laboratory, particularly at values 
>3.5. 
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Figure 22 	Relationship between CoaguChek S and laboratory INR values: 
General practice INR monitoring 
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Figure 23 	Bland-Altman plot for CoaguChek S and laboratory INR values: 
General practice INR monitoring 
Clinical agreement against published expanded and narrow criteria 256 
occurred 93% and 90% of the time, respectively. Table 38 shows the comparison 
of 1NR results determined by the laboratory and CoaguChek S. Overall, 88% of 
the dual measurements were within 0.5 INR units of each other. For laboratory 
INRs <1.9, 2.0-3.5 and? 3.6, 97%, 90% and 57% of readings were within 0.5 
INR units, respectively. 
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Parameter CoaguChek S Laboratory 
INR (mean ± SD) 
Mean difference ± SD 
Percentage within 0.5 INR units 
Percentage within 10% of laboratory 
INR 
INR value, n (%) 
2.39 ± 0.87 
55.1 
401 (100) 
-0.08 ± 0.42 
87.9 
2.54 ± 0.94 
401 (100) 
< 1.9 127 (31.7) 96 (23.9) 
Mean INR ± SD 1.55 ± 0.31 1.55 ± 0.26 
Mean difference ± SD 0.00 ± 0.23 
Percentage within 0.5 INR 
units 
96.9 
Percentage within 10% 54.2 
2.0-3.5 239 (59.6) 259 (64.6) 
Mean INR ± SD 2.55 ± 0.38 2.59 ± 0.26 
Mean difference ± SD -0.08 ± 0.34 
Percentage within 0.5 INR 
units 
90.0 
Percentage within 10% 58.3 
?3.6 35(8.7) 46 (11.5) 
Mean INR ± SD 4.33 ±0.93 4.35 ± 1.14 
Mean difference ± SD -0.27 ± 0.82 
Percentage within 0.5 INR 
units 
56.5 
Percentage within 10% 39.1 
Table 38 
	
Comparison of general practice CoaguChek S and laboratory INR 
results 
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16.3 Evaluation questionnaire 
A total of 19 questionnaires were returned from the 15 general practices. The 
survey responses are summarised in Figure 24. 
1. Was the availability of the CoaguChek S monitor useful to the clinical practice? 
I 	 *—I I 	 I I 	I 
No, not Yes, most 
at all 	 definitely 
2. Was the CoaguChek S easy to use? 
—1 1 
Yes, most 
definitely 
3. Were any difficulties experienced with the monitor? 
No, not 
	
Yes, most 
at all definitely 
4. Were you confident in the accuracy of the monitor? 
o 	 
No, not 	 Yes, most 
at all definitely 
5. Do you think there would be any problems with having the monitor available in 
Australian medical practice? 
11—* I 	I i 	 I  
No, not 	 Yes, most 
at all definitely 
6. Would you prefer to use the CoaguChek S monitor compared with conventional 
pathology practice? 
	 * —I  
No, not 	 Yes, most 
at all definitely 
7. Do you believe that your anticoagulated patients would prefer you to use the CoaguChek 
S monitor compared with conventional pathology testing? 
No, not 
	
Yes, most 
at all definitely 
8. Would you feel more confident in prescribing warfarin, knowing that you can routinely 
test your patient's LNR values with a CoaguChek S monitor? 
I  
Yes, most 
definitely 
Figure 24 	Responses to the evaluation questionnaire- General practice INR 
monitoring 
Medians, with range lines plotted at the 10 th and 90 th percentiles 
No, not 
at all 
*1 	 
No, not 
at all 
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CHAPTER SEVENTEEN: DISCUSSION 
RURAL GENERAL PRACTICE INR MONITORING 
This study was unique in evaluating the CoaguChek S in a number of diverse 
settings (e.g. vastly different climatic conditions) and with many potential users. 
The performance of the CoaguChek S in the general practice setting was 
excellent, especially when considering that data was collected from many sites 
and was compared with different laboratories. Overall, 88% of dual INRs were 
within 0.5 lNR units of each other. The correlation coefficients (r) from the 
various sites ranged from 0.84 to 1.00, with relatively little difference between the 
sites. All sites received the same training and support with the CoaguChek S 
monitor, so this is a good indication of the portability and ease of use of the 
CoaguChek S system. 
It is clear from both the Bland-Altman plot and the regression analysis that 
the CoaguChek S was most accurate when the INR was in the therapeutic range, 
with scatter becoming prominent at INR values above 3.5. Hence, it needs to be 
emphasised to clinicians that differences can exist between INR values from POC 
testing monitors and laboratory values, especially when the INR is elevated. 291 
Other studies have similarly concluded that the CoaguChek S is an accurate and 
precise alternative to laboratory assessment of the INR at values <4.0 and that the 
monitor is an efficient device with a low likelihood of errors during testing. 257 
Interpatient variability may explain some of the discrepant results with the 
CoaguChek S compared to laboratory. It has been noticed in accuracy studies 
from the anticoagulation clinic 301 described earlier in this thesis, that variability 
does exist, perhaps explaining the large variations in INR that occurred in a few 
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instances. All laboratories were accredited by the National Association of Testing 
Authorities (NATA), which requires a satisfactory performance in the external 
quality assurance program. Hence, lowering the risk of quality assurance issues 
being to blame from the laboratory. 
The CoaguChek S was adjudged 93% accurate against expanded 
agreement criteria and 90% accurate against narrow agreement criteria. 256 This 
compares favourably with data from other previously published studies where the 
older model of CoaguChek monitor was found to be 90% accurate against 
expanded agreement criteria and 86% accurate against narrow agreement criteria. 
256 Shiach et al. recently showed 98% and 97% agreement against expanded and 
narrow criteria respectively, with the CoaguChek. 272 
The results for the user questionnaire indicated that the doctors at the 
evaluation sites found the CoaguChek S to be useful and would prefer to use the 
CoaguChek S monitor compared to pathology. There were some difficulties 
experienced in its use, and training with appropriate follow-up and ongoing 
external quality control are essential if the monitor is to be widely implemented in 
general practice. The most common difficulty related to the volume of blood 
needed for a sample; the CoaguChek S machine requires a large drop of blood 
(4011L) compared to conventional blood glucose monitors (51.tL). This needs to be 
addressed during training as a squeezed finger can give errant results. 
The GPs were generally confident in the accuracy of the monitor and 
foresaw little problem with having it available for widespread use in general 
practice. Doctors also indicated that their patients preferred POC testing. There 
was also a trend towards doctors feeling more confident in prescribing warfarin, 
given access to the CoaguChek S. 
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In conclusion, any limitations of the CoaguChek S monitor would seem to 
be far outweighed by the potential benefits to patients taking warfarin. The 
availability of an instant INR value improves the safety of a recognised high-risk 
drug for adverse events. 302 Clearly, any approach that improves the safety and 
efficacy of anticoagulation has enormous potential in terms of both beneficial 
clinical outcomes and cost savings to the health care system in the management of 
patients with either VTE or AR This is particularly relevant in rural or remote 
settings because of the lack of access to pathology services. Our results indicate 
that the CoaguChek S has the potential to lead to safer and more effective 
anticoagulation, and therefore to better care of patients in rural and remote areas 
of Australia. 
The use of POC testing for anticoagulation has the potential to 
revolutionalise the management of patients on warfarin therapy. As noted by 
Bhavnani and Shiach 303 the remaining issue to be addressed is how we can best 
offer high quality external quality assurance. In the meantime we must be ready to 
embrace this technology while still appreciating its limitations. 
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CHAPTER EIGHTEEN: INTRODUCTION 
MODELS OF ANTICOAGULATION MANAGEMENT 
18.1 Anticoagulation clinics 
Anticoagulation clinics in the United States have been shown to facilitate and 
improve long-term anticoagulation management for referring primary care 
physicians. Several reports document improvement in anticoagulation control 
when managed in a clinic setting, 304-312  such as better warfarin dosage regulation, 
increased time in the therapeutic range, improved patient compliance through 
continuous regulation and early identification of risk factors (drug interactions, 
clinical conditions) for bleeding and thrombosis. 313 Gaughan et al. 314 reported an 
increase in the use of warfarin in a community hospital with the establishment of 
an anticoagulation clinic. 
A study by Beyth et al. 315 reported fewer adverse events in elderly 
patients who were randomly assigned to an anticoagulant clinic, and the rate of 
bleeding was lower with an inpatient anticoagulant-consultation service. 314 
Randomised trials have found that specialised, multidisciplinary clinics achieve 
better management than usual care for anticoagulated patients. 316 In another 
study, anticoagulation clinic patients were more satisfied with and more 
knowledgeable about their warfarin therapy. 317  These trials are consistent with 
other observational studies that also found improvement in INR control, 
satisfaction or outcomes with anticoagulation clinics. 304-312  
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18.2 Patient self-monitoring and self-management 
251 262 287 	 282-284, 286, 287, 303, Patient self-monitoring, 	and patient self-management ' 
315 ' 318-323 have been proposed as solutions to reducing the risks of anticoagulant 
misadventure. 132 Sawicki et al. 282  found improved INR control in patients 
randomly assigned to an intensive patient education program that included self-
management of anticoagulation therapy. Table 39 displays outcomes of trials 
involving patient self-monitoring and self-management. 
Self-adjustment of warfarin therapy is analogous to self-adjusted insulin 
dosing according to a pre-specified sliding scale; 318 this practice in diabetic 
patients was associated with improved outcomes by delaying the onset or slowing 
the progression of vascular and neurological complications. 251 A major cause of 
unstable anticoagulation is poor patient compliance, 289 and self-adjustment of 
warfarin dosing has the potential to improve compliance by allowing active 
participation and increasing accountability with respect to the patients' own 
health. 251 Patients in a trial of patient self-management preferred this type of 
management compared to physician managed care. 251 
A study by Anderson et al. 281 in 1993 found that patients receiving long-
term anticoagulant therapy achieved a high rate of clinically important agreement 
between self-measurements of the INR with the use of a portable monitor and 
laboratory INR results, and patients strongly preferred using the portable 
81 monitor. 2 The study concluded that the use of the portable monitor as the 
primary method for measuring the INR could be recommended in selected 
patients receiving long-term anticoagulant treatment. 
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Study Study Design 
Study 
Groups 
It. of 
Patents 
Time h Range, 
% INR 
% Time 
Major Hemorrhage, 
% per patient-year 
Thromboerrholism, 
% per patirint-yaor hdicaticns 
White 1989 RCT 
PST 23 93 0 0 Mixed 
AMS 23 75 0 0 Mind 
Anderson' s') 1993 Inception cohort 
PST 40 74 0 0 Mixed 
BeythIn 1997 RCT 
PST 162 56 5.7 9 Mixed 
UC 163 33 12 13 Mixed 
AnselP E 1995 Cbseivational cchcrt 
PRI 20 89 0 0 Mind 
AMS 20 68 0 0 Mixed 
Bernarcb 146 1995 Obsenrational 
Psm 216 El NA NA Heart rains 
Horstkotte 1936 RCT 
PRI 75 EQ 4.5 0.9 Heart niers 
UC 75 93 10.9' 3.6 Heart rains 
Hasenkare 1697 Obserraticnal 
matched control 
PSM 20 77 NA NA art rains 
UC 20 53 NA NA 143art valves 
SawhieuE 1999 RCT 
Psm 90 57153 -f 2.2 2.2 Mixed 
UC 89 34/43 -f 2.2 4.5 Mixed 
Vortical° 2001 RCT 
FSM 305 78 1.7 1.2 Mixed 
UC 295 60 2.6 2.1 Mind 
White' s° 2000 Prospective controlled 
PSM 49 es 4 a Mixed 
ACC 53 80 0 0 mind 
Ctomheockelil 2000 Randomized crossover 
PSM 50 55 0 0 Mixed 
ACC 50 49 0 16 Mixed 
RCT indicates randomized controlled trial; PST, patient self-testing; PSM, patient self-rumen -Int MIS, anticoagulation management senioe; UC, 
usual care; and Meld, mixed indications. 
'Major and mho- bleeding. 
fume in target range at 3 and 6 mo. 
fit-tentage of episodes in 49 patents. 
Table 39 	Studies of patient self-testing and self-management of 
anticoagulation. 
Reproduced from Hirsh et al. 73 
According to Cromheecke et al. 284 self-management of oral anticoagulant 
therapy with portable 1NR monitors may result in a more individualised approach, 
increased patient responsibility and enhanced compliance, which may lead to 
improvement in the regulation of anticoagulation. Another advantage noted was that 
patients could do the test at home (saving travel and time during working hours) and 
would be less dependent on their anticoagulant clinic. 284 However, this could 
potentially lead to a poorer regulation of oral anticoagulant therapy, due to a lack of 
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professional guidance. The study by Cromheecke et al., showed that there was no 
significant difference in the overall quality of anticoagulation between patients 
managed by an anticoagulation clinic and those patients managing their own warfarin 
therapy. Patients were within a range of 0.5 units from their therapeutic INR target 
range for 55% and 49% of the treatment period during self-management and 
anticoagulant clinic management, respectively. 
A patient satisfaction assessment showed superiority of self-management over 
conventional care. It was concluded that self-management of 1NR with portable 1NR 
monitors is feasible and appeared to result in control of anticoagulation that is at least 
equivalent to management by a specialist anticoagulation clinic. It was also found in 
this study that there was some variation between INR results from the portable INR 
monitor and laboratory testing. However, the variation was not larger than the 
variation encountered between different laboratories measuring a single sample. 278 
Although it was noted that a certain 'type' of person was more likely to participate in 
this study (despite being a randomised study), namely younger patients, other studies 
have found that all patients who are able to lead an independent and self-supporting 
life are in principle capable of self-management of anticoagulation, irrespective of 
education or social status. 285, 323, 324  "Self-management of anticoagulation may be 
considered as a novel, patient friendly and effective strategy to improve long-term 
treatment with anticoagulant agents." 284 
Another study of self-management of oral anticoagulation found that selected 
patients on chronic anticoagulation therapy can acquire a satisfactory ability for self 
adjustment of oral anticoagulant therapy dose, even without specific training related to 
dosage adjustment (patients still completed training related to using their monitor). 285 
It was estimated in one German study 323  that50-60% of all patients on anticoagulant 
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therapy were suitable for self-management. As noted by Vink et al., "INR home 
testing appears to be a safe and efficient anticoagulation control method which results 
in a higher percentage of target range values compared with the conventional 
laboratory-based testing regimen." 325 
18.3 Pharmacist-led anticoagulant management 
POC testing in pharmacies has two main functions. The first is in disease 
screening or risk assessment (e.g. blood glucose or cholesterol determination). 
The second function is in monitoring and management of chronic diseases and 
medicines used to manage these conditions, as with anticoagulant therapy. 
The increasing number of patients on warfarin and concerns over the 
ability of conventional health services to cope is one of the reasons for the 
expansion of POC testing, and moves to find alternative models of service 
provision within primary care for anticoagulated patients. Many models of 
anticoagulant management have been proposed in the literature; innovative 
models such as community and general practice based anticoagulant clinics run 
by nurses 307 and pharmacists, 313, 326-332 patient self-monitoring, 287 and patient 
251, 262, 282-284, 286, 287, 303, 315, 318-323 Self-management 	 have been proposed as 
solutions to reducing the risks of anticoagulant misadventure. 132 Very few studies 
have studied the effect of community pharmacists' involvement in anticoagulant 
management. 333 
The public is becoming increasingly familiar with community pharmacists 
expanding their role in providing a range of health care related services. In 
addition to the traditional role of providing advice on prescribed and over-the- 
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counter medications, pharmacists are involved in services such as blood pressure 
screening, "4 cholesterol measurement 335, 336  and home medicines review. " 7 
POC testing allows pharmacists to overcome the obstacle of lack of access 
to laboratory results, providing immediate availability of relevant laboratory tests 
that can be used for clinical decision-making. 338  POC testing provides 
opportunities for pharmacists to expand their activities and to generate income. 338 
Community pharmacists are ideally placed to assist GPs in the 
management of anticoagulated patients in the community. Pharmacists' 
undergraduate experience covers pharmacology, pharmacokinetics and drug 
interactions, and this knowledge can be used to predict disease and drug 
interactions with warfarin. Pharmacies also have instant access to patients' 
medication records. It would seem that pharmacists, being the most readily 
accessible health professional in the community setting, could fulfil a valuable 
role in ensuring the safe and effective use of anticoagulant therapy by establishing 
an INR monitoring service. Despite this, relatively few community pharmacies 
have undertaken anticoagulant monitoring, and this finding is not only restricted 
to Australia. 
18.4 Rural health 
There is clear evidence of the poorer health status of rural and remote 
Australians. 339 ' 340 Overall, average death rates in rural and especially remote 
areas are higher than in metropolitan areas. 340 The mortality rates in rural and 
remote areas are higher for many major conditions, including diabetes, 
cardiovascular disease and asthma. For instance, it has been shown that the lower 
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socio-economic groups and populations living outside capital cities have 
improved their cardiovascular disease risk factor profile in recent times, but the 
relative disadvantage compared with the higher socio-economic groups and major 
cities persists. 3413'  have been calls for the immediate introduction of 
measures to ensure optimal treatment of cardiovascular risk factors and acute 
coronary events in such populations. 342 ' 343 ' 345 Access difficulties due to distance, 
time, cost and transport availability in rural and remote regions are amplified by 
the shortages and uneven distribution of health facilities and health 
professionals. 346 
Rural areas have a lack of GPs, pharmacists and other health care 
professionals. Thus it is difficult for members of rural communities to access 
specialist treatment. This also means that those health care professionals in the 
region will be very busy, while this is also compounded by the closure of 
hospitals and other health care facilities. 
Currently, there is an undersupply of rural doctors and this lack of supply 
is pivotal to the delivery of healthcare to rural and remote communities. 347 A 
characteristic of modem medical treatment is the progressive growth in specialist 
medical services, both for assessment and treatment. Highly specialised services 
(such as pathology services) can be offered only in cities and large population 
centres, and the growth of these services can lead to a parallel increase in local 
disadvantage for people in small rural and remote communities. 348 
The first study described in this thesis has indicated that Australian 
doctors believe that the availability of portable INR monitors would assist with 
46 	i the management of anticoagulated patients. 2  This s particularly relevant in rural 
or remote settings because of the lack of access to pathology services. It is not 
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uncommon for doctors from rural or remote regions to have to wait two days for 
pathology results. The doctors also indicated that the availability of portable INR 
monitors might influence their decision to use warfarin for stroke prevention in 
AF. There appear to be two main reasons for the low use of antithrombotic 
therapy for stroke prevention in AF: inconvenience and physicians' fear of 
haemorrhage. 194-196 201 Compared with urban patients, rural patients often travel 
further to have their INRs monitored, and this greater inconvenience may 
contribute to their lower use of warfarin. 349 
18.5 Aims and objectives: Rural community pharmacy-based INR 
monitoring 
Having identified a paucity of data surrounding the use community pharmacy-
based INR monitoring, the aim of the project was to assess whether rural 
pharmacist involvement in the management of targeted 'high risk' patients (i.e. 
those receiving warfarin therapy) has the potential to lead to safer and more 
effective anticoagulation, and is valued and welcomed by patients and their GPs. 
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CHAPTER NINETEEN: METHODS 
RURAL COMMUNITY PHARMACY-BASED INR MONITORING 
19.1 Rural pharmacies and training methods 
A convenience sample of rural pharmacists (PHARIA classification > 2; or if 1, 
defined as regional) was identified by SLJ through a composite of previous 
research activities with the research team and via contact through electronic 
means (AusPharmList). Pharmacies needed to have an area where POC testing 
within the pharmacy could be reasonably completed privately during normal 
workflow. 
The pharmacists were trained in the use of the CoaguChek S INR monitor 
and given educational material relating to warfarin. 73 The training typically 
involved approximately two to three hours with the pharmacists discussing 
anticoagulation and the use of the INR monitor. Pharmacists were shown how to 
conduct INIR tests and were also observed conducting tests on consenting subjects 
or pharmacy staff. Problems or difficulties encountered by the researchers 
(through previous research activities 301 and personal experience) were raised with 
the pharmacists and potential solutions to these difficulties were discussed. The 
pharmacists were provided with a laminated colour brochure on the 1NR monitor 
(Appendix 7) along with the investigators' contact details. Pharmacists were 
provided with INR monitors, tests strips and other consumables free of charge for 
the duration of the trial. 
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19.2 Laboratory and point-of-care methods for determination of 
INR 
Local GPs were visited, given an information sheet (Appendix 10) and informed 
of the availability of the CoaguChek S INR monitor in their region, and were 
invited to refer their patients to the pharmacy for POC testing. During the visits to 
the GPs, SLJ discussed the accuracy of the CoaguChek S INR monitor and the 
use of this monitor in several overseas countries. SLJ also discussed previous 
research that had been conducted on the monitor and personal experiences 
surrounding its use. 
Patients referred to the pharmacy or who were identified as taking 
warfarin were given an information sheet (Appendix 11) and gave written 
informed consent to undergo fingerprick testing at the pharmacy. Results of the 
testing, such as INR, time taken, outcome of test (Appendix 12) were recorded. 
All results were sent to the GP via a specially designed fax form (Appendix 13). 
Pharmacists and GPs were instructed that this type of testing was not to replace 
conventional pathology testing. 
• 	Patients could have two types of testing performed in the pharmacy: 
comparison testing was defined as pharmacy-based tests taken within four hours 
of conventional laboratory testing, and additional testing which was a pharmacy-
based test with no direct comparison laboratory test taken. It was recommended to 
pharmacists that all results were recorded for patients in the standard warfarin 
booklet. The service was offered free of charge to patients for the duration of the 
trial. Pharmacies were remunerated at a rate of $4 per test for the duration of the 
trial. 
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19.3 Evaluations 
The CoaguChek S INR monitor was left with each participating pharmacy for 
approximately three months. GPs and pharmacists were later sent an anonymous 
questionnaire (using a visual analogue scale) to evaluate the pharmacy-based INR 
monitoring. The extremes of the scale were marked with (0) "strongly agree" and 
(10) "strongly disagree". Median results with tenth and ninetienth percentiles 
were plotted to represent the responses to the evaluation questionnaires. Patients 
were given an anonymous satisfaction survey (Appendix 14) from community 
pharmacists after the completion of the INR monitoring trial. 
19.4 Statistical methods 
The lNR values from CoaguChek S and the laboratory were compared using 
regression analysis. A Bland-Altman plot 280 was utilised to assess the magnitude 
of disagreement between the CoaguChek S and the laboratory. The accuracy of 
the CoaguChek S at INR values < 1.9, between 2.0-3.5 and > 3.6 was also 
evaluated. 
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CHAPTER TWENTY: RESULTS 
RURAL COMMUNITY PHARMACY-BASED INR MONITORING 
20.1 Pharmacy characteristics 
A total of 22 pharmacies were identified and invited to participate in the project. 
Sixteen pharmacies agreed to participate and were visited by SLJ and trained to 
use the CoaguChek S INR monitor. The PHARIA classifications, number of tests 
and number of patients tested per pharmacy are listed in Table 40. Ten of the 16 
(63%) participating pharmacies had Australian association of consultant 
pharmacists (AACP) accredited pharmacists as regular full-time staff members. 
Three pharmacies did not conduct any testing during the trial period. Reasons 
behind testing not being conducted included a 'lack of interest by patients in 
having additional testing done' and 'lack of time (at present) to implement the 
service.' This pharmacist expressed willingness to implement the service later, 
but time constraints associated with this study, did not allow this to happen. 
Another pharmacist cited pharmacists on holidays, store refits and the Christmas 
period as a reason for lack of implementation of the program. 
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Pharmacy MARIA 	No. Tests No. Patients 
Tas 1 3 	171 14 
Tas 2 3 	17 2 
Tas 3 2 	12 8 
Tas 4 4 	58 27 
Tas 5 3 	37 6 
Tas 6 5 	31 17 
Tas 7 4 	0 0 
Nth QLD 1 3 	37 9 
Nth QLD 2 3 	11 3 
NSW 1 1 	35 17 
NSW 2 5 	50 17 
NSW 3 3 	30 6 
NSW 4 3 	0 0 
SA 5 	18 9 
WA 1 4 	11 2 
WA 2 1 	0 0 
Total 518 137 
Table 40 
pharmacies 
PHARIA characteristics and number of tests per participating 
20.2 Testing characteristics 
Characteristics of the testing and of the patients who were tested are described in 
Table 41. A total of 518 tests were conducted in the pharmacies and 137 different 
patients were tested. Over three-quarters of the pharmacy based tests were taken 
200 
in addition to conventional laboratory testing, as opposed to having comparison 
tests. 
Testing characteristics 	 Result 
Number of tests conducted 	 518 
Tests per pharmacy median 	 31 
Proportion of tests performed on female patients n (%) 	157 (30) 
Number of patients tested 	 137 
Tests per patient median 	 2 
Proportion of female patients tested n (%) 	 66 (48) 
Age median (range) 	 72 (23-100) 
Test duration (minutes) median (range) 	 5 (2-15) 
Reason for use of warfarin (n=122*) 
Atrial fibrillation n (%) 63 (53) 
Valve replacement n (%) 20 (16) 
DVT or PE n (%) 33 (27) 
Other n (%) 6 (4) 
Number of chronic medical conditions median (range) 	 3 (1-7) 
Number of chronic medications median (range) 	 5 (1-15) 
Type of testing 
Comparison to conventional pathology testing n (%) 	120 (23) 
Additional testing in the pharmacy n (%) 	 398 (77) 
Table 41 	Characteristics of pharmacy based testing and patients involved 
*n=122 as reason for use not recorded in some cases 
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The majority of tests (67.0%) were in the expanded therapeutic range of 
2.0-3.5, with over one-quarter (27.8%) being < 1.9. The remaining tests (5.2%) 
were >3.6. 
20.3 Accuracy analysis 
One hundred and twenty pharmacy-based 1NR tests had comparison laboratory 
tests taken for which the results were made available to SU. The mean 1NR 
values for the laboratory and pharmacy-based tests are listed in Table 42. The 
pharmacy-based 1NR values were significantly correlated with the laboratory INR 
values (r = 0.88, p <0.0001; Figure 25). 
Parameter 	 CoaguChek S 	 Laboratory 
1NR (mean ± SD) 	 2.32 ± 0.77 	 2.32 ± 0.59 
Mean difference ± SD 	 -0.00 ± 0.38 
Percentage within 0.5 INR units 	 84.8 
Percentage within 10% of laboratory 1NR 	76.0 
Table 42 	Comparison of pharmacy-based CoaguChek S and laboratory INR 
results 
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Figure 25 	Relationship between CoaguChek S and laboratory INR values: 
Pharmacy-based INR monitoring 
The Bland-Altman style plot shown in Figure 26 shows the difference 
between the two readings plotted against the average of the two readings. The 
pharmacy-based tests showed only slight variation compared with laboratory 
testing for INR values <4.0. 
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Figure 26 	Bland-Altman plot for CoaguChek S and laboratory INR values: 
Pharmacy-based INR monitoring 
The categorisation of laboratory and pharmacy-based INR values is 
displayed in Table 43. There was a significant relationship between the two 
methods (x2= 130, df = 4, p < 0.0001). Discrepant categorisation of 1NR values 
from the laboratory and CoaguChek S occurred in 15% of the samples. That is, 
85% (102/120) of CoaguChek S values were placed in the same nominal category 
as the laboratory 1NR. Seven and a half percent were falsely lowered with the 
CoaguChek S (corresponded to a higher laboratory reading) and the same amount 
was falsely elevated (corresponded to a lower laboratory result). 
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CoaguChek S INR 
INR range < 1.9 2.0-3.5 > 3.6 
(n=36) (n=76) (n=8) 
< 1.9 82 18 0 
(n=33) 
Laboratory 2.0-3.5 11 85 4 
INR (n=82) 
?3.6 0 0 100 
(n=5) 
Table 43 	Comparison of INR categories for CoaguChek S and laboratory 
Values given as percentage of laboratory readings 
20.4 Clinical outcomes 
Table 44 displays INR ranges and outcomes of the 398 additional pharmacy-
based tests and whether this testing resulted in dosage changes. Eight and a half 
percent of additional testing conducted in the pharmacy resulted in a subsequent 
dosage change. 
INR range Result (%) 
(n=398) 
Dosage 
Changes 
Result (%) 
(n=390*) 
< 1.9 27.1 Dose increase 5.9 
2.0-3.5 68.1 No change 91.5 
?3.6 4.8 Dose decrease 2.6 
Table 44 Outcomes of additional testing conducted in the pharmacy 
*n=390 as some outcomes were not recorded 
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20.5 General practitioner evaluation 
Figure 27 displays the responses to the evaluation questionnaire from the GPs. 
Responses were obtained from 15 GPs. Thirty GPs were caring for patients who 
had pharmacy-based testing, giving a response rate of 50%. The median responses 
from the GPs are positive in all but one question, with wide tenth and ninetieth 
percentiles reflecting some variable views on the pharmacy-based monitoring. 
However, the response to the evaluation question "I found the suggestions made 
by the pharmacist to be useful" was negative. The median response from the GPs 
to this question was 7. This feeling was repeated in some of the comments, as 
displayed in Table 45. 
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I found this to be a valuable service provided to my patient(s) 
I 
 1- 0 
1 
	
I 	 I 	 I 
Strongly 	 Strongly 
agree disagree 
I would feel more confident in initiating or managing newly initiated patients on warfarin if 
this was a regular service 
4P 	  I 	I I 	 . 	 I 
Strongly 	 Strongly 
agree disagree 
I received adequate feedback from the pharmacist 
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Strongly 
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Strongly 
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Figure 27 	Responses to the evaluation questionnaire: General practitioner 
evaluation of pharmacy-based testing 
Medians, with range lines plotted at the 10th and 90th percentiles 
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• Perhaps patients could have a card with INRs and the date to carry with them. 
• Glad to be part of it, thanks. 
• More suited for areas where no pathology service does home or nursing home visits. 
• Seemed to reflect laboratory INRs. 
• I do not need pharmacist input. 
• Good service should be available through general practices and funded via medicare. 
• What is the point in doing this via pharmacies, when the medications are initiated, 
prescribed and monitored by doctors? If pharmacists take on these functions, presumably 
they will have malpractice indemnity etc!! 
• Discrepancy between laboratory INRs and pharmacy level suggests calibration of tests , 
needs to be reset. 
Table 45 	Comments from responding general practitioners: Pharmacy- 
based testing 
20.6 Pharmacist evaluation 
Figure 28 displays the response to the evaluation questionnaire from the 
community pharmacists. Fifteen responses were obtained from 22 (68%) 
community pharmacists who were users of the lNR monitor. The overall 
evaluation from the pharmacists was positive. The response to one question "I 
received positive feedback from the general practitioners", however, was less 
positive than the others. Comments from the responding community pharmacists 
are displayed in Table 46. Most comments reflected good patient feedback, the 
issue of training, time to conduct this type of service and the issue of 
remuneration. Four of the thirteen pharmacies that conducted testing have 
purchased or have been loaned monitors by SLJ and will continue to conduct INR 
testing in the pharmacies on an ongoing basis. 
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I found this to be a valuable service provided to my patient(s) 
1_40--4 
I 	I 	 I 	 . 	 I 
Strongly Strongly 
agree 	 disagree 
I would feel comfortable operating this service if it was ongoing 
1-10 	 
1 	I 
Strongly 
agree 
I received positive feedback from the general practitioners 
I 	 I 	 I 
Strongly 
disagree 
   
0 
   
I 
Strongly 
agree 
 
1 
 
I 	 I 	 I 
Strongly 
disagree 
    
I believe that more patients would benefit from this type of service 
1-11--4 
1 	I 	 I 	 . 	 I 
Strongly Strongly 
agree 	 disagree 
I believe that this service would increase the compliance of patients on warfarin 
1-91 
i 
Strongly 
agree 
   
1 
 
I 	 I 	 I 
Strongly 
disagree 
  
I believe that my patient(s) found this to be a worthwhile service 
I 
Strongly 
agree 
1 I 	 I 	 I 
Strongly 
disagree 
 
Figure 28 	Responses to the evaluation questionnaire: Pharmacist evaluation 
of pharmacy-based testing 
Medians, with range lines plotted at the 10th and 90th percentiles 
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• Training for technique in using the machine, very good for pharmacy, great to be able to 
offer another service to the customer 
• Great addition to any community pharmacy practice. Especially useful for nursing home 
patients 
• This type of service probably increases quality of warfarin treatment, not compliance. All 
our patients seem to be very compliant in taking the medication, some don't worry much 
about the INR-they leave that to the Dr. 
• Blood in the pharmacy is a negative in these times of hepatitis and HIV. The machine 
was almost great. The temperature requirement of the strips and the device made 
measurements more time consuming. Everyone found instant feedback of the INR a great 
advantage 
• Communication and rapport with patients a great benefit to both parties. It is an enjoyable 
service to provide to patients and they are appreciative of our efforts. It is nice to have the 
continued patient-pharmacist contact and the increased trust of the patient 
• Time involved doing testing needs to be beneficial, i.e. cost involved. 
• I found the experience worthwhile. Shane was a great educator and very thorough. 
Patients became or appeared to become more interested not only in their warfarin but 
other medications as well. A pleasure to be involved. I would encourage more of this sort 
of research. 
• Good idea, but fiddly and time consuming. Well received by patients; more convenient. 
• 
• 
While a valuable, worthwhile service, time is taken to perform and discuss. So 
remuneration is of consequence for ongoing provision. 
Much appreciated by patients. Very accurate results compared with pathology 
• Some patients found this service very valuable. I found it was great to sit down one-on-
one with the patient and develop a rapport with them. 
Table 46 
	
Comments from responding pharmacists 
20.7 Patient evaluation 
The responses and comments from patients to the satisfaction questionnaire are 
displayed in Table 47 and Table 48 respectively. Responses were received from 
62 patients, giving a response rate from patients tested of 45%. 
Most of the comments from patients reflected an appreciation of the 
convenience with using pharmacy-based testing. They seemed to be very happy 
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with POC monitoring but perhaps found it a barrier to utilisation of the service, 
that pharmacists were unable to adjust doses on the basis of these results. Some 
patients expressed views that governments or other organisations should pay for 
this type of monitoring. A number of patients compared the accuracy of the 
pharmacy-based testing with laboratory testing and went as far to include their 
results in their responses. Patients generally expressed a preference for fingerprick 
testing in their comments compared to the current invasive pathology testing. 
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Response to questions n (%) 
How satisfied are you with the monitoring conducted by your pharmacist? 
Quite dissatisfied 6 (10) 
Indifferent of mildly dissatisfied 2 (4) 
Mostly satisfied 13 (22) 
Very satisfied 37 (64) 
Has the monitoring provided by the pharmacist helped you to deal more effectively with your 
medication warfarin? 
Yes, they helped a great deal 33 (57) 
Yes, they helped somewhat 17 (29) 
No, they really didn't help 8 (14) 
No, they seemed to make things worse 0 
Which type of testing would you prefer? 
Fingerprick testing at the pharmacy 40 (66) 
Fingerprick testing at the general practitioner's surgery 6 (10) 
Conventional pathology testing 13 (21) 
Unsure 3 (5) 
Is there any other information you need, or would like, about warfarin but have not received? 
Yes, there definitely is 13 (23) 
Yes, I think there is 10 (18) 
No, I don't think there is 30 (53) 
No, there definitely is not 4 (7) 
Overall, how would you rate the quality of the service that you received from the pharmacist? 
Excellent 45 (76) 
Good 13 (22) 
Fair 0 
Poor 1 (2) 
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Response to questions 	 n (%) 
Did you find the regular wwfarin (INR) monitoring* 
Painful 5 (8) 
Informative 13 (21) 
Motivating 1 (2) 
A waste of time 3 (5) 
Interesting 12 (19) 
Annoying 3 (5) 
Convenient 27 (44) 
Beneficial 28 (45) 
Do you think this service would be best provided in your home or at your local pharmacy? 
Home 	 13 (22) 
Local pharmacy 	 38 (64) 
General practitioners' surgery 	 8 (14) 
Do you think this service should be available to all patients on warfarin? 
Yes 	 57 (98) 
No 	 1 (2) 
If this were a regular service, would you be prepared to pay for it? 
Yes 	 32 (57) 
No 	 24 (43) 
If you answered yes to the previous question, how much would you be prepared to pay per visit? 
$1-$5 	 20 (63) 
$6-$10 	 8 (25) 
$11-$15 	 4 (13) 
$16+ 	 0 
Table 47 	Response to the patient satisfaction questionnaire-pharmacy-based 
testing 
Some responses do not total 62, because some respondents did not answer all questions 
*Totals greater than 62 because respondents could indicate more than one response 
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• It is a very good idea to have an INR machine at the chemist on Saturdays for people that 
work five days a week. 
• I used the fingerprick testing at the pharmacy for 2 reasons; to see what was involved and 
to compare that reading to the reading of pathology, the readings taken 10 minutes apart 
were fingerprick 1.9, pathology 2.2. 
• I have only once used the pharmacist and that was by request. The reading was 2.8, 
which compared to 2.1 by the pathologist. Being a preference they do the testing at home. 
• I find the prick test less painful and the instant result very pleasing. As I live at Lake 
Albert I would like to see the test available at our pharmacy here. I am elderly and 
disabled and need a test weekly and sometimes more often. 
• Repat should pay, the first couple of goes I thought, hell this hurts, but then I got used to 
it. 
• We have only been to the pharmacy once. We go to the pathology at Wagga base. The 
fingerprick test was fairly accurate i.e. 2.6 as against the path 2.9 a few days later. We 
have no car so if we could have it done in the home it would help. 
• If the pharmacist had the authority to advise how much warfarin to be taken daily on INR 
reading, I would have no hesitation in using such a facility or paying a small fee. 
• I only had 2 consultations-the first test aligned with the pathology results. The second test 
resulted in a reading much higher than the pathology dept. On doctors' instructions I 
ceased the pharmacy testing. 
• 10 years ago, I had a heart valve operation and need my blood tested every two to three 
weeks, last year I had bowel cancer and had chemo that made my veins very hard to find, 
the finger prick was wonderful and I wished I could have it all the time. 
• I am very pleased with the treatment I received, thank you 
• As a pensioner, a small cash amount is feasible. The test at the pharmacy would reduce 
the load on surgery nurses, which may be appreciated 
• I only visited our local pharmacy on the same day I had my INR tested at my local 
surgery; GP result 2.1 and pharmacy result 1.8 
• The only reason I would be reluctant to pay for an 1NR service is that I am a disability 
pensioner and I require regular (every 1-3 weeks) INR monitoring and will continue to do 
so for life. Pharmacy monitoring is extremely more convenient than using the limited 
resources of an already over-stretched local GP service 
• The service at the pharmacy is excellent. 
• The pharmacy tests are an added help for my health and our pathology system. 
• It is great to know the results of the INR immediately, as with this monitor. The benefit 
of having this service provided at your local GP is that any dose adjustment (warfarin) 
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could be made on the spot, not in several days, as is the situation at present. 
• I am a 32 year-old life-long warfarin patient. I probably have another 50 years of blood 
testing. At times I have to be tested every two weeks. I find the whole process of going to 
the doctor and waiting all day for results expensive. Imagine how much I will spend on 
this in my whole lifetime. 
• Very pleased with testing. 
• Finger pricking eliminates the inevitable bruising caused by repeated attempts at 
conventional techniques. One visit required seven attempts to procure a sample. 
• I am very keen to have INR testing available at home and at pharmacies but the variance 
in results obtained between the actual pathology test and the machine test had a variance 
of up to 20%. 
• I have not been able to participate in enough tests to be absolutely sure. 
• I understood the machine was sent to the chemist to see how it compared to conventional 
pathology testing it was almost spot on. If I was just on warfarin and had it checked every 
6 weeks, the fingerprick method is quite OK and it should be done at the pharmacy. This 
would relieve the doctor from this extra work 
• The portable warfarin monitor would be a great asset to purchase if it was accurate. It 
was very inconsistent in its results compared to that from pathology. 
• Country towns, no GPs or takes 2 weeks to get in to have an INR, go to hospital and wait 
until someone can do the INR. It then misses the courier, and the blood is over one-day 
old before it leaves the hospital to be tested. Apart from the schedule fee to get an INR 
done, we are charged again when you can get an appointment to get the result-often 4-5 
days later. 
• If you are on warfarin fulltime & need INRs weekly, it is impossible to get doctor 
appointments etc. to have blood taken & then to get the result you have to get another 
appointment and pay again. Country towns' with minimal doctors & pathology services 
you are risking people's health. This INR system/machine is brilliant, convenient & vital 
in isolated & small towns. Pay-cost? — I do not know? Very messy when you have to put 
claims in weekly and you have to fax as your town has no medicare office etc. 
Table 48 	Comments from patients: Pharmacy-based testing 
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20.8 Case studies 
The following three cases have been documented by participating community 
pharmacists in order to show some clinical outcomes of pharmacy-based testing 
in each of these cases. 
Mr AB arrived at Tasmanian pharmacy no.4 late one Friday afternoon. Mr 
AB normally resides in inner city Sydney and is familiar with accessing 
pathology services when it is convenient for him. He asks the pharmacist 
where the local pathology service is, so he can "get his warfarin done". The 
pharmacist tells Mr AB that this small rural town's pathology services cannot 
be accessed after lunchtime on Friday. Fortunately for Mr AB, the pharmacist 
is able to obtain an 1NR result for him. The pharmacist obtains a past medical 
history from Mr AB of an aortic valve replacement in 1986, glaucoma, 
hypercholesterolaemia, and dyspepsia. Mr AB was using the following 
medications, in addition to warfarin: bimatoprost eye drops daily, simvastatin 
40mg daily and pantoprazole 40mg daily. The pharmacist obtains a 
fingerprick sample of blood from Mr AB and a minute later an 1NR reading of 
5.2 (target range: 2.5-3.5) was obtained from the CoaguChek S monitor. His 
warfarin dose had been increased about one week previously from 3.5mg 
daily to 5mg daily. The local general practice was very supportive of the 
pharmacy participating in this project and was contacted with a subsequent 
appointment made for Mr AB. As a result of this, his warfarin dose was 
reduced to 4 mg daily. Mr AB was also advised by the doctor to have a 
follow-up test on Monday in the next town he was to visit. 
Interestingly, Mr AB's partner was also taking warfarin. 
Mrs AB's past medical history included stroke, hypertension, arthritis and AF 
with a pacemaker fitted. Her current medications were warfarin 1 mg daily, 
digoxin 250mcg daily and candesartan 8mg daily. Mrs AB's 1NR result was 
3.2 (target range 2.0-3.0). On questioning, her last 1NR was taken some 
months ago with the results not known but considered 'stable'. The local GP 
consulted with her and reduced her warfarin dose to an alternating dose of 
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0.5mg/ 1 mg daily. Like her husband, she was advised to have a follow-up 
pathology test taken on Monday. The couple were counseled by the 
pharmacist about dietary changes, especially whilst on holiday, that may 
affect the response to warfarin therapy, compliance with therapy, and the need 
for regular INR testing. 
Ms LD was a young indigenous woman who has been taking warfarin for 
approximately six months for recurrent thrombosis. She had been increasingly 
non-compliant with therapy and "no-shows" for appointments with her GP 
were increasing. The pharmacist (Tasmanian pharmacy no.5) encouraged Ms 
LD to have fingerprick testing at the pharmacy using the CoaguChek S INR 
monitor, explaining to Ms LD that he could obtain a result quickly and any 
subsequent dosage changes could be promptly discussed with her GP. Ms 
LD's 1NR over the previous three months had ranged from 1.2-1.4 (target 
range: 2.0-3.0). Since accessing the INR monitoring in the community 
pharmacy, her dosage of warfarin had increased from lmg daily to 3mg daily, 
with 1NR results consistently in the therapeutic range. Ms LD attends the 
pharmacy weekly and appears more compliant with her therapy. 
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CHAPTER TWENTY ONE: DISCUSSION 
RURAL COMMUNITY PHARMACY-BASED INR MONITORING 
This project was designed to test the feasibility of community pharmacy-based 
INR monitoring in rural Australia. We also wanted to gauge the acceptance of this 
type of service by community pharmacists, GPs and patients. The pharmacies 
were taken from all states of Australia, except for Victoria, and had PHARIA 
classifications ranging from 1 (regional) to 5, giving a broad spread of rurality. 
We recruited a large number of pharmacies (16) for a study of this type and the 
pharmacists involved conducted a large number of tests (518) on 137 patients. 
This is the first completed study assessing the feasibility of community 
pharmacy-based INR monitoring. The author are aware of only one other study 
being conducted in Australia (Andrew McLachlan, University of Sydney) 350 
using portable INR monitors in community pharmacies. 
Utilising the CoaguChek S INR monitor in a community pharmacy has 
shown the monitor performs accurately compared to conventional laboratory 
testing. Previous studies described in this thesis have obtained correlation 
coefficients (r) of 0.90 in an anticoagulation clinic 301 and r = 0.89 in general 
practices, 258 compared with r = 0.88 in this study. Other studies have shown that 
the CoaguChek (previous version of INR monitor) and CoaguChek S devices 
produce INR values that are highly correlated with laboratory INR values (r = 
0.91 _ 0.97). 256, 259, 278, 291, 293, 294 
Eighty-five percent of all dual measurements were within 0.5 INR units in 
this study, which compares well to the figure of 79% reported by Douketis et al., 
256 and 83% described earlier in this thesis in an outpatient anticoagulant clinic. 
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301 This study also found that 76% of all comparison tests were within 10% of the 
laboratory value. This compares exceptionally well with other studies described in 
this thesis which have shown results of 55% of results within 10% of the 
laboratory in general practices 258 and 44% in an anticoagulation clinic. 301  
This study was unique in evaluating the CoaguChek S in a number of 
diverse settings and with many potential users. The performance of the 
CoaguChek S in the community pharmacies setting was excellent, especially 
when considering that data was collected from many sites and was compared with 
different laboratories. Previous studies have found that the variation between 
portable INR monitors and laboratory was not larger than the variation 
encountered between different laboratories measuring a single sample. 278 To my 
knowledge, this is the first published study comparing the accuracy of the 
CoaguChek S INR monitor in comparison to laboratory testing in a sample of 
community pharmacies. 
The pharmacy-based testing has shown that over 30% of patients had 
INRs outside of an expanded therapeutic range, our population of tested patients 
compares well with previous research, that has shown that approximately 60-70% 
of patients will have INR value in the target range. 287 '  351 '  352 
In nearly 10% of cases the additional testing conducted in the pharmacy 
resulted in a change in therapy. Clinical decisions were made (generally followed 
by pathology testing in the next day or so) on the basis of results of tests based in 
the pharmacy. It is difficult to quantify the impact that the changes in therapy had 
on clinical outcomes. Examples of these changes on therapy are documented in 
three case studies. A limitation of the study was that the pharmacists, in most 
cases, recorded only dosage changes and not clinical or actual outcomes, although 
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the study was not designed to assess clinical outcomes. Therefore, a formal cost 
analysis of changes in therapy due to additional testing is beyond the scope of this 
study. However, it is likely the availability of POC testing in community 
pharmacies may have a large impact on clinical outcomes if pharmacy-based 
testing is utilised in rural areas. If further implementation of community 
pharmacy-based INR monitoring is undertaken, systems for recording of clinical 
and actual outcomes should be developed to analyse the clinical effects of these 
types of services. 
The clinical impact of the pharmacy-based testing was unable to be fully 
assessed, although it was made known to SLJ that there were a number of 
instances where the availability of the pharmacy-based INR monitoring appeared 
to have potentially large clinical impact. Several of these instances are 
documented in the three case studies described in the Part two: results section of 
this thesis. We were made aware of other instances of appeared benefit apart from 
these three case studies, but the documentation surrounding these other cases was 
often lacking. 
Little research has been conducted in regards to recommendations made to 
patients when they are traveling, and little is also known of clinical outcomes of 
anticoagulated patients when traveling. The first two case studies described 
elevated INR results in two patients who presented to a community pharmacy 
when traveling. The lack of access to pathology services for patients who are 
traveling may adversely affect their anticoagulant stability. 353 Time, cost, access, 
and convenience factors in organising pathology testing for patients traveling in 
rural and remote regions may be barriers to stable anticoagulant control. A study 
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by Pubentz et al. noted lack of access to monitoring as a contributing factor in 
increased complication rates amongst anticoagulated patients. 354 
The issue of poor compliance in regards to regular monitoring, as 
observed in case 3, has been raised in a number of studies as a reason for 
inadequate control of anticoagulant therapy. 327, 355 Studies have shown that 
structured POC monitoring and education programs have improved compliance 
with monitoring and understanding of anticoagulant treatment. 327 ' 354 ' 355 A study 
by Arnsten et al. reported that non-compliant patients were more likely to feel 
dissatisfied with their treatment, felt more burdened by taking warfarin and 
355 perceived fewer health benefits from the therapy. 	Education of the patient 
(case 3) by the pharmacist, combined with less invasive and more convenient 
monitoring, appeared to have ameliorated these concerns and improved 
compliance with warfarin therapy in this case. 
Further research needs to be conducted on the impact of community 
pharmacy conducted INR monitoring on patient care and outcomes. Most studies 
have shown that POC testing is beneficial when combined with changes in 
healthcare delivery systems. 338  Reports of POC testing used by pharmacists in 
anticoagulation clinics appear to verify that noted by the pharmacists in this 
project, that testing should be part of a larger program, 338 such as comprehensive 
anticoagulant education. POC testing must be associated with systems designed to 
efficiently and properly use the results and monitors. All of the studies of POC 
testing have only improved clinical outcomes when associated with 
comprehensive disease management. 338 
A response rate of 45% was obtained from the anonymous self-
administered patient satisfaction surveys. The response rate to the surveys is 
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limited due to the anonymity of the survey and only one copy was given to 
patients with no reminder survey given. The authors are therefore unaware of 
which patients returned surveys, due to the delivering of surveys to patients from 
the community pharmacists, which was hoped to increase response rate. 356 
Advantages of self-administered surveys are that they help to eliminate 
interviewer bias and personal or embarrassing questions may be answered more 
frankly. 357 However, due to a response rate of less than 70%, there may be some 
non-response bias in the results of the satisfaction survey. 358 However, it has 
been demonstrated that, in general a response rate of above 40% in postal 
questionnaires is acceptable. 357 Mazor et al. have suggested that more satisfied 
patients are more likely to respond than less satisfied patients, 359 although we are 
unsure in our case if less satisfied patients were less likely to respond. Further 
qualitative research should be conducted assessing underlying themes and 
attitudes towards pharmacy-based INR monitoring. 
The question that needs to be answered is whether this service meets the 
needs and expectations of patients. Patients' assessments of care have been 
advocated as an essential component of quality assessment. 360 The quality of the 
service was rated as good or excellent in nearly all cases. In the majority of cases, 
patients were very satisfied with the service provided, with a small number of 
patients dissatisfied or indifferent. It is unlikely that they were dissatisfied with 
the conduct of the pharmacist, as 98% of patients said the quality of the service 
was good or excellent. However, it may reflect a lack of pharmacist ability to 
adjust dosing and the testing may have been seen as a futile effort as indicated in 
some of the comments. Patients may be suspicious of the professional motives or 
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had negative feedback from their GP, and they may feel their needs are not being 
addressed in the design and implementation of services offered. 361 
Importantly, the majority of patients indicated that the pharmacy-based 
monitoring helped them deal more effectively with warfarin. This emphasises the 
ability of pharmacists to educate patients regarding their anticoagulant therapy, 
and in fact the effects of education delivered through pharmacy-based 1NR 
monitoring may have larger long-term impacts on compliance and anticoagulant-
related misadventure. 327 
Sixty-four percent of patients indicated that they preferred pharmacy-
based INR testing, which reinforces the consumer-led need for pharmacy-based 
INR monitoring to be available to patients receiving anticoagulants. Importantly, 
nearly all patients said that this service should be available to all patients 
receiving warfarin. This reinforces that this program is seen as beneficial from the 
patients' perspective and they see a need for this to be available to everybody. 
Some patients commented regarding the accuracy of the pharmacy-based testing 
compared to laboratory testing. It would be interesting to know if patients knew 
the variation between laboratories and could put this into context in relation to the 
variation between laboratory and the pharmacy-based testing. Pharmacists and 
GPs were alerted to this variation in the initial training and visits, respectively. 
However, studies have shown that patients are not adept at relating the differences 
between numbers and subsequently relating these to clinical decisions. 362,363  
It is a limitation of the study and room for further research that nearly one-
third of patients indicated that there was more information that they would like 
about warfarin. Structured education programs could be developed through 
community pharmacies and could complement pharmacy-based INR monitoring. 
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It is likely that pharmacy-based INR testing if implemented in community 
pharmacies would be part of larger education programs that may incorporate 
pharmacy based anticoagulation education, home medicines review, and 
identification/training of patients suitable for self-monitoring and self-
management. 
Nearly fifty percent of respondents indicated that they found the testing 
convenient and beneficial. This finding appears to be a common theme 
throughout the comments made by patients. Consumer-based studies of pharmacy 
services have revealed the main reason in using the local pharmacy is 
convenience. 364 ' 365 Patients receiving anticoagulation are often elderly, cannot 
endure long waiting times, and find traveling to hospitals or pathology 
laboratories difficult. 308 Pharmacies are usually located in convenient, accessible 
locations improving access for patients. A more. convenient approach could be to 
provide long-term monitoring through accredited community pharmacies. In 
addition, liaison between GPs and pharmacists reduces the risk of toxicity and 
treatment failure, and patient knowledge can be improved through counseling. 308 
The inability to make timely contact with the patient and the potential for 
misinterpretation of information conveyed by the GP has been shown to result in 
367 366, dosage errors. 251, 	As noted by Moffat, 368 the pharmacy profession has a 
great opportunity to use diagnostic testing to monitor patients' responses in 
assisting them to manage their chronic conditions and their prescribed medicines. 
The testing process was well received by the community pharmacists; they 
felt confident delivering this type of service and found it be a valuable service that 
was delivered to patients. This appears to be a realistic ongoing service that could 
be implemented in community pharmacies in the future. 333 Pharmacists, however, 
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will need to address issues such as the need for separate counseling and 
consultation areas for testing, and occupational health and safety issues associated 
with handling bodily fluids. 369 Privacy in a community pharmacy has been cited 
as a potential barrier to conducting detailed consultations and therefore to 
obtaining appropriate advice and information, 361 although it has been suggested 
that patients may forgo privacy in favour of easier access to medications or to 
avoid examination. 370 
Ongoing quality assurance schemes will need to be developed to ensure 
pharmacy-based INR monitoring systems are of a high standard. As noted by 
Murdock, "There has to be seamless care between the primary and secondary 
settings so that the results found in pharmacies will dovetail in with those tests 
carried out by GPs or in hospitals". 371 
Responding pharmacists indicated that they thought that pharmacy-based 
INR monitoring would improve the compliance of patients on warfarin. In fact, 
pharmacist managed anticoagulation clinics have reported increased compliance 
after instituting education programs. 327 
There was a wide variation in the response from pharmacists' to the 
question "I would feel comfortable operating this service if it was ongoing". 
Overall, the response was positive, but the variation indicates there may be issues 
regarding delivering this service if current structures in community pharmacies 
persist. In their comments, pharmacists cited issues such as time constraints and 
remuneration as barriers to the delivery of these types of programs. 
Pharmacists indicated that they received positive feedback from the GPs 
but the range of responses indicated that there was some less than positive 
feedback in some cases. A potential reason behind this variation in responses is 
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simply the pharmacists and GPs may not know each other well enough to have 
61 developed a trusting and respectful relationship. 3 This may be made more 
difficult by the trend in both professions, towards an increasingly mobile 
workforce, more locums and part-time working. 361  Future changes to funding 
arrangements for GPs and pharmacists may allow for greater collaboration 
between professions, and remuneration schedules should also reflect this. 
The evaluation from the GPs was generally positive, but variation in a 
number of the responses was evident. A negative response was observed to the 
question "I found the comments made by the pharmacist to be useful". This may 
reflect barriers between general practice and pharmacies regarding perceived 
encroachment of pharmacy services on traditional general practice territory. 372  It 
has been suggested that models of interdisciplinary collaboration need to be 
implemented cautiously, as rapidly imposed change can create conflict and 
resistance. 373 
More formal integration of pharmacists into health care and the 
development of partnerships with GPs are crucial to the establishment of 
pharmacy-based INR monitoring. Professional barriers to the implementation of 
expanded pharmacy services have been identified in the literature. These include 
the "shopkeeper image" of community pharmacy. 372  GPs may be unaware of the 
training that community pharmacists have undertaken to perform these services. 
The design of many community pharmacies has been identified previously 
as a concern for implementation of professional services. 372 It is recognised that a 
number of community pharmacies may have to undergo structural modifications 
to cope with the array of professional services that may be funded in the future. 
Negotiations should be encouraged with government departments for funding to 
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proceed with structural modifications in community pharmacies. This will allow 
community pharmacies to meaningfully contribute to primary health care 
management. 
One of the recurring problems when pharmacy expands its role in 
providing other areas of health care is "who is going to pay". Patients are unlikely 
to pay (fully) for services that are provided free through GPs and pathology 
providers. Patients exempt from charges for conventional laboratory testing are 
not necessarily motivated, or do not have the resources, to obtain care from other 
sources. 370  Over 50% of patients expressed a willingness to pay for pharmacy-
based testing, with over 50% of this group indicating a range of payment in the 
order of $1-$5. This service may be implemented in the short-term for those 
patients who are willing to pay for the service in its entirety. 
The median testing time for pharmacists to conduct this type of service 
was five minutes in this pilot program. Pharmacists were instructed to record the 
time taken to conduct the testing and in the majority of cases' results were 
communicated to prescribers via the specially designed fax forms. If this program 
were implemented, streamlined communication channels would need to be 
designed to ensure results are communicated to GPs in a timely and accurate 
manner. It is accepted that if this program was to be implemented on a wider 
scale, monitoring may also encompass education and this process may in fact take 
a longer time. The answer lies in the pharmacy profession advocating 
remuneration for a primary role in anticoagulation management in the community 
setting. We propose a remuneration schedule similar to prescription medications 
and that pharmacists are paid a testing fee each time a test is conducted in the 
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pharmacy. This fee would encompass the cost of the testing strips and would be in 
the order of $15 per test ($6 per test strip, $1 mark-up and $8 testing fee). 
Some limitations in training may need to be assessed in a training package 
that is assembled for community pharmacy. This may have been reflected in three 
pharmacies not conducting any tests during the study period. Although reasons 
cited for not performing testing were generally due to increased work implications 
from the testing, a lack of confidence with using the monitor may have 
contributed to these feelings. The majority of community pharmacists exhibited 
good clinical skills (63% were AACP accredited) and education regarding 
warfarin focused on pharmacology and dose adjustment, with literature provided 
in all cases. The University of Birmingham (www.bham.ac.uk) conducts a course 
for anticoagulant management for health professionals who are working in or 
aiming to work in anticoagulation clinics. This course is conducted over a three-
day period, the focus of which appears to be on protocol development, history of 
anticoagulant management, warfarin use and pharmacology. We suggest the 
development of a distance-learning package could be developed covering this 
information with practical training on POC testing used in conjunction with this 
package to accredit community pharmacies to participate in INR monitoring. This 
type of warfarin monitoring service may improve patient outcomes and improve 
patient knowledge through education. Involvement of pharmacists in 
anticoagulant therapy is an accepted part of pharmacy practice in many countries. 
Studies have found that elderly rural patients with chronic AF receive 
warfarin less frequently than urban patients, despite possessing a similar high-risk 
profile for stroke and fewer relative contraindications. 197 ' 349 This is partly 
attributable to the fact that GPs prescribe anticoagulant therapy for AF less 
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frequently than cardiologists, who are scarce in rural communities. 349 The impact 
of stroke is significant in rural, regional and remote areas, and this reflects 
difficulties in instigating preventive programs. 339 
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PART FOUR: IMPROVING WARFARIN INITIATION 
CHAPTER TWENTY TWO: INTRODUCTION 
22.1 Adverse drug events 
22.1.1 Overview of adverse drug events 
Despite calls for improvements in the use of pharmaceutical drugs, and better 
373 liaison between doctors, pharmacists and patients, 	problems associated with 
the use of pharmaceutical drugs in society continue to be a significant public 
health burden. It has been estimated that problems associated with therapeutic 
drug use in Australia result in at least 80,000 hospital admissions annually 
(accounting for approximately 12% of all admissions to medical wards 374 - 
375 	 374 including at the RHH), 	at a cost of around $400 million per year. 	About 
one-half of these hospital admissions are considered to be avoidable. 
"Despite increasing attention to geriatric pharmacotherapy, there is 
an enormous need for additional research to improve the use of 
medications among older adults. The necessary research agenda 
encompasses much more than just the discovery of new drugs; better 
use of the current pharmacopoeia has great potential to improve the 
lives of older adults." 376 
In particular, adverse drug reactions remain a significant cause of hospital 
admissions 374 and unplanned re-admissions, 377 ' 378 frequently involving 
predictable high-risk situations (e.g. multiple drug use in the elderly) which are 
379 amenable to prevention through improved systems. 	A study by Gurwitz et al. 
identified an overall rate of adverse drug events (ADEs) of 50.1 per 1000 person-
years, with a rate of preventable ADEs of 13.8 per 1000 person-years. 380 
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22.1.2 Transition from hospital to community care 
Information gaps have been extensively documented in patients discharged from 
hospital. 381 Patients discharged from hospital are at high-risk of experiencing 
383 adverse effects; 382, 	significant alterations to a patients' medication may occur 
in hospital. Patients may not take dosages appropriately after discharge and may 
not understand instructions appropriately. 367 
Hospitals' pharmaceutical care aims to provide a continuum for the 
Quality use of medicines (QUM) during the patient's entry into and treatment 
within hospital, and importantly re-entry into community or residential care 
settings. 384 In view of the increasing trends for earlier discharges, the need for 
continuity of care in relation to drug therapy is likely to have a significant impact 
on quality health outcomes. 384 
Successful discharge planning should be a centralised, co-ordinated, 
multidisciplinary process that ensures all patients have a plan for continuing care 
after they leave the hospital. "The transition from the hospital is often more 
threatening than the actual hospitalisation, and a plan must exist not only to 
provide for a continuum of care, but also to address the patient's immediate needs 
following discharge." 384 
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22.1.3 Anticoagulant-related adverse drug events 
Anticoagulants have been implicated in 10.2% of all preventable ADEs in 
ambulatory patients, 3813 and 20% of ADEs in hospitalised patients taking 
cardiovascular drugs. 385 
Adverse events from warfarin use in Australia were estimated to cost over 
$100 million per annum in direct hospital costs alone (in 1992). 302 Reductions in 
the incidence of anticoagulant-related adverse events may be achieved through 
the following, as suggested by Murray and Callahan 3" 
"Many major improvements in medication use among older adults 
will also depend on closing the gap between knowledge and practice 
and increasing the ability of older adults to manage their 
medications." 
The major complication of anticoagulant therapy is bleeding. 105 '  118 '  386 
Based on estimates from randomised trials, the average annual frequencies of 
fatal, major, and total bleeding during long-term warfarin therapy are 0.6%, 3.0%, 
and 9.6%, respectively; these frequencies are approximately five times those 
expected without warfarin therapy. 105, 118, 386 Major independent risk factors for 
bleeding during long-term warfarin therapy have included comorbid conditions 
other than the indications for therapy, history of stroke, history of GI bleeding, 
advancing age (greater than 65 years), and the intensity of anticoagulant therapy. 
105, 118, 127, 315, 386 Increased variation in the INR is associated with an increased 
frequency of haemorrhage independent of the mean INR. 116, 117 This effect is 
probably attributable to increased frequency and degree of marked elevations in 
the INR. 
Bleeding complications with anticoagulant drugs appear to occur more 
frequently in older patients than in younger individuals. 105, 386-389 Most 
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individuals who receive oral anticoagulant therapy are elderly patients with AF or 
VTE. Older patients have characteristics that may place them at higher risk for 
anticoagulant-related bleeding, but they also have characteristics that make them 
more likely to benefit from the therapy. 386 '  389 
A number of studies have reported that the risk of bleeding associated with 
warfarin is highest early in the course of therapy. 105, 109, 116, 118-121 In one of these 
studies, for example, the frequency of major bleeding decreased from 3.0% 
during the first month of outpatient warfarin therapy to 0.8% per month during 
the rest of the first year of therapy and to 0.3% per month thereafter. 121 
22.2 Reducing anticoagulant adverse events 
22.2.1 Post-discharge follow-up 
As part of the National guidelines from the Australian Pharmaceutical Advisory 
Council (APAC) for continuum of care, 384 all patients deemed at risk of 
medication misadventure should be identified and followed-up in the immediate 
post-discharge period. Medication review allows an assessment of patient 
adherence and review of medication related problems. A number of problems can 
occur in the post-discharge phase such as taking the wrong dose, continuing to 
take medication despite instructions by the physician to discontinue drug therapy, 
refusal to take a needed medication, continuing to take a medication despite 
recognised adverse effects or drug interactions known to the patient, and taking 
another person's medication. 380 
A Cochrane database review examining the effect of expanding the roles 
of ambulatory pharmacists on patient outcomes and health care use suggests that 
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pharmacist intervention can improve patient behaviour and adherence and 
improve physician prescribing. 390 
22.2.2 Monitoring anticoagulation intensity 
This is covered in more detail in sections 2.1.10.1 and 2.1.10.2. Briefly, the 
intensity of anticoagulant effect is probably the most important risk factor for 
ICH, independent of the indication for therapy, with the risk increasing 
dramatically with an 1NR > 4.0. 110 The safety and efficacy of warfarin depends 
on maintaining the INR within the therapeutic range. Analysis of primary 
prevention trials for stroke prevention in AF, found that a large number of 
thromboembolic and bleeding events occurred when the INR was outside of the 
therapeutic range. 110 Analysis of other cohort studies have shown a sharp 
increase in the risk of bleeding when the INR is higher than the upper limit of the 
therapeutic range 112-114 and the risk of thromboembolism is increased when the 
INR falls below 2.0. 38 ' 111 
22.2.3 Patient knowledge and education 
Studies have generally shown a relationship between patient knowledge and 
adverse outcomes of warfarin therapy. 284, 309, 315, 391-395 Good outcomes have been 
recorded where patients have had increased participation in their care and been 
encouraged to communicate more effectively with doctors and other health 
professionals about drug interactions and changes in lifestyle or diet. 327 
Compliance with warfarin is essential to maintain good anticoagulant control and 
to prevent unnecessary dosage changes. 392 
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A recent report by Tang et al. 392 evaluated patients' knowledge of 
warfarin and the relationship to anticoagulant control. Overall, they concluded 
that patients' warfarin knowledge was poor. Less than 50% of patients knew the 
strength of their warfarin tablets, the reason for taking warfarin and its effect on 
the body. They also stated that 
"Their deficiencies in knowledge were even more obvious with 
respect to the possible consequences of under- or over-
anticoagulation, drugs and medicated oils that might interact with 
warfarin and the management of a missed dose" 392 
Patients who read the anticoagulation booklet on warfarin had better 
knowledge than those who had not. Most importantly from this study was a 
positive correlation between patients' warfarin knowledge and the number of INR 
, 395 values that were in the therapeutic range. 392 Pharmacists need to take a key 
role in reinforcing knowledge regarding anticoagulation to reduce the risk of 
complications of anticoagulant therapy. Warfarin education needs to be tailored to 
the level of education and age of the patient. 392 Education of elderly and illiterate 
patients may require special consideration and include the use of visual aids. 396 
Roddie and Pollock showed that 85% of patients with a good 
understanding of warfarin had a well controlled and stable 1NR, compared to only 
63% in the poor-understanding group. 396  Generally, patients' knowledge, drug 
compliance and anticoagulant control all generally improve after patient 
education became part of a structured management program. 395 
The Newcastle Anticoagulation Study Group found no relationship 
between knowledge and INR level but found a positive relationship between 
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education level and knowledge. Importantly they noted "knowledge was generally 
poor" and 24% of patients answered less than half of the questions correctly. 397 
Functional Health Literacy (Fl-IL) is a measure of a person's ability to 
perform basic reading and numeric tasks in the healthcare context, such as reading 
insurance forms and medication labels, and performing mathematical tasks 
associated with taking medications (numeracy). A body of research exists 
demonstrating that patients with inadequate Fl-IL have worse health status, 
problems communicating with healthcare providers, poorer knowledge of their 
chronic disease state, are at increased risk of hospitalisation, and are more likely 
to be confused about medications. 397 Inadequate Fl-IL may be a barrier to 
assessing medication adherence because these patients are more likely to have 
difficulties accurately reporting to pharmacists the drugs they are currently taking. 
A recent study among patients taking warfarin in a pharmacist-run 
anticoagulation clinic demonstrated that patients with inadequate Fl-IL were less 
likely than patients with adequate Fl-IL to articulate their weekly warfarin regimen 
accurately. Of note, providing patients with a simple visual aid (a digitised, color 
warfarin pill menu from which patients could identify their doses) significantly 
reduced the FHL-related disparities in warfarin regimen accuracy. 175 
In a study cohort of patients treated with warfarin for stroke prophylaxis in 
AF, (Figure 29) only 45% of the study cohort believed that there was some risk 
associated with warfarin therapy in the form of either bleeding or poisoning, 
whereas the majority of patients (55%) were not aware of any of the specific 
risks. 175 
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TABLE 3. 	Patient Perceptions of Warfarin 
M Groups Indo-Asian Afro-Caribbean White P Value 
Reasons for commencing warfarin 
Aware of any of the following: heart cfisease, 62 (52%) 19(50%) 14(50%) 29(55%) 
'thick blood, 	or risk of stroke 
Only because 'doctor told me to 57(48%) 20(50%) 13(50%) 24(45%) 0.85 
Awareness of warfarin preventing blood clots 
Aware 79(66%) 15(38%) 23(85%) 41 (77%) 
Not aware 40(34%) 24(72%) 4(15%) 12(23%) <0.001 
Awareness of warfarin preventing stroke 
Aware 77(65%) 19(49%) 16(59%) • 42(79%) 
Not aware 42 (35%) 20 (51%) 11(41%) 11(21%) 0.008 
Perception of any risk of warfarin treatment 
Not aware 46(39%) 22(56%) 8(30%) 16(30%) 
Bleeding 33(27%) 7(18%) 9(33%) 17(33%) 
Poisoning 21(18%) 2(5%) 8(30%) 11(20%) 
None 19(16%) 8(21%) 2(7%) 9(17%) 0.03 
Not aware +None 65(55%) 30(77%) 10(37%) 25(47%) 
Bleeding +Poison 54(45%) 9(23%) 17(63%) 28(53%) 0.002 
General feelings about warfarin therapy 
My doctor has given me enough Information about warfarin 46(39%) 12(30%) 3(11%) 31(59%) 
I am careless at times about taking warfarin 50(42%) 23(59%) 18(68%) 9(17%) 
Taking warfarin makes me worry about my health 59(50%) 29(75%) 24(90%) 6(11%) 
Figure 29 	Patient perceptions of warfarin. 
Reproduced from Lip et al. I ' 
An understanding of how patients feel about warfarin therapy is important, 
as this may be a potential reason for noncompliance to warfarin therapy. 355 
Noncompliant patients have been shown to be more likely to feel that their doctor 
was not very concerned about them or was less willing to listen to their concerns, 
but they were less likely to feel that taking warfarin benefited their health, 
prevented blood clots, or protected their future health. 398 
22.3 Project aims and objectives 
The overall aim of the final study described in this thesis was to reduce 
complications associated with anticoagulants in a population of patients 
commenced on warfarin. The objectives of this study was to implement and 
evaluate a randomised controlled trial intended to promote the smooth transition 
of patient care from hospital to the community by incorporating home follow-up 
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and POC monitoring of patients commenced on warfarin. The following 
objectives were to be measured comparing the intervention to normal care; the 
intention was to determine whether the program 
• Resulted in safer and more effective initiation of anticoagulation, as 
measured with a range of outcomes, including the achievement of a 
therapeutic INR value on day 8 after discharge from hospital, reduced 
anticoagulant-related bleeds, and less unplanned readmissions related to 
anticoagulation (thromboembolic or haemorrhagic complications) within 
90 days of initial discharge from hospital; and 
• Was valued and welcomed by patients and their GPs. 
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CHAPTER TWENTY THREE: METHODS 
IMPROVING WARFARIN INITIATION 
23.1 Recruitment procedure 
Patients were recruited from the RHH. As described previously, the RHH is a 
450-bed acute care teaching hospital and the only major public hospital in the 
southern region of Tasmania (serving a population of approximately 230,000). 
Inpatients initiated on warfarin at the RHH, between February 2002 and June 
2003, were prospectively identified by SLJ and/or ward pharmacists. SLJ was not 
a formal employee of the hospital. Those patients who provided informed consent 
(Appendix 15) were allocated to either the intervention (Home monitoring: HM) 
or control (Usual Care: UC) group using a computer-generated random number 
sequence. Patients were informed to which group they were randomised. All 
patients received regular medical, nursing and pharmacy care during their 
hospitalisation. 
23.2 Home monitoring procedures 
GPs for patients in the HM group were telephoned at discharge to inform them 
that their patient had consented to be involved in the project. HM patients 
received a home-visit by the project pharmacist on alternate days on 4 occasions, 
with an initial visit two days after discharge from hospital. The project pharmacist 
using POC INR monitoring tested the INR (CoaguChek S, Roche Diagnostics, 
Australia), and discussed a number of important educational points regarding 
anticoagulant therapy such as goals, adverse effects and interacting medications 
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with warfarin. The pharmacist used a standard warfarin educational booklet as the 
basis of the counselling and also developed an A4 warfarin document to assist in 
education purposes (Appendix 16) The pharmacist liaised with family members 
and community pharmacists where necessary to ensure follow-up education and 
support was provided. 
Patients' GPs were telephoned with each 1NR result during the four visits 
and subsequent dosage changes, if considered necessary, were discussed. All GPs 
were sent a personalised letter (Appendix 17) and information sheet (Appendix 
18) when the patient was discharged, indicating the group that the patients were 
enrolled to and what follow-up they would receive. GPs assigned to the HM 
received a personalised letter after the fourth visit containing INR results and 
doses received during the follow-up (Appendix 19); a GP survey was also sent 
with this letter with a reply paid envelope. 
23.3 Usual care group procedures 
Instructions in the letter (Appendix 20) to GPs caring for UC patients, indicated 
that this project was not responsible for the monitoring of their patients and 
patients would receive a visit from the project pharmacist 8 days after discharge 
to determine anticoagulant control. GPs caring for UC patients were telephoned 
on Day 8 if an adverse trend was identified or if the INR was out of the 
therapeutic range. 
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23.4 Data collection 
Baseline demographics, indication for anticoagulation, current medications and 
presence of contraindications to warfarin (Appendix 21) were assessed after 
consent for enrolment had been given. The quality of anticoagulation whilst in 
hospital was also recorded, and assessed against the RHH anticoagulation 
protocol (Appendix 4) for initiation of warfarin. Adherence to the protocol was 
defined as giving the appropriate dose for each patient for the first two days of 
initiation, and was assessed by SLJ. 
Alternate day INRs for four visits after discharge were recorded for the HM 
group; duration of the visits and outcomes were also assessed. The UC group had 
their 1NR measured at day 8 post-discharge. The number of pathology tests taken 
by the GP (patient and/or GP reported) and INR results obtained by the GP 
(patient and/or GP reported) were also recorded. 
A modified multiple-choice 'satisfaction questionnaire' (Appendix 22), based 
on a similar post discharge project by Naunton et al. 398 was given to each HM 
group patient, to be completed anonymously after the fourth visit, along with a 
reply-paid envelope. A systematic step-wise approach to assessing bleeding 
(major and minor) and embolic complications, adapted from Heidinger et al., 320 
was used. All patients were interviewed at 90 days after discharge to assess these 
complications, the types and frequency of these events. The event rates were 
assessed through a combination of self-reported events and medical record notes. 
Patient knowledge was assessed using a self-administered questionnaire 
(Appendix 23) with a reply paid envelope by all patients at 90 days after initial 
discharge using a composite questionnaire from previous studies. 392 '  395 '  399 
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23.5 Data analysis 
A number of outcomes were assessed, including the achievement of a therapeutic 
INR value on day 8 after discharge. Therapeutic ranges according to RHH 
anticoagulation protocols were used. The therapeutic range for AF, VTE, mural 
thrombus and biological heart valves were 2.0-3.0. The therapeutic range for 
mechanical heart valve was 2.5-3.5. 
Primary outcomes were total, major and minor bleeding complications, 
and unplanned readmissions due to anticoagulant-related complications. Bleeding 
was defined as major if it was clinically overt and associated with either a 
decrease in the haemoglobin level of at least 2g per decilitre or the need for a 
transfusion of 2 or more units of red cells; if it was retroperitoneal or intracranial; 
if it warranted the permanent discontinuation of warfarin or if it required hospital 
admission. All other bleeding complications were assessed as minor. 
The medical records of all patients who reported symptoms of embolic 
complications (TIA, stroke, AMI, complications of DVT) were examined and 
GPs contacted if necessary to confirm these events. Secondary outcomes were 
unplanned readmissions from any cause, death (cause determined from death 
certificates), proportion of patients remaining on anticoagulant therapy and 
warfarin knowledge assessed 90 days after initial discharge. Follow-up was 
complete through patient interview and medical record review for all patients. 
Rates of outcomes were expressed as number and percent of events with 
95% CI. Responses between groups were compared by Mann-Whitney tests and 
Kruskal-Wallis tests for non-parametric responses. Changes within groups for 
numerical variables were compared by Wilcoxon-signed rank tests. Categorical 
variables were compared by x2 tests. GPs were anonymously surveyed using a 10- 
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Sub-therapeutic 
Therapeutic 
point Likert scale and HM patients were anonymously surveyed (Appendix 22) 
after the fourth visit to assess their opinions of the service. The INR values during 
hospital admission and after discharge were plotted with median and inter-quartile 
ranges marked at 10, 25, 75 and 90 percentiles. The following colouring was 
applied to tables to assist in readability of outcomes at discharge, day 8 and day 
90 after discharge. 
23.6 Exclusions 
Exclusions comprised patients who were not being discharged home in Southern 
Tasmania, who had dementia and were unable to answer basic questions about 
their therapy or who were entering the Patients Acute Treatment and Care in the 
Home (PATCH) program. The PATCH program is comparable with hospital in 
the home treatment programs utilised in other hospitals. Patients are still classed 
as inpatients of the hospital but are treated at home. Patients who were having 
warfarin re-initiated after surgery were also excluded. The exclusion criteria were 
kept to a minimum to allow the data to be relevant to a large proportion of 
patients who are initiated on warfarin in hospital and discharged to community 
care. 
24.7 Cost-effectiveness 
Based on previous studies 144 ' 400 that have indicated approximately 50% of major 
bleeding complications are GI related, 20% are intracranial in origin and 30% are 
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classified as other major bleeding, the individual costs for each of these types of 
bleeds was estimated. Data for estimates of costs was obtained from diagnosis 
related grouping (DRG) codes from public hospitals in Tasmania for the years 
2001-2002. 401 The average cost per admission was estimated at $1757, $4764 & 
$1917 for GI, intracranial and other related major bleeds respectively. Given these 
proportions of major bleed subtypes, the overall estimated admission cost of a 
major bleed was $2405. There is a lack of data examining the outcomes of the 
costs associated with minor bleeding on warfarin. Therefore, It was assumed that 
the first minor bleeding episode per patient was followed by a GP's appointment 
(cost $22.65). It was assumed that I patient per 1000 of population are initiated 
on warfarin per year (data from this study). This however does not include 
estimates of patients initiated on warfarin from private hospitals or in general 
practice settings. 
25.8 Sample size calculation 
Based on previous studies showing approximately 30% of patients commenced on 
warfarin experience a bleeding complication within 3 months 89, 105, 118 	, • and given 
that the aim of the intervention program was to reduce this figure to below 10%, 
72 patients were needed per group (at a power of 80% and p = 0.05). Data from 
the RHH indicated that after a median period of hospitalisation of 8 days for DVT 
and/or PE, 63% of RHH patients had an 1NR within the therapeutic range. 402  
Assuming that approximately 65% of patients commenced on warfarin have a 
therapeutic INR on day 8 after discharge from hospital and given that the aim of 
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the intervention program was to improve this figure to at least 85%, 83 patients 
were needed per group (at a power of 80% and p = 0.05). 
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N= 68 Usual care, received 
standard care delivered by 
GP, and received visit by SLJ 
on day 8 to obtain INR 
• 
N= 68 Usual Care group LN= 59 Home monitoring group 
• 
CHAPTER TWENTY FOUR: RESULTS 
IMPROVING WARFARIN INITIATION 
24.1 Recruitment 
A total of 131 patients were identified as eligible for inclusion. One patient 
refused participation and two patients enrolled in the HM group were discharged 
under the care of the PATCH program. Recruitment is displayed in the 
recruitment flowchart (Figure 30). 
Figure 30 	Recruitment flowchart-Improving warfarin initiation 
N= 176 Initiated 
on warfarin but 
not identified by 
study pharmacist 
N=49 Excluded 
N=16 PATCH 
N=33 Warfarin 
reinitiated after 
surgery 
N=356 initiated on warfarin during study period 
1\1= 131 approached to enter study 
N=1 patient refusal 
N=2 PATCH 
• 
N= 130 Randomised 
Day 8 
follow-up 
N= 60 Home monitoring, 
received alternate day 1NR 
monitoring by SLJ for 4 
visits with patient-focused 
education 
N=1 excluded 
Day 90 
follow-up 
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24.2 Characteristics of trial participants 
Table 49 summarises the clinical and demographic features of the 128 patients 
enrolled in the study. The groups were well matched with regard to baseline 
characteristics. The HM group had a significantly greater number of patients with 
a previous AMI and trends towards higher amiodarone use at discharge and a 
history of falls. One patient (HM) was excluded after the day 8 follow-ups, due to 
the changing of therapy from warfarin to LMWH on advice from the GP on day 
8. Therefore, outcomes at 90 days were assessed for 127 patients. 
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Home monitoring 
n (%) 
Usual care 
n (%) 
P value 
Participants 60 (47) 68 (53) 
Age-median (range) 70 (19-94) 72.5 (20-91) 0.93 
Age > 75 years 20 (34) 27 (40) 0.50 
Female 28 (47) 32 (47) 0.96 
Lives alone 22 (37) 17 (25) 0.15 
Cognitive deficit 2 (3) 4 (6) 0.5 
History of documented falls 3 (5) 0 (0) 0.06 
Cardiovascular admission 39 (65) 44 (65) 0.97 
History of GI symptoms 17 (28) 23 (34) 0.50 
Previous stroke 7 (12) 7 (10) 0.80 
Hypertension 32 (53) 32 (47) 0.48 
Diabetes 8 (13) 13 (19) 0.38 
Previous AMI 11 (18) 4 (6) 0.03 
CCF 13 (22) 13 (19) 0.72 
Malignancy 4 (7) 4 (6) 0.85 
Contra-indications to warfarin 12 (20) 7 (10) 0.12 
Previous warfarin use 8 (13) 9 (13) 0.99 
Amiodarone use at discharge 16 (27) 10 (15) 0.08 
Antibiotic use at discharge 12 (20) 19 (28) 0.32 
Interacting drugs at discharge 48 (80) 52 (78) 0.74 
Initial bed stay median (range) 8 (3-72) 8 (1-65) 0.47 
Comorbidities median (range) 4 (1-12) 4(1-9) 0.17 
Chronic drugs median (range) 6 (1-12) 6 (1-15) 0.59 
Interacting drugs median (range) 1.5 (0-4) 2 (0-6) 0.91 
Table 49 	Baseline characteristics of trial participants 
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Antithrombotics Home monitoring n (%) Usual Care n (%) 
Warfarin alone 
Warfarin & aspirin 
Warfarin & clopidogrel 
Warfarin, aspirin & clopidogrel 
	
50 (83) 	 53 (78) 
9 (15) 14 (21) 
0 	 1 (1) 
1 (2) 0 
24.3 Indications for anticoagulation 
Table 50 describes the reasons for initiation of anticoagulation, with no 
significant differences between the groups. The most common indication for 
initiation of warfarin was stroke prevention in AF. 
Reason for use Home monitoring n (%) Usual Care n (%) 
AF 27 (45) 31 (46) 
DVT or PE 19 (32) 20 (29) 
Valve replacement 11 (18) 12 (18) 
Mural thrombus 3 (5) 5 (7) 
Table 50 	Reason for initiation of warfarin 
24.4 Concomitant antithrombotic therapy 
Twenty per cent of all patients were prescribed combination antithrombotics, as 
described in Table 51, with no significant differences or imbalances across the 
groups. 
Table 51 	Antithrombotics on discharge 
(P=0.44 for trends across groups) 
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24.5 Contraindications to anticoagulant therapy 
Fifteen per cent of all patients had some contraindication to anticoagulant therapy, 
according to contraindications listed in the Australian Prescription Products 
Guide, 104 and identical to those utilised in another study of anticoagulant use at 
the same institution. 193 There appeared to be a trend towards more 
contraindications in the HM group compared to UC, but this was not statistically . 
significant. Table 52 summarises actual contraindications to anticoagulant 
treatment for all patients. 
Contraindication Home monitoring, n Usual care, n 
Psychiatric illness 3 1 
Falls 3 0 
Bleeding tendency 1 2 
Blood dyscrasias 1 0 
Alcohol abuse 2 0 
Poor compliance 2 3 
Liver disease 2 0 
Malignancy 1 0 
Table 52 	Contraindications to anticoagulation 
Contraindications total 21, as some patients exhibited more than one. 
Table 53 categorises patients according to the bleeding risk index 
developed by Beyth et al. 127, 386, 389  
Bleeding Risk Home monitoring n (%) Usual care n (%) 
Low 14 (24) 17 (25) 
Medium 41 (70) 46 (68) 
High 4 (7) 5 (7) 
Table 53 	Bleeding risk index 
P=0.98 for differences between groups 
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24.6 Quality of anticoagulation at discharge 
Table 54 displays the quality of anticoagulation for all patients on discharge from 
the hospital. There were no significant differences between the groups. The 
median INR in the HM and UC groups was 2.0 (1.0-3.6) and 2.2 (1.0-4.0), 
respectively (P = 0.55, U = 1742.5). 
Home monitoring n (%) Usual care n (%) 
Sub-therapeutic 29 (49) 31 (47) 
Therapeutic 25 (42) 30 (45) 
C3 
Table 54 	Anticoagulant control at discharge 
P=0.94 for differences between HM and UC groups 
Table 55 shows the relationship between bed stay in hospital and quality 
of anticoagulation at discharge. This implies a longer bed stay for patients who 
were therapeutic at discharge compared to supra-therapeutic or sub-therapeutic 
patients. There was, however, no significant difference or imbalance between HM 
and UC groups. 
Home monitoring Usual care P value 
Sub-therapeutic 8 (3-34) 7 (1-25) 0.44, U = 397 
Therapeutic 10 (6-65) 10 (4-65) 0.77, U = 343 
06sL(- 1y:: ? MK) M PollZ 00CAU 
P value 0.02, H = 8.19 0.01, H = 9.25 
Table 55 	Bed stay and INR range at discharge 
Median and range values reported 
The median days of warfarin dosing before discharge for the HM and UC 
groups, 6 days (1-27) and 6 days (1-45), respectively (P=0.66, U=1885). Table 56 
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illustrates the relationship between number of days of warfarin dosing whilst in 
hospital and quality of anticoagulation at discharge. The data shows a longer time 
of warfarin dosing whilst in hospital is closely related to quality of 
anticoagulation at discharge. There was, however, no difference between HM and 
UC groups in this respect. 
Home monitoring Usual care P value 
Sub-therapeutic 6 (1-13) 5 (1-21) 0.51, U = 391 
Therapeutic 6 (4-27) 7 (4-45) 0.44, U = 315 
a- 'hergxm 7(5=7' 0=:)4 08 U_P-.3. 4. 
P value 0.04, H = 6.3 0.002, H = 13.0 
Table 56 	Number of days of warfarin initiation and INR range at discharge. 
Median and range values reported 
24.7 Quality of warfarin initiation 
Figure 31 plots the INR (median and inter-quartile ranges marked at 10, 25, 75 
and 90 percentiles) whilst in hospital for all patients, and for the HM and UC 
groups. A proportion of supra-therapeutic INR values are evident from day 3 after 
initiation. Figure 32 illustrates warfarin initiation whilst in hospital for the two 
groups (1-1M and UC) of patients. Forty-four percent of anticoagulant initiations 
followed the RHH anticoagulation protocols, 40% in the HM group compared 
with 47% in the UC group, (P = 0.43, x 2 = 0.62). 
Figure 33 plots warfarin initiation whilst in hospital according to 
adherence to the anticoagulation protocol. It can be seen that patients who had 
warfarin initiated according to the anticoagulation protocol had a reduced number 
of supra-therapeutic 1NRs compared to when there had been non-adherence to the 
protocol. For patients whose initiation did not follow , the RHH guidelines, 4%, 
16% and 10% had INRs greater than 4.0 on days 3, 4 and 5 of their hospital stay, 
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respectively, compared to none in the guideline-adherent group. The median 
duration of hospitalisation was one day longer in patients whose warfarin 
initiation did not follow the RHH guidelines. Eight (6%) patients had a minor 
bleed whilst in hospital; the INR was 1.0, 1.0, 1.2, 1.6 and 3.9 in five cases and 
was not ascertainable in three cases. Seven of the eight minor bleeds occurred in 
patients whose initiation did not follow the protocol, compared to one minor bleed 
whose initiation followed the protocol (x2 = 3.5, p = 0.06) 
Warfarin initiation in hospital for all patients 
1 	2 	3 	4 	5 	6 	7 	8 	9 	10 
Days in hospital during initiation of warfarin 
Tests (T) 107 61 92 96 88 76 45 25 22 15 
Patients (P) 128 115 111 105 93 82 50 35 27 24 
Figure 31 	INR level in hospital during warfarin initiation 
(T) Number of patients who had INR tests taken on the corresponding day 
(P) Number of patients remaining in hospital on the corresponding day 
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Warfarin initiation in hospital for HM group 
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Figure 32 	Warfarin initiation for usual care and home monitoring groups in hospital 
(T) Number of patients who had INR tests taken on the corresponding day 
(P) Number of patients remaining in hospital on the corresponding day 
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Warfarin initiation- not adhering to initiation protocol 
Days in hospital during initiation of warfarin  
Warfarin initiation- adhering to initiation protocol 
2 	3 	4 	5 	6 	7 	8 
	
9 	10 
Days in hospital during initiation of warfarin 
T 52 27 53 57 52 45 27 15 14 11 T 54 34 39 39 36 31 18 10 8 4 
P 71 64 64 62 56 49 32 22 16 14 P 57 51 47 43 37 33 18 13 11 10 
Figure 33 	Warfarin initiation in hospital for initiations not adhering and adhering to anticoagulation protocol. 
(T) Number of patients who had INR tests taken on the corresponding day 
(P) Number of patients remaining in hospital on the corresponding day 
24.8 Anticoagulant control day 8 after discharge 
Table 57 displays the level of anticoagulation for all patients at Day 8 after 
discharge. The median 1NR in the HM and UC groups was 2.4 (1.3-5.8) and 2.1 
(1.0-7.6), respectively (P = 0.84, U = 1602.5). 
Home monitoring n (%) Usual care n (%) 
Sub-therapeutic 15 (29) 21 (33) 
Therapeutic 35 (67) 26 (41) 
ic5-4-pm=iikarcee 2) OD 11(6 a,-* 
Table 57 	Anticoagulant control at Day 8 
P=0.0022 for differences between control and intervention groups 
Table 58 Shows a significant trend for UC patients discharged with a sub-
therapeutic INR to have a poorer outcome with respect to quality of 
anticoagulation at day 8 compared with the HM group (P <0.003). There were no 
other significant differences between the HM and UC groups with regards to level 
of anticoagulation at discharge and INR control at day 8. There was no 
relationship between INR control at discharge and INR at day 8 for the HM 
group. However, there was a trend towards significance for sub-therapeutic 
patients in the UC group to have a poorer outcome at day 8 compared to 
therapeutic and supra-therapeutic patients at discharge in the same group 
(P = 0.14). 
256 
Day 8 post discharge INR 
Discharge INR Home monitoring 
n (%) 
Usual care 
n (%) 
P value 
Sub-therapeutic 
10 (38) 8 (26) 0.003, 
x2 = 11.9 16 (62) 11 (37) 
4 (18) 
16 (73) 
10 (37) 
14 (52) Therapeutic 
Supra-therapeutic 
0.30, 
x2 = 2.4 
0.38, 
X2 = 2.0 
1 (33) 
2 (67) 
3 (60) 
1 	( 	 :2_()) 
0.34, P value 0.14, 
x2 = 6.8 
Table 58 
up type 
Anticoagulant control at Day 8 by discharge INR range and follow- 
   
  
Sub-therapeutic 
 
  
Therapeutic 
 
24.9 Problems noted in usual care group at day 8 
Table 59 displays a brief description of anticoagulant-related problems that were 
noted at day 8 after discharge in the UC group. This list is not exhaustive. 
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• Mr. JO found to be taking 2.3mg daily at day 8 after discharge. He was confusing his 
warfarin dose with his INR. His dose was meant to be 2.5mg daily, thus no adverse 
outcome was reported 
• Mrs. PE was discharged on 3mg daily with an INR of 2.0. She had an 1NR of 1.8 two 
days after discharge and her GP indicated for her to "alternate 3 and 4mg". Mrs. PE 
assumes this to mean 3mg in the morning and 4mg at night. Her INR was checked on 
Day 5 after discharge and an INR of >8 was obtained, this was complicated by the GP not 
being able to contact Mrs. PE and she took her evening dose of 4mg and 3mg morning 
dose on day 6. Her warfarin doses were withheld for two days and she was to resume 
taking warfarin on day 8 at 3mg per day. Her INR was checked by SLJ on day 8 and it 
was 7.6. The GP was contacted and he suggested withholding the dose for another two 
days, with Mrs. PE to follow-up with her GP before resuming dosing. 
• Mrs. IP aged 88, was discharged on warfarin 5mg daily after receiving two doses in 
hospital. She continues on 5mg until day 4 after discharge and her INR is 4.8. Warfarin 
was withheld for two days and her 1NR at day 6 was 4.0. Warfarin was withheld for 
another two days and when visited by SLJ at day 8 after discharge her 1NR was 1.2 
• Mrs. MW had received 27mg over 5 days in hospital with a discharge dose of 2mg daily 
and INR on discharge of 2.6. Her INR on day 3 was 2.0 and she was told to continue on 
2mg daily. Her INR when visited by SLJ at day 8 was 1.5; she had received no further 
testing by her GP. 
• Mr. SH was discharged on 3mg daily with INR of 2.9, when in fact he should have been 
on lmg daily (communication error between doctor, pharmacist and patient whilst in 
hospital). His INR on day 3 was 5.0 and Warfarin was withheld for one day, and restarted 
at 1.5mg daily. His INR when visited by SLJ at day 8 was 1.9; he had received no further 
testing by his GP. 
• Mrs. BR was discharged on 3mg daily with an INR of 3.2. Her INR on day 1 was 3.2 and 
her dose was reduced to 2mg daily. Her INR on Day 2 was 2.7 and she was told to 
continue on 2mg daily. Her INR on day 4 was 2.2 and she was told to continue on 2mg 
daily. Her INR when visited by SLJ at day 8 was 1.4; She had received no further testing 
by her GP. 
• Mr. AF was discharged on 5mg daily with 1NR of 2.5. His INR on day 2 was 3.9 and the 
dose was reduced to 4mg daily. His INR on day 4 was 5.5 and warfarin was withheld for 
one day and resumed at 3mg daily. His INR when visited by SLJ at day 8 was 1.9; he had 
received no further testing by his GP. 
• Mrs. NM was discharged on 6mg daily with an INR of 1.2. Her INR on day 6 was 3.1 
and warfarin was withheld. Her 1NR on day 7 was 2.3 and was withheld again. Her 1NR 
when visited by SLJ at day 8 was 1.5. 
• Mr. RP was discharged on 2mg daily with INR of 2.2 and whilst in hospital had received 
27mg over 6 days. His INR on day 2 was 1.6 and his dose was increased to 2.5mg daily. 
His LNR when visited by SLJ at day 8 was 1.0; he had received no further testing by his 
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GP. 
• Mr. MN was initiated on 5mg of warfarin on the day of discharge. His 1NR on day 2 was 
1.4 and the dose was increased to 7.5mg daily. His INR when visited by SLJ at day 8 was 
4.8; he had received no further testing by his GP. 
• Mr. AT was discharged with an INR 4.0 on lmg daily and was instructed to follow-up 
with his GP on day 3. He saw his GP on day 3 and no INR test was obtained. His INR 
when visited by SLJ at day 8 was 1.2 and he was still on lmg. He had received no further 
testing by his GP. 
• Mr. EM was discharged on lmg daily with INR of 3.8. He was non-compliant with 
medications and did not present to his GP for INR testing. He indicated to SLJ that he 
had ceased warfarin on discharge. A pill count indicated he had been taking 1 mg daily. 
His INR on day 8 by SLJ was 5.0. 
• Mrs. MS was discharged on 5mg daily with INR of 1.6. She was non-compliant with 
medication and ceased warfarin on discharge from hospital. Her INR was obtained by her 
GP on day 7 and the GP was intending to discuss warfarin with the patient. Her INR 
when visited by SLJ at day 8 was 1.0. 
• Mr. RP was discharged with an INR of 2.3 on 4mg daily. His INR on day one was 2.3 
and his GP increased his dose to 5mg daily. His INR when visited by SLJ at day 8 was 
5.4. He had received no further testing by his GP. 
• Mr. RS was discharged with an INR of 1.7 on 5mg daily. His INR on day one was 1.8 
and his GP increased his dose to 6mg daily. His INR on day 4 was 3.2 and the dose was 
reduced to 5mg daily. His INR when visited by SLJ at day 8 was 4.8. He had received no 
further testing by his GP. 
Table 59 	Examples of anticoagulant-related problems noted at day 8 in the 
UC group 
24.10 Anticoagulant control during follow-up 
Table 60 displays the level of anticoagulation for the HM group at each visit after 
discharge, with two-thirds of patients in the HM group having a therapeutic lNR 
at Day 8 after discharge. 
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Anticoagulant Day 2 Day 4 Day 6 Day 8 
control n (%) n (%) n (%) n (%) 
Sub-therapeutic 34 (57) 25 (42) 23 (41) 15 (29) 
Therapeutic 23 (38) 24 (40) 26 (46) 35 (67) 
Supra-therapeu ..c .2 QM RR 	11,% 7 	ll$)) 2 gl 
Table 60 
	
Anticoagulant control by day of follow-up 
Figure 34 plots the 1NR (median and inter-quartile ranges marked at 10, 
25, 75 and 90 percentiles) after discharge and day of follow-up in the HM group 
and Figure 35 shows the INR at discharge and Day 8 in the UC group, with 
slightly more than one-quarter of patients having a supra-therapeutic INR at Day 
8. 
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Day 8 
Post discharge follow -up 
Figure 34 	INR at discharge and at each day of follow-up for the home 
monitoring group 
Median and inter-quartile ranges marked at 10, 25, 75 and 90 percentiles 
Discharge 	 Da'y 8 
Post discharge follow-up 
Figure 35 	INR after discharge for the usual care group 
Median and inter-quartile ranges marked at 10, 25, 75 and 90 percentiles 
Table 61 displays the median doses for all patients at discharge, day 8 and 
day 90 after discharge. There was a trend towards a significant difference between 
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Home monitoring Usual care P value 
n (%) 	n (%) 
Same dose at discharge and day 8 
after discharge 
Same dose at day 8 and day 90 
after discharge 
	
10 (19) 	26 (42) 	0.009, 
X214 
17 (40) 	10 (19) 	0.025, 
X2=32 
discharge and day 8 doses in the UC group. Table 62 shows that significantly 
more patients in the UC group compared with the HM group had the same dose at 
discharge and day 8. Given that the difference in dose between discharge and day 
8 approaches statistical significance, it is likely that dose changes that occurred in 
sixty percent of the UC group were large. 
Table 61 shows a highly significant difference between day 90 and day 8 
doses in the UC group, and a weakly significant difference in the HM group 
between day 8 and day 90 doses. This is reinforced in Table 62 that shows 
significantly more patients in the HM group compared with UC had the same 
dose at day 8 and day 90. 
Home monitoring 	Usual care 	P value 
Discharge 
Day 8 
Day 90 
P value 
3 4 0.49, U=1860 
3 3 0.35, U=1470.5 
4 3.5 0.85, U=1264 
0.59*, t = -0.5, 
df = 51 
0.03#, t = -2.2, 
df = 42 
0.07* t = 
1.8, df= 61 
0.004#, t = - 
3.0,df= 52 
Table 61 	Median dose (mg) for patients at different days of follow-up 
*Denotes difference between discharge dose and Day 8 and denotes difference between Day 8 
and Day 90. (Paired t test) 
Table 62 	Proportion of patients in each group with the same dose at 
different times of follow-up 
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24.11 Duration of home visits 
The median duration of pharmacist visits in the intervention group at each visit 
after discharge are displayed in Table 63. Attempts to contact GPs were made in 
the majority of cases, but some home visits arose on weekends when GPs were 
non contactable. If this was reasonably foreseeable, an after hours contact number 
was obtained or dose adjustment plans were made in advance. 
Day 2 Day 4 Day 6 Day 8 
Patient visit at home 30 (15-80) 25 (10-60) 20 (10-40) 20 (10-60) 
Discussion with GP 1(0-6) 1(0-5) 1(0-3) 1(0-5) 
Table 63 	Median times taken for home visits in minutes (range) 
The range is 0 in some cases, as the GP was not contactable. 
24.12 Clinical outcomes at day 8 
After the Day 8 visit by the pharmacist to UC patients, 10% had a subsequent 
dose increase and 13% had a dose decrease. The median number of conventional 
pathology INR tests was 0 (0-2) in the HM group, and 2 (0-6) in the UC group by 
day 8 after discharge. 
Only 24 patients (37%) of UC patients were using their warfarin booklet 
to record their INR results compared to 100% of HM patients (P<0.0001, x2 = 
55.6). At 90 days after initial discharge 20 (31%) UC patients compared with 28 
(51%) HM patients were using their warfarin books to record INR results 
(P=0.02, x2 = 4.75). Table 64 describes each adverse outcome that occurred up to 
day 8 after discharge. 
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Event 
Usual care (n=5) 
• Shortness of breath on exertion with a background of PE, INR 3.7 
• Angina secondary to AF, INR 1.7 (nil enoxaparin cover) 
• Tachycardia and confusion after AVR, INR 2.5 
• Wound infection, INR 3.8 
• Death- (not readmitted)-Myocardial infarction 
Home monitoring (n=8) 
• Sudden onset of chest pain (unstable angina) INR 2.3 
• Stroke, INR 1.8 (anticoagulant cover with enoxaparin 1.5mg/kg) 
• Pleuritic chest pain (somatisation of acopia) INR 2.0 
• Headache for investigation, INR 2.8 
• Falls post AVR, INR 7.6 
• Death- (not readmitted)-Myocardial infarction 
• Wound infection after total colectomy, INR 4.6 
• Likely recurrent DVT with sub-therapeutic, INR 1.7 (nil enoxaparin 
cover) 
Table 64 	Description of readmission outcomes by study group occurring up 
to day 8 after discharge 
24.13 Rates of clinical outcomes at 90 days after discharge 
Table 65 displays number and rates of adverse events occurring up to 90 days 
after discharge for all patients (n.127). There was a significant reduction in total 
bleeding complications (9% vs 24%) between the HM and UC groups. There was 
also a significant reduction in major and minor bleeding complications between 
the HM and UC groups, (1% vs 7% for major bleeds and 9% vs 23% for minor 
bleeds respectively). For patients who were readmitted to hospital during the 90- 
day follow-up, there were no significant differences in the median readmission 
INR (the first readmission INR) between the UC and HM groups, 2.6 (1.3-9.9) 
and 2.6 (1.6-7.6) respectively. 
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Outcomes Home monitoring 
n (%) [95% CI] 
Usual care n 
(%) [95% CI] 
P value 
Total bleeding 9 (15) 24 (35) 0.009, 
[7-27] [24-48] X2=6.9 
Major bleeding 1 (2) 7 (10) 0.05, 
[0-9] [4-20] x2=4.0 
Minor bleeding 9 (15) 23 (34) 0.01, 
[7-27] [23-46] x2=6.0 
Embolic 5 (9) 7 (10) 0.73 
complication [3-19] [4-20] 
Unplanned 13 (22) 18 (27) 0.56 
readmission [12-35] [17-39] 
ED* admissions 8 (14) 13 (19) 0.36 
[6-25] [11-30] 
Any unplanned 19 (32) 27 (40) 0.38 
readmission [21-46] [28-52] 
Warfarin ceased 12 (20) 15 (22) 0.81 
prior to 90 days [11-33] [13-34] 
Unplanned 7 (12) 7 (10) 0.55 
cessation [5-23] [4-20] 
Warfarin-related 2 (3) 5 (7) 0.32 
readmission [0-12] [2-16] 
Death 4 (7) 5 (7) 0.90 
[2-16] [2-16] 
Table 65 	Adverse outcomes occurring up to 90 Days after discharge 
*Emergency department admissions 
265 
24.14 Description of clinical outcomes 
Table 66 and Table 67 document each major bleeding and embolic complication 
for all patients. Table 68 describes the cause of death from death certificates for 
all patients. 
Adverse event 
Usual care (n=7) 
• Recurrent haematuria, requiring cessation of warfarin 
• Massive epistaxis requiring hospital admission, INR 9.9 
• Recurrent gastrointestinal bleeding, warfarin ceased, hospitalised & 
transfused 2 units packed cells, INR on admission 2.6 
• (1) Massive epistaxis requiring hospital admission INR 8.3, & (2) 
Gastrointestinal bleeding for one week 1NR 7.8 both requiring hospital 
admission 
• Severe bruising causing cessation of warfarin by GP 
• Recurrent haematuria for investigation, INR on admission 2.2 
• Gastrointestinal bleeding, requiring hospital admission, four units of 
packed cells given, INR on admission 4.7 and vitamin K administered 
Home monitoring (n=1) 
• Recurrent gastrointestinal bleeding, transfused 2 units packed cells, 
requiring hospital admission 
Table 66 	Description of major bleeding complications occurring up to 90 
days after discharge 
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Adverse event 
Usual care (n=7) 
• Myocardial Infarction (3) 
• Transient ischaemic attack (2) 
• DCR cancelled due to sub-therapeutic INR and suspected formation of 
left atrial emboli on echocardiography 
• Admission to hospital with symptoms of embolic complication with 
sub-therapeutic INR 
Home monitoring (n=5) 
• Myocardial Infarction (2) 
• Admission to hospital with symptoms of embolic complication with 
sub-therapeutic 1NR 
• Unstable angina pectoris 
• Stroke 
Table 67 
	
Description of embolic complications occurring up to 90 days after 
discharge 
Adverse event 
Usual care (n=5) 
▪ Acute myocardial infarction (2) 
• Sepsis with bone marrow suppression and disseminated intravascular 
coagulation 
• Cardiac arrhythmia on background of congestive cardiac failure and 
atrial fibrillation 
• Cardiac arrest on background of ischaemic heart disease 
Home monitoring (n=5) 
• Acute myocardial infarction (2) 
• Thalamic tumour 
• Cerebrovascular accident on background of arteriosclerosis and 
hypertension 
Table 68 	Description of cause of death from death certificates 
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All unplanned cessations of warfarin assessed at 90 days after discharge 
occurred as a result of death or complications of anticoagulant therapy. There did 
not appear to be any significant correlations between anticoagulant control at day 
8 (supra-, sub- or therapeutic) and subsequent bleeding (total, major or minor) 
complications for all patients, for the HM group or UC groups. However, 25% (4 
events) of the patients in the UC group who had a supra-therapeutic INR at day 8 
had a subsequent embolic event during the 90 days after discharge, compared 
with 1 event each in the sub- and therapeutic patients (x 2 = 5.97, p <0.05). There 
was no significant correlation between anticoagulant control at day 8 and embolic 
outcomes for the HM group. 
24.15 Anticoagulant control at 90 days after discharge 
At 90 Days after discharge, INR measurements were obtained from 100 patients. 
There was a trend towards more HM patients compared to UC with a therapeutic 
INR at 90 days after discharge as displayed in Table 69. The median INR for all 
patients 90 days after discharge was 2.3 (1.0-4.5). The median 1NR in the HM and 
UC groups was 2.4 (1.0-3.7) and 2.3 (1.0-4.5), respectively (P = 0.95, U = 
1259.0). 
Home monitoring n (%) Usual care n (%) 
Sub-therapeutic 15 (32) 19 (35) 
Therapeutic 29 (62) 24 (45) 
,supra-t eraidmni)e 5 g3 110 Viln 
Table 69 	Anticoagulant control at 90 days after discharge 
P=0.13, x2 = 4.1 for trend across the usual care and home monitoring groups 
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24.16 General practitioner survey 
Of the 52 GP evaluations sent after the completion of the day 8 protocols, 42 were 
returned giving a response rate of 81%. The results are shown in Figure 36 and 
unsolicited comments are displayed in Table 70. 
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1. I found this to be a valuable service provided to my patient(s). 
1---o 	 I 
1 	 I I 	 I 	 I 
Strongly Strongly 
Agree 	 Disagree 
2. I would feel more confident in initiating or managing newly initiated 
patients on warfarin if this was a regular service. 
I 	 
I  
Strongly 
Agree 
 
f 
   
1 1 I 
Strongly 
Disagree 
   
3. I received adequate feedback from the pharmacist. 
Strongly 	 Strongly 
Agree Disagree 
4. I believe that more patients would benefit from this type of service. 
Strongly 	 Strongly 
Agree Disagree 
5. I found the suggestions made by the pharmacist to be useful. 
I_ O i 
I 	 I 	1 	I 
Strongly Strongly 
Agree 	 Disagree 
6. I believe that my patient(s) found this to be a worthwhile service. 
1 	0 	  
Strongly Strongly 
Agree 	 Disagree 
Figure 36 	GP responses to the evaluation questionnaire 
Medians, with range lines plotted at the 10 th and 90 th percentiles 
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Didn't go for long enough 
This is a fairly accurate way of measuring INR, hopefully it will be used more in general  practice 
Period of monitoring should vary according to patient. 4 visits still but a difficult patient according 
to individual circumstances 
Especially new  patients starting but also older  patients as the warfarin dose can be confusing 	 
Need to compare INR result with that of laboratory  
I have no trouble doing INRs without a  pharmacist but they were very nice  
Accuracy & cost 
I feel this service is irrelevant. We have many patients on INRs for many years for varied 
conditions and feel quite confident in managing them  
Reliability of the INR test compared to lab testing, if is reliable why aren't GPs allowed to use and 
claim for these tests in their surgeries, POC testing should be funded by the by the commonwealth 
under the medicare scheme  
1 Shane I have been away from the  practice till today, therefore I cant really comment  
The money involved could provide me with a monitor to more efficiently manage my bourgeoning 
INR load 
Improved safety factor for patient 
I am used to monitoring my own but for elderly it is useful. Is there some reason why GPs could 
not do the same thing 	  
This is like teaching us GPs how to suck eggs 
How soon can we start and keep up the good work 
Patient & Dr confidence in dealing with warfarin, especially since patient has had bleeding on 
warfarin  previously. Please keep this service going it is excellent  
Not sure about accuracy?  
Better liaison at start, I doubled up with INRs as I didn't know this service was happening 
Great because in  patients home  
Sorry Shane, but I don't think a pharmacist needs to be involved. The concept of the INR monitor 
is good though 
There would be a place for more flexibility e.g. daily INRs I'm happy with the service. In this 
particular case it seems inappropriate to have commenced the patient on 3mg this meant that the 
INR as very slow to rise and the INR was far from therapeutic at day 8  
This patient required other blood tests during the week and it would be good if somehow that 
could be coordinated with the home visit for INR 
Pleased to participate, with thanks 
It will be very useful for doctor if this service continues  
LW was scheduled to have an operation - 1 week after hospital discharge. Why not use Clexane 
to tide him over that week then start warfarin after the procedure. Note as well that he had vitamin 
K in hospital so that his initial INRs are lower than expected  
Patient was confused when pharmacist output ceased, who was giving instructions? Where was 
Shane? That nice young man! 
Table 70 	Comments about the monitoring from general practitioners 
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24.17 Patient satisfaction survey 
Of the 52 satisfaction surveys given to the HM patients on completion of the day 
8 protocol (8 did not complete the day 8 follow-up), 44 surveys were returned 
completed giving a response rate of 85%, and the results are shown in Table 71. 
All of the patients who indicated that they were quite dissatisfied with the contact 
subsequently indicated that the information they had received helped them a great 
deal. Unsolicited comments about the anticoagulant monitoring and education are 
displayed in Table 72. 
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Reponses to questions 	 n (%)  
How satisfied are you with the amount of contact you had with the pharmacist? 
Quite dissatisfied 3 (7) 
Indifferent or mildly dissatisfied 0 
Mostly satisfied 0 
Very satisfied 41 (93) 
Has the information and other services provided by the pharmacist helped you to deal more 
effectively with your new medication warfarin? 
Yes, they helped a great deal 43 (98) 
Yes, they helped somewhat 0 
No, they didn't really help 0 
No, they seemed to make things worse 1 (2) 
Did you get the kind of information and other services you wanted from the pharmacist? 
No, definitely not 1 (2) 
No, not really 0 
Yes, generally 6 (14) 
Yes, definitely 37 (84) 
Is there other information you need, or would like, about warfarin and have not received? 
the pharmacist? 
Do you think this service would be best provided in your home or at your local pharmacy? 
Home 	 38 (88) 
Local pharmacy 	 5 (12) 
Do you think this service should be available to all patients commencing warfarin therapy? 
Yes 	 41 (100) 
No 0 
If this were a regular service would you be prepared to pay for it? 
Yes 	 35 (83) 
No 7 (17) 
If you answered yes to the previous question, how much would you be prepared to pay per visit? 
19 (54) 
10 (29) 
5 (14) 
1 (3) 
Table 71 	Responses to patient satisfaction survey from patients in the 
intervention group 
Totals are less than 44 for some questions, due to non-completion. 
*Totals more than 44 responses as patients could indicate more than one response. 
Yes, there definitely is 	 3 (7) 
Yes, I think there is 3 (7) 
No, I don't think there is 	 26 (61) 
No, there definitely is not 11 (26) 
Overall, how would you rate the quality of the service that you received from 
Excellent 43 (98) 
Good 1 (2) 
Fair 0 
Poor 0 
Did you find the regular warfarin (INR) monitoring* 
Painful 1 (1) 
Informative 21 (30) 
Motivating 4 (6) 
A waste of time 0 
Interesting 15 (21) 
Annoying 0 
Too frequent 0 
Beneficial 29 (42) 
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My family and I appreciated the courtesy of Mr Jackson at all times. 
Very punctual & helpful.  
A thoughtful efficient and friendly service had been  provided.  
A very helpful young man willing to help in any way and I wish him the very best for the future, 
thank you Shane.  
Was very pleased with the service  provided by Shane Jackson.  
Definitely available to everybody, I couldn't afford it. 
As a daughter of the elderly patient on warfarin I found Shanes' help and advice of great benefit to 
assisting me to help and explain to my mum. Should be an ongoing regular service.  
Shane is the right person for this type of help as he is most informative with his detail for taking 
the prescribed dosage. Thank you Shane, God bless you in your life.  
Mum would like to say she was very satisfied and very grateful for Shanes' service and care also 
for the extra bits he did with her medication as her family we really appreciated his care and 
communication, thank you. 
Friendly, helpful service. Young man very helpful and informative. 
The treatment I received from the pharmacist Shane Jackson was excellence. 
Shane Jacksons' visits were very informative and pleasant. 
This appears to me to be a quite essential service for new patients starting warfarin. If this were to 
be implemented for all there must be a reduction in complications/failures of warfarin therapy. 
One needs at least 2-3 sessions with the pharmacist before one feels comfortable with 
understanding warfarin.  
Shane Jackson was the most helpful  person we have dealt with, ever.  
I think it is very important that the patient is kept informed of what going on. How to fill the 1 
warfarin book and all to see if the correct tablets are taken. Four visits is great benefit to the 
patient.  
As my wife does not drive we have appreciated the visits from the  pharmacist. 
Shane very helpful.  
Reference to question 10, $5.00  per visit for  pensioners.  
Shane done his job very well and answered all the questions we asked and some we did not think 
of. 
I found the pharmacist, Shane Jackson very helpful and explained every detail about warfarin 
clearly.  
Visits always very friendly and seemed immediately to put you at ease.  
Warfarin is a good tablet but it has its side effects for me. No more than one I can handle as it 
[...upsets me tummie.  
Table 72 	Unsolicited comments from patients 
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24.18 Patient knowledge questionnaire 
Patient knowledge was assessed 90 days after initial discharge, and the responses 
are shown in Table 73. Fifty-two of 63 eligible patients in the UC group and 33 of 
55 eligible patients in the HM group returned the knowledge questionnaire — a 
response rate of 83% and 60%, respectively (p = 0.01 x2 = 6.3). 
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Responses 	 All patients n 	Home 	Usual care 
(%) 	monitoring n 	n (%) 
(%) 
Since starting warfarin would you say that your general health has 
Improved P=0.09, x2=4.9 41 (53) 21 (68) 20 (43) 
Worsened 5 (6) 1 (3) 4 (9) 
Stayed the same 32 (41) 9 (29) 23 (49) 
Correct reason for using warfarin 
Yes P=0.26, x2=1.3 74 (89) 31 (94) 43 (86) 
No 9 (11) 2 (6) 7 (14) 
Do you worry about warfarin treatment? 
A lot P=0.86, x2=0.3 9 (11) 3 (9) 6 (12) 
A little 29 (35) 11 (33) 18 (36) 
Not at all 45 (54) 19 (58) 26 (52) 
When you left the Royal Hobart Hospital (RHH) were you handed a "warfarin booklet"? 
Yes 	 P=0.77, x2=0.08 
	
79 (93) 	31 (94) 	48 (92) 
No 6 (7) 	2 (6) 	4 (8) 
Not Sure 
Were you told how warfarin works, and was this clear? 
Yes, and clear 	P=0.85, x2=0.32 	64 (79) 	25 (81) 	39 (78) 
Yes, but not clear 	 13 (16) 	5 (16) 	8 (16) 
No 	 4 (5) 	1 (3) 	3 (6) 
Could you briefly explain in your own words how warfarin works 
Thins the blood 
	
P=0.35, x2=2.1 
	
50 (59) 	20 (61) 	30 (58) 
Prevents clots 	 16 (19) 	8 (24) 	8 (15) 
No written response 	 19 (22) 	5 (15) 	14 (27) 
Were you told of the possible problems with warfarin treatment, and was this clear? 
Yes, and clear 	P=0.36, X2=2.0 
	
61 (73) 	26 (81) 	35 (67) 
Yes, but not clear 	 18 (21) 	5 (16) 	13 (25) 
No 	 5 (6) 	1 (3) 	4 (8) 
Were you told what to do if you have a nosebleed or bruising and was this clear? 
Yes, and clear 	P=0.01, x2=8.7 
	58 (69) 	28 (85) 	30 (59) 
Yes, but not clear 15 (18) 	1 (3) 	14 (28) 
No 	 11 (13) 	4 (12) 	7 (14) 
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Responses 	 All patients n 	Home 	Usual care 
(T) 	monitoring n 	n (%) 
(%) 
Were you told what drugs to avoid and was this clear? 
Yes, and clear 	P=0.06, x2=5.7 
	49 (60) 	23 (77) 	26 (50) 
Yes, but not clear 	 17 (21) 	4 (13) 	13 (25) 
No 	 16 (20) 	3 (10) 	13 (25) 
Were you given advice on drinking alcohol and was this clear to you? 
Yes, and clear 	P=0.003, X2= 11.9 
	
66 (83) 	33 (100) 	33 (70) 
Yes, but not clear 	 6 (8) 	 0 	6 (13) 
No 	 8 (10) 	 0 	 8 (17) 
Could starting a new treatment or any other preparation affect your warfarin treatment? 
Yes 	 P=0.23, x2=3.0 	48 (58) 	22 (69) 	26 (51) 
No 	 6 (7) 	1 (3) 	5 (10) 
Don't know 	 29 (35) 	9 (28) 	20 (40) 
The following are statements about any patient drinking alcohol while receiving warfarin 
treatment 
Alcohol can affect anticoagulant treatment 
Yes P=0.09, x2=2.9 	56 (82) 24 (92) 32 (76) 
No 12 (18) 2 (8) 10 (24) 
Alcohol must be totally avoided 
Yes P=0.70, x2=0.15 	21 (31) 7 (28) 14 (33) 
No 47 (69) 18 (72) 29 (67) 
8 units of alcohol a night is OK (for example 8 glasses of beer or wine) 
Yes P=0.63, x2=0.24 	4 (6) 1 (4) 3 (7) 
No 62 (94) 23 (96) 39 (93) 
/ unit of alcohol a night is OK (for example 1 glass of beer or wine) 
Yes P=0.60, x2=0.28 	54 (79) 19 (76) 35 (81) 
No 14 (21) 6 (24) 8 (19) 
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Responses 	 All patients 	Home 	Usual care 
n (%) 	monitoring n 	n (%) 
(%) 
Of the list below indicate which of the following could intofere with your warfarin therapy?* 
Aspirin P=0.77, x2=0.09 67 (80) 25 (78) 42 (81) 
Weather conditions P=0.89, x2=0.03 3 (4) 1 (3) 2 (4) 
Coffee P=0.55, x2=0.35 13 (16) 4 (13) 9 (17) 
Herbal Remedies P=0.34, x2=0.93 39 (46) 17 (53) 22 (42) 
Panadol P=0.25, x2=1.4 18 (21) 9 (28) 9 (17) 
Some illnesses P=0.30, x2=1.1 36 (43) 16 (50) 20 (39) 
Missed dose of 
warfarin 
P=0.08, x2=3.1 56 (67) 25 (78) 31 (60) 
Nurofen P=0.37, x2=0.79 23 (27) 7 (22) 16 (31) 
Antacids P=0.16, x2=1.9 23 (27) 6 (19) 17 (33) 
Some foods P=0.47, x2=0.52 51 (61) 21 (66) 30 (58) 
Of the list below, which of the following could be side effects of taking the wrong (too little or too 
much) warfarin ?* 
Blood in stools P=0.34, x2=0.91 48 (58) 20 (65) 28 (54) 
Nausea P=0.59, x2=0.29 13 (16) 4 (13) 9 (17) 
Blood in the urine P=0.93, x2=0.008 45 (54) 17 (55) 28 (54) 
Nervousness P=0.02, x2=5.2 3 (4) 3 (10) 0 
Blood clots P=0.62, x2=0.25 47 (56) 19 (59) 28 (54) 
High blood pressure P=0.61, x2=0.27 16 (19) 7 (22) 9 (17) 
Weakness P=0.32, x2=1.0 14 (17) 7 (22) 7 (14) 
Ringing in the ears P=0.47, x2=0.53 8 (10) 4 (13) 4 (8) 
Nose bleeds P=0.22, x2=1.5 62 (74) 26 (81) 36 (69) 
Sleeplessness P=0.93, x2=0.01 5 (6) 2 (6) 3 (6) 
Prolonged bleeding 
after cuts 
P=0.23, x2=1.4 68 (81) 28 (88) 40 (77) 
Bruising without 
injury 
P=0.16, x2=1.9 61 (73) 26 (81) 35 (67) 
Loss of appetite P=0.55, x 2=0.35 13 (16) 4 (13) 9 (17) 
Table 73 	Patient knowledge 90 days after discharge 
Statistics comparing BM and UC groups 
Responses do not total 85 in all cases as some patients did not answer all questions 
*Proportion of patients responding "YES" to each question 
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24.19 Cost-effectiveness 
The money saved in healthcare related costs by instituting this intervention across 
the country would amount to nearly $Aust4 million dollars per annum in reduced 
bleeding costs as displayed in Table 74. From data obtained in this study, it is 
estimated that approximately 20,000 patients are initiated on warfarin in hospital 
per annum. 
Cost savings of home monitoring compared with usual care 
No. Patients initiated on warfarin per annum 	 20000 
Major bleed in the first three months of warfarin treatment (n) UC-10% 	 2000 
Major bleed in the first three months of warfarin treatment (n) HM-2% 	 400 
Major bleeds "saved" from instituting HM (first three months of treatment) 	1600 
*Costs saved from major bleeds per annum (000s) ($) 	 3848 
Minor bleed in the first three months of warfarin treatment (n) UC-34% 	 6800 
Minor bleed in the first three months of warfarin treatment (%) HM-15% 	 3000 
Minor bleeds "saved" from instituting HM (first three months of treatment) 	3800 
Costs saved from minor bleeds per annum (000s) ($) 	 86 
Total costs saved per annum (000s) ($) 	 3934 
Table 74 	Cost savings associated with home monitoring compared with usual 
care 
*Average major bleeding costs were estimated to be $2405, sourced from DRG codes from public 
hospitals in Tasmania for the years 2001-2002. (Section 24.7) 
The approximate time spent with the patient over the course of the intervention 
neared two hours in total. The approximate traveling time for this type of 
intervention is likely to be similar, therefore, the total time costs would 
approximate 4 hours, likely to be paid at $40 per hour (total time costs of $160) 
Additional costs such as test strips, lancets, telephone calls and travel costs would 
likely bring costs in the order of approximately $200 per patient. The program 
would cost approximately $Aust4 million for 20,000 patients per annum. It is 
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therefore likely that this program is cost neutral if the costs of bleeding are solely 
compared with the costs of the program. However, these estimates do not take 
into account general practice or private hospital initiation of warfarin. 
Performing a sensitivity analysis, if the difference in major bleeding risk 
was reduced to 8% from 10% in the UC group, the program would save $Aust 2.9 
million, thus bringing the cost-effectiveness of this program into question. 
280 
CHAPTER TWENTY FIVE: DISCUSSION 
IMPROVING WARFARIN INITIATION 
This study examined the effect of POC monitoring of anticoagulant therapy, with 
patient-focused education by a pharmacist, amongst a population of newly 
initiated warfarin patients who were discharged from hospital to GP care. This 
study has clearly shown that control of anticoagulation after discharge from 
hospital is sub-optimal, with some patients at high-risk of anticoagulant-related 
complications because of lack of appropriate testing and dosing. We found that 
this comprehensive program reduced the frequency of , bleeding in patients 
randomly assigned to HM at the start of anticoagulant therapy. 
The majority of the study population represented those chronically ill 
older patients, who were initiated on warfarin for the treatment of chronic 
conditions. The two groups were well matched in baseline characteristics, except 
for a significantly higher incidence of previous AMI in the HM group. We are 
unaware of any lifestyle differences between the two groups that could have been 
responsible for this difference. However, if a number of baseline demographics 
are reported the risk of random chance contributing to a significant difference in 
these variables increases. 
The study population represents those patients who are at high risk of 
anticoagulant misadventure if not adequately monitored and educated. Elderly 
patients are at an increased risk of bleeding complications but are also have a 
higher benefit with anticoagulant therapy compared to younger populations. 386 ' 
389 In fact nearly half of the patients had warfarin initiated for stroke prophylaxis 
in AF. 
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There is clear evidence that the trend to early discharge for hospital 
patients is putting strain on the primary care system. This study, which 
commenced in 2002, has shown that 44% of all patients had a therapeutic INR at 
discharge, compared to 63% in a previous audit of anticoagulant therapy at the 
same hospital, completed in 1994. 402 The median days of initiation of warfarin in 
the previous study was 8 days compared to 6 in this study. We have shown that a 
longer time in hospital generally means a longer time of warfarin initiation, and 
this is correlated with the likelihood of having a therapeutic INR at discharge. 
This study shows the actual practice of initiation of warfarin in a teaching 
hospital and subsequent discharge of patients to community care may result in 
poor outcomes, compared with follow-up after discharge. The combination of 
shorter periods of hospitalisation and increasing usage of warfarin is placing 
stress on general practice health services to care for newly anticoagulated 
patients. 
This project meets a number of the principles of the APAC national 
guidelines to achieve the continuum of quality use of medicines between hospital 
and community. 384 It appears that standard care for discharge of newly initiated 
anticoagulated patients is not fulfilling key roles of the national guidelines. 
"It is the responsibility of the admitting institution to ensure the 
development and coordination of a medication discharge plan for 
each patient" 
"Information to the patient's health care providers should include 
details of the medication management during the hospital 
stay  And any specific needs with respect to drug 
management" 
Fifteen per cent of all patients had some contraindication to anticoagulant 
therapy. This reflects clinical practice initiation of warfarin where relative 
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contraindications to warfarin exist, which may increase the risk of bleeding in 
this group of patients. It is inevitable that warfarin may be used in some patients 
who have a relative contra-indication to its use, but the benefit of warfarin may 
outweigh the risk of bleeding in some cases. For example, the mortality rate from 
93 an untreated pulmonary embolism approaches 30% and the risk of bleeding in 
patients who have relative contraindications to warfarin have not been accurately 
quantified. 
Twenty per cent of all patients were prescribed combination 
antithrombotics reflecting current trends for anticoagulant and antiplatelet therapy 
in combination for some conditions. 1, 403-405 This, , however, leaves patients at a 
higher risk of bleeding complications. 403, 406, 407 A high proportion (80%) of 
patients were discharged on medication that could interact with warfarin. This is 
higher than a study by Howard et al. 
65 years were prescribed concomitant medications that could interact with 
warfarin. As the number of interacting medications with warfarin increases, so 
does the risk of fluctuations in the INR 73, 76, 408-410 and potentially the risk of 
bleeding. 
Less than adequate initiation of warfarin may have caused problems after 
discharge in both groups of patients. Despite the availability of initiation 
protocols in the hospital, the initiation of warfarin continues to be a problem. The 
anticoagulant effect of any daily dose of warfarin in the initiation phase is 
generally seen after two days; 74 therefore poor initiation of anticoagulation whilst 
in hospital may have an impact on post-discharge INRs. The initiation of warfarin 
in hospital and adherence to RHH anticoagulation protocols appears to be well 
matched between the two groups of patients, therefore it is unlikely that 
408 reporting 54% of AF patients aged over 
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differences in warfarin initiation between the UC and HM groups are responsible 
for different outcomes at day 8 after discharge. 
It is disappointing to find that only 44% of warfarin initiations followed 
the RHH anticoagulation protocols. There was clear evidence showing a number 
of supra-therapeutic INR after day 3 of initiation in hospital, continuing in some 
cases through to discharge. Only slightly more than half of patients who were still 
in hospital on the second day of initiation had an INR ordered. This may have 
contributed to some high INRs seen after day 3 of initiation whilst in hospital. 
The HM group had two-thirds of patients in the therapeutic range at day 8, 
which had increased from 42% at discharge. Conversely, the proportion of 
patients in the UC group with therapeutic INR at day 8 was less than the 
proportion therapeutic at discharge, (41% and 45% respectively). The alarming 
part of the follow-up at day 8 in the UC group was the high proportion of supra-
therapeutic INR. Slightly more than one-quarter of patients in the UC group had a 
supra-therapeutic INR, and the risk of bleeding in this group of patients is 
elevated with increasing INR. It is evident that follow-up conducted in the HM 
group increased the proportion of therapeutic patients at day 8 compared to 
discharge and also reduced the supra-therapeutic INR that occurred in the UC 
group. 
A similar proportion of patients in both groups were sub-therapeutic at 
discharge and at day 8, suggesting that the follow-up conducted by the pharmacist 
is most beneficial at reducing preventable elevations in the INR. It also appears 
that supra-therapeutic INR at day 8 occur most frequently in patients with sub-
therapeutic INR at discharge, reinforcing the benefit of regular monitoring of 
patients who are not therapeutic or stable. 
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A proportion of patients in the HM group had supra-therapeutic INR prior 
to having a therapeutic INR at day 8. This, however, reiterates that initiation 
doses whilst in hospital may have negative impacts on all patients after discharge. 
The HM group INR at day 8 confirms that stabilisation of the INR occurred 
earlier than the UC group. Further evidence pointing to a more stable INR and 
dose in the HM group is verified by the dose-difference between day 8 and 90 
between the two groups. The dose difference in the UC group (P < 0.01) was 
highly significant and the dose difference in the HM group just reached statistical 
significance (P <0.05). This suggests a number of patients in the UC group had a 
large difference between their day 8 and day 90 dose, reflecting lack of long-term 
stability between day 8 and day 90. 
An important finding is that only 20% of patients in the HM group were 
maintained on the same dose at day 8 that they were discharged on. This suggests 
that some adjusting of doses is necessary post-discharge in most patients. 
Importantly, 40% of patients in the HM group had the same dose at day 8 and day 
90 compared with 20% of UC patients, reflecting superior long-term stability of 
the 1NR at day 8. This also indicates that patients in the HM group at day 8 were 
more likely to have reached their maintenance dose compared to patients in the 
UC group 
At 90 days after discharge there was a larger proportion of patients in the 
HM group who had a therapeutic INR compared to the UC group, 62% compared 
with 46%, respectively. This, however, was not statistically significant. Still 
alarmingly, however, nearly one-fifth of patients in the UC group had a supra-
therapeutic INR. 
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A number of anecdotal cases point to similar root causes of unstable INR 
after discharge. These cases indicate a lack of sufficient communication between 
the hospital and GPs, and GPs extending the interval of monitoring too early, 
and/or increasing dosages too quickly. The study clearly implicates the trend to 
early discharge as a potential cause for poor communication and outcomes in the 
usual care group within the study. It is well documented in the literature that 
many patients have a poorly planned discharge and the GP is not fully informed 
of their patient's admission or discharge. 411-414 
This project is an example of a systems solution to improve the 
management of anticoagulation, which looks to improve the processes of care 
rather than individual behaviour. When processes of care are examined, a 
common root cause of medication errors occurs at the time when decisions about 
416 therapy are made. 415, 	Failure to obtain sufficient information about the patient 
or about the pharmaceutical agent has contributed to medication errors. 417 This 
intervention aimed to provide patients and GPs with information regarding dose 
decisions at the POC, and has shown an improvement compared to usual care. 
A number of systems could be implemented to adhere to the APAC 
guidelines for continuity of care between hospital and the community for warfarin 
initiation. These systems include this type of program, improving transfer of 
information regarding warfarin doses and INR whilst in hospital to the GP, and 
the utilisation of existing services such as Home Medicines Review (HMR) to 
improve patient knowledge of anticoagulant therapy. Pharmacists should take a 
key role in reinforcing knowledge regarding anticoagulation to reduce the risk of 
complications of anticoagulant therapy. 
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The impact that the pharmacist had on the UC group at day 8 is difficult to 
measure, with almost one quarter of the UC group having a dose change after the 
visit on day 8. It is likely that the visit by the project pharmacist on day 8 may 
have prevented some type of adverse event in some of the patients visited and, 
although this is speculative, it is highly likely and difficult to quantify. Data for 
anticoagulant control between day 8 and day 90 after discharge was unable to be 
obtained for patients. Therefore, the contribution of the HM to anticoagulant 
control between these time intervals was unable to be assessed. However, a higher 
proportion of patients in the UC group with a supra-therapeutic INR at day 8 
subsequently developed embolic complications assessed at 90 days after 
discharge. This may have reflected poor control at day 8 as a marker for erratic 
control up to 90 days after discharge, potentially contributing to an increased risk 
of embolic complications. 
This study showed a reduction in all bleeding complications in the HM 
group compared to UC. It is likely a combination of improved monitoring post 
discharge and education resulted in better outcomes compared to usual care. Total 
bleeding was reduced in the HM group compared to UC, 15% and 36%, 
respectively. Importantly, major bleeding was reduced in the HM group compared 
to UC, 2% compared to 10% respectively. This has significant impact on costs 
associated with warfarin, and also doctors' perception of anticoagulant therapy. 
Despite low rates of warfarin-related bleeding reported in randomised 
140-143, 145 trials, 	which included strict exclusion criteria, higher rates of major 
bleeding have been reported in many studies of warfarin used in clinical 
116, 400, 418 practice. 	In this study, the sample of patients was assembled with few 
exclusion criteria, and the bleeding rates in the UC group were similar to those 
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observed in other clinical practice studies. The intervention achieved a frequency 
of major bleeding that was similar to the lower rates achieved in previous 
randomised trials assessing the efficacy of warfarin. 
Hylek et al. 419 studied a group of patients in an anticoagulation clinic who 
obtained an 1NR greater than 6.0. Nearly 10% of these patients sought medical 
attention for abnormal bleeding and 5% of these experienced a major 
haemorrhage within 14 days follow-up. Interestingly, they noted that none of the 
patients had clinically important bleeding at the time of the INR measurement. 
This raises the issue that fluctuations in the INR need to be kept to a minimum to 
reduce the potential for life-threatening bleeding complications. 
A study by Beyth et al. 315 evaluated an intervention that consisted of 
patient education about warfarin, training to increase patient participation, self-
monitoring of INR, and guideline-based management of warfarin dosing 
compared to normal care for six months. The cumulative incidence of major 
bleeding in the usual care group was similar to our study, 12% and the incidence 
of major bleeding was reduced to 5.6% in the intervention group. Importantly, 
they noted that after 6 months, major bleeding occurred with similar frequencies 
in the intervention and usual care groups. 
GP evaluations were generally positive, and they could see the benefit of 
providing this type of service for patients newly initiated on warfarin. They saw 
this program as a valuable service to patients, they also thought that more patients 
could benefit, and that their patients individually benefited from the program. 
From the evaluation questionnaire it appears that this service has mixed effects in 
regards to feeling more confident in initiating warfarin, and perhaps this reflects 
the difficulty of initiation of warfarin, irrespective of type of follow-up. 
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The pharmacist home visits were well received by patients, and they were 
very positive in their feedback and evaluation of the service. Most patients found 
it informative, beneficial and interesting. Over 80% of patients indicated that they 
would be willing to pay, with most indicating in the range of $1-$5 or $6-10 per 
visit. It must be acknowledged that most of the group was elderly and receiving 
social security benefits, which makes the willingness to pay more significant. 
Nowadays, it is not enough to show that programs reduce hospital 
admissions or composite endpoints, we must show that programs are cost-
effective or at least cost-neutral. This program was estimated to save nearly 
$Aust4 million dollars per annum in direct hospital costs if rolled out across the 
country for patients commenced on warfarin in the hospital setting. The program 
costs associated with this are likely to add up to a similar figure, and the program 
would be cost neutral. The cost-neutral assessment of this study is likely a worse 
case scenario with a larger study likely to show a reduction in other healthcare 
related expenditure such as VTE and reduced doctors visits from medication 
related problems. 
The low cost associated with bleeding complications (average cost $2405 
for a hospital admission) makes the impact of this program appear to be less 
significant. Given that most of these patients were elderly the likely reduction in 
healthcare expenditure would be greater than estimated. This type of program 
needs to be integrated into existing structures to lower the program costs 
associated with it, thus making it more cost effective. A model with accredited 
pharmacists conducting testing would have ongoing sustainability after initial 
training. Previous studies illustrate the potential health and economic benefits of 
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organised care management approaches and POC monitors in the management of 
patients receiving warfarin therapy. 420 
Although the generalisability and cost-effectiveness of this program 
remain to be demonstrated, these findings support the premise that efforts to 
reduce the likelihood of major bleeding will lead to safe and effective use of 
warfarin therapy in older patients. 
"Many major improvements in medication use among older adults 
will also depend on closing the gap between knowledge and 
practice and increasing the ability of older adults to manage their 
medications." 376 
In terms of monitoring, some of the best evidence for improvements in 
primary care relate to the monitoring of warfarin. 282, 284, 421-423 The evidence 
suggests that nurse led monitoring clinics, 422  computerised decision support 
systems, 421, 422 patient education and involvement, 284  may help improve control 
through improved monitoring. In terms of patient adherence, a number of studies 
have shown that improved education 424 and approaches that provide greater 
425 • involvement of patients in decision making 424, 	Improve patient adherence and 
may reduce drug related admissions. 
"Interventions focused on improving patient adherence with 
prescribed regimens and monitoring of prescribed medications also 
may be beneficial." 380 
It is difficult to attribute the reduced bleeding complications in the HM 
group, to any single part of the intervention. The study was not designed to 
determine the relative importance of the components of the intervention. It is 
likely that the combination of improved monitoring post-discharge and a patient-
focused education program has resulted in a reduction in the number of bleeding 
complications. It has been reported by a number of studies that adherence to 
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anticoagulant treatment is enhanced by knowledge and understanding of the drug, 
its benefits and side effects. 309, 355, 426 In a large observational study investigating 
reasons for drug related admissions, they were mainly attributed to problems with 
prescribing, monitoring and patient adherence. 427 The APAC guidelines again 
refer to follow-up education of patients after discharge 
"Factors influencing the patients' knowledge about the medication 
and the ability to comply with medication regimens should be 
identified Implementation of drug therapy should 
be accompanied by the use of appropriate education programs" 384 
The patient-focused education program employed in this project 
significantly improved knowledge in some areas, and there were clear trends to 
improved knowledge in other areas. It is possible that components of increased 
knowledge were responsible for reduced bleeding complications. There may be 
some non-response sample bias associated with the knowledge assessment, as 
significantly more patients in the UC group returned their knowledge•
questionnaire. However, over 60% of patients in the HM group returned the 
survey, therefore this may be unlikely to have caused a significant difference. 
Roddie and Pollock 396 showed that 85% of patients with a good 
understanding of warfarin had a well controlled and stable NR, compared to only 
63% in the poor-understanding group. Generally, patient's knowledge, drug 
compliance and anticoagulant control all improve after patient education became 
part of a structured management program. 315 ' 327, 396, 428 The Newcastle 
Anticoagulation Study Group 395 found no relationship between knowledge and 
lNR level, but found a positive relationship between education level and 
knowledge. Importantly, they noted "knowledge was generally poor" and 24% of 
patients answered less than half of the questions correctly. The questionnaire 
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utilised in this thesis, incorporated questions used by the Newcastle 
Anticoagulation study group, and also assessed if patients understood the 
information given to them. 
The knowledge evaluation is limited by its reliance on a questionnaire-
based survey. A reason for lower knowledge in the UC group could be due to 
poor counseling and information giving by health professionals. With regards to 
written material, Estrada et al. found that some of the patient information on 
anticoagulant therapy was above the comprehension level of most patients. 429 
More emphasis should be given to adequate education of patients on 
anticoagulant treatment post-discharge, with special emphasis on high-risk groups 
of patients, such as the elderly and poly-pharmacy users. Warfarin education 
should be tailored to the level of education and age of the patient. 392 ' 395 
Education of elderly and illiterate patients may require special consideration and 
include the use of visual aids. 392 
There are some limitations to this randomised controlled trial. We were 
able to enrol a total of only 128 subjects after exclusions during the timeframe of 
this study; therefore the actual power was less than intended. The smaller than 
expected sample size prevented us from attributing any statistical significance to a 
number of secondary outcomes such as anticoagulant-related readmissions and 
improved overall anticoagulant knowledge. These preliminary results should be 
confirmed in larger multi-centre studies. 
The trial was non-blinded to allocation concealment and outcome 
assessment. Allocation concealment would have been difficult to conduct in this 
type of project. The use of objective criteria for assessment of outcomes at 8 and 
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90 days, and strict criteria for major bleeding assessment, minimises the risk of 
blinding status exerting a major influence on trial findings. 
The true effect of the intervention may have been understated because 
patients in the UC group could have been more likely to take an active interest in 
their anticoagulant treatment due to the Hawthorne effect, which may have 
underestimated the effect of the intervention. The potential for underestimation of 
effect is very likely because of the impact the pharmacist had on the UC group 
when they were seen at day 8 after discharge. Almost one-quarter of patients in 
the UC group required dose changes as a result of the visit at day 8. It is therefore 
very likely that the intervention also had a positive impact on the UC group and 
may have prevented subsequent bleeds that may have occurred if patients' GPs 
were not contacted at day 8 after discharge and dose changes instituted. 
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PART FIVE: CONCLUSIONS 
CHAPTER TWENTY-SIX: GENERAL DISCUSSION 
The body of work covered in this thesis gives examples and solutions to address 
the adverse events associated with anticoagulants. A pertinent quote from Gurwitz 
states that "The drug itself is not the problem; the problem relates to how the 
medication is used" 430 and this has large implications surrounding the quality use 
of anticoagulants. It is important to recall that adverse events comprise under-use, 
over-use and mis-use. The works described in this thesis are examples of 
organisational and professional changes that can be made to the current structure 
and delivery of healthcare, which is likely to reduce anticoagulant-related 
misadventure. Figure 37 diagrammatically represents the level at which each of 
the interventions aimed to improve the quality use of anticoagulants. The 
interventions described were aimed at three broad areas that influence the quality 
use of anticoagulants: the patient, physician and the healthcare system. 
Under-utilisation of antithrombotics for stroke prevention in AF is a major 
healthcare problem, which may have taken a backseat to patient safety related 
issues. As stated by Woolf, 213 "people are less likely to die of an overdose of 
warfarin than of not receiving warfarin at all". He goes on to state "the attention 
policy makers give to safety should be coupled with a proportionately larger 
effort to deal with defects in healthcare that affect more lives". 
The first two studies described in this thesis, suggest one method of 
increasing the use of antithrombotics for stroke prevention in AF. The "diagnostic 
analysis" of barriers to the prescribing antithrombotics for AF enabled the 
development of an educational program targeting the perceived barriers to 
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antithrombotics. This program firstly assessed the physician-related factors that 
influence the under-use of anticoagulants for AF and then aimed to overcome 
these factors to improve the use of anticoagulants. The education program utilised 
audit and feedback data, and aimed to clarify any misperceptions that were 
identified in the nationwide survey. 
It was found that, disseminating guidelines followed by the process of 
academic detailing, significantly increased the prescription of anticoagulants for 
AF. However, further interventions such as this one needs to be undertaken to 
influence prescribing at a professional and organisational (system) level. 
A number of studies have focused on the need to implement evidence 
from clinical trials to practice, and we have had a distinct lack of success in 
closing the gap between clinical trials and clinical practice. As stated by Lenfant 
"regardless of the reasons cited for this phenomenon — structural, economic, or 
motivational — the result is the same: we are not reaping the full public health 
benefits of our investment in research". 431 
It was identified by the responding doctors to the survey investigating 
barriers to the prescribing of warfarin, that the availability of POC INR monitors 
might increase their prescribing of warfarin for AF, and improve the management 
of already anticoagulated patients. There had been no previously published 
research investigating the use of POC INR monitors in the Australian setting. 
Four projects using POC INR monitoring were described in this thesis. 
Firstly, the accuracy and clinical usefulness of the monitors was established in 
two settings, an outpatient anticoagulant clinic and a number of rural general 
practices. The monitors perfomed accurately and the use of these monitors in 
general practice would appear to be on the horizon. 432The variation encountered 
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between the monitor and the laboratory was found to be no more than variation 
that would be encountered between laboratories. The general practice evaluation 
provided a potential system change in the way warfarin is montored in the 
community setting. The availability of portable INR monitors was also suggested 
by physicians to be a factor influencing the use of anticoagulants for AF. 
The third project involving the POC INR monitoring, was based in rural 
community pharmacies. The pharmacy-based testing provided a new model for 
anticoagulant management in the community setting, influencing anticoagulant 
management at a system, patient (through education) and physician level. There is 
significant evidence that pharmacists are able to assist GPs in the management of 
chronic diseases, and management of anticoagulation seemed an area that GPs 
may have needed some assistance. This project concluded that INR monitoring in 
community pharmacy was feasible and was well received by GPs, patients and 
pharmacists. The POC monitors performed accurately, and importantly, 
potentially adverse outcomes were avoided as a result of the pharmacy-based 
testing. Appropriate training programs need to be developed, to ensure that 
pharmacy-based testing meets basic requirements for quality assurance and 
improves clinical outcomes. 
The final project described in this thesis, incorporated home-based POC 
testing and patient-focused education, and resulted in improved outcomes 
compared to standard care for patients initiated on warfarin in hospital and 
transferred to GP care. This program influences the quality use of anticoagulants 
at the three levels specified in the figure: system changes (transfer of information 
from hospital to GPs and regular monitoring), physician (improved confidence 
and outcomes with management) and patient (improved knowledge). The 
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program significantly reduced the incidence of all bleeding complications 
compared to usual care, and should ideally become incorporated into standard 
discharge planning for patients initiated on warfarin and discharged to GP care. 
There is a large potential for alternative models of anticoagulation 
management in the community setting that require further research and 
investigation. Community pharmacy-based clinics, General-practice based 
anticoagulation clinics and patient self-monitoring or management are possible 
solutions to the improved management of patients on anticoagulant treatment. 
The work described in this thesis was multifaceted in its attempt to 
influence the quality use of anticoagulants. The different projects conducted were 
complementary to one another and were successful in improving the outcomes of 
anticoagulation. 
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APPENDICES 
Appendix 1 
Covering letter to doctors 
Doctors' beliefs on antithrombotic 
therapy for AF 
UNIVERSITY OF TASMANIA 
Tasmanian School of Pharmacy 
Telephone: 6226 2203 
4 August 2000 
Dear Doctor 
We are conducting ongoing clinical research into the use and outcomes of thrombosis prophylaxis in 
atrial fibrillation (AF) 1 . To date, we have established a database of over 500 patients with AF in 
Southern Tasmania who have presented to the Royal Hobart Hospital. These patients are being 
followed for embolic and bleeding outcomes related to use of thrombosis prophylaxis. The principal 
intention is to compare the results of recent clinical trials with outcomes in the real world, and 
ultimately improve stroke prevention in patients with AF. 
We now wish to extend this research by collecting doctors' perceptions on the appropriate use and 
barriers to antithrombotic therapy in AF. 
Your name has been randomly selected from the Medical Directory of Australia 2000 (Australasian 
Medical Publishing Co). We ask you to participate in this survey by completing the enclosed four 
page questionnaire. Most questions simply involve responding via ticking a box or placing a cross on 
a scale. We appreciate your honest opinions. Responses will be treated anonymously and 
confidentially. Data from all responses will be pooled. 
Your assistance is highly valued. The information will assist in developing systems for the provision 
of safer and more effective antithrombotic therapy. 
The study has been approved by both the Research and Ethics Committees, Royal Hobart Hospital. 
If you have any questions about the project you can contact either: 
Greg Peterson (phone 03-62262197 or email G.Peterson@utas.edu.au ) or 
Janet Vial (phone 03-62264842 or email Janet.Vial@utas.edu.au ). 
Please return the completed questionnaire in the self-addressed envelope by 8 September 2000. 
We look forward to your response. Thank you for your assistance. 
Yours sincerely 
GregoryPterson 	 Janet Vial 
AssociaiWProfessor Senior Lecturer/Physician 
School of Pharmacy 	 Discipline of Medicine 
Ang SY, Peterson GM, Friesen WT, Vial JR. 
Review of antithrombotic drug usage in atrial fibrillation. J Clin Pharm Ther 1998; 23: 97-106 
Appendix 2 
Survey form 
Doctors' beliefs on antithrombotic 
therapy for AF 
Survey of medical practitioners examining the issue of 
atrial fibrillation and antithrombotic therapy 
UNIVERSITY OF TASMANIA 
We appreciate your honest opinions. 
The responses will be treated anonymously and confidentially, and data from all respondents will be pooled. 
The first set of questions relates to demographic 
and practice information. 
1 	In which year did you first register as a medical 
practitioner? 	19 	 
2 Gender? El Female El Male 
3 Which of the following best describes your 
regular medical practice? 
The remaining questions relates to doctors' views 
on AF and the use of antithrombotic drugs. 
9 For the following hypothetical patients who 
have chronic non-valvular AF, indicate what 
you perceive their annual risk of ischaemic 
stroke may be and indicate which treatment 
you feel would be appropriate. Also indicate 
the target INR you would aim for if using 
warfarin. 
O General practitioner 
CI General physician 
O Cardiologist 
El Other 	 
a) 65 year old male with a history of thrombo-
embolic stroke secondary to AF 
4 In which State or Territory do you normally 
practice? 
CI NSW 	QLD 	WC 
CI SA 	 TAS 	1:1 ACT 
▪ WA 	El NT 
5 	Which of the following best describes the 
location of your regular medical practice? 
CI City 	CI Rural 
CI Suburban El Other 	  
6 On average, how many hours each week do you 
spend seeing patients? 
7 Which of the following best describes the 
demographics of your patients? 
El Predominantly young patients 
El Mix of young and older patients 
-0 	Predominantly older patients 
El Other 	  
8 Approximately how many new cases with 
chronic/paroxysmal AF would you see per 
year? 
RISK OF STROKE 
CI LOW (annual risk of stroke = 1%) 
CI MEDIUM (annual risk of stroke = 4%) 
CI HIGH (annual risk of stroke = 8-12%) 
DRUG THERAPY 	TARGET INR 
CI WARFARIN INR 	 
El ASPIRIN 
CI ASPIRIN & WARFARIN INR 	 
El NEITHER 
El OTHER 	  
b) 75 year old male with a history of thrombo-
embolic stroke secondary to AF 
RISK OF STROKE 
CI LOW (annual risk of stroke = 1%) 
0 MEDIUM (annual risk of stroke = 4%) 
CI HIGH (annual risk of stroke = 8-12%) 
DRUG THERAPY TARGET INR 
El WARFARIN 	 INR 
El ASPIRIN 
El ASPIRIN & WARFARIN INR 
El NEITHER 
CI OTHER 	  
Page -2 
76 year old female with diabetes, hyper- 
tension and a previous AM! 10 years ago 
RISK OF STROKE 
El LOW (annual risk of stroke = 1%) 
E l MEDIUM (annual risk of stroke = 4%) 
CI HIGH (annual risk of stroke = 8-12%) 
DRUG THERAPY 	TARGET INR 
CI WARFARIN 	 INR 	 
0 ASPIRIN 
El ASPIRIN & WARFARIN INR 	 
El NEITHER 
El OTHER 	  
d) 45 year old male with hypertension, diabetes, 
ischaemic heart disease and a past history of 
TIAs 
RISK OF STROKE 
CI LOW (annual risk of stroke = 1%) 
CI MEDIUM (annual risk of stroke = 4%) 
CI HIGH (annual risk of stroke = 8-12%) 
DRUG THERAPY TARGET INR 
El WARFARIN 	 INR 	 
El ASPIRIN 
El ASPIRIN & WARFARIN INR 
O NEITHER 
El OTHER 	  
e) 60 year old female with no contributory risk 
factors 
RISK OF STROKE 
I=J LOW (annual risk of stroke = 1%) 
El MEDIUM (annual risk of stroke = 4%) 
CI HIGH (annual risk of stroke = 8-12%) 
DRUG THERAPY 	TARGET INR 
El WARFARIN 	 INR 	 
El ASPIRIN 
El ASPIRIN & WARFARIN INR 
O NEITHER 
El OTHER 	  
f) 50 year old male with hypertension and 
ischaemic heart disease and a resolved past 
history of gastrointestinal bleeding 
RISK OF STROKE 
El LOW (annual risk of stroke = 1%) 
CI MEDIUM (annual risk of stroke = 4%) 
El HIGH (annual risk of stroke = 8-12%) 
DRUG THERAPY 
	TARGET INR 
0 WARFARIN 
	 INR 
El ASPIRIN 
El ASPIRIN & WARFARIN INR 
O NEITHER 
CI OTHER 	  
10 Do you believe that the risk of stroke from 
paroxysmal AF is: 
Less than for chronic AF 
Greater than for chronic AF 
Same as for chronic AF 
11 Warfarin reduces the risk of stroke in chronic 
AF by approximately: 
El 20% 0 50% 0 66% 0 85% 
12 Aspirin reduces the risk of stroke in chronic 
AF by approximately: 
El 20% El 50% CI 66% CI 85% 
13 The annual risk of major bleeding (ie 
intracranial or intracerebral haemorrhage, or 
requiring blood transfusion) in patients with 
chronic AF treated with warfarin is 
approximately: 
El 1% 0 5% El 10% 0 20% 
Page - 3 
14 We are interested in identifying variables that 
doctors perceive as being barriers to the use of 
anticoagulation in AF. In a patient with chronic 
AF, which of the following factors would make 
you reluctant to use warfarin? Answer each by 
placing a cross anywhere on the scale provided. 
a) bad experiences with prescribing warfarin in 
the past 
1 	1 	1 	1 	1 	1 	1 	1 	1 	1 	1 
No, not at all Yes, most definitely 
b) advancing age of the patient 
II 	III 	III 	III 
No, not at all Yes, most definitely 
c) active gastrointestinal bleeding 
III 	III  
No, not at all 	 Yes, most definitely 
d) prior resolved gastrointestinal bleeding 
II 	III 	III 	Ili 
No, not at all Yes, most definitely 
e) previous intracranial haemorrhage 
1 	1 	1 	1 	1 	1 	1 	1 	1 	1 	I 
No, not at all Yes, most definitely 
f) poor control of INR in the past 
1 	I 	1 	1 	1 	1 	1 	1 	1 	1 	1 
No, not at all Yes, most definitely 
g) a history of daily falls 
1 	1 	1 	1 	1 	1 	1 	1 	1 	1  
No, not at all Yes, most definitely 
h) a history of twice-yearly falls 
1 	1 	1 	1 	1 	1 	1 	1 	1 	1 	1 
No, not at all Yes, most definitely 
i) dementia, but in an institutionalised setting 
1 	1 	1 	1 	1 	1 	1 	1 	1 	1 	1 
No, not at all Yes, most definitely 
j) alcoholism 
i  
No, not at all 	 Yes, most definitely 
k) liver disease 
II 	III  
No, not at all Yes, most definitely 
1) severe anaemia 
1 	1 	1 	1 	1 	1 	1 	1 	1 	1 	1 
No, not at all Yes, most definitely  
m) poorly controlled hypertension 
1 	1 	1 	1 	1 	1 	1 	1 	1 	1  
No, not at all Yes, most definitely 
n) concurrent use of non-steroidal anti-
inflammatory drugs (NSAIDs) 
II 	III 	III 	III 
No, not at all Yes, most definitely 
o) patient living distant from routine medical 
care 
1 	1 	1 	1 	1 	1 	1 	1 	1 	1 	I 
No, not at all Yes, most definitely 
15 Do you believe there are clear guidelines that you 
can refer to if unsure of whether to anticoagulate 
patients with AF? 
II 	III 	III 	III 
No, not at all Yes, most definitely 
16 Do you believe that the results given in large 
clinical trials can be translated into Australian 
clinical practice? 
111111 	III 
No, not at all 	 Yes, most definitely 
17 Do you believe that most patients with chronic 
AF would accept treatment with warfarin? 
II 	III 	III  
No, not at all Yes, most definitely 
18 Do you believe that anticoagulation should be 
initiated in the hospital setting in patients with 
AF? 
1 	1 
	
1 	1 	1 	1 	1 	1 	1 	1 	1 
No, not at all Yes, most definitely 
19 Do you believe that anticoagulation is 
underutilised in patients with AF? 
1 	1 	1 	1 	1 	1 	1 	1 	1 	1 	1 
No, not at all Yes, most definitely 
Page - 4 
20 In general, do you believe that the risk of 
haemorrhage with warfarin outweighs the 
potential benefit in stroke prevention in patients 
with AF? 
1 	1 	1 	1 	1 	1 	1 	1 	1 	1 	I 
No, not at all Yes, most definitely 
21 In general, do you believe that anticoagulation 
treatment has a negative impact on quality of life 
in patients with AF? 
1 	1 	1 	1 	1 	1 	1 	1 	1 	1  
No, not at all Yes, most definitely  
22 Do you believe that most patients with AF find 
the need for close monitoring while receiving 
treatment with warfarin too inconvenient? 
1 	1 	1 	1 	1 	1 	1 	1 	1 	1 	1 
No, not at all Yes, most definitely 
23 If portable INR monitors were made available to 
your practice would this assist with the 
management of your patients with AF? 
1 	1 	1 	1 	1 	1 	1 	1 	1 	1 	1 
No, not at all Yes, most definitely 
24 Do you have any further comments or suggestions on the issue of AF and the use of antithrombotic therapy? 
Please use the space below. 
Thank you for your time and assistance 
Please return this questionnaire in the enclosed reply-paid envelope 
Appendix 3 
Reminder letter to doctors 
Doctors' beliefs on antithrombotic 
therapy for AF 
UNIVERSITY OF TASMANIA 
Tasmanian School of Pharmacy 
Telephone: 6226 2203 
23 August 2000 
Dear Doctor 
Just a reminder about our survey of doctors' perceptions on the appropriate use and barriers to 
antithrombotic therapy in AF. 
An explanatory letter and survey form, with reply-paid envelope, were sent to you about two weeks 
ago. We are grateful if you have completed and returned the survey. If you have not completed the 
questionnaire yet, your assistance would be highly valued. The information will assist in developing 
systems for the provision of safer and more effective antithrombotic therapy. 
Most questions simply involve responding via ticking a box or placing a cross on a scale. Responses 
will be treated anonymously and confidentially. Data from all responses will be pooled. 
If you need another copy of the questionnaire and envelope, or have any questions about the project 
you can contact either: 
Greg Peterson (phone 03-62262197 or email G.Peterson@utas.edu.au ) or 
Janet Vial (phone 03-62264842 or email Janet.Vial@utas.edu.au). 
Thank you for your assistance. 
Yours sincerely 
iLt 
GregorPterson 	 Janet Vial 
Associa 	ofessor Senior Lecturer/Physician 
School of Pharmacy 	 Discipline of Medicine 
,A 
Appendix 4 
Royal Hobart Hospital 
anticoagulation guidelines 
Attached in sleeve of thesis 
Appendix 5 
Covering letter to doctors 
Improving antithrombotic 
prescribing in AF 
25 February 2002 
UNIVERSITY OF TASMANIA 
Tasmanian Schools of Pharmacy & Medicine 
Telephone: 6226 2203 
Dear Dr (Doctors name inserted here) 
REDUCING THE RISK OF STROKE IN ATRIAL FIBRILLATION 
We are members of the Tasmanian Schools of Pharmacy and Medicine, Faculty of Health Science at the University 
of Tasmania and are embarking on a project to assist in providing a clinical approach to reducing the risk of stroke in 
chronic or paroxysmal non-valvular Atrial Fibrillation. 
Chronic AF is the most common arrhythmia in the community with a prevalence rising with age such that it is 
present in over 10% of the general population over 80 years, and is the most important risk factor for stroke in that 
age group. The presence of AF has been confirmed in many studies as an important risk factor for ischaemic stroke 
and other thromboembolic events. The absolute annual risk of stroke in patients with AF of all causes is around 5%, 
but varies with age and other risk factors. 
We recently reviewed the medical records for 505 consecutive patients who had chronic or paroxysmal AF at the 
Royal Hobart Hospital, and followed these patients to determine clinical outcomes.' Analysis of the use of 
antithrombotic drugs in the patients indicated that a large proportion was not taking appropriate therapy. 
• 79% of the patients with previously diagnosed chronic or paroxysmal AF had a high risk of 
developing stroke at the time of admission to hospital care. 
• Only one-third (34%) of these patients were receiving warfarin (or warfarin plus aspirin), with 
almost one-quarter (24%) receiving no antithrombotic agent. 
• Of the high-risk patients without any contraindications, only 43% were receiving warfarin (or 
warfarin plus aspirin) on hospital admission. 
• At follow-up, the annual overall stroke rate for warfarin-treated patients was significantly lower than 
for patients who did not receive warfarin (3.4% to 7.0% per annum, respectively; P < 0.05), a risk 
reduction for stroke with warfarin therapy of 51%. 
• For patients who had no contraindications to the use of warfarin, the rates of major bleeds while 
receiving warfarin and not receiving warfarin were 2.1% and 1.5% per annum, respectively. 
We ask that you read and consider the enclosed information. The guidelines are based on recently published research 
papers and reviews on the prevention of stroke from AF, and similar guidelines from the UK and USA. The 
guidelines have been formulated in consultation with local Haematologists, Cardiologists and Geriatricians. 
Our project pharmacist, Shane Jackson, will be in contact with you shortly to arrange a convenient time to visit and 
briefly discuss the material with you. Any queries can be directed to Shane (phone: 0408 485 430). This project has 
been approved by the Research and Ethics Committees of the Southern Tasmanian Acute Care Program. 
Yours sincerely 
Sharte Jackson 
Project Pharmadst/PhD student 
TASMANIAN SCHOOL OF PHARMACY 
Gregory Potation 	° 
Professor of Pharmacy 
TASMANIAN SCHOOL OF PHARMACY 
Janet Vial 
Physician & Head of Clinical School 
ROYAL HOBART HOSPITAL 
PhY/20-664'. 
 
Da 	 Phil Roberts-Thomson 
Haematol 	 Associate Professor/Cardiologist 
ROYAL HO 	OSPITAL 	ROYAL HOBART HOSPITAL 
1 Jackson SL, Peterson GM, Vial MI, et al. Outcomes in the management of Atrial Fibrillation: Clinical trial results can apply in practice Intern Med 
.131 (6): 329-336 AUG 2001 
Appendix 6 
Medical Director computer-based 
risk stratification 
Improving antithrombotic 
prescribing in AF 
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Appendix 7 
Colour information sheet 
demonstrating the use of the 
CoaguChek S INR monitor 
INR monitoring projects 
Pr  
lb. Rub the outside of the finger you have 
pricked until a large, hanging drop 1)11s100(1 
has formed (Do not pinch or squeeze!). 
2. Insert the test strip: 
When the test strip icon flashes on the dis-
play, open the test strip foil pouch and insert 
the test strip into the monitor. The clock icon 
flashes next to the test strip for 45 seconds 
while the monitor warms up. 
   
Determining the INR/Quick value using c 
  
 
pillary blood 
  
   
Getting ready: Take one test strip Itill pouch out of the refrigerator and wait for at least 5 minutes to allow the test strip to come up to room temperature. The code chip from the test strip pack being used must be in the 
monitor. As you open each new test strip pack, place the code chip in the monitor before switching it on. Do not remove the code chip from the monitor until you start using a new pack of test strips (with a new code chip), 
switching the monitor off before you do so. 
I. Switch on the monitor and check: 3a. Prick your fingertip: 4. Apply sample: 5. Measurement: 
Check that the code numbers in the display A flashing drop of blood appears on the display Apply the first drop of blood to the flashing The CoaguChek S starts measurement as 
match the last three digits on the test strip foil with the number 180.11w monitor is now ready yellow area of the test strip within 15 seconds soon as the drop of blood is applied. The 
pouch and that the date and time arc set and begins counting down from 180 seconds. of pricking your fingertip. The test area must clock icon appears on the display and the 
correctly. The sample must be applied to the test strip 
within this time. 
Now prick the lip of your middle or ring finger 
at the side, using the lancet device. 
he completely covered with blood. minute hand moves until the measurement 
has been completed. The result is displayed 
after about 1 minute and is automatically 
stored in the monitor. Record the result in 
your log book. 
Please note: 
The CoaguChek must be used on a stable, flat surface. 
It is essential that a reasonably large drop of blood 
is used - it must fully cover the flashing area. 
The CoaguChek is most accurate within the I NR range of 
2.0-3.0, and it may be appropriate to redo tests 
outside of this range. 
For any queries, please phone Shane Jackson on 
03-62262203 or 0408485430. 
The most important icons are explained on the reverse of this quick reference guide. 
An explanation of all symbols that can appear on the display is given in the CoaguChek S 
user's manual. 
Indicates the room temperature is 
out of the monitor operating range. 
AERROR 
Indicates error conditions such as a 
test error or temperature error. 
CODE 
Indicates the code number of the 
current Code Chip. 
Indicates the state 
of the battery power: 
• Full power has all segments lit. 
•Depleted power shows only the 
case lit. 
• Segments disappear as power is 
drained. 
Indicates a sample application error. 
Indicates the user needs to apply a 
sample. 
Indicates there is a strip in place, 
strip requested (when flashing), 
or test error. 
Indkates the room light is too bright. 
Indicates the strip guide requires 
cleaning. 
Indicates the sample applied was a 
control solution. 
MEM 
Indicates the monitor is in memory 
retrieval mode. 
SET 
Indicates the monitor 
is in setup mode. 
/ 
"AN 
Indicates the user needs to wait for 
the monitor to complete an action. 
Indicates a "return for service" error. 
Call Roche Diagnostics. 
----i 
Indicates the beeper option. When 
the beeper is off, the symbol flashes. 
When the beeper is on, the symbol 
does not flash. 
INR 
Indicates the results 
INR units. 
are displayed in 
%0 
Indicates the results 
Percent Quick. 
are displayed as 
_ 
1 	or 1 
Indicates the results are out of range 
on the primary scale. 
Up Arrow - above range 
Down Arrow - below range 
Lid to monitor is open. 
Appendix 8 
Patient information and consent 
form 
Rural general practice INR 
monitoring 
UNIVERSITY OF TASMANIA 
Tasmanian School of Pharmacy 
Telephone: 6226 2203 
Testing the accuracy of a portable INR monitor compared with 
conventional pathology testing 
Information sheet 
The aim of the study is to look at the accuracy of a portable INR monitor as compared to 
conventional pathology testing. A portable INR monitor is a machine that can give you an INR 
result from a fingerprick sample of blood. This will include normal venous sampling for 
conventional pathology testing. 
As a patient receiving care through your normal general practitioner you will undergo venous 
sampling for the conventional pathology testing and will be asked to give a fingerprick sample to 
test the accuracy of the portable INR monitor compared to pathology testing. 
It is intended that the results from this study will be useful in improving the management of 
patients in the future on anticoagulant therapy. 
Further information can be obtained from: 
Professor Greg Peterson at the University of Tasmania (phone 62262197) 
Shane Jackson 0408485430 or Luke Bereznicki 0438 232864 
The project has received ethical approval from the Royal Hobart Hospital Ethics Committee. 
If you have any concerns of an ethical nature or complaints about the manner in which the project 
is conducted you can contact the Chair or Secretary of the Ethics Committee. 
Chair: 	Dr Janet Vial 	62 224842 
Secretary: 	Ms Chris Hooper 	62 262763 
UNIVERSITY OF TASMANIA 
Testing the accuracy of a portable INR monitor compared with 
conventional pathology testing 
Consent Form 
I have read and understood the 'Information Sheet' for this study. 
2 	The nature and possible effects of the study have been explained to me. 
3 	I understand that the study involves the following procedures: 
A fingerprick sample of blood for testing via the portable INR monitor will be 
obtained in addition to the normal venous sample for conventional pathology testing. 
4 	I have been informed that the results of the study may not be of any direct benefit to 
my medical management. 
5 	Any questions that I have asked have been answered to my satisfaction. 
6 	I agree that research data gathered for the study may be published provided that I 
cannot be identified as a subject. 
7 	I agree to participate in this investigation and understand that I may withdraw at any 
time without affecting my medical care or relationship with the hospital, doctors, 
nursing staff and research investigators. 
Name of subject 	 Signature 
Date 
Name of witness 	 Signature 
Date 
Statement by the researcher 
I have explained this study and the implications of participation in it to this volunteer 
and I believe that the consent is informed and that he/she understands the 
implications of participation. 
Name of researcher 	 Signature 
Date 
Appendix 9 
General practice INR monitoring 
data sheet 
Rural general practice INR 
monitoring 
Patient Questionnaire 
Please complete this section of the 
questionnaire during your first consultation 
with the patient 
5. Has the use of the CoaguChek monitor been 
more time consuming than pathological 
testing... 
Patient Name (to be deleted upon completion of 
trial): 
...for you? 
...for this patient? 
If yes, please explain 
Yes / No 
Yes / No 
   
Sex: 	Male / Female 
Age: 
Reason for commencement of Warfarin therapy: 
• Deep Venous Thrombosis 
• Atrial Fibrillation 
• Heart valve Replacement 
• Other (please specify) 
Length of time undergoing warfarin therapy: 
1. Has this patient suffered any 
thromboembolic complications while taking 
warfarin? 
Yes / No 
If yes, please explain 
2. Has this patient suffered any bleeding 
complications while on warfarin? 
6. Do you feel that the use of the CoaguChek 
monitor has increased compliance in this patient? 
Yes / No / Unsure 
7. Do you feel that the use of the CoaguChek 
monitor has resulted in better care of this 
patient? 
Yes / No / Unsure 
8. Did this patient prefer to use the CoaguChek 
monitor compared to pathological testing? 
Yes / No/Unsure 
If yes, please explain 
9. Please attach a record of recent past 
pathological testing for this patient if one is 
available [optional]. 
If yes, please explain 
Yes / No 10. Would this patient be a candidate for self-
management of oral anti-coagulation? 
Yes /No/Unsure 
3. How many times a month is pathological INR 
testing normally performed on this patient? 
.... Times per month 
Please complete the remaining questions upon 
completion of the trial period. 
4. Given access to the CoaguChek monitor, how 
many times a month would you test this patient's 
INR? 
.... Times per month 
CoaguChek 
INR 
Pathology 
INR 
Action Taken Date 
Table of Patient CoaguChek and Pathology INR Results 
Patients name (to be removed at end of study) 	  
Target INR range for this patient: 	  
Do you have any further comments pertaining to the CoaguChek monitor or the anticoagulant therapy of 
this patient? 
Appendix 10 
Doctor information form 
Rural community pharmacy-based 
INR monitoring 
UNIVERSITY OF TASMANIA 
Tasmanian School of Pharmacy 
Telephone: 6226 2203 
Improving the outcomes of anticoagulation in rural Australia: an evaluation of 
pharmacist-assisted monitoring of warfarin therapy 
Information sheet 
Dear Doctor 
This pharmacy in conjunction with the University of Tasmania has agreed to partcipate in a trial of 
pharmacist-assisted monitoring of warfarin therapy. The aim of this study is to improve the outcomes of 
warfarin therapy in rural Australia. This includes an examination of the effect of free INR monitoring 
by the pharmacist. You as the general practitioner will be contacted regarding all INR measurements. 
The pharmacist can discuss issues relating to warfarin therapy with the patient as well as performing a 
blood INR using a finger-prick blood sample with a portable INR monitor (a machine that can rapidly 
gives you an INR result from a fingerprick sample of blood, rather than the normal blood sampling for 
conventional pathology testing. It is similar to the blood sugar monitors used by diabetic patients). Any 
dose changes of warfarin will be made in consultation with you if needed 
Also, we will gather some brief information from the patients (e.g. age, reason for warfarin therapy). 
We will also ask you for your opinion on the use of the INR monitor. This information will be kept 
strictly confidential, and only the researchers will have access to identifying data. It is intended that the 
results from this study will be useful in improving the management of patients placed on warfarin in 
rural settings. 
Thank you for your assistance. 
Further information can be obtained from Shane Jackson (0408485430) or Professor Greg Peterson at 
the University of Tasmania (phone 03-62262197). 
The project has received ethical approval from the Southern Tasmania Health and Medical Human 
Research Ethics Committee. 
If you have any concerns of an ethical nature or complaints about the manner in which the project is 
conducted you can contact the Chair or Executive Officer of the Ethics Committee. 
Chair: 	 Dr Helen McArdle 	6222 8195 
Executive Officer: 	Mrs Amanda McAully 	6226 2763 
Appendix 11 
Patient information and consent 
form 
Rural community pharmacy-based 
INR monitoring 
UNIVERSITY OF TASMANIA 
Tasmanian School of Pharmacy 
Telephone: 6226 2203 
Improving the outcomes of anticoagulation in rural Australia: an evaluation of 
pharmacist-assisted monitoring of warfarin therapy 
Information sheet 
This pharmacy in conjunction with the University of Tasmania has agreed to participate in a trial of 
pharmacist-assisted monitoring of warfarin therapy. The aim of this study is to improve the outcomes of 
warfarin therapy in rural Australia. This includes an examination of the effect of free INR monitoring 
by the pharmacist. The General practitioner will be contacted regarding all INR measurements. 
The pharmacist can discuss issues relating to warfarin therapy with the patient as well as performing a 
blood INR using a finger-prick blood sample with a portable INR monitor (a machine that can rapidly 
give you an INR result from a fingerprick sample of blood, rather than the normal blood sampling for 
conventional pathology testing. It is similar to the blood sugar monitors used by diabetic patients). The 
General Practitioner will determine any dose changes of warfarin if needed 
Also, we will gather some brief information from the patients (e.g. age, reason for warfarin therapy). 
We will also ask you for your opinion on the use of the INR monitor. This information will be kept 
strictly confidential, and only the researchers will have access to identifying data. It is intended that the 
results from this study will be useful in improving the management of patients placed on warfarin in 
rural settings. 
Thank you for your assistance. 
Further information can be obtained from Shane Jackson (0408485430) or Professor Greg Peterson at 
the University of Tasmania (phone 03-62262197). 
The project has received ethical approval from the Southern Tasmania Health and Medical Human 
Research Ethics Committee. 
If you have any concerns of an ethical nature or complaints about the manner in which the project is 
conducted you can contact the Chair or Executive Officer of the Ethics Committee. 
Chair: 	 Dr Helen McArdle 	6222 8195 
Executive Officer: 	Mrs Amanda McAully 	6226 2763 
UNIVERSITY OF TASMANIA 
Improving the outcomes of anticoagulation in rural Australia: an evaluation of pharmacist- 
assisted monitoring of warfarin therapy 
Consent Form 
1 	I have read and understood the 'Information Sheet for this study. 
2 	The nature and possible effects of the study have been explained to me. 
3 	I understand that the study involves the following procedures: 
A fingerprick sample of blood for testing via the portable INR monitor will be obtained and 
the result forwarded to my doctor. All patients will receive their routine medical care. 
4 	I have been informed that the results of the study may not be of any direct benefit to my 
medical management. 
5 	Any questions that I have asked have been answered to my satisfaction. 
6 	I agree that research data gathered for the study may be published provided that I cannot be 
identified as a subject. 
7 	I agree to participate in this investigation and understand that I may withdraw at any time 
without affecting my medical care or relationship with the pharmacist, doctor, and research 
investigators. 
Name of subject 	 Signature 
Date 
Name of witness 	 Signature 
Date 
Statement by the researcher 
I have explained this study and the implications of participation in it to this volunteer and I 
believe that the consent is informed and that he/she understands the implications of 
participation. 
Name of researcher 	 Signature 
Date 
Appendix 12 
Data collection form 
Rural community pharmacy-based 
INR monitoring 
Rural pharmacy INR monitoring patient 
DATA SHEET 
Name: 
Address: 
Phone (home): 
Mobile: 
UNIVERSITY 
OF TASMANIA 
Date of birth: 
Indication for anticoagulation: 
Target INR: 
Length of therapy: 
Doctor: 
Other medical conditions: Medication list: 
Other relevant issues: 
INR data table: 
Date INR Dose Time involved Comparison or 
additional 
Outcome same, < / > Pathology INR if 
known 
Appendix 13 
Facsimile transmission form for 
pharmacy to general practitioner 
Rural community pharmacy-based 
INR monitoring 
Facsimile transmission 
UNIVERSITY 
OF TASMANIA 
Tasmanian School of Pharmacy 
To: Dr 
Fax number: 
Total pages: 
From: Community Pharmacist 
Date: 
Subject: RURAL PHARMACY INR MONITORING FAX SHEET FOR GENERAL PRACTITIONERS 
Name: 
Address: 
Date of birth: 
Date of test: 
Time of test: 
INR: 
Current dose: 
Comparison pathology test Yes No 
  
If out of target range call GP Yes No 
   
Phone (home): 
Mobile: 
Dose 	Mon 	Tue 	Wed 
	
Thur 	Fri 
	
Sat 
	
Sun 
Comments from pharmacist: 
GPO Box 252-26 Hobart 
Tasmania 7001 Australia 
Telephone 03 6226 2190 
Facsimilie 03 6226 2870 
Appendix 14 
Patient satisfaction survey 
Rural community pharmacy-based 
INR monitoring 
PATIENT SATISFACTION 
QUESTIONNAIRE 
UNIVERSITY OF TASMANIA 
Tasmanian School of Pharmacy 
Telephone: 6226 2203 
Please help us evaluate and improve the rural pharmacy anticoagulation monitoring 
service by answering some questions about the services you have received from the 
pharmacist. We are interested in your honest opinions, whether they are positive or 
negative. Please answer all of the questions. Thank you very much, we really appreciate . 	. 
Please Tick your Answers 
1 	How satisfied are you with the warfarin monitoring conducted by your pharmacist 
LI 	Quite dissatisfied 
01 	Indifferent or mildly dissatisfied 
D Mostly satisfied 
LI 	Very satisfied 
2 	Has the monitoring provided by the pharmacist helped you to deal more effectively 
with your medication warfarin 
O Yes, they helped a great deal 
LI 	Yes, they helped somewhat 
I0 	No, they really didn't help 
LI 	No, they seemed to make things worse 
3 	Which type of testing would you prefer 
LI 	Fingerprick testing at the pharmacy 
U Fingerprick testing at the General Practitioners surgery 
O Conventional pathology testing 
U Unsure 
4 	Is there other information you need, or would like, about warfarin but have not 
received? 
I:1 	Yes, there definitely is 
U Yes, I think there is 
O No, I don't think there is 
LI 	No, there definitely is not 
5 	Overall, how would you rate the quality of the service that you received from the 
pharmacist? 
U Excellent 
O Good 
U Fair 
10 	Poor 
6 	Did you find the regular warfarin (INTR) monitoring: (you may tick more than one) 
Li 	painful 	 U 	interesting 
O informative 	 D 	annoying 
Li 	motivating U 	convenient 
O a waste of time 	 ID 	beneficial 
7 	Do you think this service would be best provided in your home or at your local 
pharmacy? 
Li 	Home 
LI 	Local Pharmacy 
O General Practitioners Surgery (GP) 
8 	Do you think this service should be available to all patients on warfarin therapy? 
O Yes 
ID 	No 
9 	If this was a regular service, would you be prepared to pay it? 
O Yes 
LI 	No 
10 	If you answered yes to the previous question, how much would you be prepared to 
pay per visit? 
Li 	$1 - $5 
O $6 - $10 
LI 	$11 - $15 
O $16+ 
11 	If you wish to make any other comments, please feel free to do so in the space 
provided. If more space is required, use the back of this sheet. 
Thank you for taking the time to fill out this questionnaire 
Please post in the reply-paid envelope supplied 
Appendix 15 
Patient information and consent 
form 
Improving warfarin initiation 
Royal Hobart Hospital and University of Tasmania 
Home follow-up of patients commenced on warfarin therapy 
Information sheet 
UNIVERSITY OF TASMANIA 
Tasmanian School of Pharmacy 
Telephone: 6226 2203 
The aim of this study is to improve the outcomes of warfarin therapy. This includes an examination of the 
effect of regular, free follow-up sessions with a pharmacist visiting you at home, with regular blood INTR 
monitoring. An INR measurement is a measure of how thick or thin your blood is, and is used to adjust 
your warfarin dose. The pharmacist, in consultation with your doctor, can also assist with any medication 
problems or queries. 
Consecutive patients commenced on warfarin in hospital are being randomly allocated to either an 
'intervention' or 'control group'. There is a 50:50 chance of being allocated to each group. Patients in the 
'intervention' group will receive a pharmacist visit at home on alternate days on four occasions, with an 
initial visit two days after discharge from hospital (the pharmacist will visit you four times in eight days). 
At each session, the pharmacist can discuss issues relating to warfarin therapy, as well as performing a 
blood INR using a finger-prick blood sample with a portable INR monitor (a machine that can rapidly give 
you an INR result from a fingerprick sample of blood, rather than the normal blood sampling for 
conventional pathology testing. It is similar to the blood sugar monitors used by diabetic patients). There 
will be a final visit at 3 months after discharge from hospital. 
Patients in the 'control group' will be visited at 8 days after discharge from hospital and you will need to 
receive normal care from your general practitioner, the pharmacist will only take a blood sample for data 
collection. The pharmacist will then visit you again 3 months after discharge from hospital. 
All the INR results will be forwarded to your regular doctor. 
Also, we will take information (age, relevant medical and surgical history) from your hospital medical 
records. This information will be kept strictly confidential, and only the researchers will have access to 
identifying data. 
It is intended that the results from this study will be useful in improving the management of patients 
placed on warfarin. 
Further information can be obtained from Greg Peterson at the University of Tasmania (phone 62262197). 
The project has received ethical approval from the Southern Tasmania Health and Medical Human 
Research Ethics comittee. 
If you have any concerns of an ethical nature or complaints about the manner in which the project is 
conducted you can contact the Chair or Secretary of the Ethics Committee. 
Chair: 	 Dr Helen McArdle 
Executive Officer : 	 Ms Amanda McAully 	62 262763 
Royal Hobart Hospital and University of Tasmania 
Home follow-up of patients commenced on warfarin therapy 
Consent Form 
I. 	I have read and understood the Information Sheet' for this study. 
2. The nature and possible effects of the study have been explained to me. 
3. I understand that the study involves the following procedures: 
Consecutive patients commenced on warfarin in hospital are being randomly allocated to either an 
'intervention' or 'control group'. There is a 50:50 chance of being allocated to each group. Patients in the 
'intervention' group will receive a pharmacist visit at home on alternate days on four occasions, with an initial 
visit two days after discharge from hospital. At each session, the pharmacist will discuss issues relating to 
warfarin therapy, as well as performing a blood INR using a finger-prick blood sample. The pharmacist will 
also attempt to help with any medication problems or queries. There will be a final visit at 3 months after 
discharge from hospital. Patients in the 'control group' will only be visited at 3 months after discharge from 
hospital. All patients will receive their routine medical and nursing care. All the INR results will be forwarded 
to your regular doctor. 
4. I have been informed that the results of the study may not be of any direct benefit to my medical 
management. 
5. Any questions that I have asked have been answered to my satisfaction. 
6. I agree that research data gathered for the study may be published provided that I cannot be identified 
as a subject. 
7. I agree to participate in this investigation and understand that I may withdraw at any time without 
affecting my medical care or relationship with the hospital, doctors, nursing staff and research 
investigators. 
Name of subject 
	 Signature 	  
Date 	  
Name of witness  	 Signature 	  
Address 	  
Date 	  
Statement by the researcher 
I have explained this study and the implications of participation in it to this volunteer and I believe that 
the consent is informed and that he/she understands the implications of participation. 
Name of researcher 	  
Signature of researcher  	Date 	  
Appendix 16 
Patient education document 
Improving warfarin initiation 
One page guide to warfarin treatment* 
1 	Warfarin belongs to a class of medications called anticoagulants ("blood thinners") 
Warfarin keeps blood clots from forming or getting larger. 
2 	Many medications can change the way warfarin works. Ask your doctor or pharmacist about using any other medication, 
including over-the counter medications, vitamins and herbal products 
3 	Make sure your doctor or pharmacist know if you are taking aspirin or aspirin-like medications, such as medications for 
pain relief and the common cold 
4 	Avoid drinking large amounts of alcohol 
5 	Certain foods will change the way warfarin works. Do not change your diet while taking warfarin. Foods that contain 
vitamin K (such as lettuce, spinach, broccoli, cabbage, cauliflower or liver) decrease the anti-clotting effect of warfarin. If 
you eat foods that have vitamin K, do not change the amount of these foods that you normally eat per week. The main point 
regarding diet is to eat a consistent amount of foods per week that contain vitamin K. 
6 	It is very important to have regular blood tests while taking warfarin. The test is called an INR, and it measures how thin 
your blood is compared to normal. 
7 	You should carry an identification card that shows you are taking warfarin. 
8 	Make sure your doctor or dentist knows you are taking warfarin before you have any surgery or dental work. 
9 	You should report the following to your doctor immediately 
Bleeding from the gums or nose 
Coughing up blood 
Red or black bowel motions 
Red or dark-brown coloured urine 
Unusually heavy menstrual bleeding 
Heavy bleeding from cuts or wounds that does not stop 
Easy bruising 
Severe headache 
10 	If you miss a dose: Take the missed dose as soon as possible. If you do not remember until the next day, skip the missed 
dose. Only take your usual dose for the day. You should not use two doses at the same time. 
*Adapted from the institute for clinical systems improvement (www.icsi.org) 
Appendix 17 
Initial correspondence with the 
general practitioner (Home 
Monitoring group) 
Improving warfarin initiation 
UNIVERSITY OF TASMANIA 
Tasmanian Schools of Pharmacy & 
Medicine 
Telephone: 6226 2203 
Dear Dr 
HOME FOLLOW-UP OF PATIENTS COMMENCED ON WARFARIN THERAPY 
Your patient 	 has been recruited into a study of patients recently 
discharged from the Royal Hobart Hospital. This study aims to improve the outcomes of 
initiation of warfarin therapy. 
The study has been approved by the Royal Hobart Hospital Research and Ethics 
Committees. All patients have given their informed consent to participate. I have attached 
for you a copy of the information sheet that the patient has received. 
Your patient has been randomised to the intervention group. Patients in the 
'intervention' group will receive a pharmacist visit at home on alternate days on four 
occasions, with an initial visit two days after discharge from hospital. At each session, the 
pharmacist will discuss issues relating to warfarin therapy, as well as performing a blood 
INR using a finger-prick blood sample with a portable INR monitor (a machine that can 
rapidly give you an INR result from a fingerprick sample of blood, rather than the normal 
blood sampling for conventional pathology testing. It is similar to the blood sugar 
monitors used by diabetic patients). There will be a final visit at 3 months after discharge 
from hospital. You will be contacted regarding all INRs and suggestions related to 
warfarin therapy 
If you have any queries or require further information, please do not hesitate to call me 
on 0408485430 
Yours sincerely, 
Shane Jackson B.Pharm Hons 
Project Supervisor 
Appendix 18 
General practitioner information 
sheet 
Improving warfarin initiation 
 Royal Hobart Hospital and University of Tasmania 
Home follow-up of patients commenced on warfarin therapy 
Information sheet 
Dear Doctor 
UNIVERSITY OF TASMANIA 
Tasmanian Schools of Pharmacy & 
Medicine 
Telephone: 6226 2203 
Your patient has been enrolled in a study to evaluate the use of home follow-up of patients 
commenced on warfarin therapy. The aim of this study is to improve the outcomes of warfarin 
therapy. This includes an examination of the effect of regular, free follow-up sessions with a 
pharmacist visiting patients at home, with blood INR monitoring. The pharmacist, in consultation 
with the patient's doctors, will also assist with any medication problems or queries. 
Consecutive patients commenced on warfarin in hospital are being randomly allocated to either 
an 'intervention' or 'control group'. There is a 50:50 chance of being allocated to each group. 
Patients in the 'intervention' group will receive a pharmacist visit at home on alternate days on 
four occasions, with an initial visit two days after discharge from hospital. At each session, the 
pharmacist will discuss issues relating to warfarin therapy, as well as performing a blood INR 
using a finger-prick blood sample with a portable INR monitor (a machine that can rapidly give 
you an INR result from a fingerprick sample of blood, rather than the normal blood sampling for 
conventional pathology testing. It is similar to the blood sugar monitors used by diabetic 
patients). There will be a final visit at 3 months after discharge from hospital. 
Patients in the 'control group' will be visited at Day 8 and also at 3 months after discharge from 
hospital. All patients will receive their routine medical and nursing care. 
Further information can be obtained from Greg Peterson at the University of Tasmania (phone 
62262197). 
The project has received ethical approval from the Royal Hobart Hospital Ethics Committee. 
If you have any concerns of an ethical nature or complaints about the manner in which the project 
is conducted you can contact the Chair or Secretary of the Ethics Committee. 
Chair: 	Dr Janet Vial 	 62 224842 
Secretary: 	Ms Amanda McAully 	62 262763 
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Final correspondence with the 
general practitioner 
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UNIVERSITY OF TASMANIA 
Tasmanian School of Pharmacy 
Telephone: 6226 2203 
Home Follow-up of patients commenced on warfarin therapy 
EVALUATION BY GENERAL PRACTITIONERS 
Dear Dr, 
I am writing to request your feedback regarding the above study. 
The aim of this study was to optimise the benefit that patients receive from taking the 
anticoagulant warfarin, through regular home visits and INR monitoring, dietary 
information and education. 
Your patient 	  has been participating in this study, and we 
would be interested in hearing your comments and feedback. The patients INR results for 
the duration of the study are displayed. Enclosed please find a questionnaire for you to 
complete, and return in the reply paid envelope. 
Days post discharge 2 4 6 8 
Date 2002 20/2 22/2 24/2 26/2 
INR (coaguchek) 2.7 2.9 3.1 2.8 
Previous Dose (mg) 2 2 2 1 
If you require more specific information regarding your patient's participation, or a copy 
of the completed study, please don't hesitate to call me on 0408485430 
Thank you in anticipation. 
Yours sincerely, 
Shane Jackson B.Pharm Hons 
Project Manager 
Appendix 20 
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general practitioner (Usual Care 
group) 
Improving warfarin initiation 
UNIVERSITY OF TASMANIA 
Tasmanian Schools of Pharmacy & 
Medicine 
Telephone: 6226 2203 
Dear Dr 
HOME FOLLOW-UP OF PATIENTS COMMENCED ON WARFARIN THERAPY 
Your patient has been recruited into a study of patients recently discharged from the 
Royal Hobart Hospital. This study aims to improve the outcomes of initiation of warfarin 
therapy. 
The study has been approved by the Royal Hobart Hospital Research and Ethics 
Committees. All patients have given their informed consent to participate. I have attached 
for you a copy of the information sheet that the patient has received. 
Your patient has been randomised to the control group. Patients in the control group will 
receive a pharmacist visit at home on Day 8 and at 90 days after discharge from hospital. 
The patient will be asked to report any adverse effects of warfarin therapy at this time. 
If you have any queries or require further information, please do not hesitate to call me 
on 0408485430 
Yours sincerely, 
Shane Jackson B.Pharm Hons 
Project Supervisor 
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Home visit data collection form 
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IMPROVING THE OUTCOMES OF ANTICOAGULATION: AN 
EVALUATION OF HOME FOLLOW-UP OF WARFARIN THERAPY 
(Tick where appropriate) 
1 	PERSONAL DATA 
Study Number: UR Number: 
Control 
Intervention 
Admitting Unit: GP: IP/OP: 
Age: . Sex: 
Smoking history: 
Lives alone 
Ht 
BMI 	<20 20-25 
Alcohol intake: 
Instutionalised 
Wt 
>25 
Diagnosis on admission: 
Admission date: (latest) Discharge date: 
2 REASONS FOR USE: 
Atrial Fibrillation 
Valve replacement 
DVT/ PE 
Other ( please specify) 
Warfarin use in the past ( yes/no) 
  
11 ANTICOAGULANT MONITORING FOR WARFARIN ( AT HOME) 
Date and INR Dose suggested to GP Dose given 
Day 2 
Day 4 
Day 6 
Day 8 
1 
3 	MEDICATIONS ON ADMISSION AND DOSE 
Interacting medications (number) 
Minimally significant 
Moderately significant 
Very significant  
4 	MEDICATIONS ON DISCHARGE AND DOSE 
Interacting medications (number) 
Minimally significant 
Moderately significant 
Very significant  
5 	CLINICAL DISEASE RISK FACTOR (AND DURATION/DATE) 
TYPE: 
Previous stroke 
Previous TIA 
Other embolic events 
Family history of embolic 
events 
Hypertension 
Average blood pressure 
Diabetes 
Angina 
Previous AMI 
CHF 
Mitral valve disease 
Thyrotmdcosis 
Prosthetic heart valve 
Peripheral arterial disease 
Other cardiac diseases 
Malignancy 
2 
CONTRAINDICATIONS TO ANTITHROMBOTIC (AS IN APP) 
Warfarin 
History of haemorrhagic 
Tendency 
Previous exposure to 
warfarin 
Recent or contemplated 
surgery (CNS, eye) 
Spinal puncture, diagnostic 
procedure 
Bleeding tendencies 
associated with active 
ulceration/overt bleeding 
of CIT. RT, GU, cerebral 
haemorrhage, aneurysms-
cerebral, dissecting aorta, 
pericarditis, pericardial 
effusions, bacterial 
endocarditis 
Chronic liver disease Chronic alcoholism 
GGT ALA/ALP 
BILIRUBM ALBUMIN 
Blood dyscrasia 
(thrombocytopaenia) 
Unsupervised 
dementia/psychosis 
Allergy Falls 
Malignant H/T 
11 ANTICOAGULANT MONITORING FOR WARFARIN ( IN HOSPITAL) 
INR 
	
Date 
	 dose 
Discharge INR 
11 ANTICOAGULANT MONITORING FOR WARFARIN ( AT HOME) 
INR Date dose Compliance 
( pill count) 
Day 2 
Day 4 
Day 6 
Day 8 
3 
DAY 2 FOLLOW UP 
DETECTION OF DRUG RELATED PROBLEMS 
POOR COMPLIANCE 
DRUG INTERACTIONS 
DRUG FOOD INTERACTION 
OTHER DRUG RELATED PROBLEMS 
TIME SPENT WITH PATIENT 
DAY 4 FOLLOW UP 
DETECTION OF DRUG RELATED PROBLEMS 
POOR COMPLIANCE 
DRUG INTERACTIONS 
DRUG FOOD INTERACTION 
OTHER DRUG RELATED PROBLEMS 
LEVEL OF UNDERSTANDING OF WARFARIN /10 
TIME SPENT WITH PATIENT 
DAY 6 FOLLOW UP 
DETECTION OF DRUG RELATED PROBLEMS 
POOR COMPLIANCE 
DRUG INTERACTIONS 
DRUG FOOD INTERACTION 
OTHER DRUG RELATED PROBLEMS 
LEVEL OF UNDERSTANDING OF WARFARIN /10 
TIME SPENT WITH PATIENT 
DAY 8 FOLLOW UP 
DETECTION OF DRUG RELATED PROBLEMS 
POOR COMPLIANCE 
DRUG INTERACTIONS 
DRUG FOOD INTERACTION 
OTHER DRUG RELATED PROBLEMS 
LEVEL OF UNDERSTANDING OF WARFARIN /10 
TIME SPENT WITH PATIENT 
12 CLINICAL OUTCOMES ( FOR 90 DAY FOLLOW-UP) 
Bleeding complications 
Date 	of 	initiation 	of 
antithrombotics 
Dose of antithrombotic 
Interval between complications 
and prophylaxis initiation 
Type 
Date 
Morbidity 
Intracranial haemorrhage 
CT scanning 
Bleeding peptic ulcer 
Blood transfusion required 
Stroke/TIA 
Date 
Interval between AF diagnosis 
and stroke 
Type 
Date 
Prognosis 
On warfarin at 90 days 
11 ANTICOAGULANT MONITORING FOR WARFARIN ( BETWEEN DAY 8 AND 90) 
INR 
	
Date 	 dose 
14 	5-point scoring system 
Age >65 Low 
History of GI bleeds Medium 
History of stroke high 
Comorbid conditions 
AMI DM 
Cr (>1.5mg/dL) 
Hct (0.30) 
CRCL 
Compliance at 90 days 
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Patient satisfaction survey 
Improving warfarin initiation 
PATIENT SATISFACTION 
QUESTIONNAIRE 
UNIVERSITY OF TASMANIA 
Tasmanian School of Pharmacy 
Telephone: 6226 7526 
Please help us evaluate and improve the pharmacy service by answering some 
questions about the services you have received from the pharmacist, Shane Jackson. We 
are interested in your honest opinions, whether they are positive or negative. Please 
answer all of the questions. Thank you very much, we really appreciate your help. 
Please Tick your Answers 
1 	How satisfied are you with the amount of contact you had with the pharmacist? 
D Quite dissatisfied 
D Indifferent or mildly dissatisfied 
D Mostly satisfied 
O Very satisfied 
2 	Has the information and other services provided by the pharmacist helped you to 
deal more effectively with your new medication warfarin 
1:1 	Yes, they helped a great deal 
Li 	Yes, they helped somewhat 
Li 	No, they really didn't help 
Li 	No, they seemed to make things worse 
3 	Did you get the kind of information and other services you wanted from the 
pharmacist? 
Li 	No, definitely not 
Li 	No, not really 
O Yes, generally 
Li 	Yes, definitely 
4 	Is there other information you need, or would like, about warfarin but have not 
received? 
O Yes, there definitely is 
O Yes, I think there is 
O No, I don't think there is 
D No, there definitely is not 
5 	Overall, how would you rate the quality of the service that you received from the 
pharmacist? 
D Excellent 
1:11 	Good 
D Fair 
O Poor 
6 	Did you find the regular warfarin (INR) monitoring: (you may tick more than one) 
U painful 	 U 	interesting 
U informative 	 U 	annoying 
U motivating U 	too frequent 
U a waste of time 	 U 	beneficial 
7 	Do you think this service would be best provided in your home or at your local 
pharmacy? 
• Home 
• Local Pharmacy 
8 	Do you think this service should be available to all patients commencing warfarin 
therapy? 
• Yes 
• No 
9 	If this was a regular service, would you be prepared to pay it? 
• Yes 
• No 
10 	If you answered yes to the previous question, how much would you be prepared to 
pay per visit? 
U $1 - $5 
U $6 - $10 
U $11 - $15 
U $16+ 
11 	If you wish to make any other comments, please feel free to do so in the space 
provided. If more space is required, use the back of this sheet. 
Thank you for taking the time to fill out this questionnaire 
Please post in the reply-paid envelope supplied 
Appendix 23 
Patient knowledge questionnaire 
Improving warfarin initiation 
Stayed the same Improved Worsened 
Heart surgery 
Stroke 
Heart disease 
2 	As far as you know, circle which of the following are reasons for your present 
warfarin treatment? 
(DVT) — blood clot in leg vein 
Atrial Fibrillation 
PE — blood clot in lung 
Anything else? 
A lot A little Not at all 
Yes No Not sure 
4 	When you left the Royal Hobart Hospital (RHH) were you handed a "warfarin 
booklet"? please circle 
5 	Were you told how warfarin works, and was this clear? Please circle 
Yes, and clear 	 Yes, but not clear 	 No 
Could you briefly explain in your own words how warfarin works 
1 	Since starting warfarin would you say that your general health has: 
please circle) 
3 	Do you worry about being on warfarin treatment? Please circle 
If so, what are your concerns? 
Evaluation of patients knowledge regarding anticoagulant therapy 
Shane Jackson 
Tasmanian School of pharmacy, University of Tasmania 
We are interested in finding out about your general health and the anticoagulant 
(warfarin) treatment that you are now receiving. 
No Yes, but not clear Yes, and clear 
No Yes, but not clear Yes, and clear 
Some illnesses 
Missing a dose of warfarin 
Nurofen 
Antacids 
Some foods 
Aspirin 
Weather conditions 
Coffee 
Herbal remedies 
Panadol 
No Yes, but not clear Yes, and clear 
No Yes, but not clear Yes, and clear 
Yes No Don't know 
No 
11 	The following are statements about any patient drinking alcohol when receiving 
warfarin treatment (Please circle Yes or No for each statement) 
Alcohol can affect anticoagulant treatment 	 Yes 
Alcohol must be avoided totally 	 Yes 
8 units of alcohol a night is OK ( for example 8 glasses or beer or wine) Yes 
1 unit of alcohol a night is OK ( for example 1 glass of beer or wine) 	Yes 
No 
No 
No 
6 	Were you told of the possible problems with warfarin treatment, and was this 
clear? please circle 
7 Were you told what to do if you have a nosebleed or bruising and was this clear? Please 
circle 
10 	Could starting a new treatment or any other preparation affect your warfarin 
treatment? Please circle 
9 	Were you given advice on drinking alcohol and was this clear to you? Please circle 
8 	Were you told what drugs to avoid and was this clear? Please circle 
12 	Of the list below, CIRCLE which of the following factors could interfere with your 
warfarin therapy. 
Evaluation of patients knowledge regarding anticoagulant therapy 
Shane Jackson 
Tasmanian School of pharmacy, University of Tasmania 
Evaluation of patients knowledge regarding anticoagulant therapy 
Shane Jackson 
Tasmanian School of pharmacy, University of Tasmania 
13 	CIRCLE which of the following could be possible side effects of taking the wrong 
(too little or too much) amount of warfarin? Please do not be alarmed, some of the items are 
wrong, 
Blood in stools 	 Ringing in the ears 
Nausea 	 Nose bleeds 
Blood in the urine 	 Sleeplessness 
Nervousness 	 Prolonged bleeding after cuts 
Blood clots 	 Bruising without injury 
High blood pressure 	 Loss of appetite 
Weakness 
14 	Before the visit today by Shane Jackson, do you know what your most recent INR 
was? (please circle) 
Yes 	 No 
What was it? 
If you wish to make any other comments, please feel free to do so in the space provided. If more space is 
required, use the back of this sheet. 
Thank you for taking the time to fill out this questionnaire 
Please post in the reply-paid envelope supplied 
If you have any further comments feel free to use the back of the page 
